

Oncology Meets Immunology: The Cancer-Immunity Cy

Immunity

39, 1-10

DOI: [10.1016/j.immuni.2013.07.012](https://doi.org/10.1016/j.immuni.2013.07.012)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Dendritic-Cell-Based Therapeutic Cancer Vaccines. <i>Immunity</i> , 2013, 39, 38-48.	6.6	739
2	Turning Tumors into Vaccines: Co-opting the Innate Immune System. <i>Immunity</i> , 2013, 39, 27-37.	6.6	93
3	Control of T Helper 2 Responses by Transcription Factor IRF4-Dependent Dendritic Cells. <i>Immunity</i> , 2013, 39, 722-732.	6.6	385
4	Human dendritic cells are "stars" in the skin. <i>European Journal of Immunology</i> , 2013, 43, 3147-3155.	1.6	35
5	Neonatal Fc Receptor Expression in Dendritic Cells Mediates Protective Immunity against Colorectal Cancer. <i>Immunity</i> , 2013, 39, 1095-1107.	6.6	112
6	Antibody Therapeutics in Cancer. <i>Science</i> , 2013, 341, 1192-1198.	6.0	474
7	Autophagy Regulates Phagocytosis by Modulating the Expression of Scavenger Receptors. <i>Immunity</i> , 2013, 39, 537-547.	6.6	164
8	The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures. <i>Immunity</i> , 2013, 39, 11-26.	6.6	700
9	Sunitinib Indirectly Enhanced Anti-Tumor Cytotoxicity of Cytokine-Induced Killer Cells and CD3+CD56+ Subset through the Co-Culturing Dendritic Cells. <i>PLoS ONE</i> , 2013, 8, e78980.	1.1	27
10	Therapeutic cancer vaccines and combination immunotherapies involving vaccination. <i>ImmunoTargets and Therapy</i> , 2014, 3, 135.	2.7	9
11	Prognostic value of preoperative absolute lymphocyte count in recurrent hepatocellular carcinoma following thermal ablation: a retrospective analysis. <i>OncoTargets and Therapy</i> , 2014, 7, 1829.	1.0	9
12	B Cells and Ectopic Follicular Structures: Novel Players in Anti-Tumor Programming with Prognostic Power for Patients with Metastatic Colorectal Cancer. <i>PLoS ONE</i> , 2014, 9, e99008.	1.1	86
13	Deconvolution of the Gene Expression Profiles of Valuable Banked Blood Specimens for Studying the Prognostic Values of Altered Peripheral Immune Cell Proportions in Cancer Patients. <i>PLoS ONE</i> , 2014, 9, e100934.	1.1	7
14	Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. <i>Pharmacogenomics and Personalized Medicine</i> , 2014, 7, 357.	0.4	60
16	Neonatal Fc receptors for IgG drive CD8+T cell-mediated anti-cancer immunosurveillance at tolerogenic mucosal sites. <i>Oncolmmunology</i> , 2014, 3, e27844.	2.1	2
17	Adding fuel to the fire: Immunogenic intensification. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3306-3312.	1.4	4
18	PD-1 and PD-L1 antibodies for melanoma. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3111-3116.	1.4	54
19	Dual targeting of CD137 co-stimulatory and PD-1 co-inhibitory molecules for ovarian cancer immunotherapy. <i>Oncolmmunology</i> , 2014, 3, e28248.	2.1	30

#	ARTICLE	IF	CITATIONS
20	The immune landscape of human tumors. <i>Oncolmunology</i> , 2014, 3, e27456.	2.1	97
21	Neural Autoantibody Clusters Aid Diagnosis of Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 3862-3869.	3.2	62
22	Human skin dendritic cells can be targeted in situ by intradermal injection of antibodies against lectin receptors. <i>Experimental Dermatology</i> , 2014, 23, 909-915.	1.4	26
23	Malarial liver parasites awaken in culture. <i>Nature Medicine</i> , 2014, 20, 237-239.	15.2	8
24	Dendritic Cell Therapy in an Allogeneic-Hematopoietic Cell Transplantation Setting: An Effective Strategy toward Better Disease Control?. <i>Frontiers in Immunology</i> , 2014, 5, 218.	2.2	12
25	Promising Targets and Current Clinical Trials in Metastatic Squamous Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2014, 4, 320.	1.3	5
26	Exploiting Synergy: Immune-Based Combinations in the Treatment of Prostate Cancer. <i>Frontiers in Oncology</i> , 2014, 4, 351.	1.3	15
27	Impact of the Prolymphangiogenic Crosstalk in the Tumor Microenvironment on Lymphatic Cancer Metastasis. <i>BioMed Research International</i> , 2014, 2014, 1-14.	0.9	22
28	Induction of Wnt-Inducible Signaling Protein-1 Correlates with Invasive Breast Cancer Oncogenesis and Reduced Type 1 Cell-Mediated Cytotoxic Immunity: A Retrospective Study. <i>PLoS Computational Biology</i> , 2014, 10, e1003409.	1.5	43
29	Combinations of Immunotherapy and Radiation in Cancer Therapy. <i>Frontiers in Oncology</i> , 2014, 4, 325.	1.3	205
30	Execution of RIPK3-regulated necrosis. <i>Molecular and Cellular Oncology</i> , 2014, 1, e960759.	0.3	30
31	Macrophage IL-10 Blocks CD8+ T Cell-Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in Intratumoral Dendritic Cells. <i>Cancer Cell</i> , 2014, 26, 623-637.	7.7	751
32	Nano-Oncologicals. <i>Advances in Delivery Science and Technology</i> , 2014, , .	0.4	7
33	The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function. <i>Cancer Cell</i> , 2014, 26, 923-937.	7.7	851
34	MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. <i>Nature</i> , 2014, 515, 558-562.	13.7	2,109
35	Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. <i>Nature</i> , 2014, 515, 572-576.	13.7	1,010
36	Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. <i>Nature</i> , 2014, 515, 563-567.	13.7	4,342
37	The evolving genomic classification of lung cancer. <i>Journal of Pathology</i> , 2014, 232, 121-133.	2.1	87

#	ARTICLE	IF	CITATIONS
38	Intravenous Injection of MVA Virus Targets CD8+ Lymphocytes to Tumors to Control Tumor Growth upon Combinatorial Treatment with a TLR9 Agonist. <i>Cancer Immunology Research</i> , 2014, 2, 1163-1174.	1.6	19
39	(R)Evolutionary Therapy: The Potential of Immunotherapy to Fulfill the Promise of Personalized Cancer Treatment. <i>Journal of the National Cancer Institute</i> , 2014, 107, dju347-dju347.	3.0	4
41	Radical cystectomy and the implications of comorbidity. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 289-295.	1.1	15
42	Fusion Protein of Mutant B7-DC and Fc Enhances the Antitumor Immune Effect of GM-CSF-secreting Whole-cell Vaccine. <i>Journal of Immunotherapy</i> , 2014, 37, 147-154.	1.2	2
43	PD-L1 expression and tumor-infiltrating lymphocytes. <i>Oncotarget</i> , 2014, 3, e29288.	2.1	60
44	Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 2021-2031.	1.4	12
45	Copy Number Loss of the Interferon Gene Cluster in Melanomas Is Linked to Reduced T Cell Infiltrate and Poor Patient Prognosis. <i>PLoS ONE</i> , 2014, 9, e109760.	1.1	192
46	Dendritic Cell-Targeted Vaccines. <i>Frontiers in Immunology</i> , 2014, 5, 255.	2.2	173
47	Blockade of the B7-H1/PD-1 Pathway as a Basis for Combination Anticancer Therapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2014, 20, 290-295.	1.0	32
48	Enhancement of an anti-tumor immune response by transient blockade of central T cell tolerance. <i>Journal of Experimental Medicine</i> , 2014, 211, 761-768.	4.2	101
49	Genetic variations in cytotoxic T-lymphocyte antigen-4 and susceptibility to cervical cancer. <i>International Immunopharmacology</i> , 2014, 18, 71-76.	1.7	11
50	PI3K and cancer: lessons, challenges and opportunities. <i>Nature Reviews Drug Discovery</i> , 2014, 13, 140-156.	21.5	1,398
52	Antitumor Efficacy of a Bispecific Antibody That Targets HER2 and Activates T Cells. <i>Cancer Research</i> , 2014, 74, 5561-5571.	0.4	135
53	<i>Pten</i> Null Prostate Epithelium Promotes Localized Myeloid-Derived Suppressor Cell Expansion and Immune Suppression during Tumor Initiation and Progression. <i>Molecular and Cellular Biology</i> , 2014, 34, 2017-2028.	1.1	107
54	A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma. , 2014, 2, 30.		27
55	The Stress-Response Sensor Chop Regulates the Function and Accumulation of Myeloid-Derived Suppressor Cells in Tumors. <i>Immunity</i> , 2014, 41, 389-401.	6.6	200
56	Chemical Induction of Unfolded Protein Response Enhances Cancer Cell Killing through Lytic Virus Infection. <i>Journal of Virology</i> , 2014, 88, 13086-13098.	1.5	29
57	Molecular response of the axillary lymph node microenvironment to metastatic colonization. <i>Clinical and Experimental Metastasis</i> , 2014, 31, 565-572.	1.7	10

#	ARTICLE	IF	CITATIONS
58	Rescue of Notch-1 Signaling in Antigen-Specific CD8+ T Cells Overcomes Tumor-Induced T-cell Suppression and Enhances Immunotherapy in Cancer. <i>Cancer Immunology Research</i> , 2014, 2, 800-811.	1.6	71
59	Pathology in drug discovery and development. <i>Journal of Pathology</i> , 2014, 232, 99-102.	2.1	12
60	A Fox of a different color: FoxA1 programs a new regulatory T cell subset. <i>Nature Medicine</i> , 2014, 20, 236-237.	15.2	4
61	Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy. <i>Cancer Cell</i> , 2014, 25, 846-859.	7.7	1,033
62	Introduction to the Role of the Immune System in Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 537-558.	0.9	8
63	A Simple and Rapid Protocol to Non-enzymatically Dissociate Fresh Human Tissues for the Analysis of Infiltrating Lymphocytes. <i>Journal of Visualized Experiments</i> , 2014, , .	0.2	33
64	Regulation of Tumor Growth and Metastasis: The Role of Tumor Microenvironment. <i>Cancer Growth and Metastasis</i> , 2014, 7, CGM.S11285.	3.5	164
65	Intravenous injection of a modified vaccinia ankara virus induces intratumoral CD8+ lymphocyte infiltration favoring tumor control in an orthotopic tumor model upon combinatorial treatment with a TLR9 agonist. , 2014, 2, P57.		0
66	Potential of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer. <i>Molecular Therapy - Oncolytics</i> , 2014, 1, 14004.	2.0	33
67	Management and orphan drug development for acute myeloid leukemia. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 441-451.	0.5	0
68	Novel Pancreatic Cancer Vaccines Could Unleash the Army Within. <i>Cancer Control</i> , 2014, 21, 242-246.	0.7	16
69	Targeting immune checkpoints in melanoma: an update. <i>Melanoma Management</i> , 2015, 2, 339-352.	0.1	2
70	Principles of Immunotherapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 670-672.	2.3	8
71	Antigenically Modified Human Pluripotent Stem Cells Generate Antigen-Presenting Dendritic Cells. <i>Scientific Reports</i> , 2015, 5, 15262.	1.6	16
72	Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1458-1467.	0.5	50
73	Emerging immunotherapies for bladder cancer. <i>Current Opinion in Oncology</i> , 2015, 27, 191-200.	1.1	24
74	Enhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: Interleukin-12 as a case study. , 2015, 3, 27.		17
75	Principles of immunology and its nuances in the central nervous system: Fig. 1.. <i>Neuro-Oncology</i> , 2015, 17, vii3-vii8.	0.6	28

#	ARTICLE	IF	CITATIONS
76	Immune checkpoint inhibitors with radiotherapy and locoregional treatment. Current Opinion in Oncology, 2015, 27, 445-451.	1.1	39
77	The Ruesch Center Symposium 2014: Fighting a Smarter War against Cancer Using Immunotherapy. Colorectal Cancer, 2015, 4, 63-68.	0.8	0
78	A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial. , 2015, 3, 48.		26
79	Genomic alterations underlying immune privilege in malignant lymphomas. Current Opinion in Hematology, 2015, 22, 343-354.	1.2	18
80	Nanoparticle-Based Manipulation of Antigen-Presenting Cells for Cancer Immunotherapy. Small, 2015, 11, 5483-5496.	5.2	103
81	Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma. Current Opinion in Oncology, 2015, 27, 384-391.	1.1	18
82	Identification of a naturally processed <scp>HLA</scp>â€ƒw7â€ƒbinding peptide that crossâ€ƒreacts with <scp>HLAâ€ƒA24</scp>â€ƒrestricted ovarian cancerâ€ƒspecific <scp>CTLs</scp>. Tissue Antigens, 2015, 86, 164-171.	1.0	2
84	Immune cell-based screening assay for response to anticancer agents: applications in pharmacogenomics. Pharmacogenomics and Personalized Medicine, 2015, 8, 81.	0.4	10
85	Tumor neoantigens: building a framework for personalized cancer immunotherapy. Journal of Clinical Investigation, 2015, 125, 3413-3421.	3.9	502
86	New developments in the management of advanced melanoma – role of pembrolizumab. OncoTargets and Therapy, 2015, 8, 2535.	1.0	16
87	MPGES-1-derived PGE2 suppresses CD80 expression on tumor-associated phagocytes to inhibit anti-tumor immune responses in breast cancer. Oncotarget, 2015, 6, 10284-10296.	0.8	48
88	Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine. Vaccines, 2015, 3, 490-502.	2.1	43
89	Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy. Vaccines, 2015, 3, 662-685.	2.1	225
90	A Quantitative Systems Pharmacology Perspective on Cancer Immunology. Processes, 2015, 3, 235-256.	1.3	8
91	Therapeutic strategy for cancer immunotherapy in head and neck cancer. Advances in Cellular and Molecular Otolaryngology, 2015, 3, 27690.	0.4	5
92	Patient-Specific Therapeutic Vaccines for Metastatic Melanoma. Oncology Issues, 2015, 30, 48-57.	0.0	3
93	Achievements and Challenges of Molecular Targeted Therapy in Melanoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , 177-186.	1.8	37
94	Nonhuman Primate Models of Human Disease. , 2015, , 257-277.		1

#	ARTICLE	IF	CITATIONS
95	T cell exclusion, immune privilege, and the tumor microenvironment. <i>Science</i> , 2015, 348, 74-80.	6.0	1,735
96	Dendritic Cell-Based Vaccine Efficacy: Aiming for Hot Spots. <i>Frontiers in Immunology</i> , 2015, 6, 91.	2.2	59
97	Vaccines, Adjuvants, and Dendritic Cell Activators—Current Status and Future Challenges. <i>Seminars in Oncology</i> , 2015, 42, 549-561.	0.8	37
98	6-Thioguanine-loaded polymeric micelles deplete myeloid-derived suppressor cells and enhance the efficacy of T cell immunotherapy in tumor-bearing mice. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1033-1046.	2.0	56
99	Challenges and Opportunities for Quantitative Clinical Pharmacology in Cancer Immunotherapy: Something Old, Something New, Something Borrowed, and Something Blue. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015, 4, 495-497.	1.3	15
100	Statistical Challenges in the Design of Late-Stage Cancer Immunotherapy Studies. <i>Cancer Immunology Research</i> , 2015, 3, 1292-1298.	1.6	38
101	The PTEN pathway in T _{regs} is a critical driver of the suppressive tumor microenvironment. <i>Science Advances</i> , 2015, 1, e1500845.	4.7	167
102	The Nuclear Orphan Receptor NR2F6 Is a Central Checkpoint for Cancer Immune Surveillance. <i>Cell Reports</i> , 2015, 12, 2072-2085.	2.9	47
103	Current and Emerging Perspectives on Immunotherapy for Melanoma. <i>Seminars in Oncology</i> , 2015, 42, S3-S11.	0.8	19
105	The prognostic significance of PD-L1 in bladder cancer. <i>Oncology Reports</i> , 2015, 33, 3075-3084.	1.2	90
106	Microarray expression profile analysis of long non-coding RNAs in human breast cancer: A study of Chinese women. <i>Biomedicine and Pharmacotherapy</i> , 2015, 69, 221-227.	2.5	37
107	Targeting the tumor vasculature to enhance T cell activity. <i>Current Opinion in Immunology</i> , 2015, 33, 55-63.	2.4	237
108	Immune Escape Mechanisms as a Guide for Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2015, 21, 687-692.	3.2	801
109	Biomarkers in Cancer Immunotherapy. <i>Cancer Cell</i> , 2015, 27, 12-14.	7.7	130
110	Immune checkpoint modulation: Rational design of combination strategies. , 2015, 150, 23-32.		76
111	<i>APOBEC3B</i> expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 2841-2846.	3.3	118
112	Targeting the Tumor Stroma in Breast Cancer. <i>Current Breast Cancer Reports</i> , 2015, 7, 71-79.	0.5	0
113	Shaping the tumor microenvironment with Modified Vaccinia Virus Ankara and TLR9 ligand. <i>Oncimmunology</i> , 2015, 4, e1003013.	2.1	1

#	ARTICLE	IF	CITATIONS
114	Î2-Catenin Promotes Regulatory T-cell Responses in Tumors by Inducing Vitamin A Metabolism in Dendritic Cells. <i>Cancer Research</i> , 2015, 75, 656-665.	0.4	94
115	Antigen targeting to dendritic cells combined with transient regulatory T cell inhibition results in long-term tumor regression. <i>Oncolmunology</i> , 2015, 4, e970462.	2.1	30
116	CSF-1/CSF-1R targeting agents in clinical development for cancer therapy. <i>Current Opinion in Pharmacology</i> , 2015, 23, 45-51.	1.7	107
117	New advances in genitourinary cancer: evidence gathered in 2014. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 443-464.	2.7	4
118	Kick-starting the cancer-immunity cycle by targeting CD40. <i>Oncolmunology</i> , 2015, 4, e1011484.	2.1	14
119	Intravital and Whole-Organ Imaging Reveals Capture of Melanoma-Derived Antigen by Lymph Node Subcapsular Macrophages Leading to Widespread Deposition on Follicular Dendritic Cells. <i>Frontiers in Immunology</i> , 2015, 6, 114.	2.2	36
121	Charting Immune Signaling Proteomes En Route to New Therapeutic Strategies. <i>Cancer Immunology Research</i> , 2015, 3, 714-720.	1.6	7
122	Engineered materials for cancer immunotherapy. <i>Nano Today</i> , 2015, 10, 511-531.	6.2	96
123	Biological Therapy of Cancer. , 2015, , 561-593.		0
124	Targeting cancer with kinase inhibitors. <i>Journal of Clinical Investigation</i> , 2015, 125, 1780-1789.	3.9	364
125	Therapeutic Combinations of Immune-Modulating Antibodies in Melanoma and Beyond. <i>Seminars in Oncology</i> , 2015, 42, 488-494.	0.8	19
126	Antibodies regulate antitumour immunity. <i>Nature</i> , 2015, 521, 35-37.	13.7	29
127	Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. <i>Nature</i> , 2015, 521, 94-98.	13.7	451
128	Cancer vaccines. <i>BMJ, The</i> , 2015, 350, h988-h988.	3.0	199
129	Immunotherapy for urothelial cancer: from BCG to checkpoint inhibitors and beyond. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 509-523.	1.1	21
130	PD-L1 Inhibition With MPDL3280A for Solid Tumors. <i>Seminars in Oncology</i> , 2015, 42, 484-487.	0.8	46
131	Neoantigens in cancer immunotherapy. <i>Science</i> , 2015, 348, 69-74.	6.0	3,809
133	Precision Immunology: The Promise of Immunotherapy for the Treatment of Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1315-1317.	0.8	11

#	ARTICLE	IF	CITATIONS
134	The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date. <i>Drugs</i> , 2015, 75, 563-575.	4.9	18
135	Overlapping Patterns of Rapid Evolution in the Nucleic Acid Sensors cGAS and OAS1 Suggest a Common Mechanism of Pathogen Antagonism and Escape. <i>PLoS Genetics</i> , 2015, 11, e1005203.	1.5	82
136	Targeting Heat-Shock Protein 90 (HSP90) as a Complementary Strategy to Immune Checkpoint Blockade for Cancer Therapy. <i>Cancer Immunology Research</i> , 2015, 3, 583-589.	1.6	56
137	Adoptive cellular therapy: A race to the finish line. <i>Science Translational Medicine</i> , 2015, 7, 280ps7.	5.8	320
138	Curing Mice with Large Tumors by Locally Delivering Combinations of Immunomodulatory Antibodies. <i>Clinical Cancer Research</i> , 2015, 21, 1127-1138.	3.2	52
139	The development of immunotherapy in urothelial bladder cancer. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 193-194.	12.5	8
140	TGF- β 2 Regulates Hepatocellular Carcinoma Progression by Inducing Treg Cell Polarization. <i>Cellular Physiology and Biochemistry</i> , 2015, 35, 1623-1632.	1.1	90
141	Molecularly Targeted Therapies in Non-Small-Cell Lung Cancer Annual Update 2014. <i>Journal of Thoracic Oncology</i> , 2015, 10, S1-S63.	0.5	119
142	Stress, Metabolism and Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2015, 21, 97-103.	1.0	34
143	Virological and Preclinical Characterization of a Dendritic Cell Targeting, Integration-deficient Lentiviral Vector for Cancer Immunotherapy. <i>Journal of Immunotherapy</i> , 2015, 38, 41-53.	1.2	24
144	Bioorthogonal Deprotection on the Dendritic Cell Surface for Chemical Control of Antigen Cross-Presentation. <i>Angewandte Chemie - International Edition</i> , 2015, 54, 5628-5631.	7.2	36
145	Targeting the immune system to treat lung cancer: rationale and clinical experience. <i>Therapeutic Advances in Respiratory Disease</i> , 2015, 9, 105-120.	1.0	13
146	The nitric oxide radical scavenger carboxy-PTIO reduces the immunosuppressive activity of myeloid-derived suppressor cells and potentiates the antitumor activity of adoptive cytotoxic T lymphocyte immunotherapy. <i>OncImmunology</i> , 2015, 4, e1019195.	2.1	20
147	Nivolumab in combination with ipilimumab for the treatment of melanoma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1135-1141.	1.1	22
148	CD8 + T cell response to adenovirus vaccination and subsequent suppression of tumor growth: modeling, simulation and analysis. <i>BMC Systems Biology</i> , 2015, 9, 27.	3.0	16
149	Immunothérapie anticancer : les molécules immunomodulatrices en développement clinique. <i>Oncologie</i> , 2015, 17, 379-389.	0.2	0
151	Cancer immunotherapy: Strategies for personalization and combinatorial approaches. <i>Molecular Oncology</i> , 2015, 9, 2043-2053.	2.1	87
152	Diaminosulfide based polymer microparticles as cancer vaccine delivery systems. <i>Journal of Controlled Release</i> , 2015, 220, 682-690.	4.8	26

#	ARTICLE	IF	CITATIONS
153	Expansion Cohorts in First-in-Human Solid Tumor Oncology Trials. <i>Clinical Cancer Research</i> , 2015, 21, 4545-4551.	3.2	33
154	Anthracyclines potentiate anti-tumor immunity: A new opportunity for chemoimmunotherapy. <i>Cancer Letters</i> , 2015, 369, 331-335.	3.2	72
155	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 668-679.	12.8	839
156	Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1. <i>Structure</i> , 2015, 23, 2341-2348.	1.6	399
157	Prospects of immune checkpoint modulators in the treatment of glioblastoma. <i>Nature Reviews Neurology</i> , 2015, 11, 504-514.	4.9	307
158	Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma: Table 1. <i>Neuro-Oncology</i> , 2015, 17, 1043-1045.	0.6	24
159	Role of Local Radiation Therapy in Cancer Immunotherapy. <i>JAMA Oncology</i> , 2015, 1, 1325.	3.4	570
160	Global gene expression profiling reveals a suppressed immune response pathway associated with 3q amplification in squamous carcinoma of the lung. <i>Genomics Data</i> , 2015, 5, 272-274.	1.3	6
161	Efficient expression of bioactive murine IL12 as a self-processing P2A polypeptide driven by inflammation-regulated promoters in tumor cell lines. <i>Cancer Gene Therapy</i> , 2015, 22, 542-551.	2.2	6
162	Editorial overview: Cancer: Changing the landscape – new pharmacology steering the course towards improved treatment options in cancer. <i>Current Opinion in Pharmacology</i> , 2015, 23, iv-vi.	1.7	0
163	Immunological hallmarks of stromal cells in the tumour microenvironment. <i>Nature Reviews Immunology</i> , 2015, 15, 669-682.	10.6	850
165	Integrating Immunotherapies in Prostate Cancer. <i>Current Oncology Reports</i> , 2015, 17, 45.	1.8	3
166	Fas Ligand Deficiency Impairs Tumor Immunity by Promoting an Accumulation of Monocytic Myeloid-Derived Suppressor Cells. <i>Cancer Research</i> , 2015, 75, 4292-4301.	0.4	26
167	Sensitive Multiplexed Quantitative Analysis of Autoantibodies to Cancer Antigens with Chemically Cationized Full-Length and Water-Soluble Denatured Proteins. <i>Bioconjugate Chemistry</i> , 2015, 26, 2076-2084.	1.8	9
168	c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma. <i>Oncolmmunology</i> , 2015, 4, e976077.	2.1	35
169	CDKN1A regulates Langerhans cell survival and promotes Treg cell generation upon exposure to ionizing irradiation. <i>Nature Immunology</i> , 2015, 16, 1060-1068.	7.0	110
170	Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine. <i>Seminars in Cancer Biology</i> , 2015, 35, 53-61.	4.3	67
171	Nivolumab for treating non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1789-1797.	1.4	27

#	ARTICLE	IF	CITATIONS
172	Immunotherapy Combinations With Checkpoint Inhibitors in Metastatic Melanoma: Current Approaches and Future Directions. <i>Seminars in Oncology</i> , 2015, 42, S12-S19.	0.8	24
173	Introduction. <i>Seminars in Radiation Oncology</i> , 2015, 25, 1-3.	1.0	4
174	19. Translating science into therapy of lymphoma. , 2016, , 379-402.		0
175	Immune checkpoint inhibition in patients with brain metastases. <i>Annals of Translational Medicine</i> , 2016, 4, S9-S9.	0.7	29
176	Status of and prospects for cancer vaccines against hepatocellular carcinoma in clinical trials. <i>BioScience Trends</i> , 2016, 10, 85-91.	1.1	35
177	Nonmuscle invasive bladder cancer: a primer on immunotherapy. <i>Cancer Biology and Medicine</i> , 2016, 13, 194-205.	1.4	17
178	nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 101-112.	1.0	60
179	Introduction to Systemic Antineoplastic Treatments for Cardiologists. , 2016, , 15-38.		3
180	From the era of ineffective tumor vaccines to a future with effective immunotherapy. <i>Journal of Thoracic Disease</i> , 2016, 8, 1916-1917.	0.6	0
181	The Immune System in Cancer Pathogenesis: Potential Therapeutic Approaches. <i>Journal of Immunology Research</i> , 2016, 2016, 1-13.	0.9	153
182	Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice. <i>Frontiers in Cell and Developmental Biology</i> , 2016, 4, 64.	1.8	45
184	Exploring Reovirus Plasticity for Improving Its Use as Oncolytic Virus. <i>Viruses</i> , 2016, 8, 4.	1.5	29
185	The Impact of Chemotherapy, Radiation and Epigenetic Modifiers in Cancer Cell Expression of Immune Inhibitory and Stimulatory Molecules and Anti-Tumor Efficacy. <i>Vaccines</i> , 2016, 4, 43.	2.1	35
186	Challenges of Using High-Dose Fractionation Radiotherapy in Combination Therapy. <i>Frontiers in Oncology</i> , 2016, 6, 165.	1.3	9
187	Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy. <i>Frontiers in Oncology</i> , 2016, 6, 233.	1.3	148
188	Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer. <i>Bladder Cancer</i> , 2016, 2, 15-25.	0.2	29
189	Immune checkpoint blockade therapy for bladder cancer treatment. <i>Investigative and Clinical Urology</i> , 2016, 57, S98.	1.0	26
190	Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients. <i>Journal of Immunotherapy</i> , 2016, 39, 241-248.	1.2	26

#	ARTICLE	IF	CITATIONS
191	Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2016, 34, 596-603.	1.2	43
192	Systematic review of the use of granulocyte macrophage colony-stimulating factor in patients with advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1015-1034.	2.0	49
193	Computational genomics tools for dissecting tumour-immune cell interactions. <i>Nature Reviews Genetics</i> , 2016, 17, 441-458.	7.7	233
194	Novel Targets and Their Assessment for Cancer Treatment. , 2016, , 163-180.		0
195	Characterization of MHC Class I and β 2-microglobulin Expression in Pediatric Solid Malignancies to Guide Selection of Immune-Based Therapeutic Trials. <i>Pediatric Blood and Cancer</i> , 2016, 63, 618-626.	0.8	12
196	Immune-Related Adverse Events From Immune Checkpoint Inhibitors. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 242-251.	2.3	84
197	Pan-cancer analysis of copy number changes in programmed death ligand 1 (PD-L1, CD274) associations with gene expression, mutational load, and survival. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 626-639.	1.5	80
198	The role of immune checkpoint inhibition in the treatment of ovarian cancer. <i>Gynecologic Oncology Research and Practice</i> , 2016, 3, 11.	3.6	118
199	Predictive biomarkers for checkpoint inhibitor-based immunotherapy. <i>Lancet Oncology</i> , The, 2016, 17, e542-e551.	5.1	1,274
200	Single Molecule Methods to Measure Receptor-Ligand Interaction in Immunological Synapses. , 2016, , 660-666.		1
201	High expression levels of egfl7 correlate with low endothelial cell activation in peritumoral vessels of human breast cancer. <i>Oncology Letters</i> , 2016, 12, 1422-1428.	0.8	12
202	A transient increase and subsequent sharp decrease of chemo-refractory liver-metastasized uterine cervical small cell carcinoma to autologous formalin-fixed tumor vaccine plus anti-PD-1 antibody. <i>Clinical Case Reports (discontinued)</i> , 2016, 4, 687-691.	0.2	10
203	Administration and Handling of Talimogene Laherparepvec: An Intralesional Oncolytic Immunotherapy for Melanoma. <i>Oncology Nursing Forum</i> , 2016, 43, 219-226.	0.5	18
204	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. <i>ESMO Open</i> , 2016, 1, e000097.	2.0	82
205	Immune checkpoint inhibitors renal side effects and management. <i>Immunotherapy</i> , 2016, 8, 1417-1425.	1.0	13
206	Dendritic cell vaccines for melanoma: past, present and future. <i>Melanoma Management</i> , 2016, 3, 273-289.	0.1	20
207	Temporally Programmed CD8 ⁺ + DC Activation Enhances Combination Cancer Immunotherapy. <i>Cell Reports</i> , 2016, 17, 2503-2511.	2.9	37
208	An In Vitro Model That Predicts the Therapeutic Efficacy of Immunomodulatory Antibodies. <i>Journal of Immunotherapy</i> , 2016, 39, 298-305.	1.2	4

#	ARTICLE	IF	CITATIONS
209	De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute. <i>Cancer Immunology Research</i> , 2016, 4, 279-288.	1.6	29
210	CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination. <i>Cancer Research</i> , 2016, 76, 2921-2931.	0.4	113
211	Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm. <i>Oncolmunology</i> , 2016, 5, e1107698.	2.1	28
212	Beyond monotherapy: Integrating immunotherapy into current treatment regimens. <i>Journal of Thoracic Oncology</i> , 2016, 11, S8-S9.	0.5	0
214	Targeting dendritic cells in lymph node with an antigen peptide-based nanovaccine for cancer immunotherapy. <i>Biomaterials</i> , 2016, 98, 171-183.	5.7	122
215	Targeting K-Ras cancers. <i>Journal of Thoracic Oncology</i> , 2016, 11, S9-S10.	0.5	0
216	Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses. <i>Cancer Research</i> , 2016, 76, 3767-3772.	0.4	124
217	Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer. <i>Trends in Immunology</i> , 2016, 37, 462-476.	2.9	232
218	Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). <i>Annals of Oncology</i> , 2016, 27, 1492-1504.	0.6	460
219	Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling. <i>Cell</i> , 2016, 165, 272-275.	13.5	224
220	The significance and therapeutic potential of PD-1 and its ligands in ovarian cancer: A systematic review. <i>Gynecologic Oncology</i> , 2016, 142, 184-189.	0.6	18
221	T-Cell Activation Independently Associates With Immune Senescence in HIV-Infected Recipients of Long-term Antiretroviral Treatment. <i>Journal of Infectious Diseases</i> , 2016, 214, 216-225.	1.9	97
222	Editorial overview: Special section: New concepts in antibody therapeutics: What's in store for antibody therapy?. <i>Current Opinion in Immunology</i> , 2016, 40, vii-xiii.	2.4	20
223	Improving efficacy of hyperthermia in oncology by exploiting biological mechanisms. <i>International Journal of Hyperthermia</i> , 2016, 32, 446-454.	1.1	97
224	Expansion and Activation of CD103+ Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. <i>Immunity</i> , 2016, 44, 924-938.	6.6	857
225	Reving Up Dendritic Cells while Braking PD-L1 to Jump-Start the Cancer-Immunity Cycle Motor. <i>Immunity</i> , 2016, 44, 722-724.	6.6	10
226	Systems immune monitoring in cancer therapy. <i>European Journal of Cancer</i> , 2016, 61, 77-84.	1.3	38
227	Cancer immunotherapy: the beginning of the end of cancer?. <i>BMC Medicine</i> , 2016, 14, 73.	2.3	908

#	ARTICLE	IF	CITATIONS
228	Role of the tumor microenvironment in mature B-cell lymphoid malignancies. <i>Haematologica</i> , 2016, 101, 531-540.	1.7	75
229	Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2219-2231.	1.4	49
230	The "cancer immunogram". <i>Science</i> , 2016, 352, 658-660.	6.0	655
231	The double-edge role of B cells in mediating antitumor T-cell immunity: Pharmacological strategies for cancer immunotherapy. <i>International Immunopharmacology</i> , 2016, 36, 73-85.	1.7	28
233	Current Challenges in Cancer Treatment. <i>Clinical Therapeutics</i> , 2016, 38, 1551-1566.	1.1	549
234	T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells. <i>Cancer Cell</i> , 2016, 30, 377-390.	7.7	141
235	Immunotherapy in head and neck cancer: Harnessing profit on a system disruption. <i>Oral Oncology</i> , 2016, 62, 153-162.	0.8	8
236	Basic Rules of T Cell Migration. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2016, , 1-19.	0.1	3
237	Simultaneous monitoring of oxidation, deamidation, isomerization, and glycosylation of monoclonal antibodies by liquid chromatography-mass spectrometry method with ultrafast tryptic digestion. <i>MAbs</i> , 2016, 8, 1477-1486.	2.6	72
238	Homing Improvement: Boosting T Cell Trafficking for Cancer Immunotherapy. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2016, , 127-161.	0.1	0
239	Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli. <i>Leukemia Research</i> , 2016, 50, 95-103.	0.4	20
240	Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non-Small Cell Lung Cancer: A Phase I Dose Escalation Study. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2208-2217.	0.5	66
241	Current clinical trials testing the combination of immunotherapy with radiotherapy. , 2016, 4, 51.		317
242	Rekindling cancer vaccines. <i>Nature Biotechnology</i> , 2016, 34, 1019-1024.	9.4	38
243	Genomic Approaches to Understanding Response and Resistance to Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 5642-5650.	3.2	134
244	Mathematical Models for Immunology: Current State of the Art and Future Research Directions. <i>Bulletin of Mathematical Biology</i> , 2016, 78, 2091-2134.	0.9	143
245	Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 4102-4109.	0.8	528
246	CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer. <i>British Journal of Cancer</i> , 2016, 115, 553-563.	2.9	214

#	ARTICLE	IF	CITATIONS
247	Systemic DC Activation Modulates the Tumor Microenvironment and Shapes the Long-Lived Tumor-Specific Memory Mediated by CD8+ T Cells. <i>Cancer Research</i> , 2016, 76, 3756-3766.	0.4	31
248	The untold story of IFN- γ in cancer biology. <i>Cytokine and Growth Factor Reviews</i> , 2016, 31, 73-81.	3.2	125
249	PD-L1 Detection in Tumors Using [⁶⁴ Cu]Atezolizumab with PET. <i>Bioconjugate Chemistry</i> , 2016, 27, 2103-2110.	1.8	128
250	The immune system and cancer evasion strategies: therapeutic concepts. <i>Journal of Internal Medicine</i> , 2016, 279, 541-562.	2.7	212
251	Metabolic Remodeling of Cellâ€™s Surface Sialic Acids: Principles, Applications, and Recent Advances. <i>ChemBioChem</i> , 2016, 17, 11-27.	1.3	100
252	Functional exhaustion of CD4 ⁺ T cells induced by coâ€™stimulatory signals from myeloid leukaemia cells. <i>Immunology</i> , 2016, 149, 460-471.	2.0	53
253	Employing dynamical computational models for personalizing cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1373-1385.	1.4	29
254	Defects in T Cell Trafficking and Resistance to Cancer Immunotherapy. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2016, , .	0.1	2
255	Clinician Perspectives on Current Issues in Lung Cancer Drug Development. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1387-1396.	0.5	6
257	Novel Approaches to Apoptosis-Inducing Therapies. <i>Advances in Experimental Medicine and Biology</i> , 2016, 930, 173-204.	0.8	17
258	Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients. <i>Investigational New Drugs</i> , 2016, 34, 760-770.	1.2	29
259	The evolution of high complexity companion testing for targeted and immuno-oncology. <i>Personalized Medicine</i> , 2016, 13, 409-414.	0.8	2
260	Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy. <i>Science Translational Medicine</i> , 2016, 8, 352ra110.	5.8	163
261	Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RActive ^Â CV9201 immunotherapy. <i>Oncolmmunology</i> , 2016, 5, e1249560.	2.1	18
262	Melanoma cell lysosome secretory burst neutralizes the CTL-mediated cytotoxicity at the lytic synapse. <i>Nature Communications</i> , 2016, 7, 10823.	5.8	54
263	Gastric cancer: current and evolving treatment landscape. <i>Chinese Journal of Cancer</i> , 2016, 35, 83.	4.9	47
264	Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities. <i>Clinical and Translational Science</i> , 2016, 9, 89-104.	1.5	144
265	Concepts and targets in triple-negative breast cancer: recent results and clinical implications. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 351-359.	1.4	24

#	ARTICLE	IF	CITATIONS
266	High throughput peptide mapping method for analysis of site specific monoclonal antibody oxidation. <i>Journal of Chromatography A</i> , 2016, 1460, 51-60.	1.8	20
267	Induction of anti-tumor CD8 T cell responses by experimental ECP-induced human dendritic antigen presenting cells. <i>Transfusion and Apheresis Science</i> , 2016, 55, 146-152.	0.5	11
268	Recent advances and future of immunotherapy for glioblastoma. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1245-1264.	1.4	57
269	Immunotherapy for oesophagogastric cancer. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1197-1207.	1.4	10
270	Management of side effects of immune checkpoint blockade by anti-CTLA4 and anti-PD1 antibodies in metastatic melanoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 662-681.	0.4	63
271	Nebenwirkungsmanagement bei Immun-Checkpoint-Blockade durch CTLA4- und PD1-Antikörper beim metastasierten Melanom. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 662-683.	0.4	47
272	Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes. <i>Science Immunology</i> , 2016, 1, .	5.6	169
273	Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel?. <i>ESMO Open</i> , 2016, 1, e000022.	2.0	15
274	Immunotherapie et cancer du sein. <i>Oncologie</i> , 2016, 18, 551-558.	0.2	2
275	Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. <i>Genome Biology</i> , 2016, 17, 231.	3.8	746
277	BTLA identifies dysfunctional PD-1-expressing CD4 ⁺ T cells in human hepatocellular carcinoma. <i>OncImmunology</i> , 2016, 5, e1254855.	2.1	36
278	Distinct immunological activation profiles of dSLIM [®] and ProMune [®] depend on their different structural context. <i>Immunity, Inflammation and Disease</i> , 2016, 4, 446-462.	1.3	10
279	Dendritic Cells and Cancer Immunity. <i>Trends in Immunology</i> , 2016, 37, 855-865.	2.9	624
281	PARP inhibitor combination therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 108, 73-85.	2.0	175
282	Antitumor Activity of cGAMP via Stimulation of cGAS-cGAMP-STING-IRF3 Mediated Innate Immune Response. <i>Scientific Reports</i> , 2016, 6, 19049.	1.6	179
283	Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?. <i>European Journal of Cancer</i> , 2016, 68, 134-147.	1.3	103
284	Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy. <i>Nature Communications</i> , 2016, 7, 13354.	5.8	224
285	Eph Receptor Tyrosine Kinases in Tumor Immunity. <i>Cancer Research</i> , 2016, 76, 6452-6457.	0.4	55

#	ARTICLE	IF	CITATIONS
286	Immunotherapy for Renal Cancer: Sequencing and Combinations. <i>European Urology Focus</i> , 2016, 2, 582-588.	1.6	5
287	Immunotherapy with radiotherapy in urological malignancies. <i>Current Opinion in Urology</i> , 2016, 26, 514-522.	0.9	5
288	Immunotherapy in kidney cancer. <i>Current Opinion in Urology</i> , 2016, 26, 543-547.	0.9	25
289	Progress in Cancer Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2016, , .	0.8	6
290	Harnessing the antitumor immunity cycle to treat lung cancer. <i>Current Pulmonology Reports</i> , 2016, 5, 40-48.	0.5	0
291	Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients. <i>Oncolimmunology</i> , 2016, 5, e1191732.	2.1	17
292	Outsourcing the immune response to cancer. <i>Science</i> , 2016, 352, 1275-1276.	6.0	4
293	Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC). <i>Medical Oncology</i> , 2016, 33, 80.	1.2	32
294	Dendritic cell vaccination in melanoma patients: From promising results to future perspectives. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2523-2528.	1.4	15
295	Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1819-1836.	0.5	31
296	Nivolumab and Pembrolizumab for Non-“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 3713-3717.	3.2	62
297	Genomic determinants of cancer immunotherapy. <i>Current Opinion in Immunology</i> , 2016, 41, 32-38.	2.4	27
299	Oncolytic Immunotherapy for Treatment of Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2016, 909, 241-283.	0.8	17
300	No evidence for TSLP pathway activity in human breast cancer. <i>Oncolimmunology</i> , 2016, 5, e1178438.	2.1	38
301	Targeting the Tumor Environment in Squamous Cell Carcinoma of the Head and Neck. <i>Current Treatment Options in Oncology</i> , 2016, 17, 37.	1.3	26
302	Immune Checkpoint inhibitors: An introduction to the next-generation cancer immunotherapy. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 157-169.	1.0	102
303	Novel technologies and emerging biomarkers for personalized cancer immunotherapy. , 2016, 4, 3.		183
304	Signaling by Extracellular Vesicles Advances Cancer Hallmarks. <i>Trends in Cancer</i> , 2016, 2, 84-94.	3.8	97

#	ARTICLE	IF	CITATIONS
305	Current status of immunotherapy. Japanese Journal of Clinical Oncology, 2016, 46, 191-203.	0.6	52
306	Targeting B-cell non Hodgkin lymphoma: New and old tricks. Leukemia Research, 2016, 42, 93-104.	0.4	51
307	Perspective on a Modified Developmental and Reproductive Toxicity Testing Strategy for Cancer Immunotherapy. International Journal of Toxicology, 2016, 35, 263-273.	0.6	8
308	Delivery of cancer therapeutics to extracellular and intracellular targets: Determinants, barriers, challenges and opportunities. Advanced Drug Delivery Reviews, 2016, 97, 280-301.	6.6	130
309	Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-“Small-Cell Lung Cancer. JAMA Oncology, 2016, 2, 46.	3.4	693
310	Myeloid-Derived Suppressor Cells: Possible Link Between Chronic Obstructive Pulmonary Disease and Lung Cancer. Archivos De Bronconeumologia, 2016, 52, 29-35.	0.4	2
311	Novel therapeutic targets in advanced urothelial carcinoma. Critical Reviews in Oncology/Hematology, 2016, 98, 106-115.	2.0	45
312	Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy. Clinical Cancer Research, 2016, 22, 4057-4066.	3.2	433
313	Scientific Advances in Lung Cancer 2015. Journal of Thoracic Oncology, 2016, 11, 613-638.	0.5	231
314	The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer. Advances in Immunology, 2016, 130, 25-74.	1.1	181
315	Beyond CTLA-4 and PD-1: Orphan nuclear receptor NR2F6 as T cell signaling switch and emerging target in cancer immunotherapy. Immunology Letters, 2016, 178, 31-36.	1.1	39
316	The role of tumor microenvironment in melanoma therapy resistance. Melanoma Management, 2016, 3, 23-32.	0.1	18
317	Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints. Targeted Oncology, 2016, 11, 469-477.	1.7	34
318	Biomaterials for enhancing anti-cancer immunity. Current Opinion in Biotechnology, 2016, 40, 1-8.	3.3	115
319	Multifunctional nanoparticles for cancer immunotherapy. Human Vaccines and Immunotherapeutics, 2016, 12, 1-13.	1.4	33
320	Analysis of circulating CD14+/CD16+ monocyte-derived macrophages (MDMs) in the peripheral blood of patients with oral squamous cell carcinoma. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2016, 121, 301-306.	0.2	14
321	Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas. Human Pathology, 2016, 52, 9-18.	1.1	80
322	Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?. Archives of Pathology and Laboratory Medicine, 2016, 140, 326-331.	1.2	118

#	ARTICLE	IF	CITATIONS
323	Regulation of prostate cancer progression by the tumor microenvironment. <i>Cancer Letters</i> , 2016, 380, 340-348.	3.2	166
324	Rarity of adenomatous polyps in ulcerative colitis and its implications for colonic carcinogenesis. <i>Endoscopy</i> , 2016, 48, 215-222.	1.0	12
325	Coinhibitory Pathways in Immunotherapy for Cancer. <i>Annual Review of Immunology</i> , 2016, 34, 539-573.	9.5	718
326	Analysis of monoclonal antibody oxidation by simple mixed mode chromatography. <i>Journal of Chromatography A</i> , 2016, 1431, 154-165.	1.8	28
327	MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade. <i>Immunity</i> , 2016, 44, 609-621.	6.6	566
328	The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 651-665.	0.5	211
329	Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. <i>Lancet</i> , The, 2016, 387, 1837-1846.	6.3	2,390
330	The Basis of Oncoimmunology. <i>Cell</i> , 2016, 164, 1233-1247.	13.5	671
331	Development of immuno-oncology drugs " from CTLA4 to PD1 to the next generations. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 235-247.	21.5	503
332	Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti-PD-1 Therapy. <i>Cancer Immunology Research</i> , 2016, 4, 474-480.	1.6	17
333	Long story short: p53 mediates innate immunity. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1865, 220-227.	3.3	39
334	<i>Fusobacterium nucleatum</i> , inflammation, and immunity: the fire within human gut. <i>Tumor Biology</i> , 2016, 37, 2805-2810.	0.8	101
335	Células mieloides supresoras: potencial vínculo entre la enfermedad pulmonar obstructiva crónica y el cáncer de pulmón. <i>Archivos De Bronconeumología</i> , 2016, 52, 29-35.	0.4	6
336	Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 833-842.	0.8	517
337	Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events. <i>Nature Immunology</i> , 2016, 17, 204-213.	7.0	148
338	Immune checkpoint blockade: Releasing the brake towards hematological malignancies. <i>Blood Reviews</i> , 2016, 30, 189-200.	2.8	34
339	Deletion of LRP5 and LRP6 in dendritic cells enhances antitumor immunity. <i>Oncolmmunology</i> , 2016, 5, e1115941.	2.1	72
340	Tumor antigens in human cancer control. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1865, 83-89.	3.3	18

#	ARTICLE	IF	CITATIONS
341	Synthetic Polymeric Nanoparticles for Immunomodulation. <i>Methods in Pharmacology and Toxicology</i> , 2016, , 413-438.	0.1	1
342	Hitchhiking nanoparticles: Reversible coupling of lipid-based nanoparticles to cytotoxic T lymphocytes. <i>Biomaterials</i> , 2016, 77, 243-254.	5.7	68
343	Beginning of a novel frontier: T-cell-directed immune manipulation in lymphomas. <i>Expert Review of Hematology</i> , 2016, 9, 123-135.	1.0	2
344	Immunophenotyping of patients with oral squamous cell carcinoma in peripheral blood and associated tumor tissue. <i>Tumor Biology</i> , 2016, 37, 3807-3816.	0.8	25
345	Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. <i>OncoImmunology</i> , 2016, 5, e1071008.	2.1	545
346	Advances in personalized cancer immunotherapy. <i>Breast Cancer</i> , 2017, 24, 16-24.	1.3	75
347	Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer. <i>Breast Cancer</i> , 2017, 24, 111-120.	1.3	21
348	Elements of cancer immunity and the cancer’s immune set point. <i>Nature</i> , 2017, 541, 321-330.	13.7	3,558
349	Systemic Immunity Is Required for Effective Cancer Immunotherapy. <i>Cell</i> , 2017, 168, 487-502.e15.	13.5	708
350	Strategies to design clinical studies to identify predictive biomarkers in cancer research. <i>Cancer Treatment Reviews</i> , 2017, 53, 79-97.	3.4	80
351	Renal complications of immune checkpoint blockade. <i>Current Problems in Cancer</i> , 2017, 41, 100-110.	1.0	81
353	Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells. <i>Immunology and Cell Biology</i> , 2017, 95, 347-355.	1.0	160
354	Noncoding <scp>RNA</scp>s and immune checkpoints’s clinical implications as cancer therapeutics. <i>FEBS Journal</i> , 2017, 284, 1952-1966.	2.2	99
355	Targeting the Lung Cancer Microenvironment: Harnessing Host Responses. , 2017, , 309-327.		1
356	Intrinsic Resistance of Solid Tumors to Immune Checkpoint Blockade Therapy. <i>Cancer Research</i> , 2017, 77, 817-822.	0.4	132
357	Is immunotherapy here to stay in multiple myeloma?. <i>Haematologica</i> , 2017, 102, 423-432.	1.7	42
358	MHC class II restricted neoantigen: A promising target in tumor immunotherapy. <i>Cancer Letters</i> , 2017, 392, 17-25.	3.2	67
359	An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 791-803.	0.5	127

#	ARTICLE	IF	CITATIONS
360	PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective. <i>Journal of Hematology and Oncology</i> , 2017, 10, 34.	6.9	82
362	Endoplasmic reticulum proteostasis: a key checkpoint in cancer. <i>American Journal of Physiology - Cell Physiology</i> , 2017, 312, C93-C102.	2.1	81
363	Immune Checkpoint Blockade Biology in Mouse Models of Glioblastoma. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 2516-2527.	1.2	15
364	ARID2 modulates DNA damage response in human hepatocellular carcinoma cells. <i>Journal of Hepatology</i> , 2017, 66, 942-951.	1.8	53
365	NLRC5/CITA: A Key Player in Cancer Immune Surveillance. <i>Trends in Cancer</i> , 2017, 3, 28-38.	3.8	59
366	CD40 Signaling Drives Potent Cellular Immune Responses in Heterologous Cancer Vaccinations. <i>Cancer Research</i> , 2017, 77, 1918-1926.	0.4	30
367	Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. <i>Science</i> , 2017, 355, 1423-1427.	6.0	753
368	T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. <i>Science</i> , 2017, 355, 1428-1433.	6.0	1,229
369	Nanomedicine approaches to improve cancer immunotherapy. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2017, 9, e1456.	3.3	39
370	Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 683-695.	2.0	53
371	Impact of PD-L1 Expression in Patients with Surgically Resected Non-Small-Cell Lung Cancer. <i>Oncology</i> , 2017, 92, 283-290.	0.9	36
372	A comprehensive review of immunotherapies in prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 292-303.	2.0	55
373	Oncolytic measles virus encoding interleukin-12 mediates potent antitumor effects through T cell activation. <i>Oncolmmunology</i> , 2017, 6, e1285992.	2.1	60
374	Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. <i>Oncolmmunology</i> , 2017, 6, e1253654.	2.1	146
375	Cancer-immune therapy: restoration of immune response in cancer by immune cell modulation. <i>Nucleus (India)</i> , 2017, 60, 93-109.	0.9	4
376	Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials. <i>Oncology</i> , 2017, 92, 50-62.	0.9	180
377	Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 634-645.	2.3	72
378	Unveil the mysterious mask of cytokine-based immunotherapy for melanoma. <i>Cancer Letters</i> , 2017, 394, 43-51.	3.2	9

#	ARTICLE	IF	CITATIONS
379	IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model. <i>Biochemical and Biophysical Research Communications</i> , 2017, 486, 239-244.	1.0	112
380	The cancer-immunity cycle as rational design for synthetic cancer drugs: Novel DC vaccines and CAR T-cells. <i>Seminars in Cancer Biology</i> , 2017, 45, 23-35.	4.3	32
381	Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation. <i>Seminars in Cancer Biology</i> , 2017, 43, 74-89.	4.3	414
382	The clinical evidence for targeting human myeloid-derived suppressor cells in cancer patients. <i>Journal of Leukocyte Biology</i> , 2017, 102, 381-391.	1.5	50
383	The expanding role of immunotherapy. <i>Cancer Treatment Reviews</i> , 2017, 54, 74-86.	3.4	100
384	Second- and third-generation drugs for immuno-oncology treatmentâ€”The more the better?. <i>European Journal of Cancer</i> , 2017, 74, 55-72.	1.3	204
385	Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 515-523.	1.4	60
386	Immune checkpoints and their inhibition in cancer and infectious diseases. <i>European Journal of Immunology</i> , 2017, 47, 765-779.	1.6	418
387	Coordinating antigen cytosolic delivery and danger signaling to program potent cross-priming by micelle-based nanovaccine. <i>Cell Discovery</i> , 2017, 3, 17007.	3.1	43
388	Pattern recognition receptors: immune targets to enhance cancer immunotherapy. <i>Annals of Oncology</i> , 2017, 28, 1756-1766.	0.6	123
389	Nanotechnology based therapeutic modality to boost anti-tumor immunity and collapse tumor defense. <i>Journal of Controlled Release</i> , 2017, 256, 26-45.	4.8	41
390	NY-ESO-1 Protein Cancer Vaccine With Poly-ICLC and OK-432: Rapid and Strong Induction of NY-ESO-1-specific Immune Responses by Poly-ICLC. <i>Journal of Immunotherapy</i> , 2017, 40, 140-147.	1.2	17
391	Applied Cancer Immunogenomics. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 125-130.	1.0	16
392	Clinical significance of T cell clonality and expression levels of immune-related genes in endometrial cancer. <i>Oncology Reports</i> , 2017, 37, 2603-2610.	1.2	38
393	Preparation and evaluation of L- and D-5-[18 F]fluorotryptophan as PET imaging probes for indoleamine and tryptophan 2,3-dioxygenases. <i>Nuclear Medicine and Biology</i> , 2017, 51, 10-17.	0.3	18
394	Functional analysis of rare variants in mismatch repair proteins augments results from computation-based predictive methods. <i>Cancer Biology and Therapy</i> , 2017, 18, 519-533.	1.5	21
395	Mechanisms of Immune Tolerance in Leukemia and Lymphoma. <i>Trends in Immunology</i> , 2017, 38, 513-525.	2.9	86
396	IDO, PTEN-expressing Tregs and control of antigen-presentation in the murine tumor microenvironment. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1049-1058.	2.0	32

#	ARTICLE	IF	CITATIONS
397	Exploiting scavenger receptors in cancer immunotherapy: Lessons from CD5 and SR β 1. <i>European Journal of Immunology</i> , 2017, 47, 1108-1118.	1.6	23
398	Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future. <i>Immunotherapy</i> , 2017, 9, 507-520.	1.0	12
399	In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	466
400	Checkpoint inhibitors in hematological malignancies. <i>Journal of Hematology and Oncology</i> , 2017, 10, 103.	6.9	106
401	Characterizing neoantigens for personalized cancer immunotherapy. <i>Current Opinion in Immunology</i> , 2017, 46, 58-65.	2.4	59
402	Immune Biomarkers on the Radar? Comprehensive Immunograms for Multimodal Treatment Prediction. <i>Journal of Thoracic Oncology</i> , 2017, 12, 770-772.	0.5	1
403	Landscape of Combination Immunotherapy and Targeted Therapy to Improve Cancer Management. <i>Cancer Research</i> , 2017, 77, 3666-3671.	0.4	93
404	PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 3158-3167.	3.2	426
405	Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. <i>European Journal of Cancer</i> , 2017, 81, 116-129.	1.3	443
406	Thermal Ablation of Lung Tumors: Focus on Microwave Ablation. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2017, 189, 828-843.	0.7	75
407	Therapeutic Vaccine of Gastric Cancer. , 2017, , 131-147.		0
408	Hallmarks of response to immune checkpoint blockade. <i>British Journal of Cancer</i> , 2017, 117, 1-7.	2.9	194
409	Delivering safer immunotherapies for cancer. <i>Advanced Drug Delivery Reviews</i> , 2017, 114, 79-101.	6.6	233
410	Thermal ablation and immunomodulation: From preclinical experiments to clinical trials. <i>Diagnostic and Interventional Imaging</i> , 2017, 98, 651-659.	1.8	74
411	Recent progress in immunotherapy for urological cancer. <i>International Journal of Urology</i> , 2017, 24, 735-742.	0.5	12
412	Dual Targeting Nanoparticle Stimulates the Immune System To Inhibit Tumor Growth. <i>ACS Nano</i> , 2017, 11, 5417-5429.	7.3	130
413	STING signaling in tumorigenesis and cancer therapy: A friend or foe?. <i>Cancer Letters</i> , 2017, 402, 203-212.	3.2	50
414	Metabolism shapes the tumor microenvironment. <i>Current Opinion in Cell Biology</i> , 2017, 48, 47-53.	2.6	210

#	ARTICLE	IF	CITATIONS
415	Chimeric PD-1:28 Receptor Upgrades Low-Avidity T cells and Restores Effector Function of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy. <i>Cancer Research</i> , 2017, 77, 3577-3590.	0.4	32
416	Wnt/beta-catenin pathway: modulating anticancer immune response. <i>Journal of Hematology and Oncology</i> , 2017, 10, 101.	6.9	448
417	Combining radiotherapy with immunotherapy: the past, the present and the future. <i>British Journal of Radiology</i> , 2017, 90, 20170157.	1.0	99
418	Commentary on Pharmacometrics for Immunotherapy. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 8-10.	1.3	4
419	Induction of cathepsin B by the CXCR3 chemokines CXCL9 and CXCL10 in human breast cancer cells. <i>Oncology Letters</i> , 2017, 13, 4224-4230.	0.8	31
420	Tackling non-muscle invasive bladder cancer in the clinic. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 467-480.	1.1	11
421	Immunotherapy for the treatment of Hodgkin lymphoma. <i>Expert Review of Hematology</i> , 2017, 10, 417-423.	1.0	12
422	Drug-biomarker co-development in oncology – 20 years and counting. <i>Drug Resistance Updates</i> , 2017, 30, 48-62.	6.5	48
423	A Novel Numerical Scoring System for Melanoma Tumor-infiltrating Lymphocytes Has Better Prognostic Value Than Standard Scoring. <i>American Journal of Surgical Pathology</i> , 2017, 41, 906-914.	2.1	53
424	Cell of Origin Links Histotype Spectrum to Immune Microenvironment Diversity in Non-small-Cell Lung Cancer Driven by Mutant Kras and Loss of Lkb1. <i>Cell Reports</i> , 2017, 18, 673-684.	2.9	47
425	Immunotherapy in NSCLC: A Promising and Revolutionary Weapon. <i>Advances in Experimental Medicine and Biology</i> , 2017, 995, 97-125.	0.8	99
426	Prospects for combining targeted and conventional cancer therapy with immunotherapy. <i>Nature Reviews Cancer</i> , 2017, 17, 286-301.	12.8	742
427	Prospects and progress of atezolizumab in non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 781-789.	1.4	13
428	Myeloid-derived suppressor cells and T regulatory cells in tumors: unraveling the dark side of the force. <i>Journal of Leukocyte Biology</i> , 2017, 102, 407-421.	1.5	32
429	Advances in urothelial bladder cancer immunotherapy, dawn of a new age of treatment. <i>Immunotherapy</i> , 2017, 9, 451-460.	1.0	12
430	PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. <i>Journal of Experimental Medicine</i> , 2017, 214, 895-904.	4.2	614
432	MHC-I Ligand Discovery Using Targeted Database Searches of Mass Spectrometry Data: Implications for T-Cell Immunotherapies. <i>Journal of Proteome Research</i> , 2017, 16, 1806-1816.	1.8	65
433	The network of immunosuppressive pathways in glioblastoma. <i>Biochemical Pharmacology</i> , 2017, 130, 1-9.	2.0	76

#	ARTICLE	IF	CITATIONS
434	Lysozyme association with circulating RNA, extracellular vesicles, and chronic stress. <i>BBA Clinical</i> , 2017, 7, 23-35.	4.1	22
435	Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients. <i>Leukemia</i> , 2017, 31, 988-991.	3.3	41
436	Biomimetic biodegradable artificial antigen presenting cells synergize with PD-1 blockade to treat melanoma. <i>Biomaterials</i> , 2017, 118, 16-26.	5.7	91
437	Building proteomic tool boxes to monitor MHC class I and class II peptides. <i>Proteomics</i> , 2017, 17, 1600061.	1.3	29
438	Critical Issues in Head and Neck Oncology. , 2017, , .		0
439	Ex Vivo Engineering of the Tumor Microenvironment. <i>Cancer Drug Discovery and Development</i> , 2017, , .	0.2	4
440	Microfluidics and Future of Cancer Diagnostics. <i>Cancer Drug Discovery and Development</i> , 2017, , 55-70.	0.2	1
441	Signaling and Immune Regulation in Melanoma Development and Responses to Therapy. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2017, 12, 75-102.	9.6	30
442	Pharmacokinetic drug evaluation of atezolizumab for the treatment of locally advanced or metastatic urothelial carcinoma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 225-232.	1.5	20
443	Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update. <i>Liver Cancer</i> , 2017, 6, 1-12.	4.2	60
444	Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Metastatic Urothelial Carcinoma. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 305-312.	2.3	110
445	Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 1-15.	3.3	215
446	Identifying and Creating the Next Generation of Community-Based Cancer Prevention Studies: Summary of a National Cancer Institute Think Tank. <i>Cancer Prevention Research</i> , 2017, 10, 99-107.	0.7	11
447	Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. <i>Lancet, The</i> , 2017, 389, 255-265.	6.3	3,872
448	Emerging biomarkers for PD-1 pathway cancer therapy. <i>Biomarkers in Medicine</i> , 2017, 11, 53-67.	0.6	11
449	CIITA-driven MHC class II expressing tumor cells can efficiently prime naive CD4 ⁺ TH cells <i>in vivo</i> and vaccinate the host against parental MHC-II-negative tumor cells. <i>OncImmunology</i> , 2017, 6, e1261777.	2.1	29
450	Intratumoural PD-L1 expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer. <i>British Journal of Cancer</i> , 2017, 117, 1753-1760.	2.9	40
451	Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells. <i>Seminars in Immunology</i> , 2017, 34, 114-122.	2.7	29

#	ARTICLE	IF	CITATIONS
452	Toward Personalized Peptide-Based Cancer Nanovaccines: A Facile and Versatile Synthetic Approach. <i>Bioconjugate Chemistry</i> , 2017, 28, 2756-2771.	1.8	36
453	Biologically Inspired Design of Nanoparticle Artificial Antigen-Presenting Cells for Immunomodulation. <i>Nano Letters</i> , 2017, 17, 7045-7054.	4.5	116
454	A nonimmune function of T cells in promoting lung tumor progression. <i>Journal of Experimental Medicine</i> , 2017, 214, 3565-3575.	4.2	33
455	Complexity of the genomic landscape of renal cell carcinoma: Implications for targeted therapy and precision immuno-oncology. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 119, 23-28.	2.0	17
456	Epigenetic Therapeutics and Their Impact in Immunotherapy of Lung Cancer. <i>Current Pharmacology Reports</i> , 2017, 3, 360-373.	1.5	10
457	Mechanisms regulating T-cell infiltration and activity in solid tumors. <i>Annals of Oncology</i> , 2017, 28, xii18-xii32.	0.6	276
458	Targeting immunosuppressive adenosine in cancer. <i>Nature Reviews Cancer</i> , 2017, 17, 709-724.	12.8	526
459	Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study. <i>Annals of Oncology</i> , 2017, 28, 3044-3050.	0.6	198
460	Prospects and progress of immunotherapy for bladder cancer. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1-15.	1.4	29
461	Enlighting the Shadow for Advanced Hepatocellular Carcinoma: Immunotherapy with Immune Checkpoint Inhibitors. <i>Journal of Gastrointestinal Cancer</i> , 2017, 48, 288-290.	0.6	1
462	Probiotic species in the modulation of the anticancer immune response. <i>Seminars in Cancer Biology</i> , 2017, 46, 182-190.	4.3	47
463	Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors). <i>European Journal of Cancer</i> , 2017, 84, 202-211.	1.3	29
464	Co-delivery of the NKT agonist α -galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses. <i>Oncolmmunology</i> , 2017, 6, e1339855.	2.1	45
465	Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1997-2003.	1.4	8
466	CTLA-4/CD80 pathway regulates T cell infiltration into pancreatic cancer. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1609-1617.	2.0	76
467	Molecular-Targeted Immunotherapeutic Strategy for Melanoma <i>via</i> Dual-Targeting Nanoparticles Delivering Small Interfering RNA to Tumor-Associated Macrophages. <i>ACS Nano</i> , 2017, 11, 9536-9549.	7.3	268
468	Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications. <i>Oncolmmunology</i> , 2017, 6, e1371896.	2.1	36
469	Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors. <i>Journal of Clinical Pharmacology</i> , 2017, 57, S26-S42.	1.0	91

#	ARTICLE	IF	CITATIONS
470	Nanomaterials for cancer immunotherapy. <i>Biomaterials</i> , 2017, 148, 16-30.	5.7	226
471	Anti-CD137 Suppresses Tumor Growth by Blocking Reverse Signaling by CD137 Ligand. <i>Cancer Research</i> , 2017, 77, 5989-6000.	0.4	41
472	Roles for Innate Immunity in Combination Immunotherapies. <i>Cancer Research</i> , 2017, 77, 5215-5221.	0.4	81
474	MEK inhibition and immune responses in advanced melanoma. <i>Oncolmmunology</i> , 2017, 6, e1335843.	2.1	15
475	Tim-3, Lag-3, and TIGIT. <i>Current Topics in Microbiology and Immunology</i> , 2017, 410, 127-156.	0.7	109
476	Inhibiting Metastasis and Preventing Tumor Relapse by Triggering Host Immunity with Tumor-Targeted Photodynamic Therapy Using Photosensitizer-Loaded Functional Nanographenes. <i>ACS Nano</i> , 2017, 11, 10147-10158.	7.3	164
477	Discovery and application of immune biomarkers for hematological malignancies. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 983-1000.	1.5	6
478	Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer. <i>Medical Molecular Morphology</i> , 2017, 50, 185-194.	0.4	31
479	Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2017, 32, .	0.3	15
480	Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma. <i>Oncolmmunology</i> , 2017, 6, e1338237.	2.1	47
481	Contrasting effects of cyclophosphamide on anti-CTLA-4 associated protein 4 blockade therapy in two mouse tumor models. <i>Cancer Science</i> , 2017, 108, 1974-1984.	1.7	35
482	Program death-1 immune checkpoint and tumor microenvironment in malignant liver tumors. <i>Surgical Oncology</i> , 2017, 26, 423-430.	0.8	20
483	Tumor Dormancy and Recurrence. <i>Cancer Drug Discovery and Development</i> , 2017, , .	0.2	2
484	The Inhibitory Signaling Receptor Protocadherin-18 Regulates Tumor-Infiltrating CD8+ T-cell Function. <i>Cancer Immunology Research</i> , 2017, 5, 920-928.	1.6	3
485	Atezolizumab for the treatment of non-small cell lung cancer. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 935-945.	1.3	34
486	Cancer Immunotherapy in Older Patients. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 219-222.	1.0	18
487	Is It Better to Use Ipilimumab Combined With a PD-1 Inhibitor or a PD-1 Inhibitor Alone as Initial Immunotherapy in Patients With Metastatic Melanoma?. <i>Clinical Skin Cancer</i> , 2017, 2, 10-17.	0.1	1
488	Secreted Tumor Antigens as Immune Biomarkers for Diagnosis and Therapy. <i>Proteomics</i> , 2017, 17, 1600442.	1.3	27

#	ARTICLE	IF	CITATIONS
489	Progress in research on the effects of traditional Chinese medicine on the tumor microenvironment. <i>Journal of Integrative Medicine</i> , 2017, 15, 282-287.	1.4	32
490	Nivolumab and ipilimumab in the treatment of metastatic renal cell carcinoma. Report of two patients. <i>Medicina Universitaria</i> , 2017, 19, 22-26.	0.1	2
491	Emerging Role of the Unfolded Protein Response in Tumor Immunosurveillance. <i>Trends in Cancer</i> , 2017, 3, 491-505.	3.8	32
492	Evasion of immunosurveillance by genomic alterations of PPAR β /RXR α in bladder cancer. <i>Nature Communications</i> , 2017, 8, 103.	5.8	107
493	Heterogeneity of tumor-infiltrating lymphocytes ascribed to local immune status rather than neoantigens by multi-omics analysis of glioblastoma multiforme. <i>Scientific Reports</i> , 2017, 7, 6968.	1.6	26
494	Blockage of Core Fucosylation Reduces Cell-Surface Expression of PD-1 and Promotes Anti-tumor Immune Responses of T Cells. <i>Cell Reports</i> , 2017, 20, 1017-1028.	2.9	156
495	Checkpoint inhibitors in the treatment of urological malignancies. <i>ESMO Open</i> , 2017, 2, e000165.	2.0	21
496	Nrf2 suppresses the function of dendritic cells to facilitate the immune escape of glioma cells. <i>Experimental Cell Research</i> , 2017, 360, 66-73.	1.2	47
497	Anti PD-L1 combined with other agents in non-small cell lung cancer: combinations with non-immuno-oncology agents. <i>Expert Review of Respiratory Medicine</i> , 2017, 11, 791-805.	1.0	4
498	Direct Loading of iTEP-Delivered CTL Epitope onto MHC Class I Complexes on the Dendritic Cell Surface. <i>Molecular Pharmaceutics</i> , 2017, 14, 3312-3321.	2.3	7
499	Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics. <i>Future Oncology</i> , 2017, 13, 1649-1663.	1.1	10
500	Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. <i>Annals of Oncology</i> , 2017, 28, 2377-2385.	0.6	631
502	Checkpoint inhibition in pediatric hematologic malignancies. <i>Pediatric Hematology and Oncology</i> , 2017, 34, 379-394.	0.3	23
503	Recent advances in cancer immunology and immunology-based anticancer therapies. <i>Biomedicine and Pharmacotherapy</i> , 2017, 96, 1491-1500.	2.5	17
504	Modulation of immunosurveillance by tumor-intrinsic genomic alterations. <i>Immunotherapy</i> , 2017, 9, 1305-1307.	1.0	0
506	Emerging Concepts Targeting Immune Checkpoints in Cancer and Autoimmunity. <i>Current Topics in Microbiology and Immunology</i> , 2017, , .	0.7	1
507	Cancer Biology of Molecular Imaging. , 2017, , 3-34.		0
508	T cell receptor sequencing of early-stage breast cancer tumors identifies altered clonal structure of the T cell repertoire. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E10409-E10417.	3.3	53

#	ARTICLE	IF	CITATIONS
509	Conventional CD4+ T cells present bacterial antigens to induce cytotoxic and memory CD8+ T cell responses. <i>Nature Communications</i> , 2017, 8, 1591.	5.8	26
510	CD4+ T Cell Help Confers a Cytotoxic T Cell Effector Program Including Coinhibitory Receptor Downregulation and Increased Tissue Invasiveness. <i>Immunity</i> , 2017, 47, 848-861.e5.	6.6	292
511	Cardiotoxicity of immune checkpoint inhibitors. <i>ESMO Open</i> , 2017, 2, e000247.	2.0	186
512	Polyfunctional response by Imm<scp>TAC</scp> (<scp>IMC</scp>gp100) redirected <scp>CD</scp>8⁺ and <scp>CD</scp>4⁺ T cells. <i>Immunology</i> , 2017, 152, 425-438.	2.0	53
513	Breast cancer liver metastases in a UK tertiary centre: Outcomes following referral to tumour board meeting. <i>International Journal of Surgery</i> , 2017, 44, 152-159.	1.1	16
514	Immune checkpoint inhibitors and elderly people: A review. <i>European Journal of Cancer</i> , 2017, 82, 155-166.	1.3	148
515	Tethered-variable CL bispecific IgG: an antibody platform for rapid bispecific antibody screening. <i>Protein Engineering, Design and Selection</i> , 2017, 30, 627-637.	1.0	8
516	PD-1/PD-L1 as a prognostic factor in leukemia. <i>Journal of Hematopathology</i> , 2017, 10, 17-24.	0.2	17
517	Local Delivery of OncoVEXmGM-CSF Generates Systemic Antitumor Immune Responses Enhanced by Cytotoxic T-Lymphocyte-Associated Protein Blockade. <i>Clinical Cancer Research</i> , 2017, 23, 6190-6202.	3.2	82
518	Oncolytic viruses: adenoviruses. <i>Virus Genes</i> , 2017, 53, 700-706.	0.7	74
519	Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity. <i>Cancer Immunology Research</i> , 2017, 5, 685-694.	1.6	37
520	Immunotherapy-based combinations: current status and perspectives. <i>Current Opinion in Oncology</i> , 2017, 29, 382-394.	1.1	7
521	New B7 Family Checkpoints in Human Cancers. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1203-1211.	1.9	181
522	Biomarkers of response to PD-1/PD-L1 inhibition. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 116, 116-124.	2.0	249
523	Constitutive and acquired mechanisms of resistance to immune checkpoint blockade in human cancer. <i>Cytokine and Growth Factor Reviews</i> , 2017, 36, 17-24.	3.2	23
524	Probiotics-mediated suppression of cancer. <i>Current Opinion in Oncology</i> , 2017, 29, 62-72.	1.1	69
525	Addressing current challenges in cancer immunotherapy with mathematical and computational modelling. <i>Journal of the Royal Society Interface</i> , 2017, 14, 20170150.	1.5	71
526	The era of bioengineering: how will this affect the next generation of cancer immunotherapy?. <i>Journal of Translational Medicine</i> , 2017, 15, 142.	1.8	16

#	ARTICLE	IF	CITATIONS
527	Immunotherapy biomarkers 2016: overcoming the barriers. , 2017, 5, 29.		21
528	Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?. Targeted Oncology, 2017, 12, 413-447.	1.7	19
529	Inflammatory cell infiltrates in advanced metastatic uveal melanoma. Human Pathology, 2017, 66, 159-166.	1.1	55
530	Immune Checkpoint Inhibitors in Lung Cancer: Imaging Considerations. American Journal of Roentgenology, 2017, 209, 567-575.	1.0	26
531	The Evolution of Oncology Companion Diagnostics from Signal Transduction to Immuno-Oncology. Trends in Pharmacological Sciences, 2017, 38, 41-54.	4.0	21
532	TIGIT: A Key Inhibitor of the Cancer Immunity Cycle. Trends in Immunology, 2017, 38, 20-28.	2.9	310
533	TIGIT, A Novel Therapeutic Target for Tumor Immunotherapy. Immunological Investigations, 2017, 46, 172-182.	1.0	40
534	Optogenetic Immunomodulation: Shedding Light on Antitumor Immunity. Trends in Biotechnology, 2017, 35, 215-226.	4.9	77
535	Personalized cancer vaccines: Targeting the cancer mutanome. Vaccine, 2017, 35, 1094-1100.	1.7	63
536	Potential applications of nanoparticles in cancer immunotherapy. Human Vaccines and Immunotherapeutics, 2017, 13, 63-74.	1.4	35
537	Antitumor immunity and advances in cancer immunotherapy. Breast Cancer, 2017, 24, 1-2.	1.3	10
538	The role of immunonutritional support in cancer treatment: Current Evidence. Clinical Nutrition, 2017, 36, 1457-1464.	2.3	50
539	Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment. Journal of the National Cancer Institute, 2017, 109, .	3.0	139
541	Immuno-Oncology in Hepatocellular Carcinoma: 2017 Update. Oncology, 2017, 93, 147-159.	0.9	83
543	Informatics for cancer immunotherapy. Annals of Oncology, 2017, 28, xii56-xii73.	0.6	19
544	New insight into cancer immunotherapy. Allergologia Et Immunopathologia, 2017, 45, 50-55.	1.0	3
545	An update on the relevance of vaccine research for the treatment of metastatic melanoma. Melanoma Management, 2017, 4, 203-215.	0.1	8
546	Precision Medicine in Oncology and Immuno-Oncology: Where We Stand and Where We're Headed. Biomedicine Hub, 2017, 2, 1-8.	0.4	1

#	ARTICLE	IF	CITATIONS
548	The immune system in cancer metastasis: friend or foe?. , 2017, 5, 79.		193
551	Intratumoral depletion of regulatory T cells using CD25-targeted photodynamic therapy in a mouse melanoma model induces antitumoral immune responses. <i>Oncotarget</i> , 2017, 8, 47440-47453.	0.8	28
553	Deploying Immunotherapy in Pancreatic Cancer: Defining Mechanisms of Response and Resistance. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 267-278.	1.8	38
554	Cancer Immunotherapy in Older Patients. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 219-222.	1.0	4
555	How cancer immunotherapy works. , 2017, , .		0
556	Inferring the Impact of Regulatory Mechanisms that Underpin CD8+ T Cell Control of B16 Tumor Growth In vivo Using Mechanistic Models and Simulation. <i>Frontiers in Pharmacology</i> , 2017, 7, 515.	1.6	3
557	Understanding the role of PD-L1/PD1 pathway blockade and autophagy in cancer therapy. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1803-1807.	1.0	66
558	Phase II Trial of Adjuvant Immunotherapy with Autologous Tumor-derived Gp96 Vaccination in Patients with Gastric Cancer. <i>Journal of Cancer</i> , 2017, 8, 1826-1832.	1.2	24
559	Cancer Biology and the Principles of Targeted Cancer Drug Discovery. , 2017, , 1-38.		1
560	Head and neck cancer: improving outcomes with a multidisciplinary approach. <i>Cancer Management and Research</i> , 2017, Volume 9, 363-371.	0.9	150
561	PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence. <i>Gastrointestinal Cancer: Targets and Therapy</i> , 2017, Volume 7, 1-11.	5.5	49
562	Altered Leukocyte Sphingolipid Pathway in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2521.	1.8	6
563	Metabolomics of Therapy Response in Preclinical Glioblastoma: A Multi-Slice MRSI-Based Volumetric Analysis for Noninvasive Assessment of Temozolomide Treatment. <i>Metabolites</i> , 2017, 7, 20.	1.3	19
564	Novel immunotherapy in metastatic renal cell carcinoma. <i>Investigative and Clinical Urology</i> , 2017, 58, 220.	1.0	16
565	The Role of Regulatory T Cells and Indoleamine-2,3-dioxygenase in Brain Tumor Immunosuppression. , 2017, , 33-61.		3
566	Tumor abolition and antitumor immunostimulation by physico-chemical tumor nbsp ablation. <i>Frontiers in Bioscience - Landmark</i> , 2017, 22, 310-347.	3.0	38
567	Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Donâ€™t Forget the Fuel. <i>Frontiers in Immunology</i> , 2017, 8, 267.	2.2	61
568	Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2017, 8, 774.	2.2	102

#	ARTICLE	IF	CITATIONS
569	Enhancement of Adjuvant Functions of Natural Killer T Cells Using Nanovector Delivery Systems: Application in Anticancer Immune Therapy. <i>Frontiers in Immunology</i> , 2017, 8, 879.	2.2	17
570	Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma. <i>Frontiers in Immunology</i> , 2017, 8, 1617.	2.2	43
571	Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy. <i>Frontiers in Immunology</i> , 2017, 8, 1679.	2.2	171
572	Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 67.	1.3	28
573	Does Regular Exercise Counter T Cell Immunosenescence Reducing the Risk of Developing Cancer and Promoting Successful Treatment of Malignancies?. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-18.	1.9	47
574	Desired Turbulence? Gut-Lung Axis, Immunity, and Lung Cancer. <i>Journal of Oncology</i> , 2017, 2017, 1-15.	0.6	171
576	Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1487-1502.	1.0	12
577	Prognostic value of <i>KRAS</i> mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review. <i>Oncotarget</i> , 2017, 8, 48248-48252.	0.8	97
578	Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes. <i>PLoS ONE</i> , 2017, 12, e0177810.	1.1	23
579	PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2017, 12, e0182692.	1.1	200
580	Targeting CD47 Enhances the Efficacy of Anti-PD-1 and CTLA-4 in an Esophageal Squamous Cell Cancer Preclinical Model. <i>Oncology Research</i> , 2017, 25, 1579-1587.	0.6	45
581	Highlights of the 31st annual meeting of the Society for Immunotherapy of Cancer (SITC), 2016. , 2017, 5, 55.		5
582	Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC. , 2017, 5, 70.		45
584	The immunomodulatory activities of licorice polysaccharides (<i>Glycyrrhiza uralensis</i> Fisch.) in CT 26 tumor-bearing mice. <i>BMC Complementary and Alternative Medicine</i> , 2017, 17, 536.	3.7	90
585	The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?. <i>Cancer Biology and Medicine</i> , 2017, 14, 341.	1.4	4
586	Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy. <i>Oncotarget</i> , 2017, 8, 71249-71284.	0.8	138
587	IFN- γ -related mRNA profile predicts clinical response to PD-1 blockade. <i>Journal of Clinical Investigation</i> , 2017, 127, 2930-2940.	3.9	2,560
588	Immune checkpoint inhibitors: An innovation in immunotherapy for the treatment and management of patients with cancer. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2017, 4, 127-135.	0.7	156

#	ARTICLE	IF	CITATIONS
589	Impact of cavitron ultrasonic surgical aspirator (CUSA) and bipolar radiofrequency device (Habib-4X) based hepatectomy for hepatocellular carcinoma on tumour recurrence and disease-free survival. <i>Oncotarget</i> , 2017, 8, 93644-93654.	0.8	16
590	Novel role of granulocyte-macrophage colony-stimulating factor: antitumor effects through inhibition of epithelial-to-mesenchymal transition in esophageal cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2227-2237.	1.0	3
591	Immune checkpoints, their control by immunotherapy and ovarian cancer. <i>Wspolczesna Onkologia</i> , 2017, 3, 189-196.	0.7	2
592	Autophagic Mechanism in Anti-Cancer Immunity: Its Pros and Cons for Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1297.	1.8	27
593	Investigation of the Effect of Adding Stem Cells-as an Therapeutic Suggestion-on the Immune System's Response to the Cancerous Cells: A Mathematical Approach. , 2017, , .		0
594	Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors. <i>Oncotarget</i> , 2017, 8, 41641-41669.	0.8	15
595	Immunotherapy in Gynecologic Cancers. , 2017, , .		0
596	Functio Laesa: Cancer Inflammation and Therapeutic Resistance. <i>Journal of Oncology Practice</i> , 2017, 13, 173-180.	2.5	15
597	Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1â€“Selected Advanced Nonâ€“Small-Cell Lung Cancer (BIRCH). <i>Journal of Clinical Oncology</i> , 2017, 35, 2781-2789.	0.8	348
598	Evolving Treatment of Advanced Urothelial Cancer. <i>Journal of Oncology Practice</i> , 2017, 13, 309-315.	2.5	18
599	Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma. <i>Oncotarget</i> , 2017, 8, 75675-75686.	0.8	42
600	Avelumab, an Antiâ€“Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 2117-2124.	0.8	538
601	Immune system and melanoma biology: a balance between immunosurveillance and immune escape. <i>Oncotarget</i> , 2017, 8, 106132-106142.	0.8	174
602	Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology. <i>Translational Lung Cancer Research</i> , 2017, 6, 373-386.	1.3	45
603	Oncogenic pathways as the basis of primary immune ignorance. <i>Emerging Topics in Life Sciences</i> , 2017, 1, 421-428.	1.1	0
604	Quiescent Tissue Stem Cells Evade Immune Surveillance. <i>Immunity</i> , 2018, 48, 271-285.e5.	6.6	170
605	Tumor-infiltrating lymphocytes and ductal carcinoma in situ of the breast: friends or foes?. <i>Modern Pathology</i> , 2018, 31, 1012-1025.	2.9	25
606	Advances of Immune Checkpoint Inhibitors in Tumor Immunotherapy. <i>IOP Conference Series: Materials Science and Engineering</i> , 2018, 301, 012020.	0.3	3

#	ARTICLE	IF	CITATIONS
607	Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States. <i>European Urology</i> , 2018, 73, 800-806.	0.9	26
608	Association of anti-HER2 antibody with graphene oxide for curative treatment of osteosarcoma. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2018, 14, 581-593.	1.7	22
609	Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 325-340.	12.5	1,192
610	Rational combinations of in vivo cancer antigen priming and adoptive T-cell therapy mobilize immune and clinical responses in terminal cancers. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 907-915.	2.0	1
611	Atezolizumab for the treatment of colorectal cancer: <i>the latest evidence and clinical potential</i>. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 449-457.	1.4	25
612	Engineering chimeric antigen receptor-T cells for cancer treatment. <i>Molecular Cancer</i> , 2018, 17, 32.	7.9	57
613	Immunotherapy for thoracic oncology gone viral. <i>Immunotherapy</i> , 2018, 10, 383-390.	1.0	1
614	Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach. <i>Clinical Medicine Insights: Oncology</i> , 2018, 12, 117955491875907.	0.6	4
615	A dual-function epidermal growth factor receptor pathway substrate 8 (Eps8)-derived peptide exhibits a potent cytotoxic T lymphocyte-activating effect and a specific inhibitory activity. <i>Cell Death and Disease</i> , 2018, 9, 379.	2.7	15
616	Combination nivolumab with transcatheter arterial chemoembolization for clinical remission of small cell lung cancer: A case report. <i>Thoracic Cancer</i> , 2018, 9, 646-651.	0.8	4
617	Novel therapies for malignant pleural mesothelioma. <i>Lancet Oncology</i> , The, 2018, 19, e161-e172.	5.1	121
618	Antitumor activity and carrier properties of novel hemocyanins coupled to a mimotope of GD2 ganglioside. <i>European Journal of Medicinal Chemistry</i> , 2018, 150, 74-86.	2.6	11
619	A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Nonâ€“Small Cell Lung Cancer Based on Early Tumor Kinetics. <i>Clinical Cancer Research</i> , 2018, 24, 3292-3298.	3.2	41
620	Oncolytic viruses as engineering platforms for combination immunotherapy. <i>Nature Reviews Cancer</i> , 2018, 18, 419-432.	12.8	288
621	In Vivo Antitumor Effects of MK615 Led by PD-L1 Downregulation. <i>Integrative Cancer Therapies</i> , 2018, 17, 646-653.	0.8	12
622	Targeting Wnt/ β -Catenin Signaling for Cancer Immunotherapy. <i>Trends in Pharmacological Sciences</i> , 2018, 39, 648-658.	4.0	159
623	<sc>CD</sc>169â€“positive sinus macrophages in the lymph nodes determine bladder cancer prognosis. <i>Cancer Science</i> , 2018, 109, 1723-1730.	1.7	48
624	Combinational strategy for high-performance cancer chemotherapy. <i>Biomaterials</i> , 2018, 171, 178-197.	5.7	181

#	ARTICLE	IF	CITATIONS
625	Circulating histocompatibility antigen (HLA) gene products may help differentiate benign from malignant indeterminate pulmonary lesions. <i>Human Immunology</i> , 2018, 79, 558-563.	1.2	2
626	Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade. <i>Nature Communications</i> , 2018, 9, 1538.	5.8	49
627	Long noncoding RNAs in cancer's immunity cycle. <i>Journal of Cellular Physiology</i> , 2018, 233, 6518-6523.	2.0	119
628	Programmed death-ligand 1 (PD-L1) expression in pleomorphic carcinoma of the lung. <i>Journal of Surgical Oncology</i> , 2018, 117, 1563-1569.	0.8	18
629	Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. <i>Cell</i> , 2018, 173, 338-354.e15.	13.5	1,417
630	Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. <i>Cell Metabolism</i> , 2018, 27, 977-987.e4.	7.2	398
631	Immune Evasion in Tumor's Own Sweet Way. <i>Cell Metabolism</i> , 2018, 27, 945-946.	7.2	12
632	Placenta immune infiltrates and perinatal outcomes. <i>American Journal of Reproductive Immunology</i> , 2018, 79, e12850.	1.2	6
633	Obstacles to improving outcomes in the treatment of uveal melanoma. <i>Cancer</i> , 2018, 124, 2693-2703.	2.0	15
634	Combining top-ranked immunotherapeutics in lung cancer. <i>Lancet Oncology</i> , The, 2018, 19, 592-594.	5.1	0
635	T Cell Dysfunction in Cancer. <i>Cancer Cell</i> , 2018, 33, 547-562.	7.7	787
636	The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy. <i>Cancer Cell</i> , 2018, 33, 570-580.	7.7	911
637	Rational design and identification of immuno-oncology drug combinations. <i>European Journal of Cancer</i> , 2018, 95, 38-51.	1.3	9
638	Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	326
640	PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue – prognostic implications and rationale for immunotherapy. <i>Oncol Immunology</i> , 2018, 7, e1389366.	2.1	72
641	The mechanism of tumour cell death by metal-based anticancer drugs is not only a matter of DNA interactions. <i>Coordination Chemistry Reviews</i> , 2018, 360, 17-33.	9.5	94
642	A Cisplatin-Loaded Immunochemotherapeutic Nanohybrid Bearing Immune Checkpoint Inhibitors for Enhanced Cervical Cancer Therapy. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 3426-3430.	7.2	97
643	Application of nanomaterials in cancer immunotherapy. <i>Materials Today Chemistry</i> , 2018, 7, 53-64.	1.7	64

#	ARTICLE	IF	CITATIONS
644	The tumour glyco-code as a novel immune checkpoint for immunotherapy. <i>Nature Reviews Immunology</i> , 2018, 18, 204-211.	10.6	303
645	CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions. <i>Annual Review of Medicine</i> , 2018, 69, 301-318.	5.0	432
647	Immuno-oncology-101: overview of major concepts and translational perspectives. <i>Seminars in Cancer Biology</i> , 2018, 52, 1-11.	4.3	39
648	TGF β 2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. <i>Nature</i> , 2018, 554, 544-548.	13.7	3,359
649	Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 310-324.	12.5	412
650	Activation of p53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6c+CD103+ Monocytic Antigen-Presenting Cells in Tumors. <i>Immunity</i> , 2018, 48, 91-106.e6.	6.6	95
651	Optimizing Breast Cancer Management. <i>Cancer Treatment and Research</i> , 2018, , .	0.2	2
652	From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?. <i>Current Oncology Reports</i> , 2018, 20, 8.	1.8	20
653	Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer. <i>JAMA Oncology</i> , 2018, 4, 537.	3.4	104
654	Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here. <i>Cancer</i> , 2018, 124, 2086-2103.	2.0	141
655	Enhanced Immunotherapy Based on Photodynamic Therapy for Both Primary and Lung Metastasis Tumor Eradication. <i>ACS Nano</i> , 2018, 12, 1978-1989.	7.3	250
656	PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer. <i>Oncolmmunology</i> , 2018, 7, e1433981.	2.1	167
657	Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 713-727.	2.0	68
658	Cancer Immunotherapy: Factors Important for the Evaluation of Safety in Nonclinical Studies. <i>AAPS Journal</i> , 2018, 20, 28.	2.2	13
659	DKK2 imparts tumor immunity evasion through β -catenin-independent suppression of cytotoxic immune-cell activation. <i>Nature Medicine</i> , 2018, 24, 262-270.	15.2	106
663	Immune Checkpoint Blockade for Breast Cancer. <i>Cancer Treatment and Research</i> , 2018, 173, 155-165.	0.2	69
664	Challenges and Perspectives for Immunotherapy in Adenocarcinoma of the Pancreas. <i>Pancreas</i> , 2018, 47, 142-157.	0.5	19
665	Collection of real-world data on nivolumab's effectiveness in renal cell carcinoma: rationale for an observational study. <i>Future Oncology</i> , 2018, 14, 1023-1034.	1.1	1

#	ARTICLE	IF	CITATIONS
666	OMIPâ€œ44: 28â€œcolor immunophenotyping of the human dendritic cell compartment. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2018, 93, 402-405.	1.1	77
667	Recent advances in mass spectrometry-based approaches for proteomics and biologics: Great contribution for developing therapeutic antibodies. , 2018, 185, 147-154.		48
668	Recent advances in extracellular vesicles enriched with non-coding RNAs related to cancers. Genes and Diseases, 2018, 5, 36-42.	1.5	20
669	Stromal PD-L1â€œPositive Regulatory T cells and PD-1â€œPositive CD8-Positive T cells Define the Responseâ€œof Different Subsets of Nonâ€œSmall Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy. Journal of Thoracic Oncology, 2018, 13, 521-532.	0.5	119
670	Immune Checkpoint Inhibitor-Associated Type 1 Diabetes Mellitus: Case Series, Review of the Literature, and Optimal Management. Case Reports in Oncology, 2018, 10, 897-909.	0.3	57
671	Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet, The, 2018, 391, 748-757.	6.3	1,142
672	Cancer, obesity and immunometabolism â€œ Connecting the dots. Cancer Letters, 2018, 417, 11-20.	3.2	36
673	Genetics and Immunology: Tumor-Specific Genetic Alterations as a Target for Immune Modulating Therapies. , 2018, , 231-246.		0
674	Synergy Between Radiotherapy and Immunotherapy. , 2018, , 507-524.		0
675	Predictors of Response to Immune Checkpoint Blockade. , 2018, , 525-544.		0
676	Challenges of Oncoimmunology for Ovarian and Breast Cancers. , 2018, , 607-619.		0
677	Molecular pathology of lung cancer: current status and perspectives. Current Opinion in Oncology, 2018, 30, 69-76.	1.1	82
678	Using Genome Sequence to Enable the Design of Medicines and Chemical Probes. Chemical Reviews, 2018, 118, 1599-1663.	23.0	64
679	Mathematical modeling of tumor-induced immunosuppression by myeloid-derived suppressor cells: Implications for therapeutic targeting strategies. Journal of Theoretical Biology, 2018, 442, 1-10.	0.8	33
680	Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. European Journal of Cancer, 2018, 91, 21-29.	1.3	222
681	TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer. Cancer Cell, 2018, 33, 60-74.e6.	7.7	270
682	FOXOs in cancer immunity: Knowns and unknowns. Seminars in Cancer Biology, 2018, 50, 53-64.	4.3	56
683	Perspective on immune oncology with liquid biopsy, peripheral blood mononuclear cells, and microbiome with non-invasive biomarkers in cancer patients. Clinical and Translational Oncology, 2018, 20, 966-974.	1.2	31

#	ARTICLE	IF	CITATIONS
684	Selectins in cancer immunity. <i>Glycobiology</i> , 2018, 28, 648-655.	1.3	118
685	The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy. <i>Journal of the National Cancer Institute</i> , 2018, 110, 777-786.	3.0	58
686	Integration of radiation and immunotherapy in breast cancer - Treatment implications. <i>Breast</i> , 2018, 38, 66-74.	0.9	38
687	First-line vascular endothelial growth factor targeted therapy in renal cell carcinoma: priming the tumor microenvironment for immunotherapy. <i>Current Medical Research and Opinion</i> , 2018, 34, 825-831.	0.9	10
688	The Basics of Cancer Immunotherapy. , 2018, , .		5
689	The Basic Concepts in Cancer Immunology and Immunotherapy. , 2018, , 1-19.		3
690	Therapeutic Targets of FDA-Approved Immunotherapies in Oncology. , 2018, , 21-37.		3
691	Outlook: Immunotherapy in Gastrointestinal Carcinoma - Innovative Strategies. <i>Oncology Research and Treatment</i> , 2018, 41, 313-315.	0.8	8
692	Quantitative translational modeling to facilitate preclinical to clinical efficacy & toxicity translation in oncology. <i>Future Science OA</i> , 2018, 4, FSO306.	0.9	26
693	The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients. <i>BMC Cancer</i> , 2018, 18, 310.	1.1	34
694	Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2018, 11, 31.	6.9	256
695	Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems model. , 2018, 6, 17.		81
696	A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1494-1503.	1.9	150
697	Integrative Pharmacology: Advancing Development of Effective Immunotherapies. <i>AAPS Journal</i> , 2018, 20, 66.	2.2	10
698	Checkpoint Inhibitors in the Treatment of Breast Cancer. <i>Current Oncology Reports</i> , 2018, 20, 51.	1.8	10
699	Development of a primary melanoma in situ within a full-thickness skin graft overlying a free muscle flap: a case report. <i>Case Reports in Plastic Surgery & Hand Surgery</i> , 2018, 5, 23-26.	0.1	3
700	The opposing roles of CD4 ⁺ T cells in anti-tumour immunity. <i>Immunology</i> , 2018, 154, 582-592.	2.0	92
701	Cancer CRISPR Screens In Vivo. <i>Trends in Cancer</i> , 2018, 4, 349-358.	3.8	70

#	ARTICLE	IF	CITATIONS
702	Harnessing and Optimizing the Interplay between Immunotherapy and Radiotherapy to Improve Survival Outcomes. <i>Molecular Cancer Research</i> , 2018, 16, 1209-1214.	1.5	7
703	Quantifying tumor-infiltrating immune cells from transcriptomics data. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1031-1040.	2.0	292
704	Preclinical development of peptide vaccination combined with oncolytic MG1-E6E7 for HPV-associated cancer. <i>Vaccine</i> , 2018, 36, 2181-2192.	1.7	22
705	Therapeutic approaches for refractory germ cell cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 389-397.	1.1	33
706	Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer. <i>Cancer Letters</i> , 2018, 425, 174-182.	3.2	21
707	Armed oncolytic viruses: A kick-start for anti-tumor immunity. <i>Cytokine and Growth Factor Reviews</i> , 2018, 41, 28-39.	3.2	110
708	Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 63-73.	0.4	73
709	Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape. <i>Immunity</i> , 2018, 48, 399-416.	6.6	442
710	Tumor Ablation and Therapeutic Immunity Induction by an Injectable Peptide Hydrogel. <i>ACS Nano</i> , 2018, 12, 3295-3310.	7.3	143
711	Engineering nanoparticle strategies for effective cancer immunotherapy. <i>Biomaterials</i> , 2018, 178, 597-607.	5.7	117
712	Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies. <i>Clinical Lung Cancer</i> , 2018, 19, 331-339.	1.1	15
713	Recent Developments in Oncology Immunotherapy, Implications for NPs Part 1. <i>Journal for Nurse Practitioners</i> , 2018, 14, 251-258.e1.	0.4	2
714	Programmed death ligand 1 expression and CD8+ tumor-infiltrating lymphocyte density differences between paired primary and brain metastatic lesions in non-small cell lung cancer. <i>Biochemical and Biophysical Research Communications</i> , 2018, 498, 751-757.	1.0	71
715	Personalized vaccines for cancer immunotherapy. <i>Science</i> , 2018, 359, 1355-1360.	6.0	697
716	Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1024-1038.	1.9	31
717	Tissue-Specific Immunoregulation: A Call for Better Understanding of the "Immunostat" in the Context of Cancer. <i>Cancer Discovery</i> , 2018, 8, 395-402.	7.7	75
718	Atezolizumab in Japanese Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis of the Phase 3 OAK Study. <i>Clinical Lung Cancer</i> , 2018, 19, e405-e415.	1.1	77
719	A Cisplatin-Loaded Immunochemotherapeutic Nanohybrid Bearing Immune Checkpoint Inhibitors for Enhanced Cervical Cancer Therapy. <i>Angewandte Chemie</i> , 2018, 130, 3484-3488.	1.6	15

#	ARTICLE	IF	CITATIONS
720	The emerging world of breast cancer immunotherapy. <i>Breast</i> , 2018, 37, 200-206.	0.9	39
721	Prognostic impact of programmed death-ligand 1 expression in correlation with human leukocyte antigen class I expression status in stage I adenocarcinoma of the lung. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 382-392.e1.	0.4	28
722	Personalized neoantigen vaccines: A new approach to cancer immunotherapy. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 2842-2849.	1.4	85
723	Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2018, 29, 193-199.	0.6	162
724	AML-specific cytotoxic antibodies in patients with durable graft-versus-leukemia responses. <i>Blood</i> , 2018, 131, 131-143.	0.6	18
725	Cytokeratin7 expression in histologic and cytologic specimens of cystic neck metastasis from <sc>HPV</sc> positive squamous cell carcinoma of the tonsil: A case report. <i>Diagnostic Cytopathology</i> , 2018, 46, 331-335.	0.5	2
726	Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature. <i>European Urology Focus</i> , 2018, 4, 442-454.	1.6	10
727	Changing Paradigms in the Management of Breast Cancer. , 2018, , .		1
728	CD4 and CD8 T lymphocyte interplay in controlling tumor growth. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 689-713.	2.4	351
729	A review of immune therapy in cancer and a question: can thermal therapy increase tumor response?. <i>International Journal of Hyperthermia</i> , 2018, 34, 840-852.	1.1	24
730	Immune Modulation Therapy and Imaging: Workshop Report. <i>Journal of Nuclear Medicine</i> , 2018, 59, 410-417.	2.8	23
731	New Treatments for Metastatic Breast Cancer. , 2018, , 167-197.		0
732	Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-Î²Gal and MVA-MUC1 (TG4010) in a murine tumor model. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 140-145.	1.4	25
733	Prognostic value of <sc>PD</sc>â€1 expression in combination with <sc>CD</sc>8⁺<sc>TIL</sc>'s density in patients with surgically resected nonâ€small cell lung cancer. <i>Cancer Medicine</i> , 2018, 7, 32-45.	1.3	48
734	Polymer-based nanoparticles loaded with a TLR7 ligand to target the lymph node for immunostimulation. <i>International Journal of Pharmaceutics</i> , 2018, 535, 444-451.	2.6	48
735	Immunotherapy for Pediatric Malignancies. , 2018, , .		0
736	Overcoming Immune Suppression in the Tumor Microenvironment: Implications for Multi-modal Therapy. , 2018, , 13-38.		0
737	Molecular Diagnosis and Targeting for Lung Cancer. <i>Current Human Cell Research and Applications</i> , 2018, , 1-32.	0.1	0

#	ARTICLE	IF	CITATIONS
738	Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments. <i>Cancer Research</i> , 2018, 78, 463-474.	0.4	70
739	Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic Cancer. <i>Cancer Research</i> , 2018, 78, 475-488.	0.4	61
741	Nanoliposomes as the adjuvant delivery systems in cancer immunotherapy. <i>Journal of Cellular Physiology</i> , 2018, 233, 5189-5199.	2.0	65
742	Towards personalized, tumour-specific, therapeutic vaccines for cancer. <i>Nature Reviews Immunology</i> , 2018, 18, 168-182.	10.6	736
743	Navigating the "No Man's Land" of TKI-Failed EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): A Review. <i>Neoplasia</i> , 2018, 20, 92-98.	2.3	24
744	Designing In and Around Tolerability Considerations for Immunotherapy Combinations. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 558-561.	2.3	1
745	What potential does plasmonics-amplified synergistic immuno photothermal nanotherapy have for treatment of cancer?. <i>Nanomedicine</i> , 2018, 13, 139-144.	1.7	11
746	Immunotherapies for malignant glioma. <i>Oncogene</i> , 2018, 37, 1121-1141.	2.6	108
747	Current and future immunotherapies for thyroid cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 149-159.	1.1	47
748	Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIb-IV melanoma. <i>Melanoma Research</i> , 2018, 28, 44-51.	0.6	31
749	Expression of programmed death-1 in sentinel lymph nodes of breast cancer. <i>Journal of Surgical Oncology</i> , 2018, 117, 1131-1136.	0.8	3
750	Immune checkpoint inhibitors in advanced non-small cell lung cancer. <i>Cancer</i> , 2018, 124, 248-261.	2.0	94
751	Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 117-129.	0.9	28
752	Drug development in the era of precision medicine. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 183-196.	21.5	294
753	Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screening. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 471-481.	2.0	4
754	Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. <i>Seminars in Cancer Biology</i> , 2018, 52, 117-124.	4.3	302
755	Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer. <i>Annual Review of Medicine</i> , 2018, 69, 333-347.	5.0	38
756	Immunotherapeutic Biomarkers and Selection Strategies. <i>Current Cancer Research</i> , 2018, , 69-114.	0.2	0

#	ARTICLE	IF	CITATIONS
758	Primer on Cancer Immunotherapy and the Targeting of Native Proteins. <i>Current Cancer Research</i> , 2018, , 1-28.	0.2	0
759	Thoracic Immunotherapy. <i>Current Cancer Research</i> , 2018, , 281-305.	0.2	0
760	Pharmacokinetics and Pharmacodynamics of Immunotherapy. <i>Current Cancer Research</i> , 2018, , 29-67.	0.2	6
761	Combinations of Genomically and Immune-Targeted Therapies in Early-Phase Clinical Trials. <i>Current Cancer Research</i> , 2018, , 243-280.	0.2	0
762	Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. <i>Leukemia</i> , 2018, 32, 252-262.	3.3	234
763	Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part IIâ€”The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 26-34.	1.2	30
764	The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 381-392.	2.0	113
765	Biomarkers for immune checkpoint inhibitors: The importance of tumor topography and the challenges to cytopathology. <i>Cancer Cytopathology</i> , 2018, 126, 11-19.	1.4	28
766	A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment. <i>Oncolimmunology</i> , 2018, 7, e1398876.	2.1	44
767	Harnessing CXCR4 antagonists in stem cell mobilization, HIV infection, ischemic diseases, and oncology. <i>Medicinal Research Reviews</i> , 2018, 38, 1188-1234.	5.0	29
768	Cancer vaccines: a newer front of immunotherapy. <i>International Journal of Reproduction, Contraception, Obstetrics and Gynecology</i> , 2018, 7, 5214.	0.0	1
769	Duration of Antiâ€”Programmed Death-1 Therapy in Advanced Melanoma: How Much of a Good Thing Is Enough?. <i>Journal of Clinical Oncology</i> , 2018, 36, 1649-1653.	0.8	4
770	Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 1658-1667.	0.8	483
772	Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy. <i>Translational Lung Cancer Research</i> , 2018, 7, 647-660.	1.3	66
773	Shining light on advanced NSCLC in 2017: combining immune checkpoint inhibitors. <i>Journal of Thoracic Disease</i> , 2018, 10, S1534-S1546.	0.6	7
774	Real-World Benefit of Nivolumab in A Canadian Non-Small-Cell Lung Cancer Cohort. <i>Current Oncology</i> , 2018, 25, 384-392.	0.9	48
775	Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S433-S450.	0.6	15
777	â€œComparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancerâ€”is there a substantial difference or not?. <i>Journal of Thoracic Disease</i> , 2018, 10, S4065-S4068.	0.6	19

#	ARTICLE	IF	CITATIONS
778	Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer. <i>World Journal of Gastroenterology</i> , 2018, 24, 3583-3616.	1.4	118
780	The role of gut microbiota in immune checkpoint inhibitor therapy. <i>Hepatobiliary Surgery and Nutrition</i> , 2018, 7, 481-483.	0.7	16
781	Cancer Vaccines: Dendritic Cell-Based Vaccines and Related Approaches. , 2018, , 260-260.		0
782	Tumor Regression and Cure Depends on Sustained Th1 Responses. <i>Journal of Immunotherapy</i> , 2018, 41, 369-378.	1.2	26
783	Sitravatinib potentiates immune checkpoint blockade in refractory cancer models. <i>JCI Insight</i> , 2018, 3, .	2.3	81
784	Vaccines Developed for Cancer Immunotherapy. , 2018, , .		0
786	Avelumab: A Novel Anti-PD-L1 Agent in the Treatment of Merkel Cell Carcinoma and Urothelial Cell Carcinoma. <i>Critical Reviews in Immunology</i> , 2018, 38, 159-206.	1.0	8
787	Significance of Tumor Microenvironment Scoring and Immune Biomarkers in Patient Stratification and Cancer Outcomes. , 0, , .		11
789	Endocrine sequelae of immune checkpoint inhibitors. <i>Hormones</i> , 2018, 16, 341-350.	0.9	15
790	High-intensity interval training slows down tumor progression in mice bearing Lewis lung carcinoma. <i>JCSM Rapid Communications</i> , 2018, 1, 1-10.	0.6	9
791	Macrophage Depletion in Elderly Mice Improves Response to Tumor Immunotherapy, Increases Anti-tumor T Cell Activity and Reduces Treatment-Induced Cachexia. <i>Frontiers in Genetics</i> , 2018, 9, 526.	1.1	42
792	The Roles of Autophagy in Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3466.	1.8	631
793	Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2. <i>Nature Communications</i> , 2018, 9, 4682.	5.8	59
794	Interferon- γ signal may up-regulate PD-L1 expression through IRF9-dependent and independent pathways in lung cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2018, 507, 330-336.	1.0	52
795	The role of neoantigen in immune checkpoint blockade therapy. <i>Experimental Hematology and Oncology</i> , 2018, 7, 28.	2.0	99
796	Dissecting the Immune Landscape of Acute Myeloid Leukemia. <i>Biomedicines</i> , 2018, 6, 110.	1.4	32
797	Biological basis and early clinical results of immunotherapy for cisplatin-resistant germ cell cancer. <i>Current Opinion in Urology</i> , 2018, 28, 479-484.	0.9	5
798	Imunología del Cáncer I: bases moleculares y celulares de la respuesta inmune antitumoral. <i>Horizonte Médico</i> , 2018, 18, 80-89.	0.1	3

#	ARTICLE	IF	CITATIONS
799	Lung cancer, elderly and immune checkpoint inhibitors. <i>Journal of Thoracic Disease</i> , 2018, 10, S1474-S1481.	0.6	25
800	PD-L1 expression in pancreatic adenosquamous carcinoma: PD-L1 expression is limited to the squamous component. <i>Pathology Research and Practice</i> , 2018, 214, 2069-2074.	1.0	19
801	Reinforce the antitumor activity of <scp>CD</scp>8⁺ T cells via glutamine restriction. <i>Cancer Science</i> , 2018, 109, 3737-3750.	1.7	109
802	Immunotherapy in Non-Small Cell Lung Cancer: Biological Principles and Future Opportunities. <i>Current Molecular Medicine</i> , 2018, 17, 527-540.	0.6	20
803	Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy. <i>Frontiers in Immunology</i> , 2018, 9, 2759.	2.2	58
804	Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers. <i>Current Oncology Reports</i> , 2018, 20, 94.	1.8	43
805	CEA: Combination-based gene set functional enrichment analysis. <i>Scientific Reports</i> , 2018, 8, 13085.	1.6	4
806	The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies. <i>Current Treatment Options in Oncology</i> , 2018, 19, 70.	1.3	17
807	Chemokine profiling in serum from patients with ovarian cancer reveals candidate biomarkers for recurrence and immune infiltration. <i>Oncology Reports</i> , 2018, 41, 1238-1252.	1.2	14
808	Perspectives for cancer immunotherapy mediated by p19Arf plus interferon-beta gene transfer. <i>Clinics</i> , 2018, 73, e479s.	0.6	7
809	Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2018, 9, 3059.	2.2	354
810	Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer. <i>Frontiers in Medicine</i> , 2018, 5, 351.	1.2	67
811	Preliminary Study of the Effect of Stereotactic Body Radiotherapy (SBRT) on the Immune System in Lung Cancer Patients Unfit for Surgery: Immunophenotyping Analysis. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3963.	1.8	37
812	The promise of immunotherapy in genitourinary malignancies. <i>Precision Clinical Medicine</i> , 2018, 1, 97-101.	1.3	4
813	Immunotherapy and pancreatic cancer: unique challenges and potential opportunities. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591881628.	1.4	56
814	Progress of immune checkpoint therapy in the clinic (Review). <i>Oncology Reports</i> , 2019, 41, 3-14.	1.2	24
815	Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens. <i>Journal of Immunology Research</i> , 2018, 2018, 1-9.	0.9	75
816	Strategies of Combination Drug Delivery for Immune Checkpoint Blockades. <i>Advanced Healthcare Materials</i> , 2019, 8, e1801099.	3.9	32

#	ARTICLE	IF	CITATIONS
817	Immunotherapy in Lung Cancer: A New Age in Cancer Treatment. <i>Advances in Experimental Medicine and Biology</i> , 2018, 995, 65-95.	0.8	49
818	Local Anesthetics (LAs) and Cancer Cell Progression: Is There an Oncologic Protective Role for LAs in Clinical Practice?. <i>Current Anesthesiology Reports</i> , 2018, 8, 393-398.	0.9	0
820	Bioactive Nanoparticles for Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3877.	1.8	82
821	Tumor-Infiltrating Lymphocytes in Breast Cancer. Association with Clinical and Pathological Parameters. <i>Bulletin of Experimental Biology and Medicine</i> , 2018, 166, 241-244.	0.3	4
822	Prime time for immunotherapy in advanced urothelial cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 24-32.	0.7	2
823	MMP-9 inhibition promotes anti-tumor immunity through disruption of biochemical and physical barriers to T-cell trafficking to tumors. <i>PLoS ONE</i> , 2018, 13, e0207255.	1.1	65
824	Role of Endogenous Glucocorticoids in Cancer in the Elderly. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3774.	1.8	14
825	Ectopic high endothelial venules in pancreatic ductal adenocarcinoma: A unique site for targeted delivery. <i>EBioMedicine</i> , 2018, 38, 79-88.	2.7	20
826	Cancer Immunity and Gene Expression Data: A Quick Tool for Immunophenotype Evaluation. <i>Cancer Research</i> , 2018, 78, 6536-6538.	0.4	5
827	Subgrouping breast cancer patients based on immune evasion mechanisms unravels a high involvement of transforming growth factor-beta and decoy receptor 3. <i>PLoS ONE</i> , 2018, 13, e0207799.	1.1	21
828	Transformation of Old Concepts for a New Era of Cancer Immunotherapy: Cytokine Therapy and Cancer Vaccines as Combination Partners of PD1/PD-L1 Inhibitors. <i>Current Oncology Reports</i> , 2018, 20, 1.	1.8	30
829	Ruthenium pyridyl thiocyanate complex increased the production of pro-inflammatory TNF α and IL1 β cytokines by the LPS stimulated mammalian macrophages in vitro. <i>Molecular Biology Reports</i> , 2018, 45, 2307-2312.	1.0	16
830	Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study. <i>Oncolmmunology</i> , 2018, 7, e1502905.	2.1	80
831	A neoepitope derived from a novel human germline APC gene mutation in familial adenomatous polyposis shows selective immunogenicity. <i>PLoS ONE</i> , 2018, 13, e0203845.	1.1	4
832	Mechanism and Management of Cancer Chemotherapy-Induced Atherosclerosis. <i>Journal of Atherosclerosis and Thrombosis</i> , 2018, 25, 994-1002.	0.9	29
833	ICAM-1-LFA-1 Dependent CD8+ T-Lymphocyte Aggregation in Tumor Tissue Prevents Recirculation to Draining Lymph Nodes. <i>Frontiers in Immunology</i> , 2018, 9, 2084.	2.2	31
834	RNAi-Mediated β -Catenin Inhibition Promotes T Cell Infiltration and Antitumor Activity in Combination with Immune Checkpoint Blockade. <i>Molecular Therapy</i> , 2018, 26, 2567-2579.	3.7	79
835	We Are All Connected: Modeling the Tumor-Immune Ecosystem. <i>Trends in Cancer</i> , 2018, 4, 655-657.	3.8	8

#	ARTICLE	IF	CITATIONS
836	Transforming Growth Factor- β 2-Induced Cell Plasticity in Liver Fibrosis and Hepatocarcinogenesis. <i>Frontiers in Oncology</i> , 2018, 8, 357.	1.3	243
837	Biomaterials for vaccine-based cancer immunotherapy. <i>Journal of Controlled Release</i> , 2018, 292, 256-276.	4.8	146
838	Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E10119-E10126.	3.3	180
839	HIV control: Is getting there the same as staying there?. <i>PLoS Pathogens</i> , 2018, 14, e1007222.	2.1	65
840	Engineering CART Cells for Improved Function Against Solid Tumors. <i>Frontiers in Immunology</i> , 2018, 9, 2493.	2.2	67
841	Anti-PD-1/PD-L1 Antibody Therapy for Pretreated Advanced or Metastatic Nonsmall Cell Lung Carcinomas and the Correlation between PD-L1 Expression and Treatment Effectiveness: An Update Meta-Analysis of Randomized Clinical Trials. <i>BioMed Research International</i> , 2018, 2018, 1-9.	0.9	16
842	Multi-Omics Profiling of the Tumor Microenvironment: Paving the Way to Precision Immuno-Oncology. <i>Frontiers in Oncology</i> , 2018, 8, 430.	1.3	57
843	FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1733-1742.	0.5	120
844	Obesity and gastrointestinal cancer: the interrelationship of adipose and tumour microenvironments. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 699-714.	8.2	100
845	Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials. <i>Oncotarget</i> , 2018, 9, 8706-8715.	0.8	75
847	Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel. <i>BMC Cancer</i> , 2018, 18, 982.	1.1	33
848	Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time. <i>Frontiers in Immunology</i> , 2018, 9, 2265.	2.2	107
849	Immune regulation of metastasis: mechanistic insights and therapeutic opportunities. <i>DMM Disease Models and Mechanisms</i> , 2018, 11, .	1.2	102
850	Radiopharmacology and molecular imaging of PD-L1 expression in cancer. <i>Clinical and Translational Imaging</i> , 2018, 6, 429-439.	1.1	7
851	Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 2108-2121.	13.9	3,097
853	Anti-drug antibodies to LMB-100 are enhanced by mAbs targeting OX40 and CTLA4 but not by mAbs targeting PD1 or PDL-1. <i>Cellular Immunology</i> , 2018, 334, 38-41.	1.4	10
854	New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1. <i>Therapeutic Advances in Respiratory Disease</i> , 2018, 12, 175346661879413.	1.0	35
855	Rapalog combined with CCR4 antagonist improves anticancer vaccines efficacy. <i>International Journal of Cancer</i> , 2018, 143, 3008-3018.	2.3	16

#	ARTICLE	IF	CITATIONS
856	Treg Destabilization and Reprogramming: Implications for Cancer Immunotherapy. <i>Cancer Research</i> , 2018, 78, 5191-5199.	0.4	66
857	Magnetic resonance imaging and molecular features associated with tumor-infiltrating lymphocytes in breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 101.	2.2	44
858	Preclinical characterization of Sintilimab, a fully human anti-PD-1 therapeutic monoclonal antibody for cancer. <i>Antibody Therapeutics</i> , 2018, 1, 65-73.	1.2	25
859	Combinations of Bevacizumab With Cancer Immunotherapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 193-204.	1.0	144
860	Roles of the RANKL-RANK axis in antitumour immunity – implications for therapy. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 676-693.	12.5	77
861	Expression of IL-23R and IL-17 and the pathology and prognosis of urinary bladder carcinoma. <i>Oncology Letters</i> , 2018, 16, 4325-4330.	0.8	8
862	Prognostic Impact of Immune-Related Gene Expression in Preoperative Peripheral Blood from Gastric Cancer Patients. <i>Annals of Surgical Oncology</i> , 2018, 25, 3755-3763.	0.7	15
863	Regulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment. <i>Cancers</i> , 2018, 10, 302.	1.7	94
864	Application of PK-PD Modeling and Simulation Approaches for Immuno-Oncology Drugs. , 2018, , 207-222.		2
865	Evaluation of Tumor Growth Inhibition in Preclinical Tumor Models: A Quantitative Approach. , 2018, , 171-186.		0
866	Translational Platform for Immuno-Oncology Discovery. <i>Genetic Engineering and Biotechnology News</i> , 2018, 38, 10-11.	0.1	1
867	Antigen-specificity and DTIC before peptide-vaccination differently shape immune-checkpoint expression pattern, anti-tumor functionality and TCR repertoire in melanoma patients. <i>Oncolmmunology</i> , 2018, 7, e1465163.	2.1	6
868	Activation of central/effector memory T cells and T-helper 1 polarization in malignant melanoma patients treated with anti-programmed death-1 antibody. <i>Cancer Science</i> , 2018, 109, 3032-3042.	1.7	50
869	Nanoparticle Conjugation of Human Papillomavirus 16 E7-long Peptides Enhances Therapeutic Vaccine Efficacy against Solid Tumors in Mice. <i>Cancer Immunology Research</i> , 2018, 6, 1301-1313.	1.6	27
870	Bringing the Next Generation of Immuno-Oncology Biomarkers to the Clinic. <i>Biomedicines</i> , 2018, 6, 14.	1.4	66
871	TIP: A Web Server for Resolving Tumor Immunophenotype Profiling. <i>Cancer Research</i> , 2018, 78, 6575-6580.	0.4	356
872	Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 209-215.	2.0	29
873	Predicting T cell recognition of MHC class I restricted neoepitopes. <i>Oncolmmunology</i> , 2018, 7, e1492508.	2.1	82

#	ARTICLE	IF	CITATIONS
874	Macrophage-Derived Granulin Drives Resistance to Immune Checkpoint Inhibition in Metastatic Pancreatic Cancer. <i>Cancer Research</i> , 2018, 78, 4253-4269.	0.4	105
875	In Situ Vaccination with Cowpea vs Tobacco Mosaic Virus against Melanoma. <i>Molecular Pharmaceutics</i> , 2018, 15, 3700-3716.	2.3	79
876	Evaluating dendritic cells as an in vitro screening tool for immunotherapeutic formulations. <i>Journal of Immunological Methods</i> , 2018, 459, 55-62.	0.6	4
877	Preliminary investigation of extracellular vesicles in mammary cancer of dogs and cats: Identification and characterization. <i>Veterinary and Comparative Oncology</i> , 2018, 16, 489-496.	0.8	15
878	Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade. <i>Nature Communications</i> , 2018, 9, 2126.	5.8	54
880	The combined presence of CD20 ⁺ B cells and PD-L1 ⁺ tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 273-282.	1.1	65
881	Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018, 19, 441-449.e4.	1.1	65
883	A Convergence-Based Framework for Cancer Drug Resistance. <i>Cancer Cell</i> , 2018, 33, 801-815.	7.7	181
884	Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1156-1170.	0.5	195
885	Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 657-670.	3.3	14
886	Differential Expression Patterns of Eph Receptors and Ephrin Ligands in Human Cancers. <i>BioMed Research International</i> , 2018, 2018, 1-23.	0.9	43
887	Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 129, 44-53.	2.0	23
888	Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms. <i>Modern Pathology</i> , 2018, 31, 1630-1644.	2.9	33
889	The Immune Response to Glioblastoma: Overview and Focus on Checkpoint Blockade. , 2018, , 653-668.		0
890	The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 130, 1-12.	2.0	16
891	Immune Escape Mechanisms and Future Prospects for Immunotherapy in Neuroblastoma. <i>BioMed Research International</i> , 2018, 2018, 1-11.	0.9	60
892	The Integration of Radiotherapy with Immunotherapy for the Treatment of Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5792-5806.	3.2	200
893	A mathematical model of cytotoxic and helper T cell interactions in a tumour microenvironment. <i>Letters in Biomathematics</i> , 2018, 5, S36-S68.	0.3	12

#	ARTICLE	IF	CITATIONS
894	Immune cell profiling in the age of immune checkpoint inhibitors: implications for biomarker discovery and understanding of resistance mechanisms. <i>Mammalian Genome</i> , 2018, 29, 866-878.	1.0	10
895	Combination of checkpoint inhibitors with other agents as a strategy to improve anti-cancer effect – a glimpse to the future. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 569-572.	1.9	4
896	Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC). <i>Journal of UOEH</i> , 2018, 40, 173-189.	0.3	45
897	Improved Induction of Anti-Melanoma T Cells by Adenovirus-5/3 Fiber Modification to Target Human DCs. <i>Vaccines</i> , 2018, 6, 42.	2.1	8
898	Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. <i>Tuberculosis and Respiratory Diseases</i> , 2018, 81, 29.	0.7	24
900	Immune ligands for cytotoxic T Lymphocytes CTLs in cancer stem cells CSCS. <i>Frontiers in Bioscience - Landmark</i> , 2018, 23, 563-583.	3.0	6
901	Role of Tissue-Resident Memory in Intra-Tumor Heterogeneity and Response to Immune Checkpoint Blockade. <i>Frontiers in Immunology</i> , 2018, 9, 1655.	2.2	16
902	Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma. <i>Frontiers in Immunology</i> , 2018, 9, 1786.	2.2	29
903	Immunotherapy for Gastric Cancer: Time for a Personalized Approach?. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1602.	1.8	48
904	Sno-derived RNAs are prevalent molecular markers of cancer immunity. <i>Oncogene</i> , 2018, 37, 6442-6462.	2.6	28
905	Voluntary exercise slows breast tumor establishment and reduces tumor hypoxia in ApoE ^{−/−} mice. <i>Journal of Applied Physiology</i> , 2018, 124, 938-949.	1.2	27
906	Cancer growth and metastasis as a metaphor of Go gaming: An Ising model approach. <i>PLoS ONE</i> , 2018, 13, e0195654.	1.1	10
907	A Network Meta-analysis Comparing the Efficacy and Safety of Anti-PD-1 with Anti-PD-L1 in Non-small Cell Lung Cancer. <i>Journal of Cancer</i> , 2018, 9, 1200-1206.	1.2	31
908	CD4+ T cell help in cancer immunology and immunotherapy. <i>Nature Reviews Immunology</i> , 2018, 18, 635-647.	10.6	1,030
909	The evolving immunotherapeutic landscape in advanced oesophagogastric cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591878622.	1.4	5
910	Construction of an anti-programmed death ligand 1 chimeric antigen receptor and determination of its antitumor function with transduced cells. <i>Oncology Letters</i> , 2018, 16, 157-166.	0.8	9
911	Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2018, 101, 114-122.	1.3	45
912	Activity and Immune Correlates of a Programmed Death-1 Blockade Antibody in the treatment of Refractory Solid Tumors. <i>Journal of Cancer</i> , 2018, 9, 205-212.	1.2	9

#	ARTICLE	IF	CITATIONS
913	Checks and Balances in Autoimmune Vasculitis. <i>Frontiers in Immunology</i> , 2018, 9, 315.	2.2	31
914	Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy. <i>Frontiers in Immunology</i> , 2018, 9, 353.	2.2	140
915	Exosomes and Immune Response in Cancer: Friends or Foes?. <i>Frontiers in Immunology</i> , 2018, 9, 730.	2.2	151
916	NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives. <i>Frontiers in Immunology</i> , 2018, 9, 947.	2.2	261
917	Blockade of MIF-CD74 Signalling on Macrophages and Dendritic Cells Restores the Antitumour Immune Response Against Metastatic Melanoma. <i>Frontiers in Immunology</i> , 2018, 9, 1132.	2.2	109
918	Glioblastoma Stem-Like Cells Are More Susceptible Than Differentiated Cells to Natural Killer Cell Lysis Mediated Through Killer Immunoglobulin-Like Receptors-Human Leukocyte Antigen Ligand Mismatch and Activation Receptor-Ligand Interactions. <i>Frontiers in Immunology</i> , 2018, 9, 1345.	2.2	52
919	The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 82.	1.4	61
920	Platelet Metabolism and Other Targeted Drugs; Potential Impact on Immunotherapy. <i>Frontiers in Oncology</i> , 2018, 8, 107.	1.3	24
921	Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers. , 2018, 6, 65.		118
922	Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy. <i>Haematologica</i> , 2018, 103, 1256-1268.	1.7	69
923	Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer. <i>Cancers</i> , 2018, 10, 39.	1.7	44
924	Immune Response against ALK in Children with ALK-Positive Anaplastic Large Cell Lymphoma. <i>Cancers</i> , 2018, 10, 114.	1.7	8
925	Fusogenic Viruses in Oncolytic Immunotherapy. <i>Cancers</i> , 2018, 10, 216.	1.7	36
926	PD-L1 Nanobody Competitively Inhibits the Formation of the PD-1/PD-L1 Complex: Comparative Molecular Dynamics Simulations. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1984.	1.8	31
927	Adjustment of dendritic cells to the breast-cancer microenvironment is subset specific. <i>Nature Immunology</i> , 2018, 19, 885-897.	7.0	152
928	LINE-1 as a therapeutic target for castration-resistant prostate cancer. <i>Frontiers in Bioscience - Landmark</i> , 2018, 23, 1292-1309.	3.0	11
930	Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA). , 2018, 6, 63.		344
931	Immunotherapy Combinations and Sequences in Urothelial Cancer: Facts and Hopes. <i>Clinical Cancer Research</i> , 2018, 24, 6115-6124.	3.2	14

#	ARTICLE	IF	CITATIONS
932	Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells. <i>Cell Reports</i> , 2018, 24, 379-390.e6.	2.9	140
933	Gene Therapy and Virotherapy of Gliomas. <i>Progress in Neurological Surgery</i> , 2018, 32, 112-123.	1.3	11
934	Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice. <i>Future Oncology</i> , 2018, 14, 41-60.	1.1	12
935	Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 130, 13-26.	2.0	34
936	Assessing antitumor and T cell immune responses by cytokine assay in cancer patients treated with immunotherapy – A pilot study. <i>Personalized Medicine Universe</i> , 2018, 7, 28-33.	0.1	0
937	Onconeural antigen spreading in paraneoplastic neurological disease due to small cell lung cancer. <i>Oxford Medical Case Reports</i> , 2018, 2018, omy034.	0.2	3
938	Oncogenic BRAFV600E Governs Regulatory T-cell Recruitment during Melanoma Tumorigenesis. <i>Cancer Research</i> , 2018, 78, 5038-5049.	0.4	64
939	The Potential of In Vivo Imaging for Optimization of Molecular and Cellular Anti-cancer Immunotherapies. <i>Molecular Imaging and Biology</i> , 2018, 20, 696-704.	1.3	30
940	Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2018, 70, 127-137.	3.4	276
941	Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer. <i>BMC Cancer</i> , 2018, 18, 87.	1.1	33
942	A phase I/IIb study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer. <i>BMC Cancer</i> , 2018, 18, 332.	1.1	32
943	Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses. , 2018, 6, 19.		45
946	Pharmacometric Applications and Challenges in the Development of Therapeutic Antibodies in Immuno-Oncology. <i>Current Pharmacology Reports</i> , 2018, 4, 285-291.	1.5	7
947	Anticalin® Proteins as Therapeutic Agents in Human Diseases. <i>BioDrugs</i> , 2018, 32, 233-243.	2.2	78
948	Complement system's role in cancer and its therapeutic potential in ovarian cancer. <i>Scandinavian Journal of Immunology</i> , 2018, 88, e12672.	1.3	22
949	Mutated cancer autoantigen implicated cause of paraneoplastic myasthenia gravis. <i>Muscle and Nerve</i> , 2018, 58, 600-604.	1.0	10
950	Immunotherapy for pulmonary squamous cell carcinoma and colon carcinoma with pembrolizumab. <i>Medicine (United States)</i> , 2018, 97, e0718.	0.4	6
951	Combinations of Bevacizumab With Immune Checkpoint Inhibitors in Renal Cell Carcinoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 171-179.	1.0	18

#	ARTICLE	IF	CITATIONS
952	New Directions in the Study and Treatment of Metastatic Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 258.	1.3	14
953	Developmental Immunotoxicology Testing (DIT). , 2018, , 467-497.		2
954	Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). <i>Annals of Translational Medicine</i> , 2018, 6, 144-144.	0.7	19
955	CNS cancer immunity cycle and strategies to target this for glioblastoma. <i>Oncotarget</i> , 2018, 9, 22802-22816.	0.8	11
956	Next Generation Cancer Vaccinesâ€”Make It Personal!. <i>Vaccines</i> , 2018, 6, 52.	2.1	20
957	Tertiary Lymphoid Structures. <i>Methods in Molecular Biology</i> , 2018, , .	0.4	3
958	ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile. <i>PLoS ONE</i> , 2018, 13, e0201832.	1.1	102
959	Immunostimulatory effect of Zinc Phthalocyanine derivatives on macrophages based on the pro-inflammatory TNF α and IL1 β cytokine production levels. <i>Toxicology in Vitro</i> , 2018, 53, 172-177.	1.1	27
960	Effects of Combination of Anti-CTLA-4 and Anti-PD-1 on Gastric Cancer Cells Proliferation, Apoptosis and Metastasis. <i>Cellular Physiology and Biochemistry</i> , 2018, 49, 260-270.	1.1	29
961	Targeting Tertiary Lymphoid Structures for Tumor Immunotherapy. <i>Methods in Molecular Biology</i> , 2018, 1845, 275-286.	0.4	9
962	GSH-Activated Light-Up Near-Infrared Fluorescent Probe with High Affinity to α 3 β 1 Integrin for Precise Early Tumor Identification. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 30994-31007.	4.0	48
963	Treatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopes. <i>Nature Communications</i> , 2018, 9, 3417.	5.8	87
964	Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy. <i>Pharmacological Research</i> , 2018, 136, 151-159.	3.1	85
965	Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. <i>Cancer Discovery</i> , 2018, 8, 1069-1086.	7.7	2,128
966	Role of Immune Checkpoint Inhibitors in Advanced or Recurrent Endometrial Cancer. <i>Cureus</i> , 2018, 10, e2521.	0.2	18
967	Diversity of Wnt/ β -Catenin Signaling in Head and Neck Cancer: Cancer Stem Cells, Epithelial-to-Mesenchymal Transition, and Tumor Microenvironment. <i>Current Cancer Research</i> , 2018, , 491-524.	0.2	0
968	White paper on microbial anti-cancer therapy and prevention. , 2018, 6, 78.		108
969	Engineering Platforms for T Cell Modulation. <i>International Review of Cell and Molecular Biology</i> , 2018, 341, 277-362.	1.6	8

#	ARTICLE	IF	CITATIONS
970	Neutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 1291-1299.	0.8	47
971	Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 1613.	2.2	83
972	Combined Rho-kinase inhibition and immunogenic cell death triggers and propagates immunity against cancer. <i>Nature Communications</i> , 2018, 9, 2165.	5.8	80
973	Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. <i>New England Journal of Medicine</i> , 2018, 378, 2288-2301.	13.9	2,808
974	Immunobiology of the Melanoma Microenvironment. , 2018, , 133-142.		0
975	Duokines: a novel class of dual-acting co-stimulatory molecules acting in cis or trans. <i>OncoImmunology</i> , 2018, 7, e1471442.	2.1	7
976	Recent progress in therapeutic antibodies for cancer immunotherapy. <i>Current Opinion in Chemical Biology</i> , 2018, 44, 56-65.	2.8	21
977	Immunomodulation and cancer: Using mechanistic paradigms to inform risk assessment. <i>Current Opinion in Toxicology</i> , 2018, 10, 98-110.	2.6	3
978	Epigenetic treatment of multiple myeloma mediates tumor intrinsic and extrinsic immunomodulatory effects. <i>OncoImmunology</i> , 2018, 7, e1484981.	2.1	26
979	MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 916-929.	5.1	131
980	Nanotechnology Approaches to Improving Cancer Immunotherapy. <i>Advances in Cancer Research</i> , 2018, 139, 35-56.	1.9	33
981	Molecular landscape of esophageal cancer: implications for early detection and personalized therapy. <i>Annals of the New York Academy of Sciences</i> , 2018, 1434, 342-359.	1.8	56
982	Clinical Development and Initial Approval of Novel Immune Checkpoint Inhibitors in Oncology: Insights From a Global Regulatory Perspective. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 582-597.	2.3	8
983	A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab-Treated non-small Cell Lung Cancer Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 486-495.	2.3	23
984	Functional genomics: paving the way for more successful cancer immunotherapy. <i>Briefings in Functional Genomics</i> , 2019, 18, 86-98.	1.3	6
985	Development of a PD-L1-Expressing Orthotopic Liver Cancer Model: Implications for Immunotherapy for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2019, 8, 155-171.	4.2	25
986	Nanomaterials for modulating innate immune cells in cancer immunotherapy. <i>Asian Journal of Pharmaceutical Sciences</i> , 2019, 14, 16-29.	4.3	41
987	Materials-Based Cancer Immunotherapies. , 2019, , 715-739.		2

#	ARTICLE	IF	CITATIONS
988	Durch Nanopartikel vermittelter immunogener Zelltod ermöglicht und verstärkt die Immuntherapie gegen Krebs. <i>Angewandte Chemie</i> , 2019, 131, 680-691.	1.6	22
989	To do or not to do: A concise update of current clinical controversies in immune checkpoint blockade. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 663-673.	0.5	8
990	Nanoparticle-Mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 670-680.	7.2	671
991	Activity of Nivolumab and Utility of Neutrophil-to-Lymphocyte Ratio as a Predictive Biomarker for Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study. <i>Clinical Lung Cancer</i> , 2019, 20, 208-214.e2.	1.1	76
992	The silencing of indoleamine 2,3-dioxygenase 1 (IDO1) in dendritic cells by siRNA-loaded lipid nanoparticles enhances cell-based cancer immunotherapy. <i>Scientific Reports</i> , 2019, 9, 11335.	1.6	42
993	Melanoma Immunology and Immunotherapy. , 2019, , 651-665.		0
994	SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging Agents. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 537-544.	0.2	18
995	Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer. <i>British Journal of Cancer</i> , 2019, 121, 490-496.	2.9	100
996	Cancer immunotherapy: Adoptive cell therapies, cytokine-related toxicities, and the kidneys. <i>Journal of Onco-Nephrology</i> , 2019, 3, 131-143.	0.3	0
997	Upregulation of PD-L1 expression in breast cancer cells through the formation of 3D multicellular cancer aggregates under different chemical and mechanical conditions. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2019, 1866, 118526.	1.9	39
998	Prognostic impact of prognostic nutritional index in advanced (stage IIIB/IV) non-small cell lung cancer patients. <i>Neoplasma</i> , 2019, 66, 971-977.	0.7	6
999	Role of the Exosome in Ovarian Cancer Progression and Its Potential as a Therapeutic Target. <i>Cancers</i> , 2019, 11, 1147.	1.7	54
1000	Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition. , 2019, 7, 216.		56
1001	PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition. <i>Frontiers in Immunology</i> , 2019, 10, 2022.	2.2	270
1002	The application of nanotechnology in enhancing immunotherapy for cancer treatment: current effects and perspective. <i>Nanoscale</i> , 2019, 11, 17157-17178.	2.8	59
1003	Immuno-Oncology Therapy for Hepatocellular Carcinoma: Current Status and Ongoing Trials. <i>Liver Cancer</i> , 2019, 8, 221-238.	4.2	51
1004	Human Tumor-Infiltrating Dendritic Cells: From in Situ Visualization to High-Dimensional Analyses. <i>Cancers</i> , 2019, 11, 1082.	1.7	36
1005	Neutralizing monoclonal antibody against Dickkopf2 impairs lung cancer progression via activating NK cells. <i>Cell Death Discovery</i> , 2019, 5, 123.	2.0	13

#	ARTICLE	IF	CITATIONS
1006	The interplay between microglial states and major risk factors in Alzheimer's disease through the eyes of single-cell RNA-sequencing: beyond black and white. <i>Journal of Neurophysiology</i> , 2019, 122, 1291-1296.	0.9	7
1007	Apolipoprotein A-I (ApoA-I), Immunity, Inflammation and Cancer. <i>Cancers</i> , 2019, 11, 1097.	1.7	127
1009	Mucosal Vaccination via the Respiratory Tract. <i>Pharmaceutics</i> , 2019, 11, 375.	2.0	69
1010	Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 ⁺ Cells. <i>Cell</i> , 2019, 178, 1189-1204.e23.	13.5	189
1011	Tissue Site and the Cancer Immunity Cycle. <i>Trends in Cancer</i> , 2019, 5, 593-603.	3.8	37
1012	A Platform for Extracellular Interactome Discovery Identifies Novel Functional Binding Partners for the Immune Receptors B7-H3/CD276 and PVR/CD155. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 2310-2323.	2.5	51
1013	Attenuation of chronic antiviral T-cell responses through constitutive COX2-dependent prostanoid synthesis by lymph node fibroblasts. <i>PLoS Biology</i> , 2019, 17, e3000072.	2.6	18
1014	Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners. , 2019, , .		0
1016	Integrating nanomedicine into clinical radiotherapy regimens. <i>Advanced Drug Delivery Reviews</i> , 2019, 144, 35-56.	6.6	32
1017	Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells. <i>Antibodies</i> , 2019, 8, 41.	1.2	90
1019	The Impact and Toxicity of Checkpoint Inhibitors in Management of Lung Cancer. , 2019, , 65-84.		0
1020	Macrophage-Mediated Subversion of Anti-Tumour Immunity. <i>Cells</i> , 2019, 8, 747.	1.8	68
1021	Inhaled Submicron Particle Paclitaxel (NanoPac) Induces Tumor Regression and Immune Cell Infiltration in an Orthotopic Athymic Nude Rat Model of Non-Small Cell Lung Cancer. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2019, 32, 266-277.	0.7	11
1022	Quantifying immune-based counterselection of somatic mutations. <i>PLoS Genetics</i> , 2019, 15, e1008227.	1.5	14
1023	Circulating tumor cells in pulmonary vein and peripheral arterial provide a metric for PD-L1 diagnosis and prognosis of patients with non-small cell lung cancer. <i>PLoS ONE</i> , 2019, 14, e0220306.	1.1	21
1024	Immune checkpoint inhibitors: The linchpins of modern immunotherapy. <i>Immunological Reviews</i> , 2019, 290, 6-23.	2.8	150
1025	Nutrition, Immunity, and Cancer. , 2019, , 209-281.		2
1026	A user's perspective on GeoMx TM digital spatial profiling. <i>Immuno-Oncology Technology</i> , 2019, 1, 11-18.	0.2	38

#	ARTICLE	IF	CITATIONS
1027	Neurologic Autoimmunity in the Era of Checkpoint Inhibitor Cancer Immunotherapy. Mayo Clinic Proceedings, 2019, 94, 1865-1878.	1.4	49
1028	Hierarchical assembly of hyaluronan coated albumin nanoparticles for pancreatic cancer chemoimmunotherapy. Nanoscale, 2019, 11, 16476-16487.	2.8	31
1029	NIR-light-mediated spatially selective triggering of anti-tumor immunity via upconversion nanoparticle-based immunodevices. Nature Communications, 2019, 10, 2839.	5.8	114
1030	Can Dendritic Cell Vaccination Prevent Leukemia Relapse?. Cancers, 2019, 11, 875.	1.7	12
1031	Advances in Targeted Therapies for Triple-Negative Breast Cancer. Drugs, 2019, 79, 1217-1230.	4.9	71
1032	Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer. Journal of Hematology and Oncology, 2019, 12, 67.	6.9	54
1033	Innovative nanotechnologies for enhancing nucleic acids/gene therapy: Controlling intracellular trafficking to targeted biodistribution. Biomaterials, 2019, 218, 119329.	5.7	37
1034	Immunologic Targeting of Cancer Stem Cells. Surgical Oncology Clinics of North America, 2019, 28, 431-445.	0.6	10
1035	Chimeric Antigen Receptor T-Cell Therapy: Reach to Solid Tumor Experience. Oncology, 2019, 97, 59-74.	0.9	13
1036	Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?. Cancers, 2019, 11, 920.	1.7	10
1037	Differential Immunomodulatory Activities of Schiff Base Complexes Depending on their Metal Conjugation. Inflammation, 2019, 42, 1878-1885.	1.7	15
1039	Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 599-608.	1.4	45
1040	Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages. Cancer Immunology Research, 2019, 7, 1958-1969.	1.6	87
1041	NANOG helps cancer cells escape NK cell attack by downregulating ICAM1 during tumorigenesis. Journal of Experimental and Clinical Cancer Research, 2019, 38, 416.	3.5	25
1042	Expression of Immune Checkpoint Receptors on T-Cells and Their Ligands on Leukemia Blasts in Childhood Acute Leukemia. Anticancer Research, 2019, 39, 5531-5539.	0.5	21
1043	Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors. Journal of Cancer Research and Clinical Oncology, 2019, 145, 3021-3036.	1.2	20
1044	Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130). Japanese Journal of Clinical Oncology, 2019, 49, 1083-1091.	0.6	32
1045	Alphavirus-based hepatitis C virus therapeutic vaccines: can universal helper epitopes enhance HCV-specific cytotoxic T lymphocyte responses?. , 2019, 7, 251513551987467.	1.4	2

#	ARTICLE	IF	CITATIONS
1046	<p></p>Recent advances and application of PD-1 blockade in sarcoma</p>. OncoTargets and Therapy, 2019, Volume 12, 6887-6896.	1.0	17
1047	WNT/β-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment. Frontiers in Immunology, 2019, 10, 2293.	2.2	165
1048	The predictive role of preoperative and postoperative neutrophil-lymphocyte ratio in sarcomatoid renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 916-923.	0.8	8
1049	The adequacy of tissue microarrays in the assessment of inter- and intra-tumoural heterogeneity of infiltrating lymphocyte burden in leiomyosarcoma. Scientific Reports, 2019, 9, 14602.	1.6	22
1050	The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis. Experimental Hematology and Oncology, 2019, 8, 26.	2.0	58
1051	The Activity of Immune Checkpoint Inhibition in KRAS Mutated Non-small Cell Lung Cancer: A Single Centre Experience. Cancer Genomics and Proteomics, 2019, 16, 577-582.	1.0	52
1052	Imaging of T-cells and their responses during anti-cancer immunotherapy. Theranostics, 2019, 9, 7924-7947.	4.6	77
1053	Macrophages on the Peritoneum are involved in Gastric Cancer Peritoneal Metastasis. Journal of Cancer, 2019, 10, 5377-5387.	1.2	32
1054	Postablation Immune Microenvironment: Synergy between Interventional Oncology and Immuno-oncology. Seminars in Interventional Radiology, 2019, 36, 334-342.	0.3	16
1055	Is the Combination of Immunotherapy and Radiotherapy in Non-small Cell Lung Cancer a Feasible and Effective Approach?. Frontiers in Medicine, 2019, 6, 244.	1.2	31
1056	Transcriptional Signature Derived from Murine Tumor-Associated Macrophages Correlates with Poor Outcome in Breast Cancer Patients. Cell Reports, 2019, 29, 1221-1235.e5.	2.9	47
1057	A Sialylated-Bortezomib Prodrug Strategy Based on a Highly Expressed Selectin Target for the Treatment of Leukemia or Solid Tumors. Pharmaceutical Research, 2019, 36, 176.	1.7	8
1058	Injectable Polymer-“Nanoparticle Hydrogels for Local Immune Cell Recruitment. Biomacromolecules, 2019, 20, 4430-4436.	2.6	58
1059	Fibroblasts Fuel Immune Escape in the Tumor Microenvironment. Trends in Cancer, 2019, 5, 704-723.	3.8	107
1060	Anti-tumour effects of a xenogeneic fibroblast activation protein-based whole cell tumour vaccine in murine tumour models. Artificial Cells, Nanomedicine and Biotechnology, 2019, 47, 4182-4193.	1.9	12
1061	STING: a master regulator in the cancer-immunity cycle. Molecular Cancer, 2019, 18, 152.	7.9	218
1062	Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma. European Journal of Cancer, 2019, 123, 138-145.	1.3	13
1063	The role and therapeutic implications of T cells in cancer of the lung. Clinical and Translational Immunology, 2019, 8, e1076.	1.7	25

#	ARTICLE	IF	CITATIONS
1064	Interplay between dendritic cells and cancer cells. <i>International Review of Cell and Molecular Biology</i> , 2019, 348, 179-215.	1.6	37
1065	Update Breast Cancer 2019 Part 5 – Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 1090-1099.	0.8	16
1066	Chemotherapy-Induced Tumor Cell Death at the Crossroads Between Immunogenicity and Immunotolerance: Focus on Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2019, 9, 1004.	1.3	23
1067	Chemotherapeutic regimen influences the results of chemotherapy plus immunotherapy. <i>Immunotherapy</i> , 2019, 11, 1259-1261.	1.0	0
1068	Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies. <i>Genes and Diseases</i> , 2019, 6, 232-246.	1.5	44
1070	Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab. <i>Clinical Cancer Research</i> , 2019, 25, 6061-6072.	3.2	58
1071	Primary Bone Tumors: Challenges and Opportunities for CAR-T Therapies. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 1780-1788.	3.1	12
1072	Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?. <i>Annals of Intensive Care</i> , 2019, 9, 25.	2.2	46
1073	Proteolytic chemokine cleavage as a regulator of lymphocytic infiltration in solid tumors. <i>Cancer and Metastasis Reviews</i> , 2019, 38, 417-430.	2.7	27
1074	CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	117
1075	Immunotherapy with Monoclonal Antibodies in Lung Cancer of Mice: Oxidative Stress and Other Biological Events. <i>Cancers</i> , 2019, 11, 1301.	1.7	9
1076	Tumor neoantigens: from basic research to clinical applications. <i>Journal of Hematology and Oncology</i> , 2019, 12, 93.	6.9	266
1077	CIITA-Driven MHC Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor Vaccine. <i>Frontiers in Immunology</i> , 2019, 10, 1806.	2.2	63
1078	Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 155, 51-57.	0.6	14
1079	Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors. <i>Journal of Clinical Investigation</i> , 2019, 129, 2056-2070.	3.9	159
1080	Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer. <i>Experimental Hematology and Oncology</i> , 2019, 8, 19.	2.0	30
1081	Glycan-Modified Melanoma-Derived Apoptotic Extracellular Vesicles as Antigen Source for Anti-Tumor Vaccination. <i>Cancers</i> , 2019, 11, 1266.	1.7	47
1082	LEGENDplex [®] : Bead-assisted multiplex cytokine profiling by flow cytometry. <i>Methods in Enzymology</i> , 2019, 629, 151-176.	0.4	22

#	ARTICLE	IF	CITATIONS
1083	Ultrathin Metal-Organic-Layer Mediated Radiotherapy-Radiodynamic Therapy. <i>Matter</i> , 2019, 1, 1331-1353.	5.0	78
1084	The Effect of Antibody Fragments on CD25 Targeted Regulatory T Cell Near-Infrared Photoimmunotherapy. <i>Bioconjugate Chemistry</i> , 2019, 30, 2624-2633.	1.8	35
1085	Next-generation computational tools for interrogating cancer immunity. <i>Nature Reviews Genetics</i> , 2019, 20, 724-746.	7.7	131
1086	Desmoid tumors display a strong immune infiltration at the tumor margins and no PD-L1-driven immune suppression. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1573-1583.	2.0	15
1087	Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer types. <i>BMC Medical Genomics</i> , 2019, 12, 131.	0.7	47
1088	Down Regulation of c-FLIPL Enhance PD-1 Blockade Efficacy in B16 Melanoma. <i>Frontiers in Oncology</i> , 2019, 9, 857.	1.3	12
1089	Dendritic Cell Vaccination in Metastatic Melanoma Turns "Non-T Cell Inflamed" Into "T-Cell Inflamed" Tumors. <i>Frontiers in Immunology</i> , 2019, 10, 2353.	2.2	22
1090	The potential combinational immunotherapies for treatment of hepatocellular carcinoma. <i>Journal of Interventional Medicine</i> , 2019, 2, 47-51.	0.2	3
1091	Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541987635.	0.8	38
1092	LAG-3 expression on tumor-infiltrating T cells in soft tissue sarcoma correlates with poor survival. <i>Cancer Biology and Medicine</i> , 2019, 16, 331.	1.4	39
1093	Prospects for combining immune checkpoint blockade with PARP inhibition. <i>Journal of Hematology and Oncology</i> , 2019, 12, 98.	6.9	92
1094	Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. <i>Molecular Cancer</i> , 2019, 18, 139.	7.9	156
1095	Future therapeutic strategies for metastatic prostate cancer. <i>Tijdschrift Voor Urologie</i> , 2019, 9, 117-130.	0.1	5
1096	Utilization of lipopolysaccharide challenge in cynomolgus macaques to assess IL-10 receptor antagonism. <i>Journal of Immunotoxicology</i> , 2019, 16, 164-172.	0.9	5
1097	Suppression of tumor antigen presentation during aneuploid tumor evolution contributes to immune evasion. <i>Oncolmmunology</i> , 2019, 8, 1657374.	2.1	36
1098	Human immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and antitumour activities through biophysical flexibility. <i>Nature Communications</i> , 2019, 10, 4206.	5.8	21
1099	Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities. <i>Cancers</i> , 2019, 11, 1419.	1.7	54
1100	Interaction of Immune Cells and Tumor Cells in Gold Nanorod-Gelatin Composite Porous Scaffolds. <i>Nanomaterials</i> , 2019, 9, 1367.	1.9	6

#	ARTICLE	IF	CITATIONS
1101	Genome-Wide Methylation Profiling in Canine Mammary Tumor Reveals miRNA Candidates Associated with Human Breast Cancer. <i>Cancers</i> , 2019, 11, 1466.	1.7	16
1102	Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer. <i>Drug Resistance Updates</i> , 2019, 46, 100644.	6.5	133
1103	The Diversification of Cell Death and Immunity: Memento Mori. <i>Molecular Cell</i> , 2019, 76, 232-242.	4.5	106
1104	Cancer and the Immune System: The History and Background of Immunotherapy. <i>Seminars in Oncology Nursing</i> , 2019, 35, 150923.	0.7	241
1105	Ionizing radiation effects on the tumor microenvironment. <i>Seminars in Oncology</i> , 2019, 46, 254-260.	0.8	50
1106	[Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model. <i>PLoS ONE</i> , 2019, 14, e0222280.	1.1	23
1107	Role of evaluating tumor-infiltrating lymphocytes, programmed death-1 ligand 1 and mismatch repair proteins expression in malignant mesothelioma. <i>International Journal of Oncology</i> , 2019, 55, 1157-1164.	1.4	13
1108	Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 1257-1267.	1.1	58
1109	In vivo CRISPR screening in CD8 T cells with AAV-Sleeping Beauty hybrid vectors identifies membrane targets for improving immunotherapy for glioblastoma. <i>Nature Biotechnology</i> , 2019, 37, 1302-1313.	9.4	123
1110	Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors. , 2019, 7, 18.		72
1111	Unleash the power of the mighty T cells-basis of adoptive cellular therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 136, 1-12.	2.0	20
1112	Intralesional Cancer Immunotherapies. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 249-260.	0.9	10
1113	Prognostic Values of CD38 ⁺ CD101 ⁺ PD1 ⁺ CD8 ⁺ T Cells in Pancreatic Cancer. <i>Immunological Investigations</i> , 2019, 48, 466-479.	1.0	24
1114	Cold Tumors: A Therapeutic Challenge for Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 168.	2.2	733
1115	Durable anticancer immunity from intratumoral administration of IL-23, IL-36Î³, and OX40L mRNAs. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	176
1116	Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo. <i>Journal of Visualized Experiments</i> , 2019, , .	0.2	14
1117	Advancing Cancer Immunotherapies with Nanotechnology. <i>Advanced Therapeutics</i> , 2019, 2, 1800128.	1.6	45
1118	OMIP-054: Broad Immune Phenotyping of Innate and Adaptive Leukocytes in the Brain, Spleen, and Bone Marrow of an Orthotopic Murine Glioblastoma Model by Mass Cytometry. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2019, 95, 422-426.	1.1	16

#	ARTICLE	IF	CITATIONS
1119	Role of Immunotherapy in the Management of Locally Advanced and Recurrent/Metastatic Cervical Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 91-97.	2.3	47
1120	The Development of Tumor Neoantigen Vaccine Immunotherapy. <i>E3S Web of Conferences</i> , 2019, 78, 01005.	0.2	0
1121	Integrating clinical, molecular, proteomic and histopathological data within the tissue context: tissunomics. <i>Histopathology</i> , 2019, 75, 4-19.	1.6	8
1122	A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer. , 2019, 7, 16.		68
1123	Analysis of Leukocyte Behaviors on Microfluidic Chips. <i>Advanced Healthcare Materials</i> , 2019, 8, e1801406.	3.9	13
1124	Combination Cancer Immunotherapy with Molecular Targeted Agents/Anti-CTLA-4 Antibody for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2019, 8, 1-11.	4.2	48
1125	FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation. <i>Nature Communications</i> , 2019, 10, 448.	5.8	65
1126	Engineering T cell response to cancer antigens by choice of focal therapeutic conditions. <i>International Journal of Hyperthermia</i> , 2019, 36, 130-138.	1.1	74
1127	Epigenetic therapy in immune-oncology. <i>Nature Reviews Cancer</i> , 2019, 19, 151-161.	12.8	345
1128	Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor. <i>Cancer Research</i> , 2019, 79, 1996-2008.	0.4	62
1129	Immunotherapy is Here to Stay: A New Treatment Paradigm in Lung Cancer. <i>Archivos De Bronconeumologia</i> , 2019, 55, 124-125.	0.4	3
1130	Intrinsic cancer vaccination. <i>Advanced Drug Delivery Reviews</i> , 2019, 151-152, 2-22.	6.6	30
1131	Liquid biopsy for lung cancer immunotherapy (Review). <i>Oncology Letters</i> , 2019, 17, 4751-4760.	0.8	14
1132	Symmetric bis-benzoxazole-based chemicals exerted anti-inflammatory effect on danger signal LPS-stimulated macrophages. <i>Monatshefte für Chemie</i> , 2019, 150, 1137-1146.	0.9	19
1133	Combining immunotherapies to treat non-small cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 621-634.	1.0	2
1134	Expression of costimulatory and inhibitory receptors in FoxP3+ regulatory T cells within the tumor microenvironment: Implications for combination immunotherapy approaches. <i>Advances in Cancer Research</i> , 2019, 144, 193-261.	1.9	19
1135	Impact of Neoadjuvant Chemotherapy on Concordance of PD-L1 Staining Fidelity between the Primary Tumor and Lymph Node Metastases in Bladder Cancer. <i>Urology</i> , 2019, 131, 150-156.	0.5	6
1136	Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers. <i>Gynecologic Oncology</i> , 2019, 154, 314-322.	0.6	101

#	ARTICLE	IF	CITATIONS
1137	18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1859-1868.	3.3	62
1138	Fc μ r regulates mononuclear phagocyte control of anti-tumor immunity. <i>Nature Communications</i> , 2019, 10, 2678.	5.8	14
1139	Tumor-targeted IL-12 combined with tumor resection yields a survival-favorable immune profile. , 2019, 7, 154.		16
1140	Targeting the Tumor Microenvironment in Renal Cell Cancer Biology and Therapy. <i>Frontiers in Oncology</i> , 2019, 9, 490.	1.3	85
1141	Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2019, 193, 105415.	1.2	44
1142	The 6th R of Radiobiology: Reactivation of Anti-Tumor Immune Response. <i>Cancers</i> , 2019, 11, 860.	1.7	75
1143	Translational Prospects of ultrasound-mediated tumor immunotherapy: Preclinical advances and safety considerations. <i>Cancer Letters</i> , 2019, 460, 86-95.	3.2	15
1144	Rod-Scale Design Strategies for Immune-Targeted Delivery System toward Cancer Immunotherapy. <i>ACS Nano</i> , 2019, 13, 7705-7715.	7.3	40
1145	A tumor-targeting nanomedicine carrying the p53 gene crosses the blood-brain barrier and enhances anti-PD-1 immunotherapy in mouse models of glioblastoma. <i>International Journal of Cancer</i> , 2019, 145, 2535-2546.	2.3	48
1146	Intratumoral delivery of an HPV vaccine elicits a broad anti-tumor immune response that translates into a potent anti-tumor effect in a preclinical murine HPV model. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1273-1286.	2.0	5
1147	A carrier-free multiplexed gene editing system applicable for suspension cells. <i>Biomaterials</i> , 2019, 217, 119298.	5.7	26
1148	Functional genomics in cancer immunotherapy: computational approaches for biomarker and drug discovery. <i>Molecular Systems Design and Engineering</i> , 2019, 4, 689-700.	1.7	3
1149	The 100 top-cited studies in cancer immunotherapy. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2019, 47, 2282-2292.	1.9	26
1150	Illuminating the Onco-GPCRome: Novel G protein-coupled receptor-driven oncocrine networks and targets for cancer immunotherapy. <i>Journal of Biological Chemistry</i> , 2019, 294, 11062-11086.	1.6	129
1151	Immunologic cellular characteristics of the tumour microenvironment of hepatocellular carcinoma drive patient outcomes. <i>World Journal of Surgical Oncology</i> , 2019, 17, 97.	0.8	15
1152	Cardiotoxicity of Immune Checkpoint Inhibitors. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2019, 21, 32.	0.4	42
1153	High Salt Inhibits Tumor Growth by Enhancing Anti-tumor Immunity. <i>Frontiers in Immunology</i> , 2019, 10, 1141.	2.2	34
1154	Characterization of spatial distribution of tumor-infiltrating CD8+ T cells refines their prognostic utility for pancreatic cancer survival. <i>Modern Pathology</i> , 2019, 32, 1495-1507.	2.9	90

#	ARTICLE	IF	CITATIONS
1155	New oncologic emergencies: What is there to know about immunotherapy and its potential side effects?. <i>European Journal of Internal Medicine</i> , 2019, 66, 1-8.	1.0	19
1156	Tumor-associated antigens identified early in mouse mammary tumor development can be effective vaccine targets. <i>Vaccine</i> , 2019, 37, 3552-3561.	1.7	14
1157	Superparamagnetic iron oxide nanoparticles (SPIONs) as a multifunctional tool in various cancer therapies. <i>Reports of Practical Oncology and Radiotherapy</i> , 2019, 24, 307-314.	0.3	39
1158	Achieving systemic delivery of oncolytic viruses. <i>Expert Opinion on Drug Delivery</i> , 2019, 16, 607-620.	2.4	56
1159	Impaired circulating myeloid CD1c+ dendritic cell function in human glioblastoma is restored by p38 inhibition – implications for the next generation of DC vaccines. <i>Oncolmmunology</i> , 2019, 8, e1593803.	2.1	24
1160	An efficient or methodical review of immunotherapy against breast cancer. <i>Journal of Biochemical and Molecular Toxicology</i> , 2019, 33, e22339.	1.4	14
1161	Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-Vaccine. <i>Frontiers in Immunology</i> , 2019, 10, 1015.	2.2	39
1162	Induction of anti-cancer T cell immunity by in situ vaccination using systemically administered nanomedicines. <i>Cancer Letters</i> , 2019, 459, 192-203.	3.2	23
1163	Development of [¹⁸ F]FPy-WL12 as a PD-L1 Specific PET Imaging Peptide. <i>Molecular Imaging</i> , 2019, 18, 153601211985218.	0.7	52
1164	Hematologic markers of distant metastases in gastric cancer. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 529-536.	0.6	14
1165	Immunotherapy for hepatocellular carcinoma: A review of potential new drugs based on ongoing clinical studies as of 2019. <i>Digestive and Liver Disease</i> , 2019, 51, 1067-1073.	0.4	25
1166	Prognostic relevance of tertiary lymphoid organs following neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma. <i>Cancer Science</i> , 2019, 110, 1853-1862.	1.7	31
1167	The current state of molecular testing in the treatment of patients with solid tumors, 2019. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 305-343.	157.7	203
1168	Combining Nanomedicine and Immunotherapy. <i>Accounts of Chemical Research</i> , 2019, 52, 1543-1554.	7.6	310
1169	The emerging links between chromosomal instability (CIN), metastasis, inflammation and tumour immunity. <i>Molecular Cytogenetics</i> , 2019, 12, 17.	0.4	83
1170	Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. , 2019, 7, 131.		64
1171	Immunomodulation and Immunotherapy for Gastric Cancer. <i>Current Clinical Pathology</i> , 2019, , 189-212.	0.0	1
1172	Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. <i>Lancet, The</i> , 2019, 393, 2404-2415.	6.3	778

#	ARTICLE	IF	CITATIONS
1173	Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma. , 2019, 7, 128.		27
1174	Quantitative Systems Pharmacology: An Exemplar Model—Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 380-395.	1.3	33
1175	Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2019, 20, 924-937.	5.1	1,133
1176	Translation of cancer immunotherapy from the bench to the bedside. Advances in Cancer Research, 2019, 143, 1-62.	1.9	28
1177	Quantitative Mechanistic Modeling in Support of Pharmacological Therapeutics Development in Immuno-Oncology. Frontiers in Immunology, 2019, 10, 924.	2.2	31
1178	CD91 on dendritic cells governs immunosurveillance of nascent, emerging tumors. JCI Insight, 2019, 4, .	2.3	17
1179	CD38 in Adenosinergic Pathways and Metabolic Re-programming in Human Multiple Myeloma Cells: In-tandem Insights From Basic Science to Therapy. Frontiers in Immunology, 2019, 10, 760.	2.2	56
1180	Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity. Clinical Cancer Research, 2019, 25, 4808-4819.	3.2	66
1181	IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer. Future Oncology, 2019, 15, 1951-1961.	1.1	58
1182	The treatment of multiple myeloma in an era of precision medicine. Expert Review of Precision Medicine and Drug Development, 2019, 4, 153-162.	0.4	3
1183	Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker. BioMed Research International, 2019, 2019, 1-15.	0.9	37
1184	Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort. Clinical Lung Cancer, 2019, 20, e564-e575.	1.1	49
1185	Immunometabolism: A new target for improving cancer immunotherapy. Advances in Cancer Research, 2019, 143, 195-253.	1.9	30
1186	Beyond PD-L1 Markers for Lung Cancer Immunotherapy. International Journal of Molecular Sciences, 2019, 20, 1915.	1.8	61
1188	Immunotherapy in hepatocellular carcinoma. Annals of Hepatology, 2019, 18, 291-297.	0.6	66
1189	Gastric Cancer In The Precision Medicine Era. Current Clinical Pathology, 2019, , .	0.0	2
1190	The Expression of ILT4 in Myeloid Dendritic Cells in Patients with Hepatocellular Carcinoma. Immunological Investigations, 2019, 48, 704-718.	1.0	9
1191	A Network Approach to Developing Immuno-Oncology Combinations in Canada. Current Oncology, 2019, 26, 73-79.	0.9	1

#	ARTICLE	IF	CITATIONS
1192	Immunogenic Cell Death and Immunotherapy of Multiple Myeloma. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 50.	1.8	139
1193	STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models. , 2019, 7, 115.		114
1194	Beyond a chemopreventive reagent, aspirin is a master regulator of the hallmarks of cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1387-1403.	1.2	32
1195	rs4143815-PDL1, a New Potential Immunogenetic Biomarker of Biochemical Recurrence in Locally Advanced Prostate Cancer after Radiotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2082.	1.8	6
1196	Beyond the tumour microenvironment. <i>International Journal of Cancer</i> , 2019, 145, 2611-2618.	2.3	71
1197	Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2019, 20, 849-861.	5.1	368
1198	MPL nano-liposomal vaccine containing P5 HER2/neu-derived peptide pulsed PADRE as an effective vaccine in a mice TUBO model of breast cancer. <i>Journal of Controlled Release</i> , 2019, 303, 223-236.	4.8	58
1199	Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1692.	1.8	61
1200	Complementing the Cancer-Immunity Cycle. <i>Frontiers in Immunology</i> , 2019, 10, 774.	2.2	136
1201	Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment. <i>Molecular Therapy - Oncolytics</i> , 2019, 13, 67-81.	2.0	44
1202	Cancer nanomedicine for combination cancer immunotherapy. <i>Nature Reviews Materials</i> , 2019, 4, 398-414.	23.3	658
1203	Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies. <i>Journal of Hematology and Oncology</i> , 2019, 12, 42.	6.9	58
1204	From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy. <i>Advances in Cancer Research</i> , 2019, 143, 63-144.	1.9	52
1205	Heterogeneity of the Head and Neck Squamous Cell Carcinoma Immune Landscape and Its Impact on Immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 52.	1.8	222
1206	Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option. <i>Annals of Oncology</i> , 2019, 30, 721-732.	0.6	53
1207	ER stress-induced mediator C/EBP homologous protein thwarts effector T _H 1 cell activity in tumors through T-bet repression. <i>Nature Communications</i> , 2019, 10, 1280.	5.8	83
1208	Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma. , 2019, 7, 80.		65
1209	Synthetic, Supramolecular, and Self-Adjuvanting CD8 ⁺ T _H 1 Cell Epitope Vaccine Increases the Therapeutic Antitumor Immunity. <i>Advanced Therapeutics</i> , 2019, 2, 1900010.	1.6	15

#	ARTICLE	IF	CITATIONS
1210	Induction/reversal of drug resistance in gastric cancer by non-coding RNAs (Review). <i>International Journal of Oncology</i> , 2019, 54, 1511-1524.	1.4	21
1211	Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy. <i>Cancer Letters</i> , 2019, 452, 66-70.	3.2	150
1213	Distinct chemotherapy-associated anti-cancer immunity by myeloid cells inhibition in murine pancreatic cancer models. <i>Cancer Science</i> , 2019, 110, 903-912.	1.7	11
1214	Immunotherapy: Pancreatic Cancer and Extrahepatic Biliary Tract Cancer. <i>Visceral Medicine</i> , 2019, 35, 28-37.	0.5	7
1215	Biomimetic Glyconanoparticle Vaccine for Cancer Immunotherapy. <i>ACS Nano</i> , 2019, 13, 2936-2947.	7.3	42
1216	Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions. <i>Cells</i> , 2019, 8, 200.	1.8	6
1217	VEGF in Signaling and Disease: Beyond Discovery and Development. <i>Cell</i> , 2019, 176, 1248-1264.	13.5	1,468
1218	Heteroleptic Ruthenium Polypyridyl Complex Had Differential Effects on the Production of Pro-inflammatory Cytokines TNF α , IL1 β , and IL6 by the Mammalian Macrophages In Vitro. <i>Inflammation</i> , 2019, 42, 1383-1388.	1.7	10
1219	Paraneoplastic autoimmunity and small-cell lung cancer: Neurological and serological accompaniments. <i>Thoracic Cancer</i> , 2019, 10, 1001-1004.	0.8	42
1220	Multifunctional platinum(IV) complexes as immunostimulatory agents to promote cancer immunochemotherapy by inhibiting tryptophan-2,3-dioxygenase. <i>European Journal of Medicinal Chemistry</i> , 2019, 169, 29-41.	2.6	25
1221	Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2019, 76, 4-6.	0.9	8
1222	Immunotherapy is Here to Stay: A New Treatment Paradigm in Lung Cancer. <i>Archivos De Bronconeumologia</i> , 2019, 55, 124-125.	0.4	1
1223	Harnessing immune checkpoints in myeloid lineage cells for cancer immunotherapy. <i>Cancer Letters</i> , 2019, 452, 51-58.	3.2	16
1224	Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract. <i>European Urology</i> , 2019, 76, 73-81.	0.9	117
1225	Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy. <i>Gastroenterology</i> , 2019, 156, 1862-1876.e9.	0.6	92
1226	Critical role of kinase activity of hematopoietic progenitor kinase 1 in anti-tumor immune surveillance. <i>PLoS ONE</i> , 2019, 14, e0212670.	1.1	28
1227	Combining Radiation and Immune Checkpoint Blockade in the Treatment of Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 122.	1.3	63
1228	Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors. <i>Annals of Oncology</i> , 2019, 30, 1134-1142.	0.6	113

#	ARTICLE	IF	CITATIONS
1229	Reduced lung cancer burden by selective immunomodulators elicits improvements in muscle proteolysis and strength in cachectic mice. <i>Journal of Cellular Physiology</i> , 2019, 234, 18041-18052.	2.0	14
1230	Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy—Focus on Fcγ3RIIB. <i>Frontiers in Immunology</i> , 2019, 10, 481.	2.2	33
1231	Convergent Identification and Interrogation of Tumor-Intrinsic Factors that Modulate Cancer Immunity In Vivo. <i>Cell Systems</i> , 2019, 8, 136-151.e7.	2.9	14
1232	PD-L1 expression combined with microsatellite instability/CD8+ tumor infiltrating lymphocytes as a useful prognostic biomarker in gastric cancer. <i>Scientific Reports</i> , 2019, 9, 4633.	1.6	37
1233	The role of immune checkpoint inhibitors in advanced non-small cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 435-447.	1.0	7
1234	Tailoring Nanomaterials for Targeting Tumor-Associated Macrophages. <i>Advanced Materials</i> , 2019, 31, e1808303.	11.1	223
1235	Extracellular Vesicle-Based Therapeutic Targeting of β-Catenin to Modulate Anticancer Immune Responses in Hepatocellular Cancer. <i>Hepatology Communications</i> , 2019, 3, 525-541.	2.0	38
1236	Tumor-Associated Lymphatic Vessel Features and Immunomodulatory Functions. <i>Frontiers in Immunology</i> , 2019, 10, 720.	2.2	72
1237	Development of resiquimod-loaded modified PLA-based nanoparticles for cancer immunotherapy: A kinetic study. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 139, 253-261.	2.0	28
1238	Telomerase-Targeted Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1823.	1.8	80
1239	Current Landscape of Immunotherapy in Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 1205.	3.4	260
1240	Applications of molecular engineering in T cell-based immunotherapies. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2019, 11, e1557.	3.3	6
1241	Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology. <i>Molecules</i> , 2019, 24, 1190.	1.7	163
1242	Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. <i>Molecular Cancer</i> , 2019, 18, 60.	7.9	361
1243	Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities. <i>Gastroenterology</i> , 2019, 156, 2056-2072.	0.6	300
1244	Rationale for Combining Radiotherapy and Immune Checkpoint Inhibition for Patients With Hypoxic Tumors. <i>Frontiers in Immunology</i> , 2019, 10, 407.	2.2	44
1245	Immunotherapy in ovarian cancer: fake news or the real deal?. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 201-211.	1.2	37
1246	Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 430-433.	1.2	33

#	ARTICLE	IF	CITATIONS
1247	Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2019, 12, 35.	6.9	220
1248	Naringenin inhibits migration of breast cancer cells via inflammatory and apoptosis cell signaling pathways. <i>Inflammopharmacology</i> , 2019, 27, 1021-1036.	1.9	92
1249	Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity. <i>Cell</i> , 2019, 177, 556-571.e16.	13.5	405
1250	Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory. <i>Cell</i> , 2019, 177, 414-427.e13.	13.5	847
1251	Could the menagerie of the gut microbiome really cure cancer? Hope or hype. , 2019, 7, 92.		16
1252	Unlocking the therapeutic potential of primary tumor-draining lymph nodes. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1681-1688.	2.0	56
1253	Reprogramming Tumor Immune Microenvironment (TIME) and Metabolism via Biomimetic Targeting Codelivery of Shikonin/JQ1. <i>Nano Letters</i> , 2019, 19, 2935-2944.	4.5	134
1254	Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 1158-1166.	0.8	17
1255	Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy. <i>Advanced Healthcare Materials</i> , 2019, 8, e1801320.	3.9	43
1256	Immunotherapy-based combination strategies for treatment of gastrointestinal cancers: current status and future prospects. <i>Frontiers of Medicine</i> , 2019, 13, 12-23.	1.5	14
1257	The immunomodulatory potential of natural compounds in tumor-bearing mice and humans. <i>Critical Reviews in Food Science and Nutrition</i> , 2019, 59, 992-1007.	5.4	52
1258	Charge variants characterization and release assay development for co-formulated antibodies as a combination therapy. <i>MAbs</i> , 2019, 11, 489-499.	2.6	26
1259	Order of administration of combination cytokine therapies can decouple toxicity from efficacy in syngeneic mouse tumor models. <i>Oncolmmunology</i> , 2019, 8, e1558678.	2.1	10
1260	TCR Repertoire Analysis Reveals Mobilization of Novel CD8+ T Cell Clones Into the Cancer-Immunity Cycle Following Anti-CD4 Antibody Administration. <i>Frontiers in Immunology</i> , 2018, 9, 3185.	2.2	33
1261	Emerging Nano-Microapproaches for Cancer Immunotherapy. <i>Advanced Science</i> , 2019, 6, 1801847.	5.6	136
1263	Therapeutic Potential of Natural Killer Cells in Gastric Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 3095.	2.2	43
1264	Incidence of Ipilimumab-Related Serious Adverse Events in Patients with Advanced Cancer: A Meta-Analysis. <i>Journal of Cancer</i> , 2019, 10, 120-130.	1.2	5
1265	Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials. <i>Investigational New Drugs</i> , 2019, 37, 1198-1206.	1.2	11

#	ARTICLE	IF	CITATIONS
1266	Vaccine Strategies to Improve Anti-cancer Cellular Immune Responses. <i>Frontiers in Immunology</i> , 2019, 10, 8.	2.2	156
1267	Cardiac Complications in Immune Checkpoint Inhibition Therapy. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 3.	1.1	65
1268	Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Thoracic Cancer</i> , 2019, 10, 607-623.	0.8	22
1269	Programmed Death Ligand-1 expression in stage II colon cancer - experiences from a nationwide populationbased cohort. <i>BMC Cancer</i> , 2019, 19, 142.	1.1	24
1270	Activation of CD8+ T Cell Responses after Melanoma Antigen Targeting to CD169+ Antigen Presenting Cells in Mice and Humans. <i>Cancers</i> , 2019, 11, 183.	1.7	21
1271	Leveraging biomaterials for cancer immunotherapy: targeting pattern recognition receptors. <i>Materials Today Nano</i> , 2019, 5, 100029.	2.3	30
1272	Multiparametric analysis of CD8 ⁺ T cell compartment phenotype in chronic lymphocytic leukemia reveals a signature associated with progression toward therapy. <i>Oncolmmunology</i> , 2019, 8, e1570774.	2.1	6
1273	Balancing the Checkpoint: Managing Colitis Associated with Dual Checkpoint Inhibitors and High-Dose Aspirin. <i>Digestive Diseases and Sciences</i> , 2019, 64, 685-688.	1.1	1
1274	From the Hellstrom paradox toward cancer cure. <i>Progress in Molecular Biology and Translational Science</i> , 2019, 164, 1-24.	0.9	12
1275	High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes. <i>Lung Cancer</i> , 2019, 130, 35-41.	0.9	17
1276	Photo-induced anti-inflammatory activities of chloro substituted subphthalocyanines on the mammalian macrophage in vitro. <i>Photodiagnosis and Photodynamic Therapy</i> , 2019, 25, 499-503.	1.3	15
1277	Prognostic impact of CD8 and programmed death-ligand 1 expression in patients with resectable non-small cell lung cancer. <i>British Journal of Cancer</i> , 2019, 120, 547-554.	2.9	42
1278	Immunotherapeutic Blockade of Macrophage Clever-1 Reactivates the CD8+ T-cell Response against Immunosuppressive Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 3289-3303.	3.2	73
1279	Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors. <i>Clinical Pharmacokinetics</i> , 2019, 58, 835-857.	1.6	222
1280	Non-Thermal Plasma as a Unique Delivery System of Short-Lived Reactive Oxygen and Nitrogen Species for Immunogenic Cell Death in Melanoma Cells. <i>Advanced Science</i> , 2019, 6, 1802062.	5.6	177
1281	Radiotherapy and Cisplatin Increase Immunotherapy Efficacy by Enabling Local and Systemic Intratumoral T-cell Activity. <i>Cancer Immunology Research</i> , 2019, 7, 670-682.	1.6	53
1282	<p>Dexamethasone inhibits the proliferation of tumor cells</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 1141-1154.	0.9	16
1283	Aluminum doped carbon nanodots as potent adjuvants on the mammalian macrophages. <i>Molecular Biology Reports</i> , 2019, 46, 2405-2415.	1.0	18

#	ARTICLE	IF	CITATIONS
1284	Advances in immunotherapy delivery from implantable and injectable biomaterials. <i>Acta Biomaterialia</i> , 2019, 88, 15-31.	4.1	127
1285	Phase III trials in ovarian cancer: The evolving landscape of front line therapy. <i>Gynecologic Oncology</i> , 2019, 153, 436-444.	0.6	17
1286	Immunotherapy for skin cancer. <i>International Immunology</i> , 2019, 31, 465-475.	1.8	47
1287	Immunotherapy in extensive small cell lung cancer. <i>Experimental Hematology and Oncology</i> , 2019, 8, 5.	2.0	32
1288	Tumor infiltrating mast cells determine oncogenic HIF-2 α -conferred immune evasion in clear cell renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 731-741.	2.0	39
1289	Bisbenzoxazole derivatives had an antiinflammatory effect on in vitro stimulated macrophages. <i>Turkish Journal of Chemistry</i> , 2019, 43, 963-971.	0.5	4
1290	Gene-based Interventions for Cancer Immunotherapy. , 0, , .		0
1292	Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors. <i>Oncologist</i> , 2019, 24, 1128-1136.	1.9	156
1293	EVOLVING ROLE OF CAR T-CELL IN CANCER IMMUNOTHERAPY. <i>International Journal of Current Pharmaceutical Research</i> , 0, , 19-27.	0.2	0
1294	Serum CD95L Level Correlates with Tumor Immune Infiltration and Is a Positive Prognostic Marker for Advanced High-Grade Serous Ovarian Cancer. <i>Molecular Cancer Research</i> , 2019, 17, 2537-2548.	1.5	10
1295	Acute myeloid leukemia-induced T-cell suppression can be reversed by inhibition of the MAPK pathway. <i>Blood Advances</i> , 2019, 3, 3038-3051.	2.5	14
1296	How T Cells Do the "Search for the Needle in the Haystack" <i>Frontiers in Physics</i> , 2019, 7, .	1.0	8
1297	Combination immune checkpoint inhibitors with platinum-based chemotherapy in advanced non-small cell lung cancer: what's known and what's next. <i>Translational Lung Cancer Research</i> , 2019, 8, S447-S450.	1.3	12
1298	Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immune checkpoint inhibitors for first- or second-line treatment of advanced gastric and gastro-esophageal junction cancer. <i>The Cochrane Library</i> , 0, , .	1.5	0
1299	Analysis of tumour ecological balance reveals resource-dependent adaptive strategies of ovarian cancer. <i>EBioMedicine</i> , 2019, 48, 224-235.	2.7	8
1300	Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With nab-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1256.	1.3	10
1301	<p>Blocking TGF- β 2 Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 9527-9538.	1.0	93
1302	The immune landscape of esophageal cancer. <i>Cancer Communications</i> , 2019, 39, 79.	3.7	142

#	ARTICLE	IF	CITATIONS
1303	Allies or Enemies? The Multifaceted Role of Myeloid Cells in the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2019, 10, 2746.	2.2	41
1304	Genome-wide CRISPR Screen to Identify Genes that Suppress Transformation in the Presence of Endogenous KrasG12D. <i>Scientific Reports</i> , 2019, 9, 17220.	1.6	6
1305	Immune System Evasion as Hallmark of Melanoma Progression: The Role of Dendritic Cells. <i>Frontiers in Oncology</i> , 2019, 9, 1148.	1.3	90
1306	Highlights of 2019 Protein Engineering Summit (PEGS) in Boston, USA: advancing antibody-based cancer therapies to the clinic. <i>Antibody Therapeutics</i> , 2019, 2, 79-87.	1.2	6
1307	Comparative Approach to the Temporo-Spatial Organization of the Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2019, 9, 1185.	1.3	9
1308	The Evolving Landscape of Cancer Therapeutics. <i>Handbook of Experimental Pharmacology</i> , 2019, 260, 43-79.	0.9	10
1309	Nucleic Acid Nanoparticles at a Crossroads of Vaccines and Immunotherapies. <i>Molecules</i> , 2019, 24, 4620.	1.7	23
1310	Promotion on NLRC5 upregulating MHC-I expression by IFN- γ in MHC-I-deficient breast cancer cells. <i>Immunologic Research</i> , 2019, 67, 497-504.	1.3	10
1311	Hedgehog/GLI signaling in tumor immunity - new therapeutic opportunities and clinical implications. <i>Cell Communication and Signaling</i> , 2019, 17, 172.	2.7	46
1312	Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies. <i>Liver Cancer</i> , 2019, 8, 413-426.	4.2	40
1313	Immune pressures drive the promoter hypermethylation of neoantigen genes. <i>Experimental Hematology and Oncology</i> , 2019, 8, 32.	2.0	11
1314	Harnessing innate immunity in cancer therapy. <i>Nature</i> , 2019, 574, 45-56.	13.7	533
1315	Multiplexed activation of endogenous genes by CRISPRa elicits potent antitumor immunity. <i>Nature Immunology</i> , 2019, 20, 1494-1505.	7.0	83
1316	Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma. <i>Medicine (United States)</i> , 2019, 98, e16417.	0.4	28
1317	Repurposing Food and Drug Administration-Approved Drugs to Promote Antitumor Immunity. <i>Cancer Journal (Sudbury, Mass)</i> , 2019, 25, 88-99.	1.0	5
1318	Multiple Targets of the Canonical WNT/ β -Catenin Signaling in Cancers. <i>Frontiers in Oncology</i> , 2019, 9, 1248.	1.3	135
1319	Development of patient-derived xenograft models of prostate cancer for maintaining tumor heterogeneity. <i>Translational Andrology and Urology</i> , 2019, 8, 519-528.	0.6	19
1320	High CD3 and ICOS and low TIM-3 expression predict favourable survival in resected oesophageal squamous cell carcinoma. <i>Scientific Reports</i> , 2019, 9, 20197.	1.6	15

#	ARTICLE	IF	CITATIONS
1321	The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer. <i>Oncologist</i> , 2019, 24, 1348-1355.	1.9	10
1323	The molecular limitations of biomarker research in bladder cancer. <i>World Journal of Urology</i> , 2019, 37, 837-848.	1.2	31
1324	Immunomodulators targeting the PD-1/PD-L1 protein-protein interaction: From antibodies to small molecules. <i>Medicinal Research Reviews</i> , 2019, 39, 265-301.	5.0	128
1325	Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 74.	3.4	557
1326	Future of Immune Checkpoint Inhibitors. , 2019, , 227-243.		2
1327	Dendritic Cell Membrane Vesicles for Activation and Maintenance of Antigen-Specific T Cells. <i>Advanced Healthcare Materials</i> , 2019, 8, e1801091.	3.9	36
1328	Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study. <i>European Journal of Cancer</i> , 2019, 107, 124-132.	1.3	85
1329	Evaluating natural killer cell cytotoxicity against solid tumors using a microfluidic model. <i>Oncolimmunology</i> , 2019, 8, 1553477.	2.1	103
1330	Nano-, micro-, and macroscale drug delivery systems for cancer immunotherapy. <i>Acta Biomaterialia</i> , 2019, 85, 1-26.	4.1	142
1331	Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 517-527.	2.0	39
1332	Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study. <i>Lung Cancer</i> , 2019, 128, 105-112.	0.9	126
1333	Priming anti-tumor immunity by radiotherapy: Dying tumor cell-derived DAMPs trigger endothelial cell activation and recruitment of myeloid cells. <i>Oncolimmunology</i> , 2019, 8, e1523097.	2.1	91
1334	Therapeutic vaccination using minimal HPV16 epitopes in a novel MHC-humanized murine HPV tumor model. <i>Oncolimmunology</i> , 2019, 8, e1524694.	2.1	8
1335	Functional Nanomaterials Optimized to Circumvent Tumor Immunological Tolerance. <i>Advanced Functional Materials</i> , 2019, 29, 1806087.	7.8	21
1336	A review on the interactions between the tumor microenvironment and androgen receptor signaling in prostate cancer. <i>Translational Research</i> , 2019, 206, 91-106.	2.2	20
1337	Calnexin Impairs the Antitumor Immunity of CD4+ and CD8+ T Cells. <i>Cancer Immunology Research</i> , 2019, 7, 123-135.	1.6	30
1338	Cytokines in clinical cancer immunotherapy. <i>British Journal of Cancer</i> , 2019, 120, 6-15.	2.9	720
1339	RNA-Modified T Cells Mediate Effective Delivery of Immunomodulatory Cytokines to Brain Tumors. <i>Molecular Therapy</i> , 2019, 27, 837-849.	3.7	21

#	ARTICLE	IF	CITATIONS
1340	Functional insights into nucleotide-metabolizing ectoenzymes expressed by bone marrow-resident cells in patients with multiple myeloma. <i>Immunology Letters</i> , 2019, 205, 40-50.	1.1	11
1341	Heterogeneity of programmed death ligand expression in a case of Merkel cell carcinoma exhibiting complete regression after multiple metastases. <i>British Journal of Dermatology</i> , 2019, 180, 1228-1229.	1.4	8
1342	Neural regulation of drug resistance in cancer treatment. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 20-28.	3.3	8
1343	Beyond the PD-L1 horizon: In search for a good biomarker to predict success of immunotherapy in gastric and esophageal adenocarcinoma. <i>Cancer Letters</i> , 2019, 442, 279-286.	3.2	34
1344	Expert Consensus Document on Pulmonary Metastasectomy. <i>Annals of Thoracic Surgery</i> , 2019, 107, 631-649.	0.7	128
1345	Adoptive cellular therapies: the current landscape. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 449-461.	1.4	261
1346	Batf3 ⁺ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy. <i>Oncolmmunology</i> , 2019, 8, e1546068.	2.1	42
1347	Update on the Biology and Management of Renal Cell Carcinoma. <i>Journal of Investigative Medicine</i> , 2019, 67, 1-10.	0.7	12
1348	Toward the development of true off-the-shelf synthetic T cell immunotherapy. <i>Cancer Science</i> , 2019, 110, 16-22.	1.7	29
1349	Impact of Polymer-TLR-7/8 Agonist (Adjuvant) Morphology on the Potency and Mechanism of CD8 T Cell Induction. <i>Biomacromolecules</i> , 2019, 20, 854-870.	2.6	32
1350	Photothermal Ablation of Cancer Cells by Albumin-Modified Gold Nanorods and Activation of Dendritic Cells. <i>Materials</i> , 2019, 12, 31.	1.3	25
1351	Improving Cancer Vaccine Efficiency by Nanomedicine. <i>Advanced Biology</i> , 2019, 3, e1800287.	3.0	22
1352	Cancer Epigenomics on Precision Medicine and Immunotherapy. , 2019, , 483-503.		0
1353	Time for radioimmunotherapy: an overview to bring improvements in clinical practice. <i>Clinical and Translational Oncology</i> , 2019, 21, 992-1004.	1.2	13
1354	Translation control of the immune checkpoint in cancer and its therapeutic targeting. <i>Nature Medicine</i> , 2019, 25, 301-311.	15.2	184
1355	CIITA-related block of HLA class II expression, upregulation of HLA class I, and heterogeneous expression of immune checkpoints in hepatocarcinomas: implications for new therapeutic approaches. <i>Oncolmmunology</i> , 2019, 8, 1548243.	2.1	24
1356	The role of immunotherapy in small cell lung cancer. <i>Clinical and Translational Oncology</i> , 2019, 21, 961-976.	1.2	81
1357	Population Pharmacokinetics and Exposure Safety Analyses of Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 364-373.	1.0	11

#	ARTICLE	IF	CITATIONS
1358	Cell therapy products: focus on issues with manufacturing and quality control of chimeric antigen receptor T cell therapies. <i>Journal of Chemical Technology and Biotechnology</i> , 2019, 94, 1008-1016.	1.6	22
1359	Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up. <i>JAMA Oncology</i> , 2019, 5, 334.	3.4	206
1360	PD-L1 knockdown via hybrid micelle promotes paclitaxel induced Cancer-Immunity Cycle for melanoma treatment. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 127, 161-174.	1.9	23
1361	Association of Cancer Immunotherapy With Acute Macular Neuroretinopathy and Diffuse Retinal Venulitis. <i>JAMA Ophthalmology</i> , 2019, 137, 96.	1.4	22
1362	Could the Key Be Hidden in the Lysosomes?. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2019, 95, 712-713.	1.1	0
1363	Genetic associations of T cell cancer immune response with tumor aggressiveness in localized prostate cancer patients and disease reclassification in an active surveillance cohort. <i>Oncolmmunology</i> , 2019, 8, e1483303.	2.1	7
1364	A Novel Engineered Small Protein for Positron Emission Tomography Imaging of Human Programmed Death Ligand-1: Validation in Mouse Models and Human Cancer Tissues. <i>Clinical Cancer Research</i> , 2019, 25, 1774-1785.	3.2	30
1365	Immunosuppressive circuits in tumor microenvironment and their influence on cancer treatment efficacy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 407-420.	1.4	39
1366	Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions. <i>European Urology</i> , 2019, 75, 100-110.	0.9	178
1367	Predictive Biomarkers and Targeted Therapies in Immuno-oncology. , 2019, , 335-344.		1
1368	Nanomedicine and macroscale materials in immuno-oncology. <i>Chemical Society Reviews</i> , 2019, 48, 351-381.	18.7	118
1369	Composition and Clinical Impact of the Immunologic Tumor Microenvironment in Oral Squamous Cell Carcinoma. <i>Journal of Immunology</i> , 2019, 202, 278-291.	0.4	61
1370	What, Why, Where, and When: Bringing Timing to Immuno-Oncology. <i>Trends in Immunology</i> , 2019, 40, 12-21.	2.9	50
1371	Management of local or regional non-nodal disease. <i>Journal of Surgical Oncology</i> , 2019, 119, 187-199.	0.8	8
1372	Cancer immunoediting and resistance to T cell-based immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 151-167.	12.5	1,093
1373	Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies. <i>Clinical Infectious Diseases</i> , 2019, 69, 909-920.	2.9	57
1374	From peripherally unsubstituted subphthalocyanines with anti-inflammatory activity on macrophages to tri-iodo derivatives with adjuvant and immunostimulatory functions. <i>Journal of Porphyrins and Phthalocyanines</i> , 2019, 23, 56-62.	0.4	11
1375	Metal Drugs and the Anticancer Immune Response. <i>Chemical Reviews</i> , 2019, 119, 1519-1624.	23.0	237

#	ARTICLE	IF	CITATIONS
1376	Tumor Lysate-Loaded Lipid Hybrid Nanovaccine Collaborated with an Immune Checkpoint Antagonist for Combination Immunotherapy. <i>Advanced Healthcare Materials</i> , 2019, 8, e1800837.	3.9	20
1377	Immune checkpoint blockade opens a new way to cancer immunotherapy. <i>Journal of Cellular Physiology</i> , 2019, 234, 8541-8549.	2.0	84
1378	Murine RAW264.7 cells as cellular drug delivery carriers for tumor therapy: a good idea?. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 361-374.	1.1	9
1379	Immune biomarkers for predicting response to adoptive cell transfer as cancer treatment. <i>Immunogenetics</i> , 2019, 71, 71-86.	1.2	7
1380	Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis. <i>Clinical Lung Cancer</i> , 2019, 20, e97-e106.	1.1	71
1381	Durvalumab: a newly approved checkpoint inhibitor for the treatment of urothelial carcinoma. <i>Current Problems in Cancer</i> , 2019, 43, 181-194.	1.0	10
1382	The tumor microenvironment: Thousand obstacles for effector T cells. <i>Cellular Immunology</i> , 2019, 343, 103730.	1.4	9
1383	Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 92-100.	0.6	144
1384	Addressing barriers to effective cancer immunotherapy with nanotechnology: achievements, challenges, and roadmap to the next generation of nanoimmunotherapeutics. <i>Advanced Drug Delivery Reviews</i> , 2019, 141, 3-22.	6.6	44
1385	Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma. <i>Auris Nasus Larynx</i> , 2020, 47, 116-122.	0.5	33
1386	Novel therapeutic strategies for spinal osteosarcomas. <i>Seminars in Cancer Biology</i> , 2020, 64, 83-92.	4.3	32
1387	Cancer of the Kidney. , 2020, , 1361-1381.e4.		0
1388	RAF kinases are stabilized and required for dendritic cell differentiation and function. <i>Cell Death and Differentiation</i> , 2020, 27, 1300-1315.	5.0	15
1389	Application of protein set enrichment analysis to correlation of protein functional sets with mass spectral features and multivariate proteomic tests. <i>Clinical Mass Spectrometry</i> , 2020, 15, 44-53.	1.9	11
1390	Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 723-733.	5.7	102
1391	Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies. <i>Clinical and Translational Oncology</i> , 2020, 22, 919-927.	1.2	45
1392	Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials. <i>Cancer</i> , 2020, 126, 575-582.	2.0	65
1393	Immunity, Hypoxia, and Metabolism—the “Trois” of Cancer: Implications for Immunotherapy. <i>Physiological Reviews</i> , 2020, 100, 1-102.	13.1	190

#	ARTICLE	IF	CITATIONS
1394	Immunological and Clinicopathological Significance of MFG-E8 Expression in Patients with Oral Squamous Cell Carcinoma. <i>Pathology and Oncology Research</i> , 2020, 26, 1263-1268.	0.9	3
1395	<i>Cancer of the Lung.</i> , 2020, , 1108-1158.e16.		11
1396	Influence of tumour necrosis factor alpha on epithelialâ€mesenchymal transition of oral cancer cells in co-culture with mesenchymal stromal cells. <i>International Journal of Oral and Maxillofacial Surgery</i> , 2020, 49, 157-165.	0.7	13
1397	The impact of corticosteroid use during anti-PD1 treatment. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 814-822.	0.5	44
1398	VirtualCytometry: a webserver for evaluating immune cell differentiation using single-cell RNA sequencing data. <i>Bioinformatics</i> , 2020, 36, 546-551.	1.8	8
1399	The Cancer Immunotherapy Biomarker Testing Landscape. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 706-724.	1.2	57
1400	Assessment of IFN- γ and granzyme-B production by in â€œsitroâ€ technology. <i>Methods in Enzymology</i> , 2020, 631, 391-414.	0.4	3
1401	Cytofluorometric assessment of dendritic cell-mediated uptake of cancer cell apoptotic bodies. <i>Methods in Enzymology</i> , 2020, 632, 39-54.	0.4	1
1402	Changes of CD68, CD163, and PD-L1 tumor expression during high-dose-rate and pulsed-dose-rate brachytherapy for cervical cancer. <i>Brachytherapy</i> , 2020, 19, 51-59.	0.2	7
1403	Noncoding RNAs as potential mediators of resistance to cancer immunotherapy. <i>Seminars in Cancer Biology</i> , 2020, 65, 65-79.	4.3	55
1404	The relative biological effectiveness of proton irradiation in dependence of DNA damage repair. <i>British Journal of Radiology</i> , 2020, 93, 20190494.	1.0	10
1405	A TLR7 agonist strengthens T and NK cell function during BRAFâ€targeted therapy in a preclinical melanoma model. <i>International Journal of Cancer</i> , 2020, 146, 1409-1420.	2.3	22
1406	Biological regulation of diacylglycerol kinases in normal and neoplastic tissues: New opportunities for cancer immunotherapy. <i>Advances in Biological Regulation</i> , 2020, 75, 100663.	1.4	12
1407	Gut microbiome and cancer immunotherapy. <i>Journal of Cellular Physiology</i> , 2020, 235, 4082-4088.	2.0	30
1408	A Nanoscale Metalâ€Organic Framework to Mediate Photodynamic Therapy and Deliver CpG Oligodeoxynucleotides to Enhance Antigen Presentation and Cancer Immunotherapy. <i>Angewandte Chemie</i> , 2020, 132, 1124-1128.	1.6	34
1409	Nanotechnology platforms for cancer immunotherapy. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2020, 12, e1590.	3.3	82
1410	Identification of a neo-epitope dominating endogenous CD8 T cell responses to MC-38 colorectal cancer. <i>Oncolmmunology</i> , 2020, 9, 1673125.	2.1	40
1413	New Approaches on Cancer Immunotherapy. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a036863.	2.9	17

#	ARTICLE	IF	CITATIONS
1414	The Immunoscore: Colon Cancer and Beyond. <i>Clinical Cancer Research</i> , 2020, 26, 332-339.	3.2	255
1415	A Nanoscale Metal-Organic Framework to Mediate Photodynamic Therapy and Deliver CpG Oligodeoxynucleotides to Enhance Antigen Presentation and Cancer Immunotherapy. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 1108-1112.	7.2	144
1416	The potential of exosomes as theragnostics in various clinical situations. , 2020, , 467-486.		11
1417	Anti-tumour immune response in GL261 glioblastoma generated by Temozolomide Immune-Enhancing Metronomic Schedule monitored with MRSI-based nosological images. <i>NMR in Biomedicine</i> , 2020, 33, e4229.	1.6	15
1418	Immune-resistant mechanisms in cancer immunotherapy. <i>International Journal of Clinical Oncology</i> , 2020, 25, 810-817.	1.0	39
1419	Efficacy of PD-1 blockade therapy and T cell immunity in lung cancer patients. <i>Immunological Medicine</i> , 2020, 43, 10-15.	1.4	3
1420	Phenotype molding of T cells in colorectal cancer by single-cell analysis. <i>International Journal of Cancer</i> , 2020, 146, 2281-2295.	2.3	30
1421	Functional Cellular Anti-Tumor Mechanisms are Augmented by Genetic Proteoglycan Targeting. <i>Neoplasia</i> , 2020, 22, 86-97.	2.3	9
1423	Loss of myeloid-specific lamin A/C drives lung metastasis through Gfi1 and C/EBP β -mediated granulocytic differentiation. <i>Molecular Carcinogenesis</i> , 2020, 59, 679-690.	1.3	3
1425	Differential Immunomodulatory Effect of Carbon Dots Influenced by the Type of Surface Passivation Agent. <i>Inflammation</i> , 2020, 43, 777-783.	1.7	14
1426	The Immune Response in Nonmetastatic Axillary Lymph Nodes Is Associated with the Presence of Axillary Metastasis and Breast Cancer Patient Outcome. <i>American Journal of Pathology</i> , 2020, 190, 660-673.	1.9	7
1427	Tumour associated glycans: A route to boost immunotherapy?. <i>Clinica Chimica Acta</i> , 2020, 502, 167-173.	0.5	24
1428	Modelling of killer T-cell and cancer cell subpopulation dynamics under immuno- and chemotherapies. <i>Journal of Theoretical Biology</i> , 2020, 488, 110136.	0.8	4
1429	Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program. <i>Lung Cancer</i> , 2020, 140, 59-64.	0.9	33
1430	Discovery and Characterization of 1 <i>H</i> -1,2,3-Triazole Derivatives as Novel Prostanoid EP4 Receptor Antagonists for Cancer Immunotherapy. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 569-590.	2.9	32
1431	Immune stimulatory effect of anti-EpCAM immunotoxin improved overall survival of metastatic colorectal cancer patients. <i>Acta Oncologica</i> , 2020, 59, 404-409.	0.8	9
1432	The potential application of PD-1 blockade therapy for early-stage biliary tract cancer. <i>International Immunology</i> , 2020, 32, 273-281.	1.8	10
1433	Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 450-464.	3.2	62

#	ARTICLE	IF	CITATIONS
1434	18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Assessing Tumor Response to Immunotherapy in Solid Tumors. <i>PET Clinics</i> , 2020, 15, 11-22.	1.5	22
1435	Intratumoral STING activations overcome negative impact of cisplatin on antitumor immunity by inflaming tumor microenvironment in squamous cell carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2020, 522, 408-414.	1.0	19
1436	Predictors of Response to Intravesical Therapy. <i>Urologic Clinics of North America</i> , 2020, 47, 23-33.	0.8	5
1437	Immuno-Oncology. <i>Methods in Pharmacology and Toxicology</i> , 2020, , .	0.1	4
1438	Nanoparticle cancer vaccines: Design considerations and recent advances. <i>Asian Journal of Pharmaceutical Sciences</i> , 2020, 15, 576-590.	4.3	58
1439	Novel Copper Bearing Schiff Bases with Photodynamic Anti-Inflammatory and Anti-Microbial Activities. <i>Applied Biochemistry and Biotechnology</i> , 2020, 191, 716-727.	1.4	10
1440	Overcoming malignant cell-based mechanisms of resistance to immune checkpoint blockade antibodies. <i>Seminars in Cancer Biology</i> , 2020, 65, 28-37.	4.3	13
1441	Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 125-136.	1.0	51
1442	Biomarkers for Response to Immune Checkpoint Blockade. <i>Annual Review of Cancer Biology</i> , 2020, 4, 331-351.	2.3	29
1443	Interplay between inflammation and cancer. <i>Advances in Protein Chemistry and Structural Biology</i> , 2020, 119, 199-245.	1.0	122
1444	Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV+ Cancers. <i>Cancer Immunology Research</i> , 2020, 8, 131-145.	1.6	21
1445	A cytofluorimetric assay to evaluate T cell polyfunctionality. <i>Methods in Enzymology</i> , 2020, 631, 61-76.	0.4	0
1446	Promising approaches in cancer immunotherapy. <i>Immunobiology</i> , 2020, 225, 151875.	0.8	49
1447	Overexpression of B7H5/CD28H is associated with worse survival in human gastric cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 1360-1369.	1.6	13
1448	CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy. <i>Cancer Immunology Research</i> , 2020, 8, 334-344.	1.6	155
1449	Noninvasive PET tracking of post-transplant gut microbiota in living mice. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 991-1002.	3.3	14
1450	Advances of immune checkpoints in colorectal cancer treatment. <i>Biomedicine and Pharmacotherapy</i> , 2020, 123, 109745.	2.5	21
1451	Regulation of tumor growth by leukocyte-specific protein 1 in T cells. , 2020, 8, e001180.		5

#	ARTICLE	IF	CITATIONS
1452	Plant Viruses and Bacteriophage-Based Reagents for Diagnosis and Therapy. <i>Annual Review of Virology</i> , 2020, 7, 559-587.	3.0	25
1453	Emerging Blood-Based Biomarkers for Predicting Response to Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 603157.	2.2	28
1454	Prognostic Significance of Interferon- β and Its Signaling Pathway in Early Breast Cancer Depends on the Molecular Subtypes. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7178.	1.8	17
1455	Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab. <i>Auris Nasus Larynx</i> , 2020, 47, 676-686.	0.5	11
1456	DUPLICATE: Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab. <i>Auris Nasus Larynx</i> , 2020, , .	0.5	1
1457	Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors. <i>AAPS Journal</i> , 2020, 22, 132.	2.2	27
1458	ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma. <i>Frontiers in Immunology</i> , 2020, 11, 581468.	2.2	22
1459	Association Between the Occurrence and Spectrum of Immune-Related Adverse Events and Efficacy of Pembrolizumab in Asian Patients With Advanced Urothelial Cancer: Multicenter Retrospective Analyses and Systematic Literature Review. <i>Clinical Genitourinary Cancer</i> , 2020, 19, 208-216.e1.	0.9	16
1460	Immunotherapies in ovarian cancer. <i>European Journal of Cancer, Supplement</i> , 2020, 15, 87-95.	2.2	7
1461	Antibody and antibody fragments for cancer immunotherapy. <i>Journal of Controlled Release</i> , 2020, 328, 395-406.	4.8	63
1462	Evolution of drug delivery system from viewpoint of controlled intracellular trafficking and selective tissue targeting toward future nanomedicine. <i>Journal of Controlled Release</i> , 2020, 327, 533-545.	4.8	23
1463	Immunotherapy With Radiotherapy and Chemoradiotherapy for Cervical Cancer. <i>Seminars in Radiation Oncology</i> , 2020, 30, 273-280.	1.0	39
1464	IFI30 expression is an independent unfavourable prognostic factor in glioma. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 12433-12443.	1.6	15
1465	CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6968.	1.8	118
1466	Priming of Anti-tumor Immune Mechanisms by Radiotherapy Is Augmented by Inhibition of Heat Shock Protein 90. <i>Frontiers in Oncology</i> , 2020, 10, 1668.	1.3	5
1467	The current state of immunotherapy for primary and secondary brain tumors: similarities and differences. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1231-1245.	0.6	13
1468	Baseline IFN- β and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients. <i>Scientific Reports</i> , 2020, 10, 17626.	1.6	20
1469	From Conventional Therapies to Immunotherapy: Melanoma Treatment in Review. <i>Cancers</i> , 2020, 12, 3057.	1.7	50

#	ARTICLE	IF	CITATIONS
1470	<p>Management of Immune Checkpoint Inhibitor Toxicities</p>. Cancer Management and Research, 2020, Volume 12, 9139-9158.	0.9	18
1471	Predictive biomarkers for immunotherapy efficacy in non-small-cell lung cancer: current status and future perspectives. Biomarkers in Medicine, 2020, 14, 1383-1392.	0.6	16
1472	Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy. Journal of Clinical Medicine, 2020, 9, 3323.	1.0	131
1473	Investigating the Immunostimulatory and Immunomodulatory Effects of cis and trans Isomers of Ruthenium Polypyridyl Complexes on the Mammalian Macrophageâ€Like Cells. ChemistrySelect, 2020, 5, 11648-11653.	0.7	5
1474	Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1. Biomedicine and Pharmacotherapy, 2020, 130, 110621.	2.5	8
1475	Simultaneous Monitoring and Comparison of Multiple Product Quality Attributes for Cell Culture Processes at Different Scales Using a LC/MS/MS Based Multi-Attribute Method. Journal of Pharmaceutical Sciences, 2020, 109, 3319-3329.	1.6	20
1476	Hypoxic Melanoma Cells Deliver microRNAs to Dendritic Cells and Cytotoxic T Lymphocytes through Connexin-43 Channels. International Journal of Molecular Sciences, 2020, 21, 7567.	1.8	19
1477	Impact of anatomic site on antigen-presenting cells in cancer. , 2020, 8, e001204.		10
1478	The Potential of Immune Checkpoint Blockade in Cervical Cancer: Can Combinatorial Regimens Maximize Response? A Review of the Literature. Current Treatment Options in Oncology, 2020, 21, 95.	1.3	15
1479	The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy. International Journal of Molecular Sciences, 2020, 21, 7358.	1.8	48
1480	Interleukin-35 promotes progression of prostate cancer and inhibits anti-tumour immunity. Cancer Cell International, 2020, 20, 487.	1.8	14
1481	Assessing Immunotherapy with Functional and Molecular Imaging and Radiomics. Radiographics, 2020, 40, 1987-2010.	1.4	22
1482	Autonomic enteric neuropathy following nivolumab monotherapy in a patient with Lung Cancer. Current Problems in Cancer Case Reports, 2020, 1, 100014.	0.1	2
1483	Lymph-directed immunotherapy â€ Harnessing endogenous lymphatic distribution pathways for enhanced therapeutic outcomes in cancer. Advanced Drug Delivery Reviews, 2020, 160, 115-135.	6.6	18
1484	The immune phenotype of tongue squamous cell carcinoma predicts early relapse and poor prognosis. Cancer Medicine, 2020, 9, 8333-8344.	1.3	49
1485	Impact of chemoradiotherapy on the immune-related tumour microenvironment and efficacy of anti-PD-(L)1 therapy for recurrences after chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer. European Journal of Cancer, 2020, 140, 28-36.	1.3	17
1486	Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer. Expert Opinion on Emerging Drugs, 2020, 25, 445-453.	1.0	15
1488	Nano-Immune-Engineering Approaches to Advance Cancer Immunotherapy: Lessons from Ultra-pH-Sensitive Nanoparticles. Accounts of Chemical Research, 2020, 53, 2546-2557.	7.6	34

#	ARTICLE	IF	CITATIONS
1489	Emerging Prospects of Exosomes for Cancer Treatment: From Conventional Therapy to Immunotherapy. <i>Advanced Materials</i> , 2020, 32, e2002440.	11.1	160
1491	The transcription factor C/EBP β orchestrates dendritic cell maturation and functionality under homeostatic and malignant conditions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 26328-26339.	3.3	13
1492	Radiogenomics for predicting p53 status, PD-L1 expression, and prognosis with machine learning in pancreatic cancer. <i>British Journal of Cancer</i> , 2020, 123, 1253-1261.	2.9	59
1493	The NK cell "cancer cycle: advances and new challenges in NK cell" based immunotherapies. <i>Nature Immunology</i> , 2020, 21, 835-847.	7.0	243
1494	Cancer Cell Coating Nanoparticles for Optimal Tumor-Specific Cytokine Delivery. <i>ACS Nano</i> , 2020, 14, 11238-11253.	7.3	45
1495	Novel Frontiers of Treatment for Advanced Gastric or Gastroesophageal Junction Cancer (GC/GEJC): Will Immunotherapy Be a Future Direction?. <i>Frontiers in Oncology</i> , 2020, 10, 912.	1.3	6
1496	Erythrocyte-driven immunization via biomimicry of their natural antigen-presenting function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 17727-17736.	3.3	70
1497	The Immune Profile of Pituitary Adenomas and a Novel Immune Classification for Predicting Immunotherapy Responsiveness. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3207-e3223.	1.8	30
1498	Correlation of MET and PD-L1 Expression in Malignant Melanoma. <i>Cancers</i> , 2020, 12, 1847.	1.7	8
1499	Gas6/Axl Signaling Pathway in the Tumor Immune Microenvironment. <i>Cancers</i> , 2020, 12, 1850.	1.7	70
1500	Molecular Mechanisms and Potential Therapeutic Reversal of Pancreatic Cancer-Induced Immune Evasion. <i>Cancers</i> , 2020, 12, 1872.	1.7	18
1501	Combinatorial Immunotherapies for Metastatic Colorectal Cancer. <i>Cancers</i> , 2020, 12, 1875.	1.7	19
1502	Dramatic Response to Teriprilumab and Anlotinib Combination Therapy in a patient with EGFR-Mutant Lung Adenocarcinoma Who Experienced Small-Cell Transformation Mediated Erlotinib Resistance After Failure of Chemotherapy. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100010.	0.6	0
1503	Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions. <i>Journal of Immunology Research</i> , 2020, 2020, 1-12.	0.9	127
1504	Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093790.	1.4	49
1505	LAGE3 correlates with tumorigenic immune infiltrates in the clear cell renal cell carcinoma microenvironment. <i>International Immunopharmacology</i> , 2020, 87, 106793.	1.7	15
1506	Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies. <i>Drug Resistance Updates</i> , 2020, 53, 100718.	6.5	103
1507	Pluronic-based nanovehicles: Recent advances in anticancer therapeutic applications. <i>European Journal of Medicinal Chemistry</i> , 2020, 206, 112526.	2.6	45

#	ARTICLE	IF	CITATIONS
1508	The role of quantitative modeling and simulation in translational science. , 2020, , 633-655.		0
1509	IL15 synergizes with radiotherapy to reprogram the tumor immune contexture through a dendritic cell connection. <i>Onc Immunology</i> , 2020, 9, 1790716.	2.1	4
1510	Immunotherapy in Gastrointestinal Cancers. <i>Visceral Medicine</i> , 2020, 36, 231-237.	0.5	7
1511	Programmed death ligand-1 expression in gastrointestinal cancer: Clinical significance and future challenges. <i>Annals of Gastroenterological Surgery</i> , 2020, 4, 369-378.	1.2	10
1512	Necroptotic-susceptible dendritic cells exhibit enhanced antitumor activities in mice. <i>Immunity, Inflammation and Disease</i> , 2020, 8, 468-479.	1.3	3
1514	Plasmacytoid Dendritic Cell (pDC) Infiltration Correlate with Tumor Infiltrating Lymphocytes, Cancer Immunity, and Better Survival in Triple Negative Breast Cancer (TNBC) More Strongly than Conventional Dendritic Cell (cDC). <i>Cancers</i> , 2020, 12, 3342.	1.7	62
1515	Tumor Microenvironment and Immunotherapy Response in Head and Neck Cancer. <i>Cancers</i> , 2020, 12, 3377.	1.7	35
1516	Myosins: Driving us towards novel targets and biomarkers in cancer. <i>International Review of Cell and Molecular Biology</i> , 2020, 356, 291-322.	1.6	0
1517	Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma. , 2020, 8, e001681.		57
1518	Bilateral Posterior Uveitis and Retinal Detachment During Immunotherapy: A Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2020, 10, 549168.	1.3	9
1519	Innate immune activation by conditioned medium of cancer cells following combined phototherapy with photosensitizer-loaded gold nanorods. <i>Journal of Materials Chemistry B</i> , 2020, 8, 10812-10824.	2.9	17
1520	<p>Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma</p>. <i>ImmunoTargets and Therapy</i> , 2020, Volume 9, 273-288.	2.7	9
1521	Dexosomes as a cell-free vaccine for cancer immunotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 258.	3.5	79
1522	Network Analysis of Gut Microbiome and Metabolome to Discover Microbiota-Linked Biomarkers in Patients Affected by Non-Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8730.	1.8	75
1523	<p>Nanomaterial-Based Tumor Photothermal Immunotherapy</p>. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 9159-9180.	3.3	104
1524	Inmunoterapia y sus efectos secundarios: una revisi3n general. , 2020, , .		0
1525	Heparanase and the hallmarks of cancer. <i>Journal of Translational Medicine</i> , 2020, 18, 453.	1.8	78
1526	Imperfect Predictors for Lung Cancer Immunotherapyâ”A Field for Further Research. <i>Frontiers in Oncology</i> , 2020, 10, 568174.	1.3	14

#	ARTICLE	IF	CITATIONS
1527	Immune Checkpoint Inhibitor-Related Pneumonitis. <i>Respiration</i> , 2020, 99, 932-942.	1.2	30
1528	BDCA1 ⁺ cDC2s, BDCA2 ⁺ pDCs and BDCA3 ⁺ cDC1s reveal distinct pathophysiologic features and impact on clinical outcomes in melanoma patients. <i>Clinical and Translational Immunology</i> , 2020, 9, e1190.	1.7	16
1529	Modelling of Immune Checkpoint Network Explains Synergistic Effects of Combined Immune Checkpoint Inhibitor Therapy and the Impact of Cytokines in Patient Response. <i>Cancers</i> , 2020, 12, 3600.	1.7	9
1530	Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8305.	1.8	58
1531	Intratumoral Combinatorial Administration of CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors: A Phase IB Clinical Trial. <i>Vaccines</i> , 2020, 8, 670.	2.1	17
1532	Long Noncoding RNAs, New Critical Regulators in Cancer Immunity. <i>Frontiers in Oncology</i> , 2020, 10, 550987.	1.3	39
1533	Autophagy mediated danger signaling regulates tumor immunosurveillance and may potentiate the effects of anti-cancer immunotherapy through increased adjuvanticity. , 2020, , 119-140.		1
1534	How to manage patients with corticosteroids in oncology in the era of immunotherapy?. <i>European Journal of Cancer</i> , 2020, 141, 239-251.	1.3	52
1535	Antitumour dendritic cell vaccination in a priming and boosting approach. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 635-652.	21.5	148
1536	An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors. , 2020, 8, e000883.		36
1537	LC3B upregulation by NANOG promotes immune resistance and stem-like property through hyperactivation of EGFR signaling in immune-refractory tumor cells. <i>Autophagy</i> , 2021, 17, 1978-1997.	4.3	25
1538	Improving Cancer Immunotherapy by Cell Membrane-Camouflaged Nanoparticles. <i>Advanced Functional Materials</i> , 2020, 30, 2004397.	7.8	123
1539	Temporary blockade of interferon- β ameliorates doxorubicin-induced cardiotoxicity without influencing the anti-tumor effect. <i>Biomedicine and Pharmacotherapy</i> , 2020, 130, 110587.	2.5	7
1540	The non-linearity of RAF-MEK signaling in dendritic cells. <i>Cell Cycle</i> , 2020, 19, 2249-2259.	1.3	5
1541	Genetic associations of T cell cancer immune response-related genes with T cell phenotypes and clinical outcomes of early-stage lung cancer. , 2020, 8, e000336.		9
1542	Significance of tumor mutation burden combined with immune infiltrates in the progression and prognosis of ovarian cancer. <i>Cancer Cell International</i> , 2020, 20, 373.	1.8	52
1543	<p>Past, Present, and Future of Anticancer Nanomedicine</p>. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 5719-5743.	3.3	23
1544	Comprehensive analysis of multiple parameters associated with tumor immune microenvironment in ARID1A mutant cancers. <i>Future Oncology</i> , 2020, 16, 2295-2306.	1.1	5

#	ARTICLE	IF	CITATIONS
1545	Opportunities, Barriers, and a Strategy for Overcoming Translational Challenges to Therapeutic Nucleic Acid Nanotechnology. <i>ACS Nano</i> , 2020, 14, 9221-9227.	7.3	67
1546	AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer. <i>BMC Cancer</i> , 2020, 20, 683.	1.1	53
1547	Atezolizumab in combination with carboplatin and etoposide for heavily treated small cell lung cancer. <i>Thoracic Cancer</i> , 2020, 11, 2740-2742.	0.8	3
1548	Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 672.	1.8	205
1549	Overview of tumor environment responsive nano-drug delivery systems in tumor immunotherapy. <i>IOP Conference Series: Earth and Environmental Science</i> , 2020, 512, 012096.	0.2	1
1550	Innate Immune Defense Mechanisms by Myeloid Cells That Hamper Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 1395.	2.2	11
1551	Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives. <i>British Journal of Cancer</i> , 2020, 123, 885-897.	2.9	22
1552	Exploiting the Complexities of Glioblastoma Stem Cells: Insights for Cancer Initiation and Therapeutic Targeting. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5278.	1.8	20
1553	Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy. <i>Theranostics</i> , 2020, 10, 8382-8399.	4.6	42
1554	Deep learning-based image analysis methods for brightfield-acquired multiplex immunohistochemistry images. <i>Diagnostic Pathology</i> , 2020, 15, 100.	0.9	35
1555	Early Change in the Plasma Levels of Circulating Soluble Immune Checkpoint Proteins in Patients with Unresectable Hepatocellular Carcinoma Treated by Lenvatinib or Transcatheter Arterial Chemoembolization. <i>Cancers</i> , 2020, 12, 2045.	1.7	12
1556	An Immunogram for an Individualized Assessment of the Antitumor Immune Response in Patients With Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 1189.	1.3	6
1557	Anti-angiogenesis: Opening a new window for immunotherapy. <i>Life Sciences</i> , 2020, 258, 118163.	2.0	33
1558	A nanoscale metal organic frameworks-based vaccine synergises with PD-1 blockade to potentiate anti-tumour immunity. <i>Nature Communications</i> , 2020, 11, 3858.	5.8	59
1559	Shortwave-infrared (SWIR) fluorescence molecular imaging using indocyanine green-antibody conjugates for the optical diagnostics of cancerous tumours. <i>RSC Advances</i> , 2020, 10, 28171-28179.	1.7	14
1560	<p>Absolute Counts of Peripheral Lymphocyte Subsets Correlate with the Progression-Free Survival and Metastatic Status of Pancreatic Neuroendocrine Tumour Patients</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 6727-6737.	0.9	7
1561	Cell and tissue engineering in lymph nodes for cancer immunotherapy. <i>Advanced Drug Delivery Reviews</i> , 2020, 161-162, 42-62.	6.6	43
1562	An Elaborate STING Operation to Take Down NSCLC: Combination of Immunotherapies and Chemotherapies. <i>Journal of Thoracic Oncology</i> , 2020, 15, 686-688.	0.5	0

#	ARTICLE	IF	CITATIONS
1563	The neutrophil-lymphocyte ratio has a role in predicting the effectiveness of nivolumab in Japanese patients with metastatic renal cell carcinoma: a multi-institutional retrospective study. <i>BMC Urology</i> , 2020, 20, 110.	0.6	13
1564	Targeting the immune milieu in gastrointestinal cancers. <i>Journal of Gastroenterology</i> , 2020, 55, 909-926.	2.3	7
1565	Understanding the Role of Innate Immune Cells and Identifying Genes in Breast Cancer Microenvironment. <i>Cancers</i> , 2020, 12, 2226.	1.7	21
1566	Radiation Therapy and the In Situ Vaccination Approach. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 891-898.	0.4	46
1567	Host circulating biomarkers for immune-checkpoint inhibitors: single-agent and combinations. <i>Future Oncology</i> , 2020, 16, 1665-1668.	1.1	1
1568	Germline genomes have a dominant heritable contribution to cancer immune evasion and immunotherapy response. <i>Quantitative Biology</i> , 2020, 8, 216-227.	0.3	2
1569	Rational Design of a Robust Antibody-like Small-Molecule Inhibitor Nanoplatfom for Enhanced Photoimmunotherapy. <i>ACS Applied Materials & Interfaces</i> , 2020, 12, 40085-40093.	4.0	28
1570	Evaluation of cytotoxic T lymphocyte-mediated anticancer response against tumor interstitium-simulating physical barriers. <i>Scientific Reports</i> , 2020, 10, 13662.	1.6	14
1571	Therapeutic Time-restricted Feeding Reduces Renal Tumor Bioluminescence in Mice but Fails to Improve Anti-CTLA-4 Efficacy. <i>Anticancer Research</i> , 2020, 40, 5445-5456.	0.5	10
1572	Identification of Prognostic Model and Biomarkers for Cancer Stem Cell Characteristics in Glioblastoma by Network Analysis of Multi-Omics Data and Stemness Indices. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 558961.	1.8	30
1573	Crosstalk Between Mesenchymal Stromal Cells and Tumor-Associated Macrophages in Gastric Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 571516.	1.3	25
1574	First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress. <i>Frontiers in Pharmacology</i> , 2020, 11, 578091.	1.6	51
1575	The Influence of Microbial Metabolites in the Gastrointestinal Microenvironment on Anticancer Immunity. , 2020, , .		3
1576	Integrative immunogenomic analysis of gastric cancer dictates novel immunological classification and the functional status of tumor-infiltrating cells. <i>Clinical and Translational Immunology</i> , 2020, 9, e1194.	1.7	11
1577	Analysis of MarketScan Data for Immunosuppressive Conditions and Hospitalizations for Acute Respiratory Illness, United States. <i>Emerging Infectious Diseases</i> , 2020, 26, 1720-1730.	2.0	35
1578	RNA-electroporated T cells for cancer immunotherapy. <i>Oncolmmunology</i> , 2020, 9, 1792625.	2.1	6
1579	Leveraging Endogenous Dendritic Cells to Enhance the Therapeutic Efficacy of Adoptive T-Cell Therapy and Checkpoint Blockade. <i>Frontiers in Immunology</i> , 2020, 11, 578349.	2.2	11
1580	Combination of Irreversible Electroporation and STING Agonist for Effective Cancer Immunotherapy. <i>Cancers</i> , 2020, 12, 3123.	1.7	33

#	ARTICLE	IF	CITATIONS
1581	Helpless Priming Sends CD8+ T Cells on the Road to Exhaustion. <i>Frontiers in Immunology</i> , 2020, 11, 592569.	2.2	25
1582	Clinical Impact of Tumor-Infiltrating Lymphocytes and PD-L1-Positive Cells as Prognostic and Predictive Biomarkers in Urological Malignancies and Retroperitoneal Sarcoma. <i>Cancers</i> , 2020, 12, 3153.	1.7	15
1584	<p>Lung Carcinoma Cells Secrete Exosomal MALAT1 to Inhibit Dendritic Cell Phagocytosis, Inflammatory Response, Costimulatory Molecule Expression and Promote Dendritic Cell Autophagy via AKT/mTOR Pathway</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 10693-10705.	1.0	19
1585	Localized nanotheranostics: recent developments in cancer nanomedicine. <i>Materials Today Advances</i> , 2020, 8, 100087.	2.5	21
1586	Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment. <i>Frontiers in Immunology</i> , 2020, 11, 1956.	2.2	143
1587	Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer. <i>Molecules</i> , 2020, 25, 3900.	1.7	21
1588	Hepatic Artery Embolization Enhances Expression of Programmed Cell Death 1 Ligand 1 in an Orthotopic Rat Hepatocellular Carcinoma Model: InÂVivo and inÂVitro Experimentation. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 1475-1482.e2.	0.2	8
1589	Chronic activation of 4-1BB signaling induces granuloma development in tumor-draining lymph nodes that is detrimental to subsequent CD8+ T cell responses. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1956-1968.	4.8	10
1590	A Tumor-Immune Interaction Model for Synergistic Combinations of Anti PD-L1 and Ionizing Irradiation Treatment. <i>Pharmaceutics</i> , 2020, 12, 830.	2.0	8
1591	IFN- γ treatment protocol for MHC-I^{lo}/PD-L1⁺ pancreatic tumor cells selectively restores their TAP-mediated presentation competence and CD8 T-cell priming potential. , 2020, 8, e000692.		9
1592	Beyond CAR T cells: Engineered χ^2 T cells to fight solid tumors. <i>Immunological Reviews</i> , 2020, 298, 117-133.	2.8	9
1593	Immunotherapy in prostate cancer: current state and future perspectives. <i>Therapeutic Advances in Urology</i> , 2020, 12, 175628722095140.	0.9	24
1594	PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. <i>Nature Communications</i> , 2020, 11, 4835.	5.8	290
1595	Cancer-Associated Fibroblast Mediated Inhibition of CD8+ Cytotoxic T Cell Accumulation in Tumours: Mechanisms and Therapeutic Opportunities. <i>Cancers</i> , 2020, 12, 2687.	1.7	48
1596	Harnessing the bioresponsive adhesion of immuno-bioglue for enhanced local immune checkpoint blockade therapy. <i>Biomaterials</i> , 2020, 263, 120380.	5.7	11
1597	Identification of immune-related biomarkers in adrenocortical carcinoma. <i>International Immunopharmacology</i> , 2020, 88, 106930.	1.7	6
1598	The Oncocytic Variant of Poorly Differentiated Thyroid Carcinoma Shows a Specific Immune-Related Gene Expression Profile. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e4577-e4592.	1.8	8
1599	Overcoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition. <i>Trends in Immunology</i> , 2020, 41, 948-963.	2.9	41

#	ARTICLE	IF	CITATIONS
1600	Therapeutic Vaccines for Cancer Immunotherapy. ACS Biomaterials Science and Engineering, 2020, 6, 6036-6052.	2.6	24
1602	Intra-hepatic Abscopal Effect Following Radioembolization of Hepatic Metastases. CardioVascular and Interventional Radiology, 2020, 43, 1641-1649.	0.9	12
1603	Ferroptosis: a new unexpected chance to treat metastatic melanoma?. Cell Cycle, 2020, 19, 2411-2425.	1.3	27
1604	Pathogenesis of Giant Cell Arteritis and Takayasu Arteritis—Similarities and Differences. Current Rheumatology Reports, 2020, 22, 68.	2.1	56
1605	Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy. Molecular Cancer, 2020, 19, 133.	7.9	112
1606	Extracellular Vesicles in the Development of Cancer Therapeutics. International Journal of Molecular Sciences, 2020, 21, 6097.	1.8	40
1607	pH-Responsive Nanoparticles for Cancer Immunotherapy: A Brief Review. Nanomaterials, 2020, 10, 1613.	1.9	51
1608	Cancer immunotherapy—related adverse events: causes and challenges. Supportive Care in Cancer, 2020, 28, 6111-6117.	1.0	22
1609	Metformin and cancer immunity. Acta Pharmacologica Sinica, 2020, 41, 1403-1409.	2.8	54
1610	Modulating barriers of tumor microenvironment through nanocarrier systems for improved cancer immunotherapy: a review of current status and future perspective. Drug Delivery, 2020, 27, 1248-1262.	2.5	16
1611	Cellular Uptake of siRNA-Loaded Nanocarriers to Knockdown PD-L1: Strategies to Improve T-cell Functions. Cells, 2020, 9, 2043.	1.8	7
1612	A Novel Epitope Quality-Based Immune Escape Mechanism Reveals Patient's Suitability for Immune Checkpoint Inhibition. Cancer Management and Research, 2020, Volume 12, 7881-7890.	0.9	6
1613	The Role of Ras-Associated Protein 1 (Rap1) in Cancer: Bad Actor or Good Player?. Biomedicines, 2020, 8, 334.	1.4	44
1614	From tobacco smoking to cancer mutational signature: a mediation analysis strategy to explore the role of epigenetic changes. BMC Cancer, 2020, 20, 880.	1.1	9
1615	Liposomal Delivery of Mitoxantrone and a Cholesteryl Indoximod Prodrug Provides Effective Chemo-immunotherapy in Multiple Solid Tumors. ACS Nano, 2020, 14, 13343-13366.	7.3	91
1616	Neoantigen-specific CD4 ⁺ T-cell response is critical for the therapeutic efficacy of cryo-thermal therapy. , 2020, 8, e000421.		23
1617	Metabolic rivalry: circadian homeostasis and tumorigenesis. Nature Reviews Cancer, 2020, 20, 645-661.	12.8	65
1618	Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents. Frontiers in Oncology, 2020, 10, 1677.	1.3	32

#	ARTICLE	IF	CITATIONS
1620	Nanoscale Metal-Organic Frameworks for Cancer Immunotherapy. <i>Accounts of Chemical Research</i> , 2020, 53, 1739-1748.	7.6	128
1621	Oncolytic Measles Virus Encoding Interleukin-12 Mediated Antitumor Activity and Immunologic Control of Colon Cancer In Vivo and Ex Vivo. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2020, 36, 774-782.	0.7	6
1622	Cell-Mimicking Nanoparticles for Cancer Immunotherapy. <i>Advanced Materials</i> , 2020, 32, e2003368.	11.1	73
1623	Highly Enhanced Antitumor Immunity by a Three-Barreled Strategy of the Arginine-Promoted Nanovaccine and Gene-Mediated PD-L1 Blockade. <i>ACS Applied Materials & Interfaces</i> , 2020, 12, 41127-41137.	4.0	19
1624	Interleukin-10 Induces Expression of Neuroendocrine Markers and PDL1 in Prostate Cancer Cells. <i>Prostate Cancer</i> , 2020, 2020, 1-12.	0.4	10
1625	T-Cell Immunity in Pancreatic Cancer. <i>Pancreas</i> , 2020, 49, 1014-1023.	0.5	23
1626	Targeted Co-delivery of Tumor Antigen and α -Galactosylceramide to CD141+ Dendritic Cells Induces a Potent Tumor Antigen-Specific Human CD8+ T Cell Response in Human Immune System Mice. <i>Frontiers in Immunology</i> , 2020, 11, 2043.	2.2	18
1627	A Sweet Approach to Heat Up Cancer Response to Immunotherapy. <i>Cancer Discovery</i> , 2020, 10, 1789-1790.	7.7	2
1628	Highlighting the Potential for Chronic Stress to Minimize Therapeutic Responses to Radiotherapy through Increased Immunosuppression and Radiation Resistance. <i>Cancers</i> , 2020, 12, 3853.	1.7	14
1629	Current Trends in Cancer Immunotherapy. <i>Biomedicines</i> , 2020, 8, 621.	1.4	34
1630	Combining chemotherapy and autologous peptide-pulsed dendritic cells provides survival benefit in stage-IV melanoma patients. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 1270-1277.	0.4	2
1632	Local administration of submicron particle paclitaxel to solid carcinomas induces direct cytotoxicity and immune-mediated tumoricidal effects without local or systemic toxicity: preclinical and clinical studies. <i>Drug Delivery and Translational Research</i> , 2021, 11, 1806-1817.	3.0	14
1633	Toxicities from immunotherapy: From clinical trials to real-world clinical practice. <i>Medicina Clínica (English Edition)</i> , 2020, 155, 541-547.	0.1	0
1634	Emerging drugs for the treatment of chronic myelomonocytic leukemia. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 515-529.	1.0	4
1635	Designing and Engineering of Nanocarriers for Bioapplication in Cancer Immunotherapy. <i>ACS Applied Bio Materials</i> , 2020, 3, 8321-8337.	2.3	25
1636	Nanoparticles for immunotherapy. <i>Frontiers of Nanoscience</i> , 2020, , 265-306.	0.3	8
1637	Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities. <i>Frontiers in Immunology</i> , 2020, 11, 598877.	2.2	133
1638	A Holistic Perspective: Exosomes Shuttle between Nerves and Immune Cells in the Tumor Microenvironment. <i>Journal of Clinical Medicine</i> , 2020, 9, 3529.	1.0	10

#	ARTICLE	IF	CITATIONS
1639	Development and Validation of an Individualized Immune-Related Gene Pairs Prognostic Signature in Papillary Renal Cell Carcinoma. <i>Frontiers in Genetics</i> , 2020, 11, 569884.	1.1	10
1640	Hyperthermia Targeting the Tumor Microenvironment Facilitates Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2020, 11, 595207.	2.2	52
1641	Therapeutic Vaccines and Cancer Immunotherapy. <i>Vaccines</i> , 2020, 8, 596.	2.1	6
1642	Single-cell genomic profile-based analysis of tissue differentiation in colorectal cancer. <i>Science China Life Sciences</i> , 2021, 64, 1311-1325.	2.3	4
1643	Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2020, 9, 629-639.	4.2	20
1644	Pancreatic Adenocarcinoma Invasiveness and the Tumor Microenvironment: From Biology to Clinical Trials. <i>Biomedicines</i> , 2020, 8, 401.	1.4	5
1645	First-line combination immunotherapy for metastatic non-small cell lung cancer. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 433-441.	0.6	2
1646	Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 986-994.	2.8	93
1647	TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma. , 2020, 8, e000329.		93
1648	Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3054.	1.8	41
1649	Re-irradiation for oligoprogression under Nivolumab in recurrent head and neck squamous cell carcinoma: A case report. <i>Clinical and Translational Radiation Oncology</i> , 2020, 23, 16-19.	0.9	6
1650	Antibody targeting of B7-H4 enhances the immune response in urothelial carcinoma. <i>Oncolimmunology</i> , 2020, 9, 1744897.	2.1	25
1651	Systemic Immune Response and Cancer Risk: Filling the Missing Piece of Immuno-Oncology. <i>Cancer Research</i> , 2020, 80, 1801-1803.	0.4	2
1652	Novel, genetically induced mouse model that recapitulates the histological morphology and immunosuppressive tumor microenvironment of metastatic peritoneal carcinomatosis. , 2020, 8, e000480.		4
1653	Nanozymes for Catalytic Cancer Immunotherapy. <i>ACS Applied Nano Materials</i> , 2020, 3, 4925-4943.	2.4	48
1654	Immune Checkpoint Inhibition Followed by Tumor Infiltration of Dendritic Cells in Murine Neuro-2a Neuroblastoma. <i>Journal of Surgical Research</i> , 2020, 253, 201-213.	0.8	4
1655	Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint. <i>Frontiers in Immunology</i> , 2020, 11, 951.	2.2	221
1656	Developing an Arrayed CRISPR-Cas9 Co-Culture Screen for Immuno-Oncology Target ID. <i>SLAS Discovery</i> , 2020, 25, 581-590.	1.4	6

#	ARTICLE	IF	CITATIONS
1657	Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review. <i>Journal of Clinical Medicine</i> , 2020, 9, 1362.	1.0	102
1658	Opportunities for Conventional and In Situ Cancer Vaccine Strategies and Combination with Immunotherapy for Gastrointestinal Cancers, A Review. <i>Cancers</i> , 2020, 12, 1121.	1.7	31
1659	Melanoma Cancer Immunotherapy Using PD-L1 siRNA and Imatinib Promotes Cancer-Immunity Cycle. <i>Pharmaceutical Research</i> , 2020, 37, 109.	1.7	23
1660	Novel Forms of Immunomodulation for Cancer Therapy. <i>Trends in Cancer</i> , 2020, 6, 518-532.	3.8	17
1661	Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma. , 2020, 8, e000469.		59
1662	The choice of anti-tumor strategies based on micromolecules or drug loading function of biomaterials. <i>Cancer Letters</i> , 2020, 487, 45-52.	3.2	8
1663	The Underappreciated Role of the Humoral Immune System and B Cells in Tumorigenesis and Cancer Therapeutics: A Review. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 38-45.	0.4	5
1664	Acquired Resistance to Immune Checkpoint Blockade Therapies. <i>Cancers</i> , 2020, 12, 1161.	1.7	9
1665	Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 659-684.	1.9	15
1666	PD-L1 and PD-L2 Mutations in Pediatric Hodgkin Lymphoma: Do They Have Any Prognostic Significance?. <i>Fetal and Pediatric Pathology</i> , 2020, , 1-9.	0.4	2
1667	PD-L1 in squamous cell carcinoma of the oral tongue shows gender-specific association with prognosis. <i>Oral Diseases</i> , 2020, 26, 1414-1423.	1.5	7
1668	Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2020, 395, 1547-1557.	6.3	546
1669	Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, 472-476.	1.1	12
1670	Engineering nanoparticles to reprogram radiotherapy and immunotherapy: recent advances and future challenges. <i>Journal of Nanobiotechnology</i> , 2020, 18, 75.	4.2	61
1671	MR1-Restricted T Cells Are Unprecedented Cancer Fighters. <i>Frontiers in Immunology</i> , 2020, 11, 751.	2.2	22
1672	P53: A Guardian of Immunity Becomes Its Saboteur through Mutation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3452.	1.8	56
1673	CRISPR screen in mechanism and target discovery for cancer immunotherapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188378.	3.3	25
1674	Addition of ramucirumab enhances docetaxel efficacy in patients who had received anti-PD-1/PD-L1 treatment. <i>Lung Cancer</i> , 2020, 144, 71-75.	0.9	21

#	ARTICLE	IF	CITATIONS
1675	Atezolizumab in the treatment of metastatic triple-negative breast cancer. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 981-989.	1.4	20
1676	Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer. <i>Journal of Translational Medicine</i> , 2020, 18, 214.	1.8	23
1677	Clinical sequelae of the novel coronavirus: does COVID-19 infection predispose patients to cancer?. <i>Future Oncology</i> , 2020, 16, 1463-1474.	1.1	14
1678	Recent Advances: The Imbalance of Immune Cells and Cytokines in the Pathogenesis of Hepatocellular Carcinoma. <i>Diagnostics</i> , 2020, 10, 338.	1.3	14
1679	Immunological Basis of Genesis of Hepatocellular Carcinoma: Unique Challenges and Potential Opportunities through Immunomodulation. <i>Vaccines</i> , 2020, 8, 247.	2.1	9
1680	PD1/PD-L1 therapy in metastatic renal cell carcinoma. <i>Current Opinion in Urology</i> , 2020, 30, 534-541.	0.9	8
1681	Immune-gene signature: a new tool for patient selection for checkpoint inhibitors?. <i>Future Oncology</i> , 2020, 16, 1327-1330.	1.1	2
1682	Cancer immunotherapy: dawn of the death of cancer?. <i>International Reviews of Immunology</i> , 2020, 39, 205-222.	1.5	5
1683	PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?. <i>Clinical Cancer Research</i> , 2020, 26, 5287-5296.	3.2	88
1684	Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors. <i>Cancers</i> , 2020, 12, 1502.	1.7	145
1685	CTLA-4 Blockade, during HIV Virus-Like Particles Immunization, Alters HIV-Specific B-Cell Responses. <i>Vaccines</i> , 2020, 8, 284.	2.1	7
1686	Co-assembled and self-delivered epitope/CpG nanocomplex vaccine augments peptide immunogenicity for cancer immunotherapy. <i>Chemical Engineering Journal</i> , 2020, 399, 125854.	6.6	29
1687	Immune Microenvironment of Thyroid Cancer. <i>Journal of Cancer</i> , 2020, 11, 4884-4896.	1.2	26
1688	Promising abscopal effect of combination therapy with thermal tumour ablation and intratumoural OK-432 injection in the rat osteosarcoma model. <i>Scientific Reports</i> , 2020, 10, 9679.	1.6	13
1689	Prevalence of <sc>PD-1</sc> expression in head and neck squamous precancerous lesions: a systematic review and meta-analysis. <i>Head and Neck</i> , 2020, 42, 3018-3030.	0.9	23
1690	PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer. <i>Nature Cancer</i> , 2020, 1, 681-691.	5.7	240
1691	Control of foreign Ag-specific Ab responses by Treg and Tfr. <i>Immunological Reviews</i> , 2020, 296, 104-119.	2.8	40
1692	Mechanisms of immune escape in the cancer immune cycle. <i>International Immunopharmacology</i> , 2020, 86, 106700.	1.7	85

#	ARTICLE	IF	CITATIONS
1693	Modeling of the immune response in the pathogenesis of solid tumors and its prognostic significance. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 539-575.	2.1	9
1694	Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma – an update. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 582-609.	0.4	24
1695	A QSP model of prostate cancer immunotherapy to identify effective combination therapies. <i>Scientific Reports</i> , 2020, 10, 9063.	1.6	26
1696	Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers. <i>Frontiers in Oncology</i> , 2020, 10, 763.	1.3	32
1697	Manipulation of Metabolic Pathways and Its Consequences for Anti-Tumor Immunity: A Clinical Perspective. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4030.	1.8	7
1698	Dawn of lipid nanoparticles in lymph node targeting: Potential in cancer immunotherapy. <i>Advanced Drug Delivery Reviews</i> , 2020, 167, 78-88.	6.6	66
1699	Cancer nanomedicine meets immunotherapy: opportunities and challenges. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 954-958.	2.8	33
1700	Clinical relevance of tumor microenvironment: immune cells, vessels, and mouse models. <i>Human Cell</i> , 2020, 33, 930-937.	1.2	53
1701	Dendritic Cells and Their Role in Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 924.	2.2	253
1702	The Cancer-Immune Set Point in Oesophageal Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 891.	1.3	15
1703	The pattern and prognostic relevance of immune activity scores and tumor-infiltrating immune cells in metastatic clear cell renal cell carcinoma: Evidence from multiple datasets. <i>International Immunopharmacology</i> , 2020, 85, 106651.	1.7	4
1704	Immunometabolism: new insights and lessons from antigen-directed cellular immune responses. <i>Seminars in Immunopathology</i> , 2020, 42, 279-313.	2.8	37
1705	Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial. , 2020, 8, e000829.		34
1706	Supramolecular Self-Assembled Nanostructures for Cancer Immunotherapy. <i>Frontiers in Chemistry</i> , 2020, 8, 380.	1.8	25
1707	ASCL1 promotes tumor progression through cell-autonomous signaling and immune modulation in a subset of lung adenocarcinoma. <i>Cancer Letters</i> , 2020, 489, 121-132.	3.2	8
1708	Immune landscape of human prostate cancer: immune evasion mechanisms and biomarkers for personalized immunotherapy. <i>BMC Cancer</i> , 2020, 20, 572.	1.1	25
1709	Rechallenge of programmed cell death 1 inhibitor after an interval with dacarbazine treatment may be effective for advanced malignant melanoma. <i>Journal of Dermatology</i> , 2020, 47, 907-910.	0.6	9
1710	Integrated immune gene expression signature and molecular classification in gastric cancer: New insights. <i>Journal of Leukocyte Biology</i> , 2020, 108, 633-646.	1.5	26

#	ARTICLE	IF	CITATIONS
1711	CD29 identifies IFN- γ -producing human CD8 ⁺ T cells with an increased cytotoxic potential. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 6686-6696.	3.3	76
1712	Biomaterial-based strategies to prime dendritic cell-mediated anti-cancer immune responses. International Materials Reviews, 2020, 65, 445-462.	9.4	16
1713	From cellular microbiology to bacteria-based next generations of cancer immunotherapies. Cellular Microbiology, 2020, 22, e13187.	1.1	3
1714	Dendritic Cells in Anticancer Vaccination: Rationale for Ex Vivo Loading or In Vivo Targeting. Cancers, 2020, 12, 590.	1.7	56
1715	Tumor-Derived Retinoic Acid Regulates Intratumoral Monocyte Differentiation to Promote Immune Suppression. Cell, 2020, 180, 1098-1114.e16.	13.5	140
1716	Drastic healing process after pembrolizumab monotherapy in a case of advanced squamous cell carcinoma with severe bronchial stenosis observed over a two-year period using continuous bronchoscopy: A case report. Thoracic Cancer, 2020, 11, 1339-1343.	0.8	3
1717	Noncoding RNAs in cancer immunity: functions, regulatory mechanisms, and clinical application. Molecular Cancer, 2020, 19, 48.	7.9	64
1718	Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents. Journal of Clinical Medicine, 2020, 9, 675.	1.0	57
1719	Combining Immunotherapy and Chemotherapy for Non-Small Cell Lung Cancer. Thoracic Surgery Clinics, 2020, 30, 199-206.	0.4	30
1720	Epithelial-mesenchymal transition gene signature is associated with prognosis and tumor microenvironment in head and neck squamous cell carcinoma. Scientific Reports, 2020, 10, 3652.	1.6	68
1721	Human Hepatic Cancer Stem Cells (HCSCs) Markers Correlated With Immune Infiltrates Reveal Prognostic Significance of Hepatocellular Carcinoma. Frontiers in Genetics, 2020, 11, 112.	1.1	10
1722	Modulation of tumor microenvironment for immunotherapy: focus on nanomaterial-based strategies. Theranostics, 2020, 10, 3099-3117.	4.6	70
1723	Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept. Frontiers in Medicine, 2020, 7, 90.	1.2	31
1724	OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody. British Journal of Cancer, 2020, 122, 1507-1517.	2.9	48
1725	Prostaglandin E Receptor 4 Antagonist in Cancer Immunotherapy: Mechanisms of Action. Frontiers in Immunology, 2020, 11, 324.	2.2	42
1726	Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592090750.	1.4	94
1727	Tumor Microenvironment. Cancer Treatment and Research, 2020, , .	0.2	12
1728	TGF-beta: a master immune regulator. Expert Opinion on Therapeutic Targets, 2020, 24, 427-438.	1.5	101

#	ARTICLE	IF	CITATIONS
1729	In situ genetic engineering of tumors for long-lasting and systemic immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 4043-4052.	3.3	35
1730	Identification of immune cells and mRNA associated with prognosis of gastric cancer. BMC Cancer, 2020, 20, 206.	1.1	37
1731	Inflammatory Mechanisms of HCC Development. Cancers, 2020, 12, 641.	1.7	114
1732	The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer. Frontiers in Oncology, 2020, 10, 300.	1.3	26
1733	Naringenin Enhances the Antitumor Effect of Therapeutic Vaccines by Promoting Antigen Cross-Presentation. Journal of Immunology, 2020, 204, 622-631.	0.4	12
1734	Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment. Frontiers in Immunology, 2020, 11, 159.	2.2	73
1735	Development of Tumor Cell-Based Vaccine with IL-12 Gene Electrotransfer as Adjuvant. Vaccines, 2020, 8, 111.	2.1	10
1736	GPCRs in head and neck squamous cell carcinoma. , 2020, , 317-334.		1
1737	Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancer. International Journal of Cancer, 2020, 147, 1963-1969.	2.3	28
1738	New tools to prevent cancer growth and spread: a "Clever" approach. British Journal of Cancer, 2020, 123, 501-509.	2.9	34
1739	Nanotechnologies for enhancing cancer immunotherapy. Nano Research, 2020, 13, 2595-2616.	5.8	22
1740	Multifunctional Nanomodulators Regulate Multiple Pathways To Enhance Antitumor Immunity. ACS Applied Bio Materials, 2020, 3, 4635-4642.	2.3	15
1741	Tumor invasion in draining lymph nodes is associated with Treg accumulation in breast cancer patients. Nature Communications, 2020, 11, 3272.	5.8	106
1742	Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination. OncoImmunology, 2020, 9, 1738814.	2.1	13
1743	CD8 ⁺ CD57 ⁺ T cells exhibit distinct features in human non-small cell lung cancer. , 2020, 8, e000639.		24
1745	Recent Advances of Gold Compounds in Anticancer Immunity. Frontiers in Chemistry, 2020, 8, 543.	1.8	54
1746	Selectins" The Two Dr. Jekyll and Mr. Hyde Faces of Adhesion Molecules" A Review. Molecules, 2020, 25, 2835.	1.7	38
1747	Epidermal activation of Hedgehog signaling establishes an immunosuppressive microenvironment in basal cell carcinoma by modulating skin immunity. Molecular Oncology, 2020, 14, 1930-1946.	2.1	21

#	ARTICLE	IF	CITATIONS
1748	Sequential PDT and PTT Using Dual-Modal Single-Walled Carbon Nanohorns Synergistically Promote Systemic Immune Responses against Tumor Metastasis and Relapse. <i>Advanced Science</i> , 2020, 7, 2001088.	5.6	119
1749	Immune related proteins and tumor infiltrating CD8 + lymphocytes in hypopharyngeal cancer in relation to human papillomavirus (HPV) and clinical outcome. <i>Head and Neck</i> , 2020, 42, 3206-3217.	0.9	7
1750	Nanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers. <i>Nanomaterials</i> , 2020, 10, 1274.	1.9	26
1751	Tumors Resistant to Checkpoint Inhibitors Can Become Sensitive after Treatment with Vascular Disrupting Agents. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4778.	1.8	9
1752	A Review on Nano-Based Drug Delivery System for Cancer Chemoimmunotherapy. <i>Nano-Micro Letters</i> , 2020, 12, 142.	14.4	156
1753	Higher neutrophil-lymphocyte ratio is associated with better prognosis of hepatocellular carcinoma. <i>Medicine (United States)</i> , 2020, 99, e20919.	0.4	6
1754	Interferons: role in cancer therapy. <i>Immunotherapy</i> , 2020, 12, 833-855.	1.0	26
1755	Advances in Molecular Mechanisms for Traditional Chinese Medicine Actions in Regulating Tumor Immune Responses. <i>Frontiers in Pharmacology</i> , 2020, 11, 1009.	1.6	20
1756	Quantitative Translation in Immuno-Oncology Research and Development. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 430-433.	2.3	2
1757	Immunogenomic Landscape of Hematological Malignancies. <i>Cancer Cell</i> , 2020, 38, 380-399.e13.	7.7	109
1758	Gene expression of prostaglandin EP4 receptor in three canine carcinomas. <i>BMC Veterinary Research</i> , 2020, 16, 213.	0.7	4
1759	Modulation of Anti-Tumour Immune Responses by Probiotic Bacteria. <i>Vaccines</i> , 2020, 8, 329.	2.1	15
1760	Dendritic Cells and Their Roles in Anti-Tumour Immunity. , 2020, , .		0
1761	Neoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC). <i>Cancer Letters</i> , 2020, 490, 12-19.	3.2	10
1762	Genetic Screening for Novel Regulators of Immune Checkpoint Molecules. <i>Trends in Immunology</i> , 2020, 41, 692-705.	2.9	2
1763	BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions. <i>Cancers</i> , 2020, 12, 1823.	1.7	82
1764	Tumor cell membrane enveloped aluminum phosphate nanoparticles for enhanced cancer vaccination. <i>Journal of Controlled Release</i> , 2020, 326, 297-309.	4.8	66
1765	Association between the mutational smoking signature and the immune microenvironment in lung adenocarcinoma. <i>Lung Cancer</i> , 2020, 147, 12-20.	0.9	5

#	ARTICLE	IF	CITATIONS
1766	Nanoparticles-encapsulated polymeric microneedles for transdermal drug delivery. <i>Journal of Controlled Release</i> , 2020, 325, 163-175.	4.8	75
1767	Cancer Epigenetics, Tumor Immunity, and Immunotherapy. <i>Trends in Cancer</i> , 2020, 6, 580-592.	3.8	166
1768	Emerging precision therapies for gastric cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 299-311.	0.4	1
1769	Recent Advances in Peptide-Based Approaches for Cancer Treatment. <i>Current Medicinal Chemistry</i> , 2020, 27, 1174-1205.	1.2	30
1770	Intratumoral immune activation with TLR4 agonist synergizes with effector T cells to eradicate established murine tumors. <i>Npj Vaccines</i> , 2020, 5, 50.	2.9	19
1771	Presence of a 34-gene signature is a favorable prognostic marker in squamous non-small cell lung carcinoma. <i>Journal of Translational Medicine</i> , 2020, 18, 271.	1.8	8
1772	Immunological microenvironment gene expression in patients with diffuse large B cell non Hodgkin lymphoma. <i>Biochemistry and Biophysics Reports</i> , 2020, 21, 100731.	0.7	6
1773	KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures. <i>Cancer Treatment Reviews</i> , 2020, 85, 101978.	3.4	85
1774	The expression and immunoregulation of immune checkpoint molecule VISTA in autoimmune diseases and cancers. <i>Cytokine and Growth Factor Reviews</i> , 2020, 52, 1-14.	3.2	18
1775	Biological mechanisms linked to inflammation in cancer: Discovery of tumor microenvironment-related biomarkers and their clinical application in solid tumors. <i>International Journal of Biological Markers</i> , 2020, 35, 8-11.	0.7	15
1776	Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study. <i>Cancers</i> , 2020, 12, 473.	1.7	72
1777	Decitabine Augments Chemotherapy-Induced PD-L1 Upregulation for PD-L1 Blockade in Colorectal Cancer. <i>Cancers</i> , 2020, 12, 462.	1.7	57
1778	Circulating Tumor Cells and Metabolic Parameters in NSCLC Patients Treated with Checkpoint Inhibitors. <i>Cancers</i> , 2020, 12, 487.	1.7	29
1779	Clinical significance of circulating soluble immune checkpoint proteins in sorafenib-treated patients with advanced hepatocellular carcinoma. <i>Scientific Reports</i> , 2020, 10, 3392.	1.6	46
1780	CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis. <i>Molecular Cancer</i> , 2020, 19, 41.	7.9	200
1781	Recent Progress of Potentiating Immune Checkpoint Blockade with External Stimuli—an Industry Perspective. <i>Advanced Science</i> , 2020, 7, 1903394.	5.6	40
1782	Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. <i>Oncolmmunology</i> , 2020, 9, 1708065.	2.1	41
1783	Integrating the “Immune” in the Stratification of Myelodysplastic Syndromes and Future Clinical Trial Design. <i>Journal of Clinical Oncology</i> , 2020, 38, 1723-1735.	0.8	56

#	ARTICLE	IF	CITATIONS
1784	Prognostic impact of PD-L1 expression in correlation with neutrophil-to-lymphocyte ratio in squamous cell carcinoma of the lung. <i>Scientific Reports</i> , 2020, 10, 1243.	1.6	23
1785	Wnt Signaling Cascade in Dendritic Cells and Regulation of Anti-tumor Immunity. <i>Frontiers in Immunology</i> , 2020, 11, 122.	2.2	33
1786	Helper T cell-dominant tertiary lymphoid structures are associated with disease relapse of advanced colorectal cancer. <i>Onc Immunology</i> , 2020, 9, 1724763.	2.1	36
1787	<p>Peripheral Blood Platelet&€“Lymphocyte Ratio Is Good Predictor of Chemosensitivity and Prognosis in Gastric Cancer Patients</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 1303-1311.	0.9	24
1788	Development and characterization of a novel anti-OX40 antibody for potent immune activation. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 939-950.	2.0	15
1789	Ruthenium Bipyridyl Dithiocyanate Complex Exerted Adjuvant Activity on the Activated Mammalian Macrophages in vitro. <i>Inflammation</i> , 2020, 43, 1120-1126.	1.7	2
1790	Mining Prognostic Biomarkers of Hepatocellular Carcinoma Based on Immune-Associated Genes. <i>DNA and Cell Biology</i> , 2020, 39, 499-512.	0.9	8
1791	Substantial tumor regression in prostate cancer patient with extensive skeletal metastases upon Immunotherapy (APCEDEN). <i>Medicine (United States)</i> , 2020, 99, e18889.	0.4	1
1792	Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?. <i>Gastroenterology Report</i> , 2020, 8, 11-24.	0.6	68
1793	Regulation of cancer&€“immunity cycle and tumor microenvironment by nanobiomaterials to enhance tumor immunotherapy. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2020, 12, e1612.	3.3	33
1794	Bioinformatics for Cancer Immunotherapy. <i>Methods in Molecular Biology</i> , 2020, , .	0.4	1
1795	Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies. <i>Journal of Gastroenterology</i> , 2020, 55, 653-661.	2.3	38
1797	Tumor antigens in glioma. <i>Seminars in Immunology</i> , 2020, 47, 101385.	2.7	34
1799	The Diagnostic, Prognostic, and Therapeutic Potential of Adaptive Immune Receptor Repertoire Profiling in Cancer. <i>Cancer Research</i> , 2020, 80, 643-654.	0.4	28
1800	Overcoming immunotherapeutic resistance by targeting the cancer inflammation cycle. <i>Seminars in Cancer Biology</i> , 2020, 65, 38-50.	4.3	34
1801	VISTA: Coming of age as a multi-lineage immune checkpoint. <i>Clinical and Experimental Immunology</i> , 2020, 200, 120-130.	1.1	66
1802	Targeting the orphan nuclear receptor NR2F6 in T cells primes tumors for immune checkpoint therapy. <i>Cell Communication and Signaling</i> , 2020, 18, 8.	2.7	16
1803	TYK2 in Tumor Immunosurveillance. <i>Cancers</i> , 2020, 12, 150.	1.7	18

#	ARTICLE	IF	CITATIONS
1804	Directing Traffic: How to Effectively Drive T Cells into Tumors. <i>Cancer Discovery</i> , 2020, 10, 185-197.	7.7	68
1805	Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma. <i>Cells</i> , 2020, 9, 263.	1.8	43
1806	Local heroes or villains: tissue-resident memory T cells in human health and disease. <i>Cellular and Molecular Immunology</i> , 2020, 17, 113-122.	4.8	65
1807	Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges. <i>International Journal of Molecular Sciences</i> , 2020, 21, 597.	1.8	58
1808	A historical turning point for the treatment of advanced renal cell carcinoma: inhibition of immune checkpoint. <i>Current Medical Research and Opinion</i> , 2020, 36, 625-635.	0.9	4
1809	Immune biological rationales for the design of combined radio- and immunotherapies. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 293-306.	2.0	39
1810	Hashimoto's thyroiditis attenuates progression of papillary thyroid carcinoma: deciphering immunological links. <i>Heliyon</i> , 2020, 6, e03077.	1.4	18
1811	Cancer immunotherapy through the prism of adaptation: Will Achilles catch the tortoise?. <i>Medical Hypotheses</i> , 2020, 137, 109545.	0.8	0
1812	Modularly Designed Peptide Nanoprodrug Augments Antitumor Immunity of PD-L1 Checkpoint Blockade by Targeting Indoleamine 2,3-Dioxygenase. <i>Journal of the American Chemical Society</i> , 2020, 142, 2490-2496.	6.6	98
1813	Screening and Identifying Immune-Related Cells and Genes in the Tumor Microenvironment of Bladder Urothelial Carcinoma: Based on TCGA Database and Bioinformatics. <i>Frontiers in Oncology</i> , 2019, 9, 1533.	1.3	53
1814	Integration of Omics Data Sources to Inform Mechanistic Modeling of Immune-Oncology Therapies: A Tutorial for Clinical Pharmacologists. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 858-870.	2.3	24
1815	Competitive glucose metabolism as a target to boost bladder cancer immunotherapy. <i>Nature Reviews Urology</i> , 2020, 17, 77-106.	1.9	91
1816	Study on the anti-tumor mechanism related to immune microenvironment of <i>Bombyx Batryticatus</i> on viral and non-viral infections of hepatocellular carcinoma. <i>Biomedicine and Pharmacotherapy</i> , 2020, 124, 109838.	2.5	8
1817	Screening and Identification of Key Biomarkers for Bladder Cancer: A Study Based on TCGA and GEO Data. <i>BioMed Research International</i> , 2020, 2020, 1-20.	0.9	32
1818	Preclinical and Clinical Evidence of Immune Responses Triggered in Oncologic Photodynamic Therapy: Clinical Recommendations. <i>Journal of Clinical Medicine</i> , 2020, 9, 333.	1.0	72
1819	HSP90A inhibition promotes anti-tumor immunity by reversing multi-modal resistance and stem-like property of immune-refractory tumors. <i>Nature Communications</i> , 2020, 11, 562.	5.8	54
1820	Biomarkers for immunotherapy response in head and neck cancer. <i>Cancer Treatment Reviews</i> , 2020, 84, 101977.	3.4	153
1821	Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody. <i>Molecular Therapy</i> , 2020, 28, 794-804.	3.7	42

#	ARTICLE	IF	CITATIONS
1822	A Four-Chemokine Signature Is Associated with a T-cellâ€œInflamed Phenotype in Primary and Metastatic Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1997-2010.	3.2	91
1823	Nanotechnology in the arena of cancer immunotherapy. <i>Archives of Pharmacal Research</i> , 2020, 43, 58-79.	2.7	14
1824	<p>Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle</p>,. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 83-94.	1.0	27
1825	Top 10 Challenges in Cancer Immunotherapy. <i>Immunity</i> , 2020, 52, 17-35.	6.6	1,177
1826	Tumor Immunology and Tumor Evolution: Intertwined Histories. <i>Immunity</i> , 2020, 52, 55-81.	6.6	357
1827	A size and space structured model describing interactions of tumor cells with immune cells reveals cancer persistent equilibrium states in tumorigenesis. <i>Journal of Theoretical Biology</i> , 2020, 490, 110163.	0.8	8
1828	Tumor Timeâ€œCourse Predicts Overall Survival in Nonâ€œSmall Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Followâ€œUp Time. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 115-123.	1.3	8
1829	Interferon-Î±2b enhances survival and modulates transcriptional profiles and the immune response in melanoma patients treated with dendritic cell vaccines. <i>Biomedicine and Pharmacotherapy</i> , 2020, 125, 109966.	2.5	8
1830	AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells. <i>Journal of Thoracic Oncology</i> , 2020, 15, 973-999.	0.5	66
1831	Ibrutinib treatment inhibits breast cancer progression and metastasis by inducing conversion of myeloid-derived suppressor cells to dendritic cells. <i>British Journal of Cancer</i> , 2020, 122, 1005-1013.	2.9	52
1832	Complete response to pembrolizumab in advanced hepatocellular carcinoma with microsatellite instability. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 867-872.	0.4	16
1833	Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 3671-3681.	3.2	53
1834	Inhibition of protein phosphatase-2A with LB-100 enhances antitumor immunity against glioblastoma. <i>Journal of Neuro-Oncology</i> , 2020, 148, 231-244.	1.4	17
1835	Progress and challenges of personalized neoantigens in the clinical treatment of tumors. <i>Medicine in Drug Discovery</i> , 2020, 6, 100030.	2.3	3
1836	Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 1089.	1.7	119
1837	Breast cancer: Biology, biomarkers, and treatments. <i>International Immunopharmacology</i> , 2020, 84, 106535.	1.7	307
1838	The role of cancer-derived microRNAs in cancer immune escape. <i>Journal of Hematology and Oncology</i> , 2020, 13, 25.	6.9	145
1839	The interplay between innate and adaptive immunity in cancer shapes the productivity of cancer immunosurveillance. <i>Journal of Leukocyte Biology</i> , 2020, 108, 363-376.	1.5	40

#	ARTICLE	IF	CITATIONS
1840	Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, 856.	3.4	103
1842	Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer. <i>Annals of Oncology</i> , 2020, 31, 582-589.	0.6	69
1843	Combination of multiple tumor-infiltrating immune cells predicts clinical outcome in colon cancer. <i>Clinical Immunology</i> , 2020, 215, 108412.	1.4	17
1844	Nanomedicine for improvement of dendritic cell-based cancer immunotherapy. <i>International Immunopharmacology</i> , 2020, 83, 106446.	1.7	30
1845	A tumor-specific neoepitope expressed in homologous/self or heterologous/viral antigens induced comparable effector CD8 ⁺ T-cell responses by DNA vaccination. <i>Vaccine</i> , 2020, 38, 3711-3719.	1.7	9
1846	Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source. <i>Drug Delivery</i> , 2020, 27, 585-598.	2.5	295
1847	Enhancing CAR T cell efficacy: the next step toward a clinical revolution?. <i>Expert Review of Hematology</i> , 2020, 13, 533-543.	1.0	10
1848	PD-1 ⁺ Tim3 ⁺ tumor-infiltrating CD8 T cells sustain the potential for IFN- γ production, but lose cytotoxic activity in ovarian cancer. <i>International Immunology</i> , 2020, 32, 397-405.	1.8	22
1849	Cellular cytotoxicity is a form of immunogenic cell death. , 2020, 8, e000325.		61
1850	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
1851	Characterization of Hypoxia Signature to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Glioma Groups. <i>Frontiers in Oncology</i> , 2020, 10, 796.	1.3	118
1852	Future Challenges in Cancer Resistance to Immunotherapy. <i>Cancers</i> , 2020, 12, 935.	1.7	41
1853	Novel Genetic Melanoma Vaccines Based on Induced Pluripotent Stem Cells or Melanosphere-Derived Stem-Like Cells Display High Efficacy in a murine Tumor Rejection Model. <i>Vaccines</i> , 2020, 8, 147.	2.1	10
1854	Reprogramming the tumor immunologic microenvironment using neoadjuvant chemotherapy in osteosarcoma. <i>Cancer Science</i> , 2020, 111, 1899-1909.	1.7	54
1855	Contribution of Macrophages and T Cells in Skeletal Metastasis. <i>Cancers</i> , 2020, 12, 1014.	1.7	19
1856	The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 2156-2170.	5.7	178
1857	What is the potential use of platelet-rich-plasma (PRP) in cancer treatment? A mini review. <i>Heliyon</i> , 2020, 6, e03660.	1.4	16
1858	Characterization of a Novel Murine Colon Carcinoma Subline with High-Metastatic Activity Established by In Vivo Selection Method. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2829.	1.8	3

#	ARTICLE	IF	CITATIONS
1859	DNT Cell-based Immunotherapy: Progress and Applications. <i>Journal of Cancer</i> , 2020, 11, 3717-3724.	1.2	23
1860	Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself. <i>Angiogenesis</i> , 2020, 23, 279-298.	3.7	30
1861	Platelet Membraneâ€Camouflaged Magnetic Nanoparticles for Ferroptosisâ€Enhanced Cancer Immunotherapy. <i>Small</i> , 2020, 16, e2001704.	5.2	223
1862	A gene signature for immune subtyping of desert, excluded, and inflamed ovarian tumors. <i>American Journal of Reproductive Immunology</i> , 2020, 84, e13244.	1.2	18
1863	Improving Cancer Immunotherapy Outcomes Using Biomaterials. <i>Angewandte Chemie</i> , 2020, 132, 17484-17495.	1.6	12
1864	Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies. <i>Cell</i> , 2020, 181, 728-744.e21.	13.5	131
1865	Improving Cancer Immunotherapy Outcomes Using Biomaterials. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 17332-17343.	7.2	48
1867	Immunotherapy in Lung Cancer: From a Minor God to the Olympus. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 69-92.	0.8	15
1869	Identifying and characterising the impact of excitability in a mathematical model of tumour-immune interactions. <i>Journal of Theoretical Biology</i> , 2020, 501, 110250.	0.8	7
1870	Rational design of peptides for identification of linear epitopes and generation of neutralizing monoclonal antibodies against DKK2 for cancer therapy. <i>Antibody Therapeutics</i> , 2020, 3, 63-70.	1.2	5
1871	Oncolytic vaccinia virus delivering tethered IL-12 enhances antitumor effects with improved safety. , 2020, 8, e000710.		43
1872	The Key Characteristics of Carcinogens: Relationship to the Hallmarks of Cancer, Relevant Biomarkers, and Assays to Measure Them. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1887-1903.	1.1	52
1873	Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 988-998.	1.9	13
1874	A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy. <i>Liver Cancer</i> , 2020, 9, 119-137.	4.2	45
1875	Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival. <i>Blood Advances</i> , 2020, 4, 274-286.	2.5	38
1876	Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2020, 13, 29.	6.9	146
1877	And Now for Something Completely Different: Immunotherapy Beyond Checkpoints in Melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 386-397.	1.8	0
1878	<p>Detection of PD-L1 Expression and Its Clinical Significance in Circulating Tumor Cells from Patients with Non-Small-Cell Lung Cancer</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 2069-2078.	0.9	25

#	ARTICLE	IF	CITATIONS
1879	Tumor Targeted Nanocarriers for Immunotherapy. <i>Molecules</i> , 2020, 25, 1508.	1.7	26
1880	The immune infiltration in clear cell Renal Cell Carcinoma and their clinical implications: A study based on TCGA and GEO databases. <i>Journal of Cancer</i> , 2020, 11, 3207-3215.	1.2	49
1881	Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis. <i>Clinical Research in Cardiology</i> , 2021, 110, 50-60.	1.5	20
1882	Epigenetic modulation of immunotherapy cofactors to enhance tumor response in lung cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 51-54.	1.4	7
1883	Upregulation of TIGIT and PD-1 in Colorectal Cancer with Mismatch-repair Deficiency. <i>Immunological Investigations</i> , 2021, 50, 338-355.	1.0	18
1884	Less correlation between mismatch repair proteins deficiency and decreased expression of HLA class I molecules in endometrial carcinoma: a different propensity from colorectal cancer. <i>Medical Molecular Morphology</i> , 2021, 54, 14-22.	0.4	2
1885	Immune microenvironment of hepatocellular carcinoma, intrahepatic cholangiocarcinoma and liver metastasis of colorectal adenocarcinoma: Relationship with histopathological and molecular classifications. <i>Hepatology Research</i> , 2021, 51, 5-18.	1.8	29
1886	Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association?. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 55-61.	1.4	42
1887	Near-infrared photoimmunotherapy of cancer: a new approach that kills cancer cells and enhances anti-cancer host immunity. <i>International Immunology</i> , 2021, 33, 7-15.	1.8	79
1888	A signature of 14 immune-related gene pairs predicts overall survival in gastric cancer. <i>Clinical and Translational Oncology</i> , 2021, 23, 265-274.	1.2	45
1889	MHC class I transactivator NLRC5 in host immunity, cancer and beyond. <i>Immunology</i> , 2021, 162, 252-261.	2.0	24
1890	Chimeric antigen receptorâ€modified macrophages trigger systemic antiâ€tumour immunity. <i>Journal of Pathology</i> , 2021, 253, 247-257.	2.1	42
1891	Telomerase-specific oncolytic immunotherapy for promoting efficacy of PD-1 blockade in osteosarcoma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1405-1417.	2.0	19
1892	Immunotherapeutic strategies in breast cancer: A clinical update. <i>Journal of Surgical Oncology</i> , 2021, 123, 710-717.	0.8	4
1893	Downregulation of Interferon- γ Receptor Expression Endows Resistance to Antiâ€Programmed Death Protein 1 Therapy in Colorectal Cancer. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 376, 21-28.	1.3	5
1894	A Review of the Current State of Nanomedicines for Targeting and Treatment of Cancers: Achievements and Future Challenges. <i>Advanced Therapeutics</i> , 2021, 4, 2000186.	1.6	7
1895	Immunotherapy for older patients with melanoma: From darkness to light?. <i>Pigment Cell and Melanoma Research</i> , 2021, 34, 550-563.	1.5	11
1896	TGF β 2 biology in cancer progression and immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 9-34.	12.5	420

#	ARTICLE	IF	CITATIONS
1897	Quantitative Systems Pharmacology Approaches for Immuno-Oncology: Adding Virtual Patients to the Development Paradigm. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 605-618.	2.3	40
1898	Immune-Checkpoint Blockade Enhances ²²⁵ Ac-PSMA617 Efficacy in a Mouse Model of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2021, 62, 228-231.	2.8	44
1899	Cancer incidence and risk factors in dialysis patients with human immunodeficiency virus: a cohort study. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 624-630.	1.4	1
1900	Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms. , 2021, 219, 107694.		79
1901	Improving safety of cancer immunotherapy via delivery technology. <i>Biomaterials</i> , 2021, 265, 120407.	5.7	22
1902	A multicentre analytical comparison study of inter-reader and inter-assay agreement of four programmed death-ligand 1 immunohistochemistry assays for scoring in triple-negative breast cancer. <i>Histopathology</i> , 2021, 78, 567-577.	1.6	23
1903	Rova-T enhances the anti-tumor activity of anti-PD1 in a murine model of small cell lung cancer with endogenous DLL3 expression. <i>Translational Oncology</i> , 2021, 14, 100883.	1.7	12
1904	Multicenter Phase II Trial of Axitinib Monotherapy for Gemcitabine-Based Chemotherapy Refractory Advanced Biliary Tract Cancer (AX-BC Study). <i>Oncologist</i> , 2021, 26, 97-e201.	1.9	2
1905	Combination therapy: Future directions of immunotherapy in small cell lung cancer. <i>Translational Oncology</i> , 2021, 14, 100889.	1.7	35
1906	Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities. <i>Molecular Therapy</i> , 2021, 29, 555-570.	3.7	130
1907	Oncolytic Virus Therapy with HSV-1 for Hematological Malignancies. <i>Molecular Therapy</i> , 2021, 29, 762-774.	3.7	22
1908	Pharmacodynamic biomarkers in metronomic chemotherapy: multiplex cytokine measurements in gastrointestinal cancer patients. <i>Clinical and Experimental Medicine</i> , 2021, 21, 149-159.	1.9	5
1909	PD-1/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines. <i>Journal of Advanced Research</i> , 2021, 29, 45-54.	4.4	31
1910	Neoadjuvant immune checkpoint inhibitors in cancer, current state of the art. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103172.	2.0	8
1911	Nanomedicine enables spatiotemporally regulating macrophage-based cancer immunotherapy. <i>Biomaterials</i> , 2021, 268, 120552.	5.7	23
1912	Polymer-lipid hybrid nanovesicle-enabled combination of immunogenic chemotherapy and RNAi-mediated PD-L1 knockdown elicits antitumor immunity against melanoma. <i>Biomaterials</i> , 2021, 268, 120579.	5.7	46
1913	Nanodelivery of immunogenic cell death-inducers for cancer immunotherapy. <i>Drug Discovery Today</i> , 2021, 26, 651-662.	3.2	23
1914	Microneedle-mediated transdermal drug delivery for treating diverse skin diseases. <i>Acta Biomaterialia</i> , 2021, 121, 119-133.	4.1	92

#	ARTICLE	IF	CITATIONS
1915	Treatments after first progression in metastatic colorectal cancer. A literature review and evidence-based algorithm. <i>Cancer Treatment Reviews</i> , 2021, 92, 102135.	3.4	2
1916	Phase-specific cancer-immune model considering acquired resistance to therapeutic agents. <i>Applied Mathematics and Computation</i> , 2021, 391, 125555.	1.4	0
1917	Pharmacologic Screening Identifies Metabolic Vulnerabilities of CD8+ T Cells. <i>Cancer Immunology Research</i> , 2021, 9, 184-199.	1.6	74
1918	Autophagy in the cancer-immunity dialogue. <i>Advanced Drug Delivery Reviews</i> , 2021, 169, 40-50.	6.6	46
1919	Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model. <i>Journal of Virology</i> , 2021, 95, .	1.5	13
1920	Oncolytic herpes simplex virus type 1 (HSV α 1) in combination with lenalidomide for plasma cell neoplasms. <i>British Journal of Haematology</i> , 2021, 192, 343-353.	1.2	15
1921	Genomic profile and immune microenvironment in patients with relapsed stage IA lung adenocarcinoma. <i>Translational Oncology</i> , 2021, 14, 100942.	1.7	3
1922	In situ activation of STING pathway with polymeric SN38 for cancer chemoimmunotherapy. <i>Biomaterials</i> , 2021, 268, 120542.	5.7	57
1923	Long non-coding RNAs: Emerging regulators for chemo/immunotherapy resistance in cancer stem cells. <i>Cancer Letters</i> , 2021, 500, 244-252.	3.2	22
1924	Engineering a photosensitizer nanoplatform for amplified photodynamic immunotherapy <i>via</i> tumor microenvironment modulation. <i>Nanoscale Horizons</i> , 2021, 6, 120-131.	4.1	108
1925	Engineered drug-loaded cells and cell derivatives as a delivery platform for cancer immunotherapy. <i>Biomaterials Science</i> , 2021, 9, 1104-1116.	2.6	7
1926	Acid-activatable micelleplex delivering siRNA-PD-L1 for improved cancer immunotherapy of CDK4/6 inhibition. <i>Chinese Chemical Letters</i> , 2021, 32, 1929-1936.	4.8	31
1927	Identification and validation of L Antigen Family Member 3 as an immune-related biomarker associated with the progression of papillary thyroid cancer. <i>International Immunopharmacology</i> , 2021, 90, 107267.	1.7	9
1928	Nano-immunotherapy: Unique mechanisms of nanomaterials in synergizing cancer immunotherapy. <i>Nano Today</i> , 2021, 36, 101023.	6.2	45
1929	Immunotherapy combinations in advanced nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , 2021, 33, 73-79.	1.1	5
1930	Predicting Non-Alcoholic Fatty Liver Disease Progression and Immune Deregulations by Specific Gene Expression Patterns. <i>Frontiers in Immunology</i> , 2020, 11, 609900.	2.2	16
1931	Emerging immunotherapies for metastasis. <i>British Journal of Cancer</i> , 2021, 124, 37-48.	2.9	32
1932	Pembrolizumab for advanced cervical cancer: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 221-228.	1.1	17

#	ARTICLE	IF	CITATIONS
1933	Tumor-Infiltrating T Cells Concurrently Overexpress CD200R with Immune Checkpoints PD-1, CTLA-4, and TIM-3 in Non-Small-Cell Lung Cancer. <i>Pathobiology</i> , 2021, 88, 218-227.	1.9	2
1934	Tumor-permeated bioinspired theranostic nanovehicle remodels tumor immunosuppression for cancer therapy. <i>Biomaterials</i> , 2021, 269, 120609.	5.7	23
1935	Immune response drives outcomes in prostate cancer: implications for immunotherapy. <i>Molecular Oncology</i> , 2021, 15, 1358-1375.	2.1	48
1936	Toll-like receptor-4 deficiency inhibits ultraviolet radiation-induced tumor development by modulation of immune and inflammatory responses. <i>Molecular Carcinogenesis</i> , 2021, 60, 60-70.	1.3	8
1937	IL-6 in inflammation, autoimmunity and cancer. <i>International Immunology</i> , 2021, 33, 127-148.	1.8	500
1938	Current status of PD-1/PD-L1 blockade immunotherapy in breast cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 321-332.	0.6	22
1939	A prognostic immune predictor, HLA-DRA, plays diverse roles in non-muscle invasive and muscle invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 237.e21-237.e29.	0.8	12
1940	DNA scaffolds enable efficient and tunable functionalization of biomaterials for immune cell modulation. <i>Nature Nanotechnology</i> , 2021, 16, 214-223.	15.6	60
1941	Single-Dose Anti-PD-L1/IL-15 Fusion Protein KD033 Generates Synergistic Antitumor Immunity with Robust Tumor-Immune Gene Signatures and Memory Responses. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 347-356.	1.9	15
1942	Extinction and persistence of a tumor-immune model with white noise and pulsed comprehensive therapy. <i>Mathematics and Computers in Simulation</i> , 2021, 182, 456-470.	2.4	11
1943	Hemagglutinating virus of Japan-envelope containing programmed cell death-ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma. <i>Cancer Science</i> , 2021, 112, 81-90.	1.7	9
1944	Characterization of a single chain variable fragment of nivolumab that targets PD-1 and blocks PD-L1 binding. <i>Protein Expression and Purification</i> , 2021, 177, 105766.	0.6	7
1945	Predictors of survival among Japanese patients receiving first-line chemoimmunotherapy for advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 97-105.	0.8	20
1946	Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer. <i>British Journal of Cancer</i> , 2021, 124, 595-603.	2.9	24
1947	Immune privilege of skin stem cells: What do we know and what can we learn?. <i>Experimental Dermatology</i> , 2021, 30, 522-528.	1.4	8
1948	Comprehensive Phenotyping of Dendritic Cells in Cancer Patients by Flow Cytometry. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2021, 99, 218-230.	1.1	6
1949	Early change in peripheral CD4 ⁺ T cells associated with clinical outcomes of immunotherapy in gastrointestinal cancer. <i>Immunotherapy</i> , 2021, 13, 55-66.	1.0	15
1950	Polyethyleneimine-CpG Nanocomplex as an In Situ Vaccine for Boosting Anticancer Immunity in Melanoma. <i>Macromolecular Bioscience</i> , 2021, 21, 2000207.	2.1	15

#	ARTICLE	IF	CITATIONS
1951	Immune checkpoint inhibition in upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2021, 39, 1357-1367.	1.2	27
1952	A pragmatic adaptive enrichment design for selecting the right target population for cancer immunotherapies. <i>Pharmaceutical Statistics</i> , 2021, 20, 202-211.	0.7	3
1953	Serum levels of soluble PD1 in pemphigus vulgaris: A useful marker for disease severity. <i>Journal of Cosmetic Dermatology</i> , 2021, 20, 1298-1302.	0.8	2
1954	Exosomes as mediators of immune regulation and immunotherapy in cancer. <i>FEBS Journal</i> , 2021, 288, 10-35.	2.2	110
1955	<i>In silico</i> tools for accurate HLA and KIR inference from clinical sequencing data empower immunogenetics on individual-patient and population scales. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	19
1956	Pancreatic Cancer Immuno-oncology in the Era of Precision Medicine. <i>Indian Journal of Surgical Oncology</i> , 2021, 12, 118-127.	0.3	0
1957	Reinvigorating exhausted CD8 ⁺ cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy. <i>Medicinal Research Reviews</i> , 2021, 41, 156-201.	5.0	56
1958	The prognostic value and potential subtypes of immune activity scores in three major urological cancers. <i>Journal of Cellular Physiology</i> , 2021, 236, 2620-2630.	2.0	3
1959	Nanomedicines as Multifunctional Modulators of Melanoma Immune Microenvironment. <i>Advanced Therapeutics</i> , 2021, 4, 2000147.	1.6	2
1960	Immune checkpoint: The novel target for antitumor therapy. <i>Genes and Diseases</i> , 2021, 8, 25-37.	1.5	27
1961	PD-L1 status in breast cancer: Current view and perspectives. <i>Seminars in Cancer Biology</i> , 2021, 72, 146-154.	4.3	69
1962	The balance between breast cancer and the immune system: Challenges for prognosis and clinical benefit from immunotherapies. <i>Seminars in Cancer Biology</i> , 2021, 72, 76-89.	4.3	87
1963	Co-delivery of anionic epitope/CpG vaccine and IDO inhibitor by self-assembled cationic liposomes for combination melanoma immunotherapy. <i>Journal of Materials Chemistry B</i> , 2021, 9, 3892-3899.	2.9	18
1964	The synergistic antitumor activity of 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs) and anti-PD-L1 antibody inducing immunogenic cell death. <i>Drug Delivery</i> , 2021, 28, 800-813.	2.5	7
1965	Pingyangmycin enhances the antitumor efficacy of anti-PD-1 therapy associated with tumor-infiltrating CD8 ⁺ T cell augmentation. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 425-436.	1.1	11
1966	A New Model to Improve the Prediction of Prognosis of Endometrial Carcinoma by Combining Traditional Classification With the Presence of Tumor-infiltrating Lymphocytes. <i>Anticancer Research</i> , 2021, 41, 1047-1053.	0.5	1
1967	Predictive Systems Biomarkers of Response to Immune Checkpoint Inhibitors. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1968	Interaction of dendrimers with the immune system: An insight into cancer nanotheranostics. <i>View</i> , 2021, 2, 20200120.	2.7	19

#	ARTICLE	IF	CITATIONS
1969	Peripheral T cell receptor repertoire features predict durable responses to anti-PD-1 inhibitor monotherapy in advanced renal cell carcinoma. <i>OncolImmunology</i> , 2021, 10, 1862948.	2.1	20
1970	Radiation Response in the Tumour Microenvironment: Predictive Biomarkers and Future Perspectives. <i>Journal of Personalized Medicine</i> , 2021, 11, 53.	1.1	17
1971	Identification of mast cells as a candidate significant target of immunotherapy for acute myeloid leukemia. <i>Hematology</i> , 2021, 26, 284-294.	0.7	7
1972	Targeting cancer-promoting inflammation "have anti-inflammatory therapies come of age?". <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 261-279.	12.5	171
1973	An immunogenic first-in-human immune modulatory vaccine with PD-L1 and PD-L2 peptides is feasible and shows early signs of efficacy in follicular lymphoma. <i>OncolImmunology</i> , 2021, 10, .	2.1	5
1974	Immune signature-based risk stratification and prediction of immune checkpoint inhibitor's efficacy for lung adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1705-1719.	2.0	96
1975	Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 31-44.	1.4	23
1976	Two-dimensional biomaterials: material science, biological effect and biomedical engineering applications. <i>Chemical Society Reviews</i> , 2021, 50, 11381-11485.	18.7	129
1977	Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFN γ /CXCL10-dependent peripheral T cell recruitment in humanized murine model. <i>PLoS ONE</i> , 2021, 16, e0241091.	1.1	22
1978	Supramolecular Assembled Programmable Nanomedicine As In Situ Cancer Vaccine for Cancer Immunotherapy. <i>Advanced Materials</i> , 2021, 33, e2007293.	11.1	106
1979	The MHC-II antigen presentation machinery and B7 checkpoint ligands display distinctive patterns correlated with acute myeloid leukaemias blast cells HLA-DR expression. <i>Immunobiology</i> , 2021, 226, 152049.	0.8	6
1980	Development of a Non-IgG PD-1/PD-L1 Inhibitor by <i>in Silico</i> Mutagenesis and an In-Cell Protein-Protein Interaction Assay. <i>ACS Chemical Biology</i> , 2021, 16, 316-323.	1.6	7
1981	Proteomic Alterations in Multiple Myeloma: A Comprehensive Study Using Bone Marrow Interstitial Fluid and Serum Samples. <i>Frontiers in Oncology</i> , 2020, 10, 566804.	1.3	19
1982	Nano-immunotherapy for each stage of cancer cellular immunity: which, why, and what?. <i>Theranostics</i> , 2021, 11, 7471-7487.	4.6	26
1983	Malignant Melanoma: From Molecular Characterization to Targeted Therapies. , 2021, , .		0
1984	Immunotherapy for Pancreatic Cancer and Cholangiocarcinoma. , 2021, , 185-194.		0
1985	Biomarkers for the Immune Checkpoint Inhibitors. , 2021, , 493-531.		0
1986	Intraepithelial Lymphocytes Suppress Intestinal Tumor Growth by Cell-to-Cell Contact via CD103/E-Cadherin Signal. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 11, 1483-1503.	2.3	14

#	ARTICLE	IF	CITATIONS
1988	Interactions between Biomedical Microâ€¦Nanoâ€¦Motors and the Immune Molecules, Immune Cells, and the Immune System: Challenges and Opportunities. <i>Advanced Healthcare Materials</i> , 2021, 10, e2001788.	3.9	32
1989	Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy. <i>BMB Reports</i> , 2021, 54, 2-11.	1.1	36
1990	Tumor-intrinsic determinants of immunogenic cell death modalities. <i>OncolImmunology</i> , 2021, 10, 1893466.	2.1	30
1991	Factors Modifying the Associations of Single or Combination Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Inhibitor Therapies With Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma. <i>JAMA Network Open</i> , 2021, 4, e2034201.	2.8	4
1992	Enhanced Expression of miR-181b in B Cells of CLL Improves the Anti-Tumor Cytotoxic T Cell Response. <i>Cancers</i> , 2021, 13, 257.	1.7	10
1993	Tumour inflammation signature and expression of S100A12 and HLA class I improve survival in HPV-negative hypopharyngeal cancer. <i>Scientific Reports</i> , 2021, 11, 1782.	1.6	11
1994	Nanoscale coordination polymers induce immunogenic cell death by amplifying radiation therapy mediated oxidative stress. <i>Nature Communications</i> , 2021, 12, 145.	5.8	131
1995	STING Activated Tumor-Intrinsic Type I Interferon Signaling Promotes CXCR3 Dependent Antitumor Immunity in Pancreatic Cancer. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 12, 41-58.	2.3	35
1996	The Impact of Priming Effect of Immune Checkpoint Inhibitor Therapy for Advanced Stage Non-Small Cell Lung Cancer: A Meta-Epidemiological Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1997	Clonal Expansion of Tumor-Infiltrating T Cells and Analysis of the Tumor Microenvironment within Esophageal Squamous Cell Carcinoma Relapsed after Definitive Chemoradiation Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1098.	1.8	6
1998	Clinical pattern of failure after a durable response to immune checkpoint inhibitors in non-small cell lung cancer patients. <i>Scientific Reports</i> , 2021, 11, 2514.	1.6	17
1999	Development of prognostic signature based on immune-related genes in muscle-invasive bladder cancer: bioinformatics analysis of TCGA database. <i>Aging</i> , 2021, 13, 1859-1871.	1.4	32
2001	Therapeutic cancer vaccines for pediatric malignancies: advances, challenges, and emerging technologies. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab027.	0.4	13
2002	Immunomodulatory potential of chitosan-based materials for cancer therapy: a systematic review of <i>in vitro</i> , <i>in vivo</i> and clinical studies. <i>Biomaterials Science</i> , 2021, 9, 3209-3227.	2.6	22
2003	Exploring the clinical value of tumor microenvironment in platinum-resistant ovarian cancer. <i>Seminars in Cancer Biology</i> , 2021, 77, 83-98.	4.3	28
2004	Modeling 3D Human Tumor Lymphatic Vessel Network Using Highâ€¦Throughput Platform. <i>Advanced Biology</i> , 2021, 5, 2000195.	1.4	15
2005	Insights on neuroendocrine regulation of immune mediators in female reproductive aging and cancer. <i>AIMS Molecular Science</i> , 2021, 8, 127-148.	0.3	0
2006	The Interplay of Exosomes and NK Cells in Cancer Biology. <i>Cancers</i> , 2021, 13, 473.	1.7	30

#	ARTICLE	IF	CITATIONS
2007	Circulating leukocyte-platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1691-1704.	2.0	6
2008	Complex Interaction Among Immune, Inflammatory, and Carcinogenic Mechanisms in the Head and Neck Squamous Cell Carcinoma. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1335, 11-35.	0.8	11
2009	A critical role of STING-triggered tumor-migrating neutrophils for anti-tumor effect of intratumoral cGAMP treatment. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2301-2312.	2.0	11
2010	Integrating CD4 ⁺ T cell help for therapeutic cancer vaccination in a preclinical head and neck cancer model. <i>Oncolmmunology</i> , 2021, 10, 1958589.	2.1	9
2011	The inflammatory tumor microenvironment and tumor cell plasticity in the pathogenesis of colorectal cancer. <i>Onkologiya Zhurnal Imeni P A Gertsena</i> , 2021, 10, 66.	0.0	0
2012	Turning cold tumors into hot tumors by improving T-cell infiltration. <i>Theranostics</i> , 2021, 11, 5365-5386.	4.6	324
2013	Therapeutic Approaches to Employ Monoclonal Antibody for Cancer Treatment. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2021, , 42-88.	0.1	0
2014	Cancer immunotherapy with T-cell targeting cytokines: IL-2 and IL-7. <i>BMB Reports</i> , 2021, 54, 21-30.	1.1	22
2015	Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer. <i>Theranostics</i> , 2021, 11, 3089-3108.	4.6	207
2016	Tumor-targeted gene therapy with lipid nanoparticles inhibits tumor-associated adipocytes and remodels the immunosuppressive tumor microenvironment in triple-negative breast cancer. <i>Nanoscale Horizons</i> , 2021, 6, 319-329.	4.1	39
2017	The role of dendritic cells in tumor microenvironments and their uses as therapeutic targets. <i>BMB Reports</i> , 2021, 54, 31-43.	1.1	33
2018	Viral Nanoparticles: Cancer Vaccines and Immune Modulators. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1295, 317-325.	0.8	2
2019	A near-infrared light-excitable immunomodulating nano-photosensitizer for effective photoimmunotherapy. <i>Biomaterials Science</i> , 2021, 9, 4191-4198.	2.6	8
2020	Interleukin-1 as Innate Mediator of T Cell Immunity. <i>Frontiers in Immunology</i> , 2020, 11, 621931.	2.2	75
2021	Distinct difference in tumor-infiltrating immune cells between Wilms TM tumor gene 1 peptide vaccine and anti-programmed cell death-1 antibody therapies. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab091.	0.4	2
2022	Identification and Characterization of Alcohol-related Hepatocellular Carcinoma Prognostic Subtypes based on an Integrative N6-methyladenosine methylation Model. <i>International Journal of Biological Sciences</i> , 2021, 17, 3554-3572.	2.6	12
2023	Recent progress in nanomedicine for enhanced cancer chemotherapy. <i>Theranostics</i> , 2021, 11, 6370-6392.	4.6	177
2024	Imaging Tumor-Infiltrating Lymphocytes in Brain Tumors with [64Cu]Cu-NOTA-anti-CD8 PET. <i>Clinical Cancer Research</i> , 2021, 27, 1958-1966.	3.2	21

#	ARTICLE	IF	CITATIONS
2025	Mechanisms and Management of Immune Checkpoint Inhibitor-Related Cardiac Adverse Events. <i>JMA Journal</i> , 2021, 4, 91-98.	0.6	13
2026	Patients'™ Responses to the Sudden Interruption of Chemotherapy During the Outbreak of the Novel Coronavirus: A Cross-Sectional Study. <i>Cancer Management and Research</i> , 2021, Volume 13, 351-358.	0.9	9
2027	Remodeling of the Lymph Node High Endothelial Venules Reflects Tumor Invasiveness in Breast Cancer and is Associated with Dysregulation of Perivascular Stromal Cells. <i>Cancers</i> , 2021, 13, 211.	1.7	22
2028	Combination of EP ₄ antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both lymphocytes and myeloid cells. <i>Oncimmunology</i> , 2021, 10, 1896643.	2.1	28
2029	Development of a novel gene signature to predict prognosis and response to PD-1 blockade in clear cell renal cell carcinoma. <i>Oncimmunology</i> , 2021, 10, 1933332.	2.1	26
2030	Activation of NF- κ B and p300/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	47
2031	Phosphorylation of SMAD3 in immune cells predicts survival of patients with early stage non-small cell lung cancer. , 2021, 9, e001469.		12
2032	Introduction: Immuno- ∞ ncology seminar. <i>Journal of Surgical Oncology</i> , 2021, 123, 708-709.	0.8	0
2033	The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF- β 2 and PD-L1. <i>Journal of Hematology and Oncology</i> , 2021, 14, 27.	6.9	118
2034	Enhancing the Efficacy of Tumor Vaccines Based on Immune Evasion Mechanisms. <i>Frontiers in Oncology</i> , 2020, 10, 584367.	1.3	8
2035	Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 622509.	2.2	148
2036	Nanomaterials-Mediated Immunomodulation for Cancer Therapeutics. <i>Frontiers in Chemistry</i> , 2021, 9, 629635.	1.8	15
2037	Microfluidic Tumor Vasculature Model to Recapitulate an Endothelial Immune Barrier Expressing FasL. <i>ACS Biomaterials Science and Engineering</i> , 2021, 7, 1230-1241.	2.6	17
2038	Key chemokines direct migration of immune cells in solid tumors. <i>Cancer Gene Therapy</i> , 2022, 29, 10-21.	2.2	186
2039	Potential of Photodynamic Therapy Based on Sugar-Conjugated Photosensitizers. <i>Journal of Clinical Medicine</i> , 2021, 10, 841.	1.0	21
2041	Characterization of an endoplasmic reticulum stress-related signature to evaluate immune features and predict prognosis in glioma. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 3870-3884.	1.6	40
2042	Differential Expression of CD49a and CD49b Determines Localization and Function of Tumor-Infiltrating CD8+ T Cells. <i>Cancer Immunology Research</i> , 2021, 9, 583-597.	1.6	9
2043	Polymeric Micelles in Cancer Immunotherapy. <i>Molecules</i> , 2021, 26, 1220.	1.7	22

#	ARTICLE	IF	CITATIONS
2044	Remarkable response to pembrolizumab with platinumâ€¦doublet in PDâ€¦L1â€¦low pulmonary sarcomatoid carcinoma: A case report. <i>Thoracic Cancer</i> , 2021, 12, 1126-1130.	0.8	11
2045	<i>In Situ</i> Self-Assembly Nanomicelle Microneedles for Enhanced Photoimmunotherapy <i>via</i> Autophagy Regulation Strategy. <i>ACS Nano</i> , 2021, 15, 3387-3401.	7.3	84
2046	The nanomedicine rush: New strategies for unmet medical needs based on innovative nano DDS. <i>Journal of Controlled Release</i> , 2021, 330, 305-316.	4.8	24
2047	Targeting tumor-associated macrophages to synergize tumor immunotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 75.	7.1	323
2048	C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients. <i>PLoS ONE</i> , 2021, 16, e0246486.	1.1	6
2049	Modulation of intratumoural myeloid cells, the hallmark of the anti-tumour efficacy induced by a triple combination: tumour-associated peptide, TLR-3 ligand and Î±-PD-1. <i>British Journal of Cancer</i> , 2021, 124, 1275-1285.	2.9	5
2050	Exploration of the Prognostic and Immunotherapeutic Value of B and T Lymphocyte Attenuator in Skin Cutaneous Melanoma. <i>Frontiers in Oncology</i> , 2020, 10, 592811.	1.3	10
2051	The MHC Class-I Transactivator NLRC5: Implications to Cancer Immunology and Potential Applications to Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1964.	1.8	27
2052	Immunotherapy for Merkel cell carcinoma. <i>Journal of Surgical Oncology</i> , 2021, 123, 775-781.	0.8	17
2053	Targeting Innate Immunity in Cancer Therapy. <i>Vaccines</i> , 2021, 9, 138.	2.1	57
2054	Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer. <i>Biomarker Research</i> , 2021, 9, 14.	2.8	24
2055	Local Depletion of Immune Checkpoint Ligand CTLA4 Expressing Cells in Tumor Beds Enhances Antitumor Host Immunity. <i>Advanced Therapeutics</i> , 2021, 4, 2000269.	1.6	27
2056	Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 153-162.	1.5	11
2057	Immune classification of clear cell renal cell carcinoma. <i>Scientific Reports</i> , 2021, 11, 4338.	1.6	18
2058	Immunotherapy in gynecological cancers. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , .	0.5	1
2059	Overcoming biological barriers to improve solid tumor immunotherapy. <i>Drug Delivery and Translational Research</i> , 2021, 11, 2276-2301.	3.0	11
2060	Comprehensive Analysis of the Immune and Prognostic Implication of COL6A6 in Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 633420.	1.3	6
2061	Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study. <i>Clinical Cancer Research</i> , 2021, 27, 3360-3369.	3.2	47

#	ARTICLE	IF	CITATIONS
2062	DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint Inhibitors. <i>Frontiers in Oncology</i> , 2020, 10, 549777.	1.3	26
2064	Lytic Polyplex Vaccines Enhance Antigen-Specific Cytotoxic T Cell Response through Induction of Local Cell Death. <i>Advanced Therapeutics</i> , 2021, 4, 2100005.	1.6	5
2065	Nano-Oncologicals: A Tortoise Trail Reaching New Avenues. <i>Advanced Functional Materials</i> , 2021, 31, 2009860.	7.8	13
2066	Identification of immune checkpoint and cytokine signatures associated with the response to immune checkpoint blockade in gastrointestinal cancers. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2669-2679.	2.0	4
2067	Understanding relevant immune mechanisms in gastrointestinal oncology. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 107815522199286.	0.5	0
2068	Tumour-Infiltrating Lymphocytes (TILs) and PD-L1 Expression Correlate with Lymph Node Metastasis, High-Grade Transformation and Shorter Metastasis-Free Survival in Patients with Acinic Cell Carcinoma (AciCC) of the Salivary Glands. <i>Cancers</i> , 2021, 13, 965.	1.7	12
2069	Non-canonical PD-1 signaling in cancer and its potential implications in clinic. , 2021, 9, e001230.		15
2070	Recent Advances in Cell Membrane-Derived Biomimetic Nanotechnology for Cancer Immunotherapy. <i>Advanced Healthcare Materials</i> , 2021, 10, e2002081.	3.9	78
2071	Crosstalk between Macrophages, T Cells, and Iron Metabolism in Tumor Microenvironment. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-14.	1.9	40
2072	Mechanisms of immunogenic cell death and immune checkpoint blockade therapy. <i>Kaohsiung Journal of Medical Sciences</i> , 2021, 37, 448-458.	0.8	15
2073	Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades. <i>Molecular Cancer</i> , 2021, 20, 27.	7.9	54
2074	Adoptive T Cell Therapy Is Complemented by Oncolytic Virotherapy with Fusogenic VSV-NDV in Combination Treatment of Murine Melanoma. <i>Cancers</i> , 2021, 13, 1044.	1.7	8
2076	Emerging Trends for Radio-Immunotherapy in Rectal Cancer. <i>Cancers</i> , 2021, 13, 1374.	1.7	18
2077	High numbers of programmed cell death-1-positive tumor infiltrating lymphocytes correlate with early onset of post-transplant lymphoproliferative disorder. <i>International Journal of Hematology</i> , 2021, 114, 53-64.	0.7	1
2078	Meningeal lymphatics prime tumor immunity in glioblastoma. <i>Cancer Cell</i> , 2021, 39, 304-306.	7.7	20
2079	The right Timing, right combination, right sequence, and right delivery for Cancer immunotherapy. <i>Journal of Controlled Release</i> , 2021, 331, 321-334.	4.8	35
2080	Epstein-Barr Virus LMP1 Induces Soluble PD-L1 in Nasopharyngeal Carcinoma. <i>Microorganisms</i> , 2021, 9, 603.	1.6	11
2081	CD169 Expression on Lymph Node Macrophages Predicts in Patients With Gastric Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 636751.	1.3	9

#	ARTICLE	IF	CITATIONS
2083	Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC. <i>Experimental Hematology and Oncology</i> , 2021, 10, 18.	2.0	64
2084	The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 975-985.	1.9	79
2085	miRNAs and lncRNAs as Novel Therapeutic Targets to Improve Cancer Immunotherapy. <i>Cancers</i> , 2021, 13, 1587.	1.7	47
2086	Harnessing and Enhancing Macrophage Phagocytosis for Cancer Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 635173.	2.2	41
2087	Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors. <i>Cancers</i> , 2021, 13, 1298.	1.7	24
2088	Dual-Sensitive PEG-Sheddable Nanodrug Hierarchically Incorporating PD-L1 Antibody and Zinc Phthalocyanine for Improved Immuno-Photodynamic Therapy. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 12845-12856.	4.0	35
2089	Visceral Obesity, Metabolic Syndrome, and Esophageal Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 627270.	1.3	25
2090	The role of immunotherapy in metastatic triple negative breast cancer: a narrative review of the current clinical trials. <i>Precision Cancer Medicine</i> , 0, 4, 1-1.	1.8	0
2091	Nanomaterials Enhance the Immunomodulatory Effect of Molecular Targeted Therapy. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 1631-1661.	3.3	19
2092	Transient Depletion of CD4+ Cells Induces Remodeling of the TCR Repertoire in Gastrointestinal Cancer. <i>Cancer Immunology Research</i> , 2021, 9, 624-636.	1.6	13
2093	Immunotherapy in Advanced Biliary Tract Cancers. <i>Cancers</i> , 2021, 13, 1569.	1.7	19
2094	Druggable genome and precision medicine in cancer: current challenges. <i>FEBS Journal</i> , 2021, 288, 6142-6158.	2.2	25
2095	Radiotherapy as an immune checkpoint blockade combination strategy for hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2021, 27, 919-927.	1.4	14
2096	Bladder preservation therapy in combination with atezolizumab and radiation therapy for invasive bladder cancer (BPT-ART) – A study protocol for an open-label, phase II, multicenter study. <i>Contemporary Clinical Trials Communications</i> , 2021, 21, 100724.	0.5	3
2097	Circadian clock: a regulator of the immunity in cancer. <i>Cell Communication and Signaling</i> , 2021, 19, 37.	2.7	41
2098	Identification of an Immune-Related Risk Signature Correlates With Immunophenotype and Predicts Anti-PD-L1 Efficacy of Urothelial Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 646982.	1.8	7
2099	Challenging Hurdles of Current Targeting in Glioblastoma: A Focus on Immunotherapeutic Strategies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3493.	1.8	4
2100	Identification of Biomarkers Related to CD8+ T Cell Infiltration With Gene Co-expression Network in Lung Squamous Cell Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 606106.	1.8	12

#	ARTICLE	IF	CITATIONS
2101	Precision Oncology, Signaling, and Anticancer Agents in Cancer Therapeutics. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 433-468.	0.9	7
2102	Point-source burst of coordination polymer nanoparticles for tri-modality cancer therapy. <i>Biomaterials</i> , 2021, 270, 120690.	5.7	21
2103	Genomic and neoantigen evolution from primary tumor to first metastases in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2021, 12, 534-548.	0.8	6
2104	Discovery of core gene families associated with liver metastasis in colorectal cancer and regulatory roles in tumor cell immune infiltration. <i>Translational Oncology</i> , 2021, 14, 101011.	1.7	9
2105	Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2971-2980.	2.0	9
2106	Self-Replicating RNAs Drive Protective Anti-tumor T Cell Responses to Neoantigen Vaccine Targets in a Combinatorial Approach. <i>Molecular Therapy</i> , 2021, 29, 1186-1198.	3.7	14
2107	Gene silencing-mediated immune checkpoint blockade for tumor therapy boosted by dendrimer-entrapped gold nanoparticles. <i>Science China Materials</i> , 2021, 64, 2045-2055.	3.5	19
2108	PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 3120-3133.	5.7	16
2109	RNA Modification of N6-Methyladenosine Predicts Immune Phenotypes and Therapeutic Opportunities in Kidney Renal Clear Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 642159.	1.3	30
2110	P14/ARF-Positive Malignant Pleural Mesothelioma: A Phenotype With Distinct Immune Microenvironment. <i>Frontiers in Oncology</i> , 2021, 11, 653497.	1.3	8
2111	Rational nanocarrier design towards clinical translation of cancer nanotherapy. <i>Biomedical Materials (Bristol)</i> , 2021, 16, 032005.	1.7	14
2112	Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. <i>Nature Reviews Cancer</i> , 2021, 21, 298-312.	12.8	553
2113	Improving Breast Cancer Responses to Immunotherapy—a Search for the Achilles Heel of the Tumor Microenvironment. <i>Current Oncology Reports</i> , 2021, 23, 55.	1.8	12
2114	Evaluation of Combination Strategies for the A2AR Inhibitor AZD4635 Across Tumor Microenvironment Conditions via a Systems Pharmacology Model. <i>Frontiers in Immunology</i> , 2021, 12, 617316.	2.2	10
2115	Efficacy and safety of first-line treatments with immune checkpoint inhibitors plus chemotherapy for non-squamous non-small cell lung cancer: a meta-analysis and indirect comparison. <i>Annals of Palliative Medicine</i> , 2021, 10, 2766-2775.	0.5	8
2116	Enhancing Cancer Immunotherapy Treatment Goals by Using Nanoparticle Delivery System. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 2389-2404.	3.3	17
2117	Mass spectrometry and the cellular surfaceome. <i>Mass Spectrometry Reviews</i> , 2022, 41, 804-841.	2.8	19
2118	Cancer vs. SARS-CoV-2 induced inflammation, overlapping functions, and pharmacological targeting. <i>Inflammopharmacology</i> , 2021, 29, 343-366.	1.9	9

#	ARTICLE	IF	CITATIONS
2119	Targeting loss of heterozygosity for cancer-specific immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	39
2120	Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy. European Journal of Cancer, 2021, 145, 221-229.	1.3	42
2121	Sarcomatoid hepatocellular carcinoma is distinct from ordinary hepatocellular carcinoma: Clinicopathologic, transcriptomic and immunologic analyses. International Journal of Cancer, 2021, 149, 546-560.	2.3	18
2122	A tumor-specific mechanism of T _{reg} enrichment mediated by the integrin $\alpha 8$. Science Immunology, 2021, 6, .	5.6	17
2123	Emerging nanotechnological strategies to reshape tumor microenvironment for enhanced therapeutic outcomes of cancer immunotherapy. Biomedical Materials (Bristol), 2021, 16, 042001.	1.7	6
2124	Tumor Immunometabolism Characterization in Ovarian Cancer With Prognostic and Therapeutic Implications. Frontiers in Oncology, 2021, 11, 622752.	1.3	9
2125	Defining Immunogenic and Radioimmunogenic Tumors. Frontiers in Oncology, 2021, 11, 667075.	1.3	22
2126	Injectable Adhesive Hydrogel as Photothermal-Derived Antigen Reservoir for Enhanced Anti-Tumor Immunity. Advanced Functional Materials, 2021, 31, 2010587.	7.8	54
2127	Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics. AAPS Journal, 2021, 23, 39.	2.2	356
2128	Plinabulin, a Distinct Microtubule-Targeting Chemotherapy, Promotes M1-Like Macrophage Polarization and Anti-tumor Immunity. Frontiers in Oncology, 2021, 11, 644608.	1.3	19
2129	Renal cell carcinoma pathology in 2021: a new need for renal cancer immune profiling™. Current Opinion in Urology, 2021, 31, 228-235.	0.9	5
2130	Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas. Frontiers in Oncology, 2021, 11, 596290.	1.3	18
2131	Beyond immune checkpoint blockade: emerging immunological strategies. Nature Reviews Drug Discovery, 2021, 20, 899-919.	21.5	208
2132	The complexity of p53-mediated metabolic regulation in tumor suppression. Seminars in Cancer Biology, 2022, 85, 4-32.	4.3	104
2133	Mesoporous Silica Nanoparticles as pH-Responsive Carrier for the Immune-Activating Drug Resiquimod Enhance the Local Immune Response in Mice. ACS Nano, 2021, 15, 4450-4466.	7.3	94
2134	Exploiting Tumor Neoantigens to Target Cancer Evolution: Current Challenges and Promising Therapeutic Approaches. Cancer Discovery, 2021, 11, 1024-1039.	7.7	56
2135	Molecular and Clinical Premises for the Combination Therapy Consisting of Radiochemotherapy and Immunotherapy in Non-Small Cell Lung Cancer Patients. Cancers, 2021, 13, 1222.	1.7	8
2136	Modeling Radioimmune Response—Current Status and Perspectives. Frontiers in Oncology, 2021, 11, 647272.	1.3	10

#	ARTICLE	IF	CITATIONS
2137	Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade. <i>Frontiers in Oncology</i> , 2021, 11, 617335.	1.3	49
2138	Identification of an Individualized Immune-Related Prognostic Risk Score in Lung Squamous Cell Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 546455.	1.3	10
2139	A Nano "Immune" Guide Recruiting Lymphocytes and Modulating the Ratio of Macrophages from Different Origins to Enhance Cancer Immunotherapy. <i>Advanced Functional Materials</i> , 2021, 31, 2009116.	7.8	24
2140	A Supramolecular "Trident" for Cancer Immunotherapy. <i>Advanced Functional Materials</i> , 2021, 31, 2100729.	7.8	29
2141	Body mass index and absolute lymphocyte count predict disease-free survival in Korean breast cancer patients. <i>British Journal of Cancer</i> , 2021, 125, 119-125.	2.9	15
2142	Assessing Preclinical Research Models for Immunotherapy for Gynecologic Malignancies. <i>Cancers</i> , 2021, 13, 1694.	1.7	1
2143	The Usefulness of Lymphadenectomy in Bladder Cancer" Current Status. <i>Medicina (Lithuania)</i> , 2021, 57, 415.	0.8	8
2144	Innate Immune Checkpoint Inhibitors: The Next Breakthrough in Medical Oncology?. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 961-974.	1.9	58
2145	Nanocatalytic Innate Immunity Activation by Mitochondrial DNA Oxidative Damage for Tumor-Specific Therapy. <i>Advanced Materials</i> , 2021, 33, e2008065.	11.1	78
2146	Tumor-infiltrating CD8+ T cell antitumor efficacy and exhaustion: molecular insights. <i>Drug Discovery Today</i> , 2021, 26, 951-967.	3.2	25
2147	Time-dependent population PK models of single-agent atezolizumab in patients with cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 211-221.	1.1	13
2148	The safety and efficacy of immune-checkpoint inhibitors in patients with cancer and pre-existing autoimmune diseases. <i>Immunotherapy</i> , 2021, 13, 527-539.	1.0	12
2149	Cancer Immunology and CAR-T Cells: A Turning Point Therapeutic Approach in Colorectal Carcinoma with Clinical Insight. <i>Current Molecular Medicine</i> , 2021, 21, 221-236.	0.6	6
2150	Gastrointestinal and liver immune-related adverse effects induced by immune checkpoint inhibitors: A descriptive observational study. <i>Gastroenterology & Hepatology (English Edition)</i> , 2021, 44, 261-268.	0.0	3
2151	The confounding effect of interleukin-6 on apoptosis of MCF-7 cells through down-regulation of MMP-2/-9 mRNA expression. <i>Turkish Journal of Biochemistry</i> , 2021, 46, 549-555.	0.3	7
2152	Synergistic Activation of Antitumor Immunity by a Particulate Therapeutic Vaccine. <i>Advanced Science</i> , 2021, 8, 2100166.	5.6	18
2153	Anti-angiogenic agents "overcoming tumour endothelial cell energy and improving immunotherapy outcomes. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 527-540.	12.5	162
2154	Correlation between the immune checkpoints and EMT genes proposes potential prognostic and therapeutic targets in ESCC. <i>Journal of Molecular Histology</i> , 2021, 52, 597-609.	1.0	16

#	ARTICLE	IF	CITATIONS
2155	Development of Immunotherapy Combination Strategies in Cancer. <i>Cancer Discovery</i> , 2021, 11, 1368-1397.	7.7	130
2156	Injectable Hydrogels as Local Depots at Tumor Sites for Antitumor Immunotherapy and Immune-Based Combination Therapy. <i>Macromolecular Bioscience</i> , 2021, 21, e2100039.	2.1	34
2157	Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel?. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 180-192.	0.7	47
2158	Systemic immunity in cancer. <i>Nature Reviews Cancer</i> , 2021, 21, 345-359.	12.8	605
2159	Challenges and perspectives for immunotherapy in Esophageal cancer: A look to the future (Review). <i>International Journal of Molecular Medicine</i> , 2021, 47, .	1.8	3
2160	Psychosocial stress and immunosuppression in cancer: what can we learn from new research?. <i>BJ Psych Advances</i> , 2021, 27, 187-197.	0.5	3
2161	PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer. <i>Digestive and Liver Disease</i> , 2021, 53, 420-426.	0.4	10
2162	High-throughput identification of conditional MHC-I ligands and scaled-up production of conditional MHC-I complexes. <i>Protein Science</i> , 2021, 30, 1169-1183.	3.1	5
2163	The role of macrophages in anti-tumor immune responses: pathological significance and potential as therapeutic targets. <i>Human Cell</i> , 2021, 34, 1031-1039.	1.2	9
2164	Paraneoplastic Neurological Syndromes and Beyond Emerging With the Introduction of Immune Checkpoint Inhibitor Cancer Immunotherapy. <i>Frontiers in Neurology</i> , 2021, 12, 642800.	1.1	26
2165	Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma Cells. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1283-1294.	1.9	1
2166	Polymeric Nanosystems for Immunogenic Cell Death-Based Cancer Immunotherapy. <i>Macromolecular Bioscience</i> , 2021, 21, e2100075.	2.1	10
2167	Professional killers: The role of extracellular vesicles in the reciprocal interactions between natural killer, CD8+ cytotoxic T cells and tumour cells. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12075.	5.5	33
2168	Radiotherapy, immunotherapy, and the tumour microenvironment: Turning an immunosuppressive milieu into a therapeutic opportunity. <i>Cancer Letters</i> , 2021, 502, 84-96.	3.2	80
2169	Endogenous Stimuli-Activatable Nanomedicine for Immune Theranostics for Cancer. <i>Advanced Functional Materials</i> , 2021, 31, 2100386.	7.8	36
2170	Application of Immune Infiltration Signature and Machine Learning Model in the Differential Diagnosis and Prognosis of Bone-Related Malignancies. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 630355.	1.8	10
2171	Gastrointestinal disorders as immune-related adverse events. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , .	0.5	2
2173	Interfacing Biomaterials with Synthetic T Cell Immunity. <i>Advanced Healthcare Materials</i> , 2021, 10, e2100157.	3.9	4

#	ARTICLE	IF	CITATIONS
2174	Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model. <i>Journal of Nanobiotechnology</i> , 2021, 19, 102.	4.2	27
2175	Tumor-Intrinsic Mechanisms Regulating Immune Exclusion in Liver Cancers. <i>Frontiers in Immunology</i> , 2021, 12, 642958.	2.2	12
2176	A Review of Cancer Immunotherapy Toxicity II: Adoptive Cellular Therapies, Kinase Inhibitors, Monoclonal Antibodies, and Oncolytic Viruses. <i>Journal of Medical Toxicology</i> , 2022, 18, 43-55.	0.8	18
2177	Bioengineered bacteria-derived outer membrane vesicles as a versatile antigen display platform for tumor vaccination via Plug-and-Display technology. <i>Nature Communications</i> , 2021, 12, 2041.	5.8	207
2178	Cancer Nanopharmaceuticals: Physicochemical Characterization and In Vitro/In Vivo Applications. <i>Cancers</i> , 2021, 13, 1896.	1.7	15
2179	Effect of physicochemical properties on in vivo fate of nanoparticle-based cancer immunotherapies. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 886-902.	5.7	42
2180	PD-L1 lncRNA splice isoform promotes lung adenocarcinoma progression via enhancing c-Myc activity. <i>Genome Biology</i> , 2021, 22, 104.	3.8	42
2181	Feasibility of semiquantitative 18F-fluorodeoxyglucose PET/computed tomography in patients with advanced lung cancer for interim treatment evaluation of combining immunotherapy and chemotherapy. <i>Nuclear Medicine Communications</i> , 2021, 42, 1017-1023.	0.5	3
2182	Supramolecular Nanofibrils Formed by Coassembly of Clinically Approved Drugs for Tumor Photothermal Immunotherapy. <i>Advanced Materials</i> , 2021, 33, e2100595.	11.1	105
2183	Immune Landscape of Thyroid Cancers: New Insights. <i>Frontiers in Endocrinology</i> , 2020, 11, 637826.	1.5	30
2184	Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2021, 14, 68.	6.9	153
2185	Efectos adversos inmunomediados gastrointestinales y hepáticos inducidos por los inhibidores del punto de control inmunitario: estudio descriptivo observacional. <i>Gastroenterología Y Hepatología</i> , 2021, 44, 261-268.	0.2	8
2186	Screening of immunosuppressive cells from colorectal adenocarcinoma and identification of prognostic markers. <i>Bioscience Reports</i> , 2021, 41, .	1.1	5
2187	The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low-Expressing Cancer In Vitro and In Vivo. <i>Cancer Immunology Research</i> , 2021, 9, 779-789.	1.6	10
2188	Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naïve clear cell renal cell cancer. <i>International Urology and Nephrology</i> , 2021, 53, 2493-2503.	0.6	11
2189	Exploring the Modulatory Effects of Gut Microbiota in Anti-Cancer Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 644454.	1.3	27
2190	Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade. , 2021, 9, e002231.		69
2191	Clinical and Immunologic Responses to a B-Cell Epitope Vaccine in Patients with HER2/neu-Overexpressing Advanced Gastric Cancer—Results from Phase Ib Trial IMU.ACS.001. <i>Clinical Cancer Research</i> , 2021, 27, 3649-3660.	3.2	23

#	ARTICLE	IF	CITATIONS
2192	Analysis of Tumor Microenvironment Characteristics in Bladder Cancer: Implications for Immune Checkpoint Inhibitor Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 672158.	2.2	26
2193	Diet-Induced Obesity Impairs Outcomes and Induces Multi-Factorial Deficiencies in Effector T Cell Responses Following Anti-CTLA-4 Combinatorial Immunotherapy in Renal Tumor-Bearing Mice. <i>Cancers</i> , 2021, 13, 2295.	1.7	2
2194	Combination of Immune Checkpoint Inhibitors and Anti-Angiogenic Agents in Brain Metastases From Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 670313.	1.3	9
2195	Cancer neoantigens as potential targets for immunotherapy. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 51-60.	1.7	24
2196	Safety and Efficacy of Personalized Cancer Vaccines in Combination With Immune Checkpoint Inhibitors in Cancer Treatment. <i>Frontiers in Oncology</i> , 2021, 11, 663264.	1.3	19
2197	Lymph Node Immune Profiles as Predictive Biomarkers for Immune Checkpoint Inhibitor Response. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 674558.	1.6	10
2198	Stay on Target: Reengaging Cancer Vaccines in Combination Immunotherapy. <i>Vaccines</i> , 2021, 9, 509.	2.1	14
2200	Immunomodulation by the Commensal Microbiome During Immune-Targeted Interventions: Focus on Cancer Immune Checkpoint Inhibitor Therapy and Vaccination. <i>Frontiers in Immunology</i> , 2021, 12, 643255.	2.2	6
2201	Five-year follow-up of nivolumab treatment in Japanese patients with esophageal squamous-cell carcinoma (ATTRACTION-1/ONO-4538-07). <i>Esophagus</i> , 2021, 18, 835-843.	1.0	15
2202	Immunotherapy for non-small cell lung cancer in the elderly population: a generic protocol. <i>The Cochrane Library</i> , 0, , .	1.5	0
2203	Low-Temperature Photothermal Therapy: Strategies and Applications. <i>Research</i> , 2021, 2021, 9816594.	2.8	92
2204	Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors. , 2021, 9, e002493.		44
2205	Modulation of lactate-lysosome axis in dendritic cells by clotrimazole potentiates antitumor immunity. , 2021, 9, e002155.		9
2206	The Endless Sources of Hepatocellular Carcinoma Heterogeneity. <i>Cancers</i> , 2021, 13, 2621.	1.7	15
2207	Zoledronic Acid-Gadolinium Coordination Polymer Nanorods for Improved Tumor Radioimmunotherapy by Synergetically Inducing Immunogenic Cell Death and Reprogramming the Immunosuppressive Microenvironment. <i>ACS Nano</i> , 2021, 15, 8450-8465.	7.3	59
2208	Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer. <i>JCI Insight</i> , 2021, 6, .	2.3	17
2209	Emerging concepts in PD-1 checkpoint biology. <i>Seminars in Immunology</i> , 2021, 52, 101480.	2.7	84
2210	Nano- and Microscale Drug Delivery Approaches for Therapeutic Immunomodulation. <i>ChemNanoMat</i> , 2021, 7, 773-788.	1.5	5

#	ARTICLE	IF	CITATIONS
2211	Neurological complications of immune checkpoint inhibitor cancer immunotherapy. <i>Journal of the Neurological Sciences</i> , 2021, 424, 117424.	0.3	14
2212	Control of Tumor Progression by Angiocrine Factors. <i>Cancers</i> , 2021, 13, 2610.	1.7	19
2213	Mast Cells: A New Frontier for Cancer Immunotherapy. <i>Cells</i> , 2021, 10, 1270.	1.8	59
2214	Pembrolizumabâ€caused polyradiculoneuropathy as an immuneâ€related adverse event. <i>Neuropathology</i> , 2021, 41, 266-272.	0.7	3
2215	Exosomes: Isolation, characterization, and biomedical applications. <i>Cell Biology International</i> , 2021, 45, 1807-1831.	1.4	59
2216	Cooperative Self-Assembled Nanoparticle Induces Sequential Immunogenic Cell Death and Toll-Like Receptor Activation for Synergistic Chemo-immunotherapy. <i>Nano Letters</i> , 2021, 21, 4371-4380.	4.5	39
2217	Optimal timing of PD-1 blockade in combination with oncolytic virus therapy. <i>Seminars in Cancer Biology</i> , 2022, 86, 971-980.	4.3	17
2218	Inhibitors of immuno-oncology target HPK1 â€“ a patent review (2016 to 2020). <i>Expert Opinion on Therapeutic Patents</i> , 2021, 31, 893-910.	2.4	13
2219	Immunotherapy for pancreatic cancer. <i>World Journal of Clinical Cases</i> , 2021, 9, 2969-2982.	0.3	16
2220	ROS Cocktails as an Adjuvant for Personalized Antitumor Vaccination?. <i>Vaccines</i> , 2021, 9, 527.	2.1	12
2221	Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis. <i>Immunotherapy</i> , 2021, 13, 621-631.	1.0	35
2222	Ferroptosisâ€related gene signature predicts prognosis and immunotherapy in glioma. <i>CNS Neuroscience and Therapeutics</i> , 2021, 27, 973-986.	1.9	55
2223	Imaging of T-cell Responses in the Context of Cancer Immunotherapy. <i>Cancer Immunology Research</i> , 2021, 9, 490-502.	1.6	8
2224	High endothelial venules (HEVs) in immunity, inflammation and cancer. <i>Angiogenesis</i> , 2021, 24, 719-753.	3.7	64
2225	MicroRNA-1: Diverse role of a small player in multiple cancers. <i>Seminars in Cell and Developmental Biology</i> , 2022, 124, 114-126.	2.3	14
2226	Progesterone promotes immunomodulation and tumor development in the murine mammary gland. , 2021, 9, e001710.		12
2227	Development of Effective Tumor Vaccine Strategies Based on Immune Response Cascade Reactions. <i>Advanced Healthcare Materials</i> , 2021, 10, e2100299.	3.9	20
2228	Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5801.	1.8	182

#	ARTICLE	IF	CITATIONS
2229	Magnetic Nanostructures as Emerging Therapeutic Tools to Boost Anti-Tumour Immunity. <i>Cancers</i> , 2021, 13, 2735.	1.7	21
2230	Expanding the Role of Checkpoint Inhibitors in Immune Cold Tumors. <i>Advances in Oncology</i> , 2021, 1, 85-95.	0.1	0
2231	Stimuli responsive and receptor targeted iron oxide based nanoplatfoms for multimodal therapy and imaging of cancer: Conjugation chemistry and alternative therapeutic strategies. <i>Journal of Controlled Release</i> , 2021, 333, 188-245.	4.8	31
2232	Immunotherapy in the Treatment of Urothelial Bladder Cancer: Insights From Single-Cell Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 696716.	1.3	15
2233	Translational Applications of Hydrogels. <i>Chemical Reviews</i> , 2021, 121, 11385-11457.	23.0	438
2234	Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies. <i>Frontiers in Oncology</i> , 2021, 11, 635007.	1.3	76
2235	Glycosylation of Immune Receptors in Cancer. <i>Cells</i> , 2021, 10, 1100.	1.8	32
2236	Developing a Novel Anticancer Gold(III) Agent to Integrate Chemotherapy and Immunotherapy. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 6777-6791.	2.9	23
2237	Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently?. <i>Seminars in Liver Disease</i> , 2021, 41, 136-141.	1.8	10
2238	Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. <i>European Urology</i> , 2021, 79, 665-673.	0.9	20
2239	Turning tumors from cold to inflamed to improve immunotherapy response. <i>Cancer Treatment Reviews</i> , 2021, 101, 102227.	3.4	42
2240	Nanoparticle-based approaches to target the lymphatic system for antitumor treatment. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 5139-5161.	2.4	17
2241	Intratumoural administration and tumour tissue targeting of cancer immunotherapies. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 558-576.	12.5	202
2242	In situ vaccination and gene-mediated PD-L1 blockade for enhanced tumor immunotherapy. <i>Chinese Chemical Letters</i> , 2021, 32, 1770-1774.	4.8	41
2243	Immune System-Related Changes in Preclinical GL261 Glioblastoma under TMZ Treatment: Explaining MRSI-Based Nosological Imaging Findings with RT-PCR Analyses. <i>Cancers</i> , 2021, 13, 2663.	1.7	7
2244	The role of dendritic cells in cancer and anti-tumor immunity. <i>Seminars in Immunology</i> , 2021, 52, 101481.	2.7	91
2246	Clinical Application of Cytokines in Cancer Immunotherapy. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 2269-2287.	2.0	48
2247	Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-“Small Cell Lung Cancer: Results From the Randomized OAK Trial. <i>Clinical Lung Cancer</i> , 2022, 23, 21-33.	1.1	12

#	ARTICLE	IF	CITATIONS
2248	Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study. <i>Clinical Breast Cancer</i> , 2021, 21, 539-551.	1.1	13
2249	Heterogeneity of Colorectal Cancer Progression: Molecular Gas and Brakes. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5246.	1.8	9
2250	The Effect of Herpes Simplex Virus-Type-1 (HSV-1) Oncolytic Immunotherapy on the Tumor Microenvironment. <i>Viruses</i> , 2021, 13, 1200.	1.5	14
2251	Boosting Antitumor Response by Costimulatory Strategies Driven to 4-1BB and OX40 T-cell Receptors. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 692982.	1.8	12
2252	Viral Control of Glioblastoma. <i>Viruses</i> , 2021, 13, 1264.	1.5	7
2253	A Novel Immune-Related lncRNA-Based Model for Survival Prediction in Clear Cell Renal Cell Carcinoma. <i>Journal of Immunology Research</i> , 2021, 2021, 1-37.	0.9	8
2254	The Role of Sphingolipids in Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6492.	1.8	11
2255	Identification of G-protein signaling modulator 2 as a diagnostic and prognostic biomarker of pancreatic adenocarcinoma: an exploration of its regulatory mechanisms. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 1164-1179.	0.6	3
2256	Glyoxalase-1-Dependent Methylglyoxal Depletion Sustains PD-L1 Expression in Metastatic Prostate Cancer Cells: A Novel Mechanism in Cancer Immunosurveillance Escape and a Potential Novel Target to Overcome PD-L1 Blockade Resistance. <i>Cancers</i> , 2021, 13, 2965.	1.7	14
2257	The PD-L1/PD-1 Axis Blocks Neutrophil Cytotoxicity in Cancer. <i>Cells</i> , 2021, 10, 1510.	1.8	33
2258	Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges. <i>Cancer Communications</i> , 2021, 41, 830-850.	3.7	42
2259	A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 10.e1-10.e6.	0.8	20
2260	Monitoring Immunotherapy With Optical Molecular Imaging. <i>ChemMedChem</i> , 2021, 16, 2547-2557.	1.6	6
2261	Targeting regulator of G protein signaling 1 in tumor-specific T cells enhances their trafficking to breast cancer. <i>Nature Immunology</i> , 2021, 22, 865-879.	7.0	41
2262	Current and Future Scenario of Immunotherapy for the Treatment of Hepatocellular Carcinoma. <i>Current Cancer Therapy Reviews</i> , 2021, 17, 148-158.	0.2	0
2263	Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma. <i>Journal of Immunotherapy</i> , 2021, 9, e002181.		42
2264	Critical role of the CD44 ^{low} CD62L ^{low} CD8 ⁺ T cell subset in restoring antitumor immunity in aged mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	28
2265	Cancer immunotherapy by NC410, a LAIR-2 Fc protein blocking human LAIR-collagen interaction. <i>ELife</i> , 2021, 10, .	2.8	40

#	ARTICLE	IF	CITATIONS
2266	Symphony of nanomaterials and immunotherapy based on the cancer's immunity cycle. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 107-134.	5.7	70
2267	Immunotherapy for Advanced Non-Small Cell Lung Cancer: A Decade of Progress. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e105-e127.	1.8	67
2268	Inhibition of the DNA damage response phosphatase PPM1D reprograms neutrophils to enhance anti-tumor immune responses. <i>Nature Communications</i> , 2021, 12, 3622.	5.8	15
2269	Ionizing Radiation Curtails Immunosuppressive Effects From Cancer-Associated Fibroblasts on Dendritic Cells. <i>Frontiers in Immunology</i> , 2021, 12, 662594.	2.2	17
2270	Trials of Immunotherapy in Triple Negative Breast Cancer. <i>Current Breast Cancer Reports</i> , 2021, 13, 171-185.	0.5	1
2271	Immunotherapy in small cell lung cancer: one step at a time: a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 2970-2987.	1.3	11
2272	Portal hypertension and hepatocellular carcinoma: Des liaisons dangereuses. <i>Liver International</i> , 2021, 41, 1734-1743.	1.9	31
2273	Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor Therapy. <i>Urology</i> , 2021, 157, 93-101.	0.5	6
2274	Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to nivolumab plus ipilimumab. <i>IJU Case Reports</i> , 2021, 4, 333-337.	0.1	5
2275	A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 213.	3.5	42
2276	Influence of Different Age Cutoff Points on the Prediction of Prognosis of Cancer Patients Receiving ICIs and Potential Mechanistic Exploration. <i>Frontiers in Oncology</i> , 2021, 11, 670927.	1.3	9
2277	Smart biomimetic metal organic frameworks based on ROS-ferroptosis-glycolysis regulation for enhanced tumor chemo-immunotherapy. <i>Journal of Controlled Release</i> , 2021, 334, 21-33.	4.8	94
2278	Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. <i>Cancer Cell</i> , 2021, 39, 845-865.e7.	7.7	503
2279	Acquired Resistance to Immune Checkpoint Blockades: The Underlying Mechanisms and Potential Strategies. <i>Frontiers in Immunology</i> , 2021, 12, 693609.	2.2	21
2280	Imaging the cellular components of the immune system for advancing diagnosis and immunotherapy of cancers. <i>Materials Today Advances</i> , 2021, 10, 100138.	2.5	1
2281	Frontline Maintenance Treatment for Ovarian Cancer. <i>Current Oncology Reports</i> , 2021, 23, 97.	1.8	3
2282	Thermal ablation in non-small cell lung cancer: a review of treatment modalities and the evidence for combination with immune checkpoint inhibitors. <i>Translational Lung Cancer Research</i> , 2021, 10, 2842-2857.	1.3	28
2283	Kidney injury associated with antitumor therapy: focus on the adverse events of modern immuno-oncological drugs. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 649-660.	0.2	0

#	ARTICLE	IF	CITATIONS
2284	Perspectives on Hypoxia Signaling in Tumor Stroma. <i>Cancers</i> , 2021, 13, 3070.	1.7	18
2286	New Insights into Molecular Mechanism behind Anti-Cancer Activities of Lycopene. <i>Molecules</i> , 2021, 26, 3888.	1.7	47
2287	Comparing the frequency of CD33 ⁺ pSTAT3 ⁺ myeloid-derived suppressor cells and IL-17 ⁺ lymphocytes in patients with prostate cancer and benign prostatic hyperplasia. <i>Cell Biology International</i> , 2021, 45, 2086-2095.	1.4	5
2288	Efficacy of pembrolizumab in microsatellite instability-high locally advanced cholangiocarcinoma: a case report. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 1459-1463.	0.4	4
2289	AXL Inhibition in Macrophages Stimulates Host-versus-Leukemia Immunity and Eradicates Naïve and Treatment-Resistant Leukemia. <i>Cancer Discovery</i> , 2021, 11, 2924-2943.	7.7	20
2290	Advancing to the era of cancer immunotherapy. <i>Cancer Communications</i> , 2021, 41, 803-829.	3.7	90
2291	Biomarkers of therapeutic response with immune checkpoint inhibitors. <i>Annals of Translational Medicine</i> , 2021, 9, 1040-1040.	0.7	3
2292	Differences in treatment effect size between progression-free survival and overall survival in anti-PD-1/PD-L1 inhibitors-based trials in advanced NSCLC: a systematic review and meta-analysis. <i>Translational Lung Cancer Research</i> , 2021, 10, 2562-2572.	1.3	0
2293	Hyperbaric Oxygen Boosts PD-1 Antibody Delivery and T Cell Infiltration for Augmented Immune Responses Against Solid Tumors. <i>Advanced Science</i> , 2021, 8, e2100233.	5.6	42
2295	Immunotherapy in the treatment of lymphoma. <i>World Journal of Stem Cells</i> , 2021, 13, 503-520.	1.3	3
2296	Association between pretreatment neutrophil-to-lymphocyte ratio and immune-related adverse events due to immune checkpoint inhibitors in patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 2198-2204.	0.8	19
2297	Stoichiometry of multi-specific immune checkpoint RNA Abs for T cell activation and tumor inhibition using ultra-stable RNA nanoparticles. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 24, 426-435.	2.3	5
2298	Serum IL-5 and IFN- γ Are Novel Predictive Biomarkers for Anti-PD-1 Treatment in NSCLC and GC Patients. <i>Disease Markers</i> , 2021, 2021, 1-7.	0.6	9
2299	Microfluidics sorting enables the isolation of an intact cellular pair complex of CD8 ⁺ T cells and antigen-presenting cells in a cognate antigen recognition-dependent manner. <i>PLoS ONE</i> , 2021, 16, e0252666.	1.1	2
2300	Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1635-1646.	1.4	15
2301	Memory CD8 T Cells Generated by Cytomegalovirus Vaccine Vector Expressing NKG2D Ligand Have Effector-Like Phenotype and Distinct Functional Features. <i>Frontiers in Immunology</i> , 2021, 12, 681380.	2.2	4
2302	Immunocompetent cancer-on-chip models to assess immuno-oncology therapy. <i>Advanced Drug Delivery Reviews</i> , 2021, 173, 281-305.	6.6	38
2303	Atezolizumab Monotherapy or Plus Chemotherapy in First-Line Treatment for Advanced Non-Small Cell Lung Cancer Patients: A Meta-Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 666909.	2.2	2

#	ARTICLE	IF	CITATIONS
2304	Leptin, Both Bad and Good Actor in Cancer. <i>Biomolecules</i> , 2021, 11, 913.	1.8	31
2305	Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 945-962.	1.4	26
2306	Greater extent of blood-tumor TCR repertoire overlap is associated with favorable clinical responses to PD-1 blockade. <i>Cancer Science</i> , 2021, 112, 2993-3004.	1.7	5
2307	Prospects and Challenges for T Cell-Based Therapies of HCC. <i>Cells</i> , 2021, 10, 1651.	1.8	13
2308	B cell heterogeneity, plasticity, and functional diversity in cancer microenvironments. <i>Oncogene</i> , 2021, 40, 4737-4745.	2.6	16
2309	Effective Photothermal Therapy Mediated by Indocyanine Green Nanoparticle Tip-Loaded Microneedles to Enhance Checkpoint Inhibitor Immunotherapy for Melanoma Treatment. <i>ACS Applied Nano Materials</i> , 2021, 4, 5921-5931.	2.4	21
2310	DC-Derived Exosomes for Cancer Immunotherapy. <i>Cancers</i> , 2021, 13, 3667.	1.7	43
2311	Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130. <i>Journal of the National Cancer Institute</i> , 2022, 114, 664-675.	3.0	31
2312	Imaging in Tumor Immunology. <i>Nuclear Medicine and Molecular Imaging</i> , 2021, 55, 225-236.	0.6	2
2313	Engineered immune cells with nanomaterials to improve adoptive cell therapy. <i>Biomedical Engineering Letters</i> , 2021, 11, 183-195.	2.1	1
2314	Integrating Intrinsic Radiosensitivity and Immune Status for Predicting Benefits of Radiotherapy in Head and Neck Squamous Cell Carcinoma. <i>Medical Science Monitor</i> , 2021, 27, e932126.	0.5	3
2316	Colloidal Assemblies Composed of Polymeric Micellar/Emulsified Systems Integrate Cancer Therapy Combining a Tumor-Associated Antigen Vaccine and Chemotherapeutic Regimens. <i>Nanomaterials</i> , 2021, 11, 1844.	1.9	2
2317	A hypoxia risk signature for the tumor immune microenvironment evaluation and prognosis prediction in acute myeloid leukemia. <i>Scientific Reports</i> , 2021, 11, 14657.	1.6	13
2318	A Hypoxia Gene-Based Signature to Predict the Survival and Affect the Tumor Immune Microenvironment of Osteosarcoma in Children. <i>Journal of Immunology Research</i> , 2021, 2021, 1-13.	0.9	21
2319	The role of NFAT2/miR-20a-5p signaling pathway in the regulation of CD8+ naïve T cells activation and differentiation. <i>Immunobiology</i> , 2021, 226, 152111.	0.8	2
2320	Prevalence and Prognostic Implications of PD-L1 Expression in Soft Tissue Sarcomas. <i>Pathology and Oncology Research</i> , 2021, 27, 1609804.	0.9	6
2321	IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1909-1924.	0.5	212
2322	Genetic evidence for the causal association between programmed death-ligand 1 and lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3279-3288.	1.2	3

#	ARTICLE	IF	CITATIONS
2323	Establishment of an Immune Cell Infiltration Score to Help Predict the Prognosis and Chemotherapy Responsiveness of Gastric Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 650673.	1.3	26
2324	Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab. <i>Scientific Reports</i> , 2021, 11, 13912.	1.6	10
2325	Comprehensive Characterization of Immune Landscape Based on Epithelial-Mesenchymal Transition Signature in OSCC: Implication for Prognosis and Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 587862.	1.3	6
2326	Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting. <i>Journal of Clinical Medicine</i> , 2021, 10, 3201.	1.0	13
2327	The Role of Mathematical Models in Immuno-Oncology: Challenges and Future Perspectives. <i>Pharmaceutics</i> , 2021, 13, 1016.	2.0	9
2328	Immunotherapy Strategies for Gastrointestinal Stromal Tumor. <i>Cancers</i> , 2021, 13, 3525.	1.7	18
2329	Development and validation of prognostic model based on the analysis of autophagy-related genes in colon cancer. <i>Aging</i> , 2021, 13, 19028-19047.	1.4	10
2330	Gut microbiota-mediated immunomodulation in tumor. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 221.	3.5	42
2331	Applications and analytical tools of cell communication based on ligand-receptor interactions at single cell level. <i>Cell and Bioscience</i> , 2021, 11, 121.	2.1	21
2332	Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced NSCLC: A Systematic Review and Network Meta-Analysis. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1099-1117.	0.5	64
2333	Extracellular Vesicles as an Advanced Delivery Biomaterial for Precision Cancer Immunotherapy. <i>Advanced Healthcare Materials</i> , 2022, 11, e2100650.	3.9	27
2334	Targeting the spectrum of immune checkpoints in prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1253-1266.	1.3	13
2335	Identification of KRAS G12V associated clonal neoantigens and immune microenvironment in long-term survival of pancreatic adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 491-504.	2.0	1
2336	Anti-Cancer Immune Reaction and Lymph Node Macrophage; A Review from Human and Animal Studies. <i>Immuno</i> , 2021, 1, 223-230.	0.6	1
2337	The Cancer-Immunity Cycle in Multiple Myeloma. <i>ImmunoTargets and Therapy</i> , 2021, Volume 10, 247-260.	2.7	11
2338	Refractoriness of STING therapy is relieved by AKT inhibitor through effective vascular disruption in tumour. <i>Nature Communications</i> , 2021, 12, 4405.	5.8	19
2339	Immunology and Immune Checkpoint Inhibition in Ovarian Cancer – Current Aspects. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 1128-1144.	0.8	10
2340	Cell Fate Reprogramming in the Era of Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 714822.	2.2	27

#	ARTICLE	IF	CITATIONS
2341	Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8035.	1.8	30
2342	Near-Infrared Light Remote-Controlled Activation of Cancer Immunotherapy Using Photothermal Conjugated Polymer Nanoparticles. <i>Advanced Materials</i> , 2021, 33, e2102570.	11.1	58
2343	SENTI-101, a Preparation of Mesenchymal Stromal Cells Engineered to Express IL12 and IL21, Induces Localized and Durable Antitumor Immunity in Preclinical Models of Peritoneal Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1508-1520.	1.9	8
2344	A comprehensive analysis of immune infiltration in the tumor microenvironment of osteosarcoma. <i>Cancer Medicine</i> , 2021, 10, 5696-5711.	1.3	20
2345	The therapeutic implications of immunosuppressive tumor aerobic glycolysis. <i>Cellular and Molecular Immunology</i> , 2022, 19, 46-58.	4.8	39
2346	Secretions from hypochlorous acid-treated tumor cells delivered in a melittin hydrogel potentiate cancer immunotherapy. <i>Bioactive Materials</i> , 2022, 9, 541-553.	8.6	19
2348	Elevated expression of B7 homolog 4 is associated with disease progression in upper urinary tract urothelial carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 565-578.	2.0	7
2349	Development of neoantigens: from identification in cancer cells to application in cancer vaccines. <i>Expert Review of Vaccines</i> , 2022, 21, 941-955.	2.0	11
2350	Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1086-1098.	0.5	53
2351	Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential. <i>Frontiers in Immunology</i> , 2021, 12, 682492.	2.2	18
2352	High WHSC1L1 Expression Reduces Survival Rates in Operated Breast Cancer Patients with Decreased CD8+ T Cells: Machine Learning Approach. <i>Journal of Personalized Medicine</i> , 2021, 11, 636.	1.1	6
2353	Platelet-to-Lymphocyte Ratio Is Associated With Favorable Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: A Study on 120 Patients. <i>Frontiers in Oncology</i> , 2021, 11, 678315.	1.3	17
2354	A Novel Insight into the Role of PLA2R and THSD7A in Membranous Nephropathy. <i>Journal of Immunology Research</i> , 2021, 2021, 1-12.	0.9	11
2355	Chronic Psychological Stress Attenuates the Efficacy of anti-PD-L1 Immunotherapy for Bladder Cancer in Immunocompetent Mice. <i>Cancer Investigation</i> , 2021, 39, 571-581.	0.6	7
2356	Integrative medicine in the era of cancer immunotherapy: Challenges and opportunities. <i>Journal of Integrative Medicine</i> , 2021, 19, 291-294.	1.4	14
2357	Graphene-based nanomaterials for breast cancer treatment: promising therapeutic strategies. <i>Journal of Nanobiotechnology</i> , 2021, 19, 211.	4.2	36
2358	Fundamental and Essential Knowledge for Pathologists Engaged in the Research and Practice of Immune Checkpoint Inhibitor-Based Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 679095.	1.3	7
2359	Consequences of Extracellular Matrix Remodeling in Headway and Metastasis of Cancer along with Novel Immunotherapies: A Great Promise for Future Endeavor. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 1257-1271.	0.9	5

#	ARTICLE	IF	CITATIONS
2360	Personalized combination nano-immunotherapy for robust induction and tumor infiltration of CD8+ T cells. <i>Biomaterials</i> , 2021, 274, 120844.	5.7	19
2361	Immune checkpoints and cancer development: Therapeutic implications and future directions. <i>Pathology Research and Practice</i> , 2021, 223, 153485.	1.0	29
2362	Review of Dendritic Cells, Their Role in Clinical Immunology, and Distribution in Various Animal Species. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8044.	1.8	40
2363	High-affinity decoy PD-1 mutant screened from an epitope-specific cell library. <i>Engineering</i> , 2021, , .	3.2	1
2364	Exercise and the immune system: taking steps to improve responses to cancer immunotherapy. , 2021, 9, e001872.		49
2365	Lactate-Dependent Regulation of Immune Responses by Dendritic Cells and Macrophages. <i>Frontiers in Immunology</i> , 2021, 12, 691134.	2.2	59
2366	Can Immune Suppression and Epigenome Regulation in Placenta Offer Novel Insights into Cancer Immune Evasion and Immunotherapy Resistance?. <i>Epigenomes</i> , 2021, 5, 16.	0.8	5
2367	Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies. <i>Vaccines</i> , 2021, 9, 724.	2.1	27
2368	Insights into an Immunotherapeutic Approach to Combat Multidrug Resistance in Hepatocellular Carcinoma. <i>Pharmaceuticals</i> , 2021, 14, 656.	1.7	14
2369	STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation. , 2021, 9, e002852.		102
2370	Overcoming T Cell Exhaustion via Immune Checkpoint Modulation with a Dendrimer-Based Hybrid Nanocomplex. <i>Advanced Healthcare Materials</i> , 2021, 10, e2100833.	3.9	31
2371	Combining nanomedicine and immune checkpoint therapy for cancer immunotherapy. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2022, 14, e1739.	3.3	19
2372	Mevalonate Blockade in Cancer Cells Triggers CLEC9A+ Dendritic Cell-Mediated Antitumor Immunity. <i>Cancer Research</i> , 2021, 81, 4514-4528.	0.4	12
2373	Pulsed Radiation Therapy to Improve Systemic Control of Metastatic Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 737425.	1.3	6
2375	An amphiphilic dendrimer as a light-activable immunological adjuvant for in situ cancer vaccination. <i>Nature Communications</i> , 2021, 12, 4964.	5.8	44
2376	IL7-Fc Enhances the Efficacy of Adoptive T Cell Therapy under Lymphopenic Conditions in a Murine Melanoma Model. <i>Cells</i> , 2021, 10, 2018.	1.8	4
2377	Identification of Immune-Related Subtypes and Characterization of Tumor Microenvironment Infiltration in Bladder Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 723817.	1.8	9
2378	First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly. <i>Current Oncology Reports</i> , 2021, 23, 119.	1.8	4

#	ARTICLE	IF	CITATIONS
2379	Identification of a Five-Gene Prognostic Signature Related to B Cells Infiltration in Pancreatic Adenocarcinoma. <i>International Journal of General Medicine</i> , 2021, Volume 14, 5051-5068.	0.8	6
2380	Epigenetic Regulation of Immunotherapy Response in Triple-Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 4139.	1.7	10
2381	Immune Checkpoint Therapy: Tumor Draining Lymph Nodes in the Spotlights. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9401.	1.8	16
2382	Immunoprofiling: An Encouraging Method for Predictive Factors Examination in Lung Cancer Patients Treated with Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9133.	1.8	4
2383	DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application. <i>Clinical Epigenetics</i> , 2021, 13, 166.	1.8	85
2384	Nanotechnology for Boosting Cancer Immunotherapy and Remodeling Tumor Microenvironment: The Horizons in Cancer Treatment. <i>ACS Nano</i> , 2021, 15, 12567-12603.	7.3	112
2385	Entinostat induces antitumor immune responses through immune editing of tumor neoantigens. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	43
2386	Pharmacokinetics and Pharmacodynamic Effects of Nemvaleukin Alfa, a Selective Agonist of the Intermediate-Affinity IL-2 Receptor, in Cynomolgus Monkeys. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 379, 203-210.	1.3	13
2387	Novel insights on gut microbiota manipulation and immune checkpoint inhibition in cancer (Review). <i>International Journal of Oncology</i> , 2021, 59, .	1.4	17
2388	Combination chemotherapeutic and immune-therapeutic anticancer approach via anti-PD-L1 antibody conjugated albumin nanoparticles. <i>International Journal of Pharmaceutics</i> , 2021, 605, 120816.	2.6	19
2389	Trinity immune enhancing nanoparticles for boosting antitumor immune responses of immunogenic chemotherapy. <i>Nano Research</i> , 2022, 15, 1183-1192.	5.8	7
2390	Interpretable systems biomarkers predict response to immune-checkpoint inhibitors. <i>Patterns</i> , 2021, 2, 100293.	3.1	47
2391	Vascular Normalization: A New Window Opened for Cancer Therapies. <i>Frontiers in Oncology</i> , 2021, 11, 719836.	1.3	39
2392	Multifunctional Nanocarriersâ€Mediated Synergistic Combination of Immune Checkpoint Inhibitor Cancer Immunotherapy and Interventional Oncology Therapy. <i>Advanced NanoBiomed Research</i> , 2021, 1, 2100010.	1.7	5
2393	To inhibit or to boost the ATP/P2RX7 pathway to fight cancerâ€that is the question. <i>Purinergic Signalling</i> , 2021, 17, 619-631.	1.1	13
2394	Dual-functional super bispecific nano-antibodies derived from monoclonal antibodies potentiate the antitumor effect of innate immune cells. <i>Nano Today</i> , 2021, 39, 101209.	6.2	8
2395	Targeting the DNA damage response in immuno-oncology: developments and opportunities. <i>Nature Reviews Cancer</i> , 2021, 21, 701-717.	12.8	150
2396	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. , 2021, 9, e002597.		45

#	ARTICLE	IF	CITATIONS
2397	Breast Cancer Treatments: Updates and New Challenges. <i>Journal of Personalized Medicine</i> , 2021, 11, 808.	1.1	108
2398	Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective, observational study. <i>Translational Lung Cancer Research</i> , 2021, 10, 3538-3549.	1.3	21
2399	The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma. <i>Cancer Research and Treatment</i> , 2022, 54, 434-444.	1.3	9
2400	The relationship of the tertiary lymphoid structures with the tumor-infiltrating lymphocytes and its prognostic value in gastric cancer. <i>Archives of Medical Science</i> , 2024, 20, 255-266.	0.4	0
2401	Ansamitocin P3-Loaded Gold-NanoCage Conjugated with Immune Checkpoint Inhibitor to Enhance Photo-Chemo-Thermal Maturation of Dendritic Cells for Hepatocellular Carcinoma. <i>Polymers</i> , 2021, 13, 2726.	2.0	6
2402	Challenges and Future Perspectives of Immunotherapy in Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 4235.	1.7	16
2403	Quickly evolving near-infrared photoimmunotherapy provides multifaceted approach to modern cancer treatment. <i>View</i> , 2022, 3, 20200110.	2.7	28
2404	First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. <i>Annals of Oncology</i> , 2021, 32, 983-993.	0.6	205
2405	The Combiome Hypothesis: Selecting Optimal Treatment for Cancer Patients. <i>Clinical Lung Cancer</i> , 2021, , .	1.1	4
2406	Predator-Prey in Tumor-Immune Interactions: A Wrong Model or Just an Incomplete One?. <i>Frontiers in Immunology</i> , 2021, 12, 668221.	2.2	17
2407	Immunotherapy for non-small cell lung cancer (NSCLC), as a stand-alone and in combination therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 164, 103417.	2.0	18
2408	Double enhancement of immunogenic cell death and antigen presentation for cancer immunotherapy. <i>Nano Today</i> , 2021, 39, 101225.	6.2	45
2409	Anti-PD-1 and Anti-PD-L1 in Head and Neck Cancer: A Network Meta-Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 705096.	2.2	47
2410	Mesenchymal stem/stromal cells as next-generation drug delivery vehicles for cancer therapeutics. <i>Expert Opinion on Drug Delivery</i> , 2021, 18, 1627-1642.	2.4	24
2411	Tumor immune microenvironment of primary colorectal adenocarcinomas metastasizing to the liver or lungs. <i>Journal of Surgical Oncology</i> , 2021, 124, 1136-1145.	0.8	3
2412	The Prognostic Value of the Lymph Node in Oesophageal Adenocarcinoma; Incorporating Clinicopathological and Immunological Profiling. <i>Cancers</i> , 2021, 13, 4005.	1.7	4
2413	Engineering Endogenous Tumor-Associated Macrophage-Targeted Biomimetic Nano-RBC to Reprogram Tumor Immunosuppressive Microenvironment for Enhanced Chemo-Immunotherapy. <i>Advanced Materials</i> , 2021, 33, e2103497.	11.1	73
2414	Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies. <i>Hepatology International</i> , 2021, 15, 1278-1287.	1.9	16

#	ARTICLE	IF	CITATIONS
2415	An analysis of the immunological tumor microenvironment of primary tumors and regional lymph nodes in squamous cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 3520-3537.	1.3	3
2416	T cell exhaustion is associated with the risk of papillary thyroid carcinoma and can be a predictive and sensitive biomarker for diagnosis. <i>Diagnostic Pathology</i> , 2021, 16, 84.	0.9	7
2417	<i>CTLA4</i> promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma. , 2021, 9, e002949.		22
2418	N6-Methyladenosine Writer Gene ZC3H13 Predicts Immune Phenotype and Therapeutic Opportunities in Kidney Renal Clear Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 718644.	1.3	15
2419	Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 693062.	2.2	15
2420	Characterization of Tumor-immune Microenvironment by High-throughput Image Analysis of CD8 Immunohistochemistry Combined With Modified Masson's Trichrome. <i>Journal of Histochemistry and Cytochemistry</i> , 2021, 69, 611-615.	1.3	1
2421	The Fibronectin-ILT3 Interaction Functions as a Stromal Checkpoint that Suppresses Myeloid Cells. <i>Cancer Immunology Research</i> , 2021, 9, 1283-1297.	1.6	23
2422	Preclinical Characterization of a Novel Anti-Cancer PD-L1 Inhibitor RPH-120. <i>Frontiers in Pharmacology</i> , 2021, 12, 723038.	1.6	2
2423	The Potential of Tissue-Resident Memory T Cells for Adoptive Immunotherapy against Cancer. <i>Cells</i> , 2021, 10, 2234.	1.8	10
2424	IL-33 Induces Sema4A Expression in Dendritic Cells and Exerts Antitumor Immunity. <i>Journal of Immunology</i> , 2021, 207, 1456-1467.	0.4	7
2425	Intravascular emboli relates to immunosuppressive tumor microenvironment and predicts prognosis in stage III colorectal cancer. <i>Aging</i> , 2021, 13, 20609-20628.	1.4	1
2426	Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K- γ and β . <i>Frontiers in Immunology</i> , 2021, 12, 718621.	2.2	16
2427	Regulation of antitumor immunity by inflammation-induced epigenetic alterations. <i>Cellular and Molecular Immunology</i> , 2022, 19, 59-66.	4.8	29
2428	Nanotechnology-based immunotherapies to combat cancer metastasis. <i>Molecular Biology Reports</i> , 2021, 48, 6563-6580.	1.0	8
2429	The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer. <i>Cancer Cell</i> , 2021, 39, 1342-1360.e14.	7.7	119
2430	Cancer diagnosis among women with recurrent pregnancy loss: a retrospective cohort study. <i>Reproductive BioMedicine Online</i> , 2021, 43, 1057-1062.	1.1	2
2431	Histological differentiation impacts the tumor immune microenvironment in gastric carcinoma: Relation to the immune cycle. <i>World Journal of Gastroenterology</i> , 2021, 27, 5259-5271.	1.4	6
2432	A user's guide to multicolor flow cytometry panels for comprehensive immune profiling. <i>Analytical Biochemistry</i> , 2021, 627, 114210.	1.1	12

#	ARTICLE	IF	CITATIONS
2433	Immune checkpoint inhibitors for brain metastases in non-small-cell lung cancer: from rationale to clinical application. <i>Immunotherapy</i> , 2021, 13, 1031-1051.	1.0	14
2434	Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment. <i>Prostate</i> , 2021, 81, 1125-1134.	1.2	26
2435	Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibitionâ€œoverall survival modeling framework. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 1171-1182.	1.3	15
2436	Hidden Treasures: Macrophage Long Non-Coding RNAs in Lung Cancer Progression. <i>Cancers</i> , 2021, 13, 4127.	1.7	7
2437	Technological advances in cancer immunity: from immunogenomics to single-cell analysis and artificial intelligence. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 312.	7.1	50
2438	Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2078-2090.	0.5	29
2439	mTOR Inhibition Increases Transcription Factor E3 (TFE3) Activity and Modulates Programmed Death-Ligand 1 (PD-L1) Expression in Translocation Renal Cell Carcinoma. <i>American Journal of Pathology</i> , 2021, 191, 1999-2008.	1.9	4
2440	Dynamic alterations of circulating T lymphocytes and the clinical response in patients with head and neck squamous cell carcinoma treated with nivolumab. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 851-863.	2.0	6
2441	Responsive Dual-Targeting Exosome as a Drug Carrier for Combination Cancer Immunotherapy. <i>Research</i> , 2021, 2021, 9862876.	2.8	17
2442	Cancer and immunotherapy: a role for microbiota composition. <i>European Journal of Cancer</i> , 2021, 155, 145-154.	1.3	15
2443	Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study. <i>Gastric Cancer</i> , 2022, 25, 207-217.	2.7	9
2444	Bringing Macrophages to the Frontline against Cancer: Current Immunotherapies Targeting Macrophages. <i>Cells</i> , 2021, 10, 2364.	1.8	13
2445	Sex-based heterogeneity in non-small cell lung cancer (NSCLC) and response to immune checkpoint inhibitors (ICIs): a narrative review. <i>Precision Cancer Medicine</i> , 0, 4, 26-26.	1.8	1
2446	Cancer immunotherapy: Classification, therapeutic mechanisms, and nanomaterial-based synergistic therapy. <i>Applied Materials Today</i> , 2021, 24, 101149.	2.3	7
2447	Comparative Immunogenomics of Canine Natural Killer Cells as Immunotherapy Target. <i>Frontiers in Immunology</i> , 2021, 12, 670309.	2.2	11
2448	SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer. <i>JCI Insight</i> , 2021, 6, .	2.3	14
2449	Discovery of LYC-55716: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor- β (ROR β) Agonist for Use in Treating Cancer. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 13410-13428.	2.9	11
2450	Characterization of METTL7B to Evaluate TME and Predict Prognosis by Integrative Analysis of Multi-Omics Data in Glioma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 727481.	1.6	11

#	ARTICLE	IF	CITATIONS
2451	Immunopathological basis of immune-related adverse events induced by immune checkpoint blockade therapy. <i>Immunological Medicine</i> , 2022, 45, 108-118.	1.4	10
2452	Sustained Antitumor Immunity Based on Persistent Luminescence Nanoparticles for Cancer Immunotherapy. <i>Advanced Functional Materials</i> , 2021, 31, 2106884.	7.8	21
2453	The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges. <i>Targeted Oncology</i> , 2021, 16, 537-552.	1.7	20
2454	The Yin and Yang of Type I IFNs in Cancer Promotion and Immune Activation. <i>Biology</i> , 2021, 10, 856.	1.3	21
2455	Polymersome Nanoreactor-Mediated Combination Chemodynamic Immunotherapy via ROS Production and Enhanced STING Activation. <i>Advanced Therapeutics</i> , 2021, 4, 2100130.	1.6	15
2456	Immune Checkpoint Inhibitors and the Heart. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 726426.	1.1	8
2457	Emerging therapeutic opportunities for integrin inhibitors. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 60-78.	21.5	191
2458	Integrated bioinformatics analysis reveals correlations of high TRIM59 expression with worse prognosis and immune infiltrates in lung adenocarcinoma. <i>Journal of Bio-X Research</i> , 2021, Publish Ahead of Print, .	0.3	0
2459	Combine and conquer: manganese synergizing anti-TGF- β 2/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers. <i>Journal of Hematology and Oncology</i> , 2021, 14, 146.	6.9	68
2460	Evaluation of Comprehensive Gene Expression and NK Cell-Mediated Killing in Glioblastoma Cell Line-Derived Spheroids. <i>Cancers</i> , 2021, 13, 4896.	1.7	12
2461	The promise of bispecific antibodies: Clinical applications and challenges. <i>Cancer Treatment Reviews</i> , 2021, 99, 102240.	3.4	28
2462	Exosomes: A Forthcoming Era of Breast Cancer Therapeutics. <i>Cancers</i> , 2021, 13, 4672.	1.7	18
2463	Loss of Von Hippel-Lindau (VHL) Tumor Suppressor Gene Function: VHL-HIF Pathway and Advances in Treatments for Metastatic Renal Cell Carcinoma (RCC). <i>International Journal of Molecular Sciences</i> , 2021, 22, 9795.	1.8	32
2464	Decreased IL-6 and NK Cells in Early-Stage Lung Adenocarcinoma Presenting as Ground-Glass Opacity. <i>Frontiers in Oncology</i> , 2021, 11, 705888.	1.3	1
2465	Compromised anti-tumor immune features of myeloid cell components in chronic myeloid leukemia patients. <i>Scientific Reports</i> , 2021, 11, 18046.	1.6	2
2466	Prognostic Value of Inflammatory Biomarkers in Patients With Stage I Lung Adenocarcinoma Treated With Surgical Dissection. <i>Frontiers in Oncology</i> , 2021, 11, 711206.	1.3	18
2467	CYP3A Activity in End-of-Life Cancer Patients Measured by 4 β -Hydroxycholesterol/cholesterol Ratio, in Men and Women. <i>Cancers</i> , 2021, 13, 4689.	1.7	0
2469	Molecular Characteristics, Clinical Implication, and Cancer Immunity Interactions of Pyroptosis-Related Genes in Breast Cancer. <i>Frontiers in Medicine</i> , 2021, 8, 702638.	1.2	39

#	ARTICLE	IF	CITATIONS
2470	Extracellular Vesicles (Exosomes) as Immunosuppressive Mediating Variables in Tumor and Chronic Inflammatory Microenvironments. <i>Cells</i> , 2021, 10, 2533.	1.8	8
2471	A Versatile NanoplatforM for Broad-Spectrum Immunotherapy by Reversing the Tumor Microenvironment. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 45335-45345.	4.0	4
2472	Tertiary Lymphoid Structures in the Central Nervous System: Implications for Glioblastoma. <i>Frontiers in Immunology</i> , 2021, 12, 724739.	2.2	11
2473	Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 716844.	1.3	12
2474	Identification of Autophagy Related circRNA-miRNA-mRNA-Subtypes Network With Radiotherapy Responses and Tumor Immune Microenvironment in Non-small Cell Lung Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 730003.	1.1	17
2475	Lung cancer-associated T cell repertoire as potential biomarker for early detection of stage I lung cancer. <i>Lung Cancer</i> , 2021, 162, 16-22.	0.9	9
2476	The Expression Patterns and Prognostic Value of the Proteasome Activator Subunit Gene Family in Gastric Cancer Based on Integrated Analysis. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 663001.	1.8	8
2477	Effector T cell responses unleashed by regulatory T cell ablation exacerbate oral squamous cell carcinoma. <i>Cell Reports Medicine</i> , 2021, 2, 100399.	3.3	11
2478	Mitochondrial reactive oxygen species trigger metformin-dependent antitumor immunity via activation of Nrf2/mTORC1/p62 axis in tumor-infiltrating CD8T lymphocytes. , 2021, 9, e002954.		44
2479	Exosomes as natural delivery carriers for programmable therapeutic nucleic acid nanoparticles (NANPs). <i>Advanced Drug Delivery Reviews</i> , 2021, 176, 113835.	6.6	50
2480	Association of tumor burden with outcome in first-line therapy with nivolumab plus ipilimumab for previously untreated metastatic renal cell carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1751-1756.	0.6	7
2481	Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy. <i>World Journal of Surgical Oncology</i> , 2021, 19, 264.	0.8	21
2482	Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Frontiers in Oncology</i> , 2021, 11, 705614.	1.3	19
2483	Comparison of two routes of administration of a cationic liposome formulation for a prophylactic DC vaccination in a murine melanoma model. <i>International Immunopharmacology</i> , 2021, 98, 107833.	1.7	4
2484	Effects of lactate in immunosuppression and inflammation: Progress and prospects. <i>International Reviews of Immunology</i> , 2022, 41, 19-29.	1.5	25
2485	Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy. , 2021, 9, e003032.		20
2486	A Fully Integrated Online Platform For Real Time Monitoring Of Multiple Product Quality Attributes In Biopharmaceutical Processes For Monoclonal Antibody Therapeutics. <i>Journal of Pharmaceutical Sciences</i> , 2022, 111, 358-367.	1.6	31
2487	Combination strategies to maximize the benefits of cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2021, 14, 156.	6.9	202

#	ARTICLE	IF	CITATIONS
2488	Integrated Analysis of Transcriptome and Differential Methylation of Neurofibromatosis Type 2 Vestibular Schwannomas. <i>World Neurosurgery</i> , 2022, 157, e66-e76.	0.7	3
2489	Nanocomplex-Mediated In Vivo Programming to Chimeric Antigen Receptor-M1 Macrophages for Cancer Therapy. <i>Advanced Materials</i> , 2021, 33, e2103258.	11.1	68
2490	The Role of Immunotherapy in the Treatment of Advanced Cervical Cancer: Current Status and Future Perspectives. <i>Journal of Clinical Medicine</i> , 2021, 10, 4523.	1.0	12
2491	Therapeutic cancer vaccines revamping: technology advancements and pitfalls. <i>Annals of Oncology</i> , 2021, 32, 1537-1551.	0.6	36
2492	Harnessing the therapeutic potential of extracellular vesicles for cancer treatment. <i>Seminars in Cancer Biology</i> , 2021, 74, 92-104.	4.3	9
2493	Antagonism of inhibitors of apoptosis proteins reveals a novel, immune response-based therapeutic approach for T-cell lymphoma. <i>Blood Advances</i> , 2021, 5, 4003-4016.	2.5	4
2494	Concomitant High Apoptosis Inhibitor of Macrophage (AIM) and Low Prostate-Specific Antigen (PSA) Indicates Activated T Cell-Mediated Anticancer Immunity, Enhance Sensitivity to Pembrolizumab, and Elicit Good Prognosis in Prostate Cancer. <i>Biomedicines</i> , 2021, 9, 1225.	1.4	4
2495	The Role of Somatic Mutations on the Immune Response of the Tumor Microenvironment in Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9550.	1.8	15
2496	Extracellular vesicles in anti-tumor immunity. <i>Seminars in Cancer Biology</i> , 2022, 86, 64-79.	4.3	21
2497	Application of molecular docking in elaborating molecular mechanisms and interactions of supramolecular cyclodextrin. <i>Carbohydrate Polymers</i> , 2022, 276, 118644.	5.1	52
2498	Rechallenge of immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 165, 103434.	2.0	26
2499	Plant Viral Nanoparticle Conjugated with Anti-PD-1 Peptide for Ovarian Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9733.	1.8	26
2500	Type 2 dendritic cells mediate control of cytotoxic T cell resistant tumors. <i>JCI Insight</i> , 2021, 6, .	2.3	21
2501	Molecular Heterogeneity in Localized Diffuse Large B-Cell Lymphoma. <i>Frontiers in Oncology</i> , 2021, 11, 638757.	1.3	6
2502	Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study. <i>Frontiers in Oncology</i> , 2021, 11, 696512.	1.3	22
2503	Activation of interferon regulatory factor 3 by replication-competent vaccinia viruses improves antitumor efficacy mediated by T cell responses. <i>Molecular Therapy - Oncolytics</i> , 2021, 22, 399-409.	2.0	2
2504	Clinical course and management of pembrolizumab-associated isolated adrenocorticotrophic hormone deficiency: a new case and literature review. <i>Immunotherapy</i> , 2021, 13, 1157-1163.	1.0	5
2505	Short Review on Advances in Hydrogel-Based Drug Delivery Strategies for Cancer Immunotherapy. <i>Tissue Engineering and Regenerative Medicine</i> , 2022, 19, 263-280.	1.6	11

#	ARTICLE	IF	CITATIONS
2506	Comprehensive analysis of prognostic immune-related genes in the tumor microenvironment of hepatocellular carcinoma (HCC). <i>Medicine (United States)</i> , 2021, 100, e27332.	0.4	1
2507	Immunobiology of Melanoma. <i>Clinics in Plastic Surgery</i> , 2021, 48, 561-576.	0.7	5
2508	Development of bifunctional anti-PD-L1 antibody MMAE conjugate with cytotoxicity and immunostimulation. <i>Bioorganic Chemistry</i> , 2021, 116, 105366.	2.0	11
2509	Supramolecular co-assembly of self-adjuvanting nanofibrous peptide hydrogel enhances cancer vaccination by activating MyD88-dependent NF- κ B signaling pathway without inflammation. <i>Bioactive Materials</i> , 2021, 6, 3924-3934.	8.6	23
2510	PET/CT metabolic patterns in systemic immune activation: A new perspective on the assessment of immunotherapy response and efficacy. <i>Cancer Letters</i> , 2021, 520, 91-99.	3.2	14
2511	Prolactin enhances T regulatory cell promotion of breast cancer through the long form prolactin receptor. <i>Translational Oncology</i> , 2021, 14, 101195.	1.7	5
2512	Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2021, 161, 26-33.	0.9	31
2513	Integrating metabolic engineering and immunotherapy. <i>Current Opinion in Systems Biology</i> , 2021, 28, 100361.	1.3	2
2514	Connexin channels modulation in pathophysiology and treatment of immune and inflammatory disorders. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2021, 1867, 166258.	1.8	7
2515	Metabolic reprogramming and immunity in cancer. , 2022, , 137-196.		1
2516	Heat shock protein vaccines in glioblastoma. , 2022, , 39-53.		0
2517	Delivery strategies to overcome tumor immunotherapy resistance. , 2022, , 529-547.		0
2518	Innate and adaptive immunity in cancer. , 2022, , 19-61.		0
2519	Immunoediting and cancer priming. , 2022, , 111-136.		1
2520	Immune checkpoint blockade therapy in high-grade glioma. , 2022, , 91-108.		0
2521	Immunotherapy in non-small cell lung cancer: update and new insights. <i>Journal of Clinical and Translational Research</i> , 0, , .	0.3	23
2522	Nano drug delivery strategies for the treatment and diagnosis of oral and throat cancers. , 2021, , 75-106.		0
2523	Immune classification of osteosarcoma. <i>Mathematical Biosciences and Engineering</i> , 2021, 18, 1879-1897.	1.0	20

#	ARTICLE	IF	CITATIONS
2524	Role of Bladder Cancer Metabolic Reprogramming in the Effectiveness of Immunotherapy. <i>Cancers</i> , 2021, 13, 288.	1.7	12
2525	Future perspectives and new directions in chemosensitizing activities to reverse drug resistance in gynecologic cancers: Emphasis on challenges and opportunities. , 2021, , 339-355.		1
2526	Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma. <i>Chinese Clinical Oncology</i> , 2021, 10, 11-11.	0.4	8
2527	PLK1 Inhibition Induces Immunogenic Cell Death and Enhances Immunity against NSCLC. <i>International Journal of Medical Sciences</i> , 2021, 18, 3516-3525.	1.1	18
2528	Role of Hypoxia-Mediated Autophagy in Tumor Cell Death and Survival. <i>Cancers</i> , 2021, 13, 533.	1.7	41
2529	Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. <i>Nature Medicine</i> , 2021, 27, 152-164.	15.2	451
2530	Typical Tumor Immune Microenvironment Status Determine Prognosis in Lung Adenocarcinoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2531	Cell-derived biomimetic nanocarriers for targeted cancer therapy: cell membranes and extracellular vesicles. <i>Drug Delivery</i> , 2021, 28, 1237-1255.	2.5	62
2532	Therapeutic targeting of TGF- β 2 in cancer: hacking a master switch of immune suppression. <i>Clinical Science</i> , 2021, 135, 35-52.	1.8	42
2533	Interleukin-6 Blockade Abrogates Immunotherapy Toxicity and Promotes Tumor Immunity. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2534	Self-assembling, self-adjuvanting and fully synthetic peptide nanovaccine for cancer immunotherapy. <i>Smart Materials in Medicine</i> , 2021, 2, 237-249.	3.7	14
2535	Application Prospects for New Immune Checkpoints in Cervical Cancer. <i>Advances in Clinical Medicine</i> , 2021, 11, 3418-3425.	0.0	0
2536	Up-regulation of L Antigen Family Member 3 Associates With Aggressive Progression of Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 553628.	1.3	3
2538	Hematopoietic versus Solid Cancers and T Cell Dysfunction: Looking for Similarities and Distinctions. <i>Cancers</i> , 2021, 13, 284.	1.7	15
2539	Employing hypoxia characterization to predict tumour immune microenvironment, treatment sensitivity and prognosis in hepatocellular carcinoma. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 2775-2789.	1.9	22
2540	Iron oxide nanoparticles for immune cell labeling and cancer immunotherapy. <i>Nanoscale Horizons</i> , 2021, 6, 696-717.	4.1	28
2541	A hypoxia-linked gene signature for prognosis prediction and evaluating the immune microenvironment in patients with hepatocellular carcinoma. <i>Translational Cancer Research</i> , 2021, 10, 3979-3992.	0.4	3
2542	Modularly Programmable Nanoparticle Vaccine Based on Polyethyleneimine for Personalized Cancer Immunotherapy. <i>Advanced Science</i> , 2021, 8, 2002577.	5.6	46

#	ARTICLE	IF	CITATIONS
2543	Radiobiology of the Liver. , 2021, , 15-30.		0
2544	Rediscovery of nanoparticle-based therapeutics: boosting immunogenic cell death for potential application in cancer immunotherapy. Journal of Materials Chemistry B, 2021, 9, 3983-4001.	2.9	28
2545	Engineering nanomedicine for glutathione depletion-augmented cancer therapy. Chemical Society Reviews, 2021, 50, 6013-6041.	18.7	342
2546	CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. Cancer Immunology, Immunotherapy, 2021, 70, 1965-1976.	2.0	14
2547	The Growing Skyline of Advanced Hepatocellular Carcinoma Treatment: A Review. Pharmaceuticals, 2021, 14, 43.	1.7	8
2548	Immune checkpoint inhibitors in ovarian cancer: where do we stand?. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110398.	1.4	36
2549	Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening?. Cancer Treatment and Research Communications, 2021, 28, 100442.	0.7	14
2550	Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches. Breast Cancer: Basic and Clinical Research, 2021, 15, 117822342199585.	0.6	22
2551	Targeting ubiquitin signaling for cancer immunotherapy. Signal Transduction and Targeted Therapy, 2021, 6, 16.	7.1	34
2552	Severe Skin Disorders Due to Sorafenib Use After Nivolumab Treatment in Renal Cell Carcinoma Patients. In Vivo, 2021, 35, 2969-2974.	0.6	2
2553	Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor. , 2021, 9, e001402.		40
2554	Beyond conventional immune-checkpoint inhibition â€” novel immunotherapies for renal cell carcinoma. Nature Reviews Clinical Oncology, 2021, 18, 199-214.	12.5	179
2555	Differential PD-1/LAG-3 expression and immune phenotypes in metastatic sites of breast cancer. Breast Cancer Research, 2021, 23, 4.	2.2	23
2556	Metabolites and the tumour microenvironment: from cellular mechanisms to systemic metabolism. Nature Metabolism, 2021, 3, 21-32.	5.1	250
2557	Infiltrating Immune Cells in Gastric Cancer: A Novel Predicting Model for Prognosis. Journal of Cancer, 2021, 12, 965-975.	1.2	8
2558	Immunotherapy in Colorectal Cancer: Current and Future Strategies. Journal of the Anus, Rectum and Colon, 2021, 5, 11-24.	0.4	59
2559	Utilizing Xenogeneic Cells As a Therapeutic Agent for Treating Diseases. Cell Transplantation, 2021, 30, 096368972110119.	1.2	11
2560	Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. Cancer Journal (Sudbury, Mass), 2021, 27, 25-31.	1.0	12

#	ARTICLE	IF	CITATIONS
2561	Assessment of Clinical Activity of PD-1 Checkpoint Inhibitor Combination Therapies Reported in Clinical Trials. <i>JAMA Network Open</i> , 2020, 3, e1920833.	2.8	43
2562	Effects of checkpoint kinase 1 inhibition by prexasertib on the tumor immune microenvironment of head and neck squamous cell carcinoma. <i>Molecular Carcinogenesis</i> , 2021, 60, 138-150.	1.3	11
2563	Status of Immune Oncology: Challenges and Opportunities. <i>Methods in Molecular Biology</i> , 2020, 2055, 3-21.	0.4	6
2564	Immunomodulation in Oncolytic Measles Virotherapy. <i>Methods in Molecular Biology</i> , 2020, 2058, 111-126.	0.4	10
2565	Radio-Immunology of Ablative Radiation. , 2019, , 15-29.		3
2566	Stromal and Immune Drivers of Hepatocarcinogenesis. <i>Molecular and Translational Medicine</i> , 2019, , 317-331.	0.4	5
2568	CCL22 Signaling in the Tumor Environment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1231, 79-96.	0.8	30
2569	The Role of the Immune Infiltrate in Distinct Cancer Types and Its Clinical Implications. <i>Cancer Treatment and Research</i> , 2020, 180, 197-211.	0.2	4
2570	Translational Biomarkers and Rationale Strategies to Overcome Resistance to Immune Checkpoint Inhibitors in Solid Tumors. <i>Cancer Treatment and Research</i> , 2020, 180, 251-279.	0.2	15
2571	Immunotherapy for Melanoma. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 51-68.	0.8	41
2572	Toluquinol, A Marine Fungus Metabolite, Inhibits Some of the Hallmarks of Cancer. , 2015, , 269-299.		1
2573	Immuno-oncology of Dormant Tumours. <i>Cancer Drug Discovery and Development</i> , 2017, , 51-60.	0.2	1
2574	Next Generation of Cancer Immunotherapy: Targeting the Cancer-Immunity Cycle with Nanotechnology. , 2020, , 191-253.		2
2575	Multimodal stratified imaging of nanovaccines in lymph nodes for improving cancer immunotherapy. <i>Advanced Drug Delivery Reviews</i> , 2020, 161-162, 145-160.	6.6	21
2576	Synergistic tumor immunological strategy by combining tumor nanovaccine with gene-mediated extracellular matrix scavenger. <i>Biomaterials</i> , 2020, 252, 120114.	5.7	58
2577	COVID-19 and Cancer: Current Challenges and Perspectives. <i>Cancer Cell</i> , 2020, 38, 629-646.	7.7	196
2578	Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer. <i>International Immunopharmacology</i> , 2020, 85, 106613.	1.7	24
2579	Correlation between the expression of folate receptor alpha (FR α) and clinicopathological features in patients with lung adenocarcinoma. <i>Lung Cancer</i> , 2020, 145, 152-157.	0.9	4

#	ARTICLE	IF	CITATIONS
2580	Toxicities from immunotherapy: From clinical trials to real-world clinical practice. <i>Medicina Clínica</i> , 2020, 155, 541-547.	0.3	8
2581	The Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer. <i>Urologic Clinics of North America</i> , 2020, 47, e17-e54.	0.8	39
2582	Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). <i>Journal of Clinical Oncology</i> , 2017, 35, 2781-2789.	0.8	24
2583	Engineering bionic T cells: signal 1, signal 2, signal 3, reprogramming and the removal of inhibitory mechanisms. <i>Cellular and Molecular Immunology</i> , 2020, 17, 576-586.	4.8	12
2584	Immune crosstalk in cancer progression and metastatic spread: a complex conversation. <i>Nature Reviews Immunology</i> , 2020, 20, 483-497.	10.6	241
2585	In situ vaccination with nanoparticles for cancer immunotherapy: understanding the immunology. <i>International Journal of Hyperthermia</i> , 2020, 37, 4-17.	1.1	12
2586	Radiation therapy and immunotherapy in breast cancer treatment: preliminary data and perspectives. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 501-510.	1.1	10
2587	Modulation of the immune microenvironment by tumor-intrinsic oncogenic signaling. <i>Journal of Cell Biology</i> , 2020, 219, .	2.3	42
2588	Tumor-infiltrating dendritic cell states are conserved across solid human cancers. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	113
2589	Expression of PD-1/PD-L1 and P53 in hepatocellular carcinoma. <i>Egyptian Journal of Pathology</i> , 2018, 38, 131-138.	0.0	1
2590	Innovations in targeted therapies for triple negative breast cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2021, 33, 34-47.	0.9	4
2591	Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors. <i>Current Opinion in Hematology</i> , 2018, 25, 136-145.	1.2	73
2605	Phagocytic function of tumor-associated macrophages as a key determinant of tumor progression control: a review. , 2020, 8, e001408.		100
2606	Enhanced Antitumor Immunity via Endocrine Therapy Prevents Mammary Tumor Relapse and Increases Immune Checkpoint Blockade Sensitivity. <i>Cancer Research</i> , 2021, 81, 1375-1387.	0.4	17
2607	Cancer-Associated Fibroblasts Affect Intratumoral CD8+ and FoxP3+ T Cells Via IL6 in the Tumor Microenvironment. <i>Clinical Cancer Research</i> , 2018, 24, 4820-4833.	3.2	225
2608	Integrating Radiosensitivity and Immune Gene Signatures for Predicting Benefit of Radiotherapy in Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 4754-4762.	3.2	48
2609	Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell Carcinoma. <i>Cancer Prevention Research</i> , 2021, 14, 313-324.	0.7	17
2610	Therapy of Established Tumors with Rationally Designed Multiple Agents Targeting Diverse Immune-Tumor Interactions: Engage, Expand, Enable. <i>Cancer Immunology Research</i> , 2021, 9, 239-252.	1.6	11

#	ARTICLE	IF	CITATIONS
2611	RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report. <i>Case Reports in Oncology</i> , 2016, 9, 45-50.	0.3	13
2612	Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy. <i>JCI Insight</i> , 2018, 3, .	2.3	90
2613	2B4 but not PD-1 blockade improves mortality in septic animals with preexisting malignancy. <i>JCI Insight</i> , 2019, 4, .	2.3	18
2614	Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy. <i>JCI Insight</i> , 2020, 5, .	2.3	58
2615	Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells. <i>JCI Insight</i> , 2016, 1, e88955.	2.3	111
2616	Autophagy orchestrates the regulatory program of tumor-associated myeloid-derived suppressor cells. <i>Journal of Clinical Investigation</i> , 2018, 128, 3840-3852.	3.9	79
2617	Antigen-loaded monocyte administration induces potent therapeutic antitumor T cell responses. <i>Journal of Clinical Investigation</i> , 2020, 130, 774-788.	3.9	47
2618	OX40+ plasmacytoid dendritic cells in the tumor microenvironment promote antitumor immunity. <i>Journal of Clinical Investigation</i> , 2020, 130, 3528-3542.	3.9	54
2619	Dendritic cell-derived exosomes for cancer therapy. <i>Journal of Clinical Investigation</i> , 2016, 126, 1224-1232.	3.9	427
2620	Notch-effector CSL promotes squamous cell carcinoma by repressing histone demethylase KDM6B. <i>Journal of Clinical Investigation</i> , 2018, 128, 2581-2599.	3.9	24
2621	Spleen mediates a distinct hematopoietic progenitor response supporting tumor-promoting myelopoiesis. <i>Journal of Clinical Investigation</i> , 2018, 128, 3425-3438.	3.9	111
2622	A Case Report of Atezolizumab Induced Tumor Lysis Syndrome. <i>American Journal of Case Reports</i> , 2019, 20, 785-789.	0.3	9
2623	Recent advances in HIV-associated Kaposi sarcoma. <i>F1000Research</i> , 2019, 8, 970.	0.8	24
2624	Triple-negative breast cancer: recent treatment advances. <i>F1000Research</i> , 2019, 8, 1342.	0.8	152
2625	Host deficiency in ephrin-A1 inhibits breast cancer metastasis. <i>F1000Research</i> , 2020, 9, 217.	0.8	13
2626	Recent advances in understanding antitumor immunity. <i>F1000Research</i> , 2016, 5, 2545.	0.8	29
2627	A Biased Competition Theory of Cytotoxic T Lymphocyte Interaction with Tumor Nodules. <i>PLoS ONE</i> , 2015, 10, e0120053.	1.1	9
2628	The Relationship of Immune Cell Signatures to Patient Survival Varies within and between Tumor Types. <i>PLoS ONE</i> , 2015, 10, e0138726.	1.1	24

#	ARTICLE	IF	CITATIONS
2629	ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1). PLoS ONE, 2017, 12, e0177919.	1.1	8
2630	Pharmacological inhibition of hematopoietic progenitor kinase 1 positively regulates T-cell function. PLoS ONE, 2020, 15, e0243145.	1.1	10
2631	TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection. PLoS Pathogens, 2016, 12, e1005349.	2.1	271
2632	Profiling of Target Molecules for Immunotherapy in Mesenchymal Tumors. Journal of Clinical Medicine Research, 2019, 11, 609-613.	0.6	1
2633	Evolving Paradigms in the Management and Outcomes of Sarcomatoid Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors. World Journal of Oncology, 2020, 11, 183-187.	0.6	4
2634	Recent development and applications of nanomaterials for cancer immunotherapy. Nanotechnology Reviews, 2020, 9, 367-384.	2.6	26
2635	Melanoma Immunotherapy: Mechanisms and Opportunities. Investigative Dermatology and Venereology Research, 2016, 2, 1-7.	0.1	1
2636	Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe. European Journal of Dermatology, 2018, 28, 736-749.	0.3	6
2637	New treatment options for advanced urothelial cancer: a combination of atezolizumab with chemotherapy. Onkourologiya, 2020, 16, 104-117.	0.1	1
2638	Relationship between PD-L1 expression and 18F-FDG uptake in gastric cancer. Aging, 2019, 11, 12270-12277.	1.4	11
2639	Soluble fibrinogen like protein 2 (sFGL2), the novel effector molecule for immunoregulation. Oncotarget, 2017, 8, 3711-3723.	0.8	18
2640	Elevated serum granulocyte-macrophage colony-stimulating factor levels during radiotherapy predict favorable outcomes in lung and esophageal cancer. Oncotarget, 2016, 7, 85142-85150.	0.8	7
2641	Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects. Oncotarget, 2017, 8, 17313-17327.	0.8	31
2642	5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy. Oncotarget, 2017, 8, 47474-47489.	0.8	25
2643	PD-L1 expression on immune cells is a favorable prognostic factor for vulvar squamous cell carcinoma patients. Oncotarget, 2017, 8, 89903-89912.	0.8	31
2644	PD-L1 expression in tumor tissue and peripheral blood of patients with oral squamous cell carcinoma. Oncotarget, 2017, 8, 112584-112597.	0.8	37
2645	Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer. Oncotarget, 2018, 9, 10284-10293.	0.8	44
2646	Comprehensive immunotherapy combined with intratumoral injection of zoledronate-pulsed dendritic cells, intravenous adoptive activated T lymphocyte and gemcitabine in unresectable locally advanced pancreatic carcinoma: a phase I/II trial. Oncotarget, 2018, 9, 2838-2847.	0.8	27

#	ARTICLE	IF	CITATIONS
2647	A comparative study of PD-L1 immunohistochemical assays with four reliable antibodies in thymic carcinoma. <i>Oncotarget</i> , 2018, 9, 6993-7009.	0.8	31
2648	Role of tumor microenvironment in ovarian cancer pathobiology. <i>Oncotarget</i> , 2018, 9, 22832-22849.	0.8	54
2649	Novel immunotherapeutic approaches in head and neck cancer. <i>Journal of Cancer Metastasis and Treatment</i> , 2019, 2019, .	0.5	9
2650	The dark side of immunotherapy: pancreatic cancer. , 2020, 3, 491-520.		15
2651	https://cdrjournal.com/article/view/3531 . , 2020, 3, 454-471.		4
2652	Decoding cancer's camouflage: epithelial-mesenchymal plasticity in resistance to immune checkpoint blockade. , 2020, 3, 832-853.		7
2653	Current applications and future prospects of nanotechnology in cancer immunotherapy. <i>Cancer Biology and Medicine</i> , 2019, 16, 487-497.	1.4	40
2654	Current state and future of co-inhibitory immune checkpoints for the treatment of glioblastoma. <i>Cancer Biology and Medicine</i> , 2020, 17, 555-568.	1.4	14
2655	Towards tumor immunodiagnostics. <i>Annals of Translational Medicine</i> , 2016, 4, 263-263.	0.7	11
2656	Therapeutic vaccination strategies to treat nasopharyngeal carcinoma. <i>Chinese Clinical Oncology</i> , 2016, 5, 23-23.	0.4	30
2657	The evolving role of lymphadenectomy for bladder cancer: why, when, and how. <i>Translational Andrology and Urology</i> , 2020, 9, 3082-3093.	0.6	7
2658	Perioperative immunotherapy in muscle-invasive bladder cancer. <i>Translational Cancer Research</i> , 2020, 9, 6546-6553.	0.4	8
2659	The Next Generation of Pattern Recognition Receptor Agonists: Improving Response Rates in Cancer Immunotherapy. <i>Current Medicinal Chemistry</i> , 2020, 27, 5654-5674.	1.2	13
2660	Human Papillomavirus Induced Cervical and Oropharyngeal Cancers: From Mechanisms to Potential Immuno-therapeutic Strategies. <i>Current Drug Metabolism</i> , 2020, 21, 167-177.	0.7	4
2661	Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer. <i>Current Cancer Drug Targets</i> , 2019, 19, 595-630.	0.8	61
2662	STING Activation and its Application in Immuno-Oncology. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 2205-2227.	1.0	11
2663	Telomerase-based Cancer Therapeutics: A Review on their Clinical Trials. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 433-457.	1.0	33
2664	Immunology Behind Tumors: A Mini Review. <i>Current Cancer Therapy Reviews</i> , 2019, 15, 174-183.	0.2	4

#	ARTICLE	IF	CITATIONS
2665	Cancer Immunology and Immunotherapy. <i>Anticancer Research</i> , 2016, 36, 5593-5606.	0.5	69
2666	Correlation of Blood T-Cells to Intratumoural Density and Location of CD3+ and CD8+ T-Cells in Colorectal Cancer. <i>Anticancer Research</i> , 2017, 37, 675-684.	0.5	18
2667	Immune Checkpoint Inhibitors in Gynecological Cancers: Update of Literature and Perspectives of Clinical Research. <i>Anticancer Research</i> , 2017, 37, 5955-5965.	0.5	45
2668	Baseline Tumor Size as a Predictive and Prognostic Factor of Immune Checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2019, 39, 815-825.	0.5	73
2669	Immunoscore and its introduction in clinical practice. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 152-161.	0.4	48
2670	The LIPI score and inflammatory biomarkers for selection of patients with solid tumors treated with checkpoint inhibitors. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 162-174.	0.4	38
2671	[¹⁸ F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab. <i>Radiology and Oncology</i> , 2020, 54, 285-294.	0.6	48
2672	Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 1: The Role of ¹⁸ F-FDG PET/CT. <i>Journal of Nuclear Medicine</i> , 2020, 61, 943-950.	2.8	39
2673	Combinations using checkpoint blockade to overcome resistance. <i>Ecancermedalscience</i> , 2020, 14, 1148.	0.6	11
2674	Oncolytic virotherapy: new weapon for breast cancer treatment. <i>Ecancermedalscience</i> , 2020, 14, 1149.	0.6	12
2675	Friend or Foe? Recent Strategies to Target Myeloid Cells in Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 351.	1.8	45
2676	T-Box Transcription Factor 22 Is an Immune Microenvironment-Related Biomarker Associated With the BRAFV600E Mutation in Papillary Thyroid Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 590898.	1.8	4
2677	Epigenetic Alterations and Biomarkers for Immune Checkpoint Inhibitors—Current Standards and Future Perspectives in Malignant Pleural Mesothelioma Treatment. <i>Frontiers in Oncology</i> , 2020, 10, 554570.	1.3	16
2678	Acidosis-Induced TGF- β 2 Production Promotes Lipid Droplet Formation in Dendritic Cells and Alters Their Potential to Support Anti-Mesothelioma T Cell Response. <i>Cancers</i> , 2020, 12, 1284.	1.7	25
2679	Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. <i>Cancers</i> , 2020, 12, 1303.	1.7	6
2680	Pembrolizumab Induces an Unexpected Conformational Change in the CC β -loop of PD-1. <i>Cancers</i> , 2021, 13, 5.	1.7	8
2681	The Impact of Immunofunctional Phenotyping on the Malfunction of the Cancer Immunity Cycle in Breast Cancer. <i>Cancers</i> , 2021, 13, 110.	1.7	11
2682	Phage Display-Based Nanotechnology Applications in Cancer Immunotherapy. <i>Molecules</i> , 2020, 25, 843.	1.7	32

#	ARTICLE	IF	CITATIONS
2683	Peptide-Based Nanomaterials for Tumor Immunotherapy. <i>Molecules</i> , 2021, 26, 132.	1.7	12
2684	PD-L1 Targeting Immune-Microbubble Complex Enhances Therapeutic Index in Murine Colon Cancer Models. <i>Pharmaceuticals</i> , 2021, 14, 6.	1.7	15
2685	When Molecular-Targeted Agents Meet Immunotherapy: The Opportunities for Soft Tissue Sarcoma. <i>Journal of Immunotherapy and Precision Oncology</i> , 2020, 3, 69-82.	0.6	2
2686	Expression of PD-L1 for Predicting Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis. <i>Current Oncology</i> , 2020, 27, 656-663.	0.9	8
2687	Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?. <i>World Journal of Gastroenterology</i> , 2018, 24, 2137-2151.	1.4	99
2688	ADOPTIVE CELL THERAPY: CURRENT ADVANCES. <i>South Russian Journal of Cancer</i> , 2020, 1, 43-59.	0.1	5
2691	Mechanisms of the Impact of Hashimoto Thyroiditis on Papillary Thyroid Carcinoma Progression: Relationship with the Tumor Immune Microenvironment. <i>Endocrinology and Metabolism</i> , 2020, 35, 443-455.	1.3	14
2692	Prognostic and therapeutic value of CD103 cells in renal cell carcinoma. <i>Experimental and Therapeutic Medicine</i> , 2018, 15, 4979-4986.	0.8	11
2693	High expression of immune checkpoints is associated with the TIL load, mutation rate and patient survival in colorectal cancer. <i>International Journal of Oncology</i> , 2020, 57, 237-248.	1.4	47
2694	Identification of core differentially methylated genes in glioma. <i>Oncology Letters</i> , 2019, 18, 6033-6045.	0.8	31
2695	Breast cancer stem cell RNA ϵ pulsed dendritic cells enhance tumor cell killing by effector T ϵ $\frac{1}{2}$ cells ϵ $\frac{1}{2}$. <i>Oncology Letters</i> , 2020, 19, 2422-2430.	0.8	8
2696	Impact of inflammation and immunotherapy in renal cell carcinoma (Review). <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	19
2697	Siglec-7 is a predictive biomarker for the efficacy of cancer vaccination against metastatic colorectal cancer. <i>Oncology Letters</i> , 2020, 21, 1-1.	0.8	10
2698	Milk fermented by <i>Lactobacillus casei</i> CRL431 modifies cytokine profiles associated to different stages of breast cancer development in mice. <i>Beneficial Microbes</i> , 2019, 10, 689-697.	1.0	6
2699	Immunological interactions in radiotherapy-opening a new window of opportunity. <i>Annals of Translational Medicine</i> , 2016, 4, 51.	0.7	7
2700			

#	ARTICLE	IF	CITATIONS
2703	Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma. <i>Journal of Cancer Research and Therapeutics</i> , 2018, 14, 1167-1175.	0.3	51
2704	Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy. <i>Immune Network</i> , 2020, 20, e8.	1.6	19
2705	PD-L1 Expression and Combined Status of PD-L1/PD-1 ⁺ Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients. <i>Journal of Pathology and Translational Medicine</i> , 2017, 51, 40-48.	0.4	36
2706	Tumor immune response and immunotherapy in gastric cancer. <i>Journal of Pathology and Translational Medicine</i> , 2020, 54, 20-33.	0.4	59
2707	Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer. <i>Cancer Research and Treatment</i> , 2020, 52, 149-166.	1.3	28
2708	Immune Checkpoint Inhibitor Related Neuropathic Adverse Effects on Cancer Patients. <i>Journal of Biosciences and Medicines</i> , 2019, 07, 1-12.	0.1	1
2709	Clinical significance of tumor-infiltrating lymphocytes for gastric cancer in the era of immunology. <i>World Journal of Gastrointestinal Oncology</i> , 2017, 9, 293.	0.8	48
2710	Immunotherapies in sarcoma: Updates and future perspectives. <i>World Journal of Clinical Oncology</i> , 2017, 8, 145.	0.9	10
2711	Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors. <i>World Journal of Clinical Oncology</i> , 2017, 8, 320.	0.9	8
2712	Advances in personalized neoantigen vaccines for cancer immunotherapy. <i>BioScience Trends</i> , 2020, 14, 349-353.	1.1	8
2713	Topography of cancer-associated immune cells in human solid tumors. <i>ELife</i> , 2018, 7, .	2.8	206
2714	Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy. <i>ELife</i> , 2020, 9, .	2.8	40
2715	A perspective on HPK1 as a novel immuno-oncology drug target. <i>ELife</i> , 2020, 9, .	2.8	31
2716	Tumor-infiltrating CD8 ⁺ lymphocytes predict different clinical outcomes in organ- and non-organ-confined urothelial carcinoma of the bladder following radical cystectomy. <i>PeerJ</i> , 2017, 5, e3921.	0.9	11
2717	Reduced Number of Lymphocytes by X-ray Irradiation: A Problem in a Combination Therapy Trial that Elicits the Abscopal Effect in Preclinical Studies Using Electron Beam Irradiation. <i>Cureus</i> , 2019, 11, e4142.	0.2	2
2718	Immunogenic cell death inducers for enhanced cancer immunotherapy. <i>Chemical Communications</i> , 2021, 57, 12087-12097.	2.2	56
2719	Identification of three tumor antigens and immune subtypes for mRNA vaccine development in diffuse glioma. <i>Theranostics</i> , 2021, 11, 9775-9790.	4.6	29
2720	Light-responsive hyaluronic acid nanomicelles co-loaded with an IDO inhibitor focus targeted photoimmunotherapy against immune cold cancer. <i>Biomaterials Science</i> , 2021, 9, 8019-8031.	2.6	18

#	ARTICLE	IF	CITATIONS
2721	Trial watch: intratumoral immunotherapy. <i>Oncolimmunology</i> , 2021, 10, 1984677.	2.1	31
2722	Multifunctional Nanoparticles for Targeting Cancer Nanotheranostics. <i>Nanotechnology in the Life Sciences</i> , 2021, , 29-48.	0.4	0
2723	The safety and efficacy of immunotherapy with anti-programmed cell death 1 monoclonal antibody for lung cancer complicated with Mycobacterium tuberculosis infection. <i>Translational Lung Cancer Research</i> , 2021, 10, 3929-3942.	1.3	6
2724	Advancements in Human Breast Cancer Targeted Therapy and Immunotherapy. <i>Journal of Cancer</i> , 2021, 12, 6949-6963.	1.2	11
2725	Intratumoral cancer immunotherapy exploiting anti-viral immunity. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2022, 62, 1-8.	0.3	4
2726	The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma. <i>Cancer Medicine</i> , 2021, 10, 7977-7987.	1.3	16
2727	The immune landscape in BCR α ABL negative myeloproliferative neoplasms: inflammation, infections and opportunities for immunotherapy. <i>British Journal of Haematology</i> , 2022, 196, 1149-1158.	1.2	11
2728	Immune checkpoint inhibitor-induced pneumonitis: Incidence, clinical characteristics, and outcomes. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, , .	0.6	3
2729	Autophagy in Tumor Immunity and Viral-Based Immunotherapeutic Approaches in Cancer. <i>Cells</i> , 2021, 10, 2672.	1.8	5
2730	Siglec-15 Is an Immune Suppressor and Potential Target for Immunotherapy in the Pre-Metastatic Lymph Node of Colorectal Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 691937.	1.8	7
2731	Estrogens and the Schrödinger's Cat in the Ovarian Tumor Microenvironment. <i>Cancers</i> , 2021, 13, 5011.	1.7	5
2732	Expression Pattern of Purinergic Signaling Components in Colorectal Cancer Cells and Differential Cellular Outcomes Induced by Extracellular ATP and Adenosine. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11472.	1.8	12
2733	Challenges and Prospects for Designer T and NK Cells in Glioblastoma Immunotherapy. <i>Cancers</i> , 2021, 13, 4986.	1.7	6
2734	IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain. <i>Journal of Thoracic Oncology</i> , 2022, 17, 309-323.	0.5	114
2735	Establishment and validation of five autophagy-related signatures for predicting survival and immune microenvironment in glioma. <i>Genes and Genomics</i> , 2022, 44, 79-95.	0.5	5
2736	A randomized phase II trial of efficacy and safety of the immunotherapy ALECSAT as an adjunct to radiotherapy and temozolomide for newly diagnosed glioblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdb156.	0.4	4
2737	A Forgotten Corner in Cancer Immunotherapy: The Role of Lipids. <i>Frontiers in Oncology</i> , 2021, 11, 751086.	1.3	10
2738	CD8 T Cell Vaccines and a Cytomegalovirus-Based Vector Approach. <i>Life</i> , 2021, 11, 1097.	1.1	1

#	ARTICLE	IF	CITATIONS
2739	Engineering living therapeutics with synthetic biology. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 941-960.	21.5	142
2740	Combination of radiation therapy-immunotherapy for head and neck cancers: Promises kept?. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2021, 25, 811-815.	0.6	2
2741	Improving cancer treatments via dynamical biophysical models. <i>Physics of Life Reviews</i> , 2021, 39, 1-48.	1.5	31
2742	Comprehensive Analyses Identify APOBEC3A as a Genomic Instability-Associated Immune Prognostic Biomarker in Ovarian Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 749369.	2.2	7
2743	Metabolic regulation of the cancer-immunity cycle. <i>Trends in Immunology</i> , 2021, 42, 975-993.	2.9	28
2744	A combination strategy based on an Au nanorod/doxorubicin gel via mild photothermal therapy combined with antigen-capturing liposomes and anti-PD-L1 agent promote a positive shift in the cancer-immunity cycle. <i>Acta Biomaterialia</i> , 2021, 136, 495-507.	4.1	28
2745	Semi-Mechanistic Model for the Antitumor Response of a Combination Cocktail of Immuno-Modulators in Non-Inflamed (Cold) Tumors. <i>Cancers</i> , 2021, 13, 5049.	1.7	2
2746	Conventional type 1 dendritic cells (cDC1) as cancer therapeutics: challenges and opportunities. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 465-472.	1.4	12
2747	Immune Signatures Combined With BRCA1-Associated Protein 1 Mutations Predict Prognosis and Immunotherapy Efficacy in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 747985.	1.8	2
2748	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges. <i>Frontiers in Oncology</i> , 2021, 11, 737497.	1.3	22
2749	Novel classes of immunotherapy for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 15-29.	1.1	8
2750	Proportional Tumor Infiltration of T Cells via Circulation Duplicates the T Cell Receptor Repertoire in a Bilateral Tumor Mouse Model. <i>Frontiers in Immunology</i> , 2021, 12, 744381.	2.2	4
2751	Clinical factors associated with long-term benefit in patients with metastatic renal cell carcinoma treated with axitinib: Real-world AXILONG study. <i>Clinical Genitourinary Cancer</i> , 2021, , .	0.9	2
2752	The Abscopal Effect: A Review of Pre-Clinical and Clinical Advances. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11061.	1.8	49
2753	Intelligent photothermal dendritic cells restart the cancer immunity cycle through enhanced immunogenic cell death. <i>Biomaterials</i> , 2021, 279, 121228.	5.7	41
2754	A nanoplatform to boost multi-phases of cancer-immunity-cycle for enhancing immunotherapy. <i>Journal of Controlled Release</i> , 2021, 339, 403-415.	4.8	18
2755	Nonclinical safety assessment of engineered T cell therapies. <i>Regulatory Toxicology and Pharmacology</i> , 2021, 127, 105064.	1.3	2
2756	Predictive potential of STEAP family for survival, immune microenvironment and therapy response in glioma. <i>International Immunopharmacology</i> , 2021, 101, 108183.	1.7	14

#	ARTICLE	IF	CITATIONS
2757	Drug-eluting immune checkpoint blockade antibody-nanoparticle conjugate enhances locoregional and systemic combination cancer immunotherapy through T lymphocyte targeting. <i>Biomaterials</i> , 2021, 279, 121184.	5.7	10
2758	Multifunctional polymeric micelle-based nucleic acid delivery: Current advances and future perspectives. <i>Applied Materials Today</i> , 2021, 25, 101217.	2.3	21
2759	Perioperative care and cancer recurrence: Is there a connection. <i>World Journal of Anesthesiology</i> , 2014, 3, 31.	0.5	0
2760	Cancer Vaccines: Fundamentals and Strategies. <i>Advances in Delivery Science and Technology</i> , 2014, , 163-185.	0.4	0
2761	Cancer Biology of Molecular Imaging. , 2016, , 1-31.		0
2762	High Response Rate to Second-Line Combination Antiangiogenic Chemotherapy in Patients with Metastatic Melanoma. <i>Journal of Cancer Therapy</i> , 2016, 07, 908-918.	0.1	0
2766	Relevance of PD-L1 expression status in thymic malignancies. <i>Mediastinum</i> , 0, 1, 3-3.	0.6	0
2767	Delivery of Peptide Antigen with Lipid-based Fluorescent-trackable Nanoparticles in Vivo for Cancer Immunotherapy. , 2017, , .		0
2768	Moderne Immuntherapien in der Onkologie. <i>Der Merkurstab</i> , 2017, 70, 384-391.	0.0	3
2769	Validation of Anti-Mouse PDL-1 Goat Polyclonal Antibody Staining with Mouse PDL-1 In Situ Hybridization on Adjacent Sections of Cell Pellets and Mouse Tumors. <i>Methods in Molecular Biology</i> , 2017, 1554, 253-262.	0.4	2
2770	Clinical Pharmacology of Therapeutic Antibodies for Precision Medicine. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2017, 48, 99-103.	0.1	0
2771	Cancer Epigenomics on Precision Medicine and Immunotherapy. , 2017, , 1-21.		0
2772	Immunotherapie van kanker. , 2017, , 181-190.		0
2775	Immunotherapy and Lung Cancer: Programmed Death 1 and Its Ligand as a Target for Therapy. <i>Molecular Pathology Library</i> , 2018, , 257-273.	0.1	0
2776	REVIEW OF APPROACHES TO IMMUNOTHERAPY IN ONCOLOGY. <i>IssledovaniĀ I Praktika V Medicine</i> , 2017, 4, 51-65.	0.1	4
2777	Benchmarking the Foreign Antigen Space of Human Malignancies. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2779	New Progress in Breast Cancer Immunotherapy. <i>Advances in Clinical Medicine</i> , 2018, 08, 47-52.	0.0	0
2780	Immunosenescence and Cancer Immunotherapy at Old Age: Basics. , 2018, , 1-20.		1

#	ARTICLE	IF	CITATIONS
2781	Synergistic immuno photothermal nanotherapy (SYMPHONY) to treat unresectable and metastatic cancers and produce and cancer vaccine effect. , 2018, , .		0
2783	ULTRASOUND TUMOR ABLATION: IMMUNE EFFECTS AND PERSPECTIVES OF INTEGRATION IN THE MODERN TREATMENT OF ADVANCED CANCER. Malignant Tumours, 2018, 8, 31-42.	0.1	0
2784	Pembrolizumab in Advanced Gastrointestinal Malignancies with Defective DNA Mismatch Repair: A Case Series. Journal of Immunotherapy and Precision Oncology, 2018, 1, 1-6.	0.6	0
2787	Personalized Cancer Immunotherapy: Today's Challenge and Tomorrow's Promise. Journal of Immunotherapy and Precision Oncology, 2018, 1, 56-67.	0.6	4
2788	Toxicités sÃ©vÃ©res des immunothÃ©rapies du cancer. Medecine Intensive Reanimation, 2018, 27, 522-536.	0.1	0
2789	Makrofajlar Ã¶zerinde Ã¼stÃ¼nÃ¼mlÃ¼latÄ±r ve Adjuvan Etkisi Olan Rutenyum Bazlı İYİ BaÄl MolekÃ¼l. Cumhuriyet Science Journal, 2018, 39, 991-998.	0.1	12
2790	Systemische Therapie: Grundlagen. Springer Reference Medizin, 2019, , 1-7.	0.0	0
2791	A Multifunctional Envelope-Type Nano Device for Cancer Therapy. , 2019, , 217-251.		0
2792	Response to salvage chemotherapy after progression on nivolumab in patients with recurrent/metastatic head and neck squamous cell carcinoma. Japanese Journal of Head and Neck Cancer, 2019, 45, 41-45.	0.0	1
2794	Emerging Immune Context. , 2019, , 269-329.		0
2795	Introduction to Melanoma Immunology. , 2019, , 1-15.		0
2796	Immunotherapy with mRNA vaccination and immunomodulation nanomedicine for cancer therapy. , 2019, , 551-600.		0
2797	Melanoma Immunology and Immunotherapy. , 2019, , 1-15.		0
2798	1 Inleiding in de radiotherapie. Medische Beeldvorming En Radiotherapie, 2019, , 1-11.	0.0	0
2799	Novel Methods to Overcome Acquired Resistance to Immunotherapy. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 97-129.	0.1	0
2800	The Expression of CD155 on Renal Cell Carcinoma Cells. Advances in Clinical Medicine, 2019, 09, 373-381.	0.0	0
2807	Beyond PD-1/PD-L1 Axis Blockade: New Combination Strategies in Metastatic Melanoma Treatment. Current Cancer Therapy Reviews, 2019, 15, 110-119.	0.2	0
2810	Functional Genome Profiling to Understand Cancer Immune Responsiveness. Methods in Molecular Biology, 2020, 2055, 231-244.	0.4	0

#	ARTICLE	IF	CITATIONS
2811	The dark side of immunotherapy: challenges facing the new hope in cancer treatment. <i>Annals of Translational Medicine</i> , 2019, 7, S183-S183.	0.7	5
2812	Perspectives on the Therapeutic Benefits of Arginine Supplementation in Cancer Treatment. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2019, 19, 913-920.	0.6	1
2813	Experience of using atezolizumab in 1st line therapy of metastatic urothelial cancer. <i>Onkourologiya</i> , 2019, 15, 113-119.	0.1	0
2815	Prognostic significance of PD-L1 expression and evaluation of microsatellite instability status in patients with retroperitoneal leiomyosarcomas. <i>Uspehi Molekularnoj Onkologii</i> , 2019, 6, 37-48.	0.1	0
2816	Immunotherapy in Oral Cancer: A Fourth Dimension of Cancer Treatment. , 2020, , 129-154.		1
2817	Antiangiogenic therapy of advanced non-squamous non-small cell lung cancer in era of immuno-oncology: role, place and optimization of treatment approaches. <i>Medical Alphabet</i> , 2019, 3, 18-24.	0.0	0
2818	Immunotherapy in Oncology. , 2020, , 3-6.		0
2819	Will neo-adjuvant immunotherapy become a new paradigm in the treatment of lung cancer patients. <i>Meditsinskiy Sovet</i> , 2019, , 22-29.	0.1	0
2820	Immunosenescence and Cancer Immunotherapy at Old Age: Basics. , 2020, , 71-90.		1
2821	Multi-agent Modeling Simulation of In-vitro T-cells for Immunologic Alternatives to Cancer Treatment. , 2020, , .		0
2822	A Case of Tongue Cancer with Induction of the Abscopal Effect Treated with Nivolumab. <i>Practica Otologica</i> , 2020, 113, 575-579.	0.0	0
2823	Assessing the Potency of T Cell-Redirecting Therapeutics Using In Vitro Cancer Cell Killing Assays. <i>Methods in Pharmacology and Toxicology</i> , 2020, , 51-72.	0.1	1
2824	Immune Checkpoint Blockade in Gastrointestinal Cancers: The Current Status and Emerging Paradigms. <i>Journal of Immunotherapy and Precision Oncology</i> , 2020, 3, 3-15.	0.6	3
2826	Check and Checkmate: Battling Cancer with Multiplex Immunotherapy. <i>Molecular Therapy</i> , 2020, 28, 1236-1237.	3.7	1
2827	Radiation induces iatrogenic immunosuppression by indirectly affecting hematopoiesis in bone marrow. <i>Oncotarget</i> , 2020, 11, 1681-1690.	0.8	7
2828	Host deficiency in ephrin-A1 inhibits breast cancer metastasis. <i>F1000Research</i> , 2020, 9, 217.	0.8	11
2829	Anti-Tumour Drugs: Planning Preclinical Efficacy and Safety Studies. <i>The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products</i> , 2020, 10, 96-110.	0.1	3
2830	The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Extrapulmonary Small Cell Carcinoma. <i>Cureus</i> , 2020, 12, e8862.	0.2	2

#	ARTICLE	IF	CITATIONS
2831	Modeling and Analyzing Stem-Cell Therapy toward Cancer: Evolutionary Game Theory Perspective. Iranian Journal of Public Health, 0, , .	0.3	0
2832	Effect of the hairpin structure of peptide inhibitors on the blockade of PD-1/PD-L1 axis. Biochemical and Biophysical Research Communications, 2020, 527, 453-457.	1.0	10
2833	Toll-Like Receptor-4 Antagonist Enhances the Repair of Ultraviolet Radiation-Induced DNA Damage and Augments Anti-Tumor Immune Responses in Mice. Cancers, 2021, 13, 5406.	1.7	3
2834	Peripheral Lymphocyte Subsets Absolute Counts as Feasible Clinical Markers for Predicting Surgical Outcome in Gastric Cancer Patients After Laparoscopic D2 Gastrectomy: A Prospective Cohort Study. Journal of Inflammation Research, 2021, Volume 14, 5633-5646.	1.6	5
2835	Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody-drug conjugates and bispecific antibodies. Breast Cancer Research and Treatment, 2022, 191, 291-302.	1.1	18
2836	Avengers against cancer: A new era of nano-biomaterial-based therapeutics. Materials Today, 2021, 51, 317-349.	8.3	24
2837	Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy. Cancers, 2021, 13, 5475.	1.7	10
2840	EPHA5 mutations predict survival after immunotherapy in lung adenocarcinoma. Aging, 2021, 13, 598-618.	1.4	10
2842	Lentinan, a Shiitake Mushroom β -Glucan, Downregulates the Enhanced PD-L1 Expression Induced by Platinum Compounds in Gastric Cancer Cells -. Journal of Analytical Oncology, 0, 9, 1-10.	0.1	2
2843	S-1 Plus Leucovorin and Oxaliplatin in Combination with Lentinan as First-line Therapy in Patients with Metastatic Gastric Cancer. Journal of Cancer Research Updates, 0, 9, 69-74.	0.3	0
2844	Immunotherapy for Autoimmune Diseases. , 2021, , 63-115.		0
2845	Postoperative Low Molecular Weight Heparin-induced Infection in Gastrointestinal Cancer Patients. A 2-year Single Centre Experience. Folia Medica, 2020, 62, 769-776.	0.2	0
2846	Combination Treatment with in Situ Tumor Vaccination Therapy and Nutritional Intervention Utilizing Lentinula Edodes Mycelia Extract for Patient with Lingual Cancer: A Case Report. Japanese Journal of Complementary and Alternative Medicine, 2020, 17, 155-159.	1.0	0
2847	Activation of T helper cells in sentinel node predicts poor prognosis in oral squamous cell carcinoma. Scientific Reports, 2020, 10, 22352.	1.6	4
2848	Immune checkpoint inhibitor myocarditis: a systematic case study. Russian Journal of Cardiology, 2020, 25, 3910.	0.4	6
2849	Cryoablation versus cryoablation for the treatment of stage III non-small cell lung cancer: A prospective, noninferiority, randomized, controlled trial (RCT). Thoracic Cancer, 2021, 12, 475-483.	0.8	8
2850	Presumed cancer-associated retinopathy (CAR) mimicking Sudden Acquired Retinal Degeneration Syndrome (SARDS) in canines. Veterinary Ophthalmology, 2021, 24, 125-155.	0.6	3
2851	ARID1A Deficiency Is Associated With High Programmed Death Ligand 1 Expression in Hepatocellular Carcinoma. Hepatology Communications, 2021, 5, 675-688.	2.0	17

#	ARTICLE	IF	CITATIONS
2871	CHAPTER 10. Intratumoral Fibrosis: Emerging Concepts and Therapeutic Opportunities. RSC Drug Discovery Series, 2020, , 259-306.	0.2	1
2873	Immunotherapie van kanker. , 2020, , 191-201.		0
2874	Meningioma Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1296, 33-48.	0.8	5
2875	AGE-RELATED FEATURES OF SYSTEMIC ANTITUMOR IMMUNE RESPONSE IN PATIENTS WITH PRIMARY OPERABLE BREAST CANCER AND CANCER OF THE ORAL MUCOSA. , 2020, 19, 81-88.	0.3	0
2876	Theoretical Substantiation of Personalized (Target) Therapy of Testicular Germ Cell Tumors. UkraïnsE ¹ kij A ³ urnal Medicini B ^A -ologA ^{-A} Ta Sportu, 2020, 5, 228-236.	0.0	0
2877	Imunoterapia. , 2020, 99, 148-155.	0.0	0
2879	The Immune Infiltration in HNSCC and Its Clinical Value: A Comprehensive Study Based on the TCGA and GEO Databases. Computational and Mathematical Methods in Medicine, 2021, 2021, 1-11.	0.7	9
2880	Current Perspectives on the Immunosuppressive Niche and Role of Fibrosis in Hepatocellular Carcinoma and the Development of Antitumor Immunity. Journal of Histochemistry and Cytochemistry, 2022, 70, 53-81.	1.3	6
2881	Comprehensive Analysis of m6A RNA Methylation Regulators and the Immune Microenvironment to Aid Immunotherapy in Pancreatic Cancer. Frontiers in Immunology, 2021, 12, 769425.	2.2	21
2882	Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy. BMC Cancer, 2021, 21, 1187.	1.1	6
2883	Drugging the lymphatic system: An emerging opportunity for cancer immunotherapy. Advanced Drug Delivery Reviews, 2021, 180, 114040.	6.6	1
2884	Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13RÎ±2 and Suppress Malignant Glioma: A Preclinical Study. Frontiers in Immunology, 2021, 12, 715000.	2.2	10
2885	Neoantigen Dendritic Cell Vaccination Combined with Anti-CD38 and CpG Elicits Anti-Tumor Immunity against the Immune Checkpoint Therapy-Resistant Murine Lung Cancer Cell Line LLC1. Cancers, 2021, 13, 5508.	1.7	9
2886	Cellâ€Derived Biogenetic Gold Nanoparticles for Sensitizing Radiotherapy and Boosting Immune Response against Cancer. Small, 2021, 17, e2103984.	5.2	38
2887	Two distinct phenotypes of immunologically hot gastric cancer subtypes. Biochemistry and Biophysics Reports, 2021, 28, 101167.	0.7	1
2888	Synergistic effects of lowâ€dose chemotherapy and T cells in renal cell carcinoma. Oncology Reports, 2020, 44, 897-908.	1.2	4
2889	éé,éf ^ç ™CEâ«â ⁻³ 4â ⁷ ™â, NKT ç ^º èfzâ,â [^] ©ç [”] ”â ⁻ â ^ÿ âf ⁻ â,â ^f âf ³ æ ² »ç [™] ,. Journal of Otolaryngology of Japan, 2020, 126,1543-546.		
2895	<sc>MLLT</sc>6 maintains <i><sc>PD</sc></i> expression and mediates tumor immune resistance. EMBO Reports, 2020, 21, e50155.	2.0	13

#	ARTICLE	IF	CITATIONS
2896	Role of cGAS-STING signaling pathway in colon cancer. <i>World Chinese Journal of Digestology</i> , 2020, 28, 1084-1089.	0.0	0
2897	Combination of pembrolizumab and axitinib: a new gold standard in the first-line therapy for metastatic clear-cell renal-cell carcinoma?. <i>Onkourologiya</i> , 2020, 16, 29-37.	0.1	0
2898	New Development of Ultrasonic Cancer Therapy. <i>Thermal Medicine</i> , 2020, 36, 75-90.	0.0	0
2899	Overview of Tumor Immunotherapy based on Indoleamine 2,3 Dioxygenase Inhibitors. , 2020, , .		1
2900	Novel adjuvant therapies for pancreatic adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 430-5.	0.6	3
2901	Immunotherapy: New Strategies for the Treatment of Gynecologic Malignancies. <i>Oncology</i> , 2016, 30, 59-66, 69.	0.4	14
2902	Image-guided dendritic cell-based vaccine immunotherapy in murine carcinoma models. <i>American Journal of Translational Research (discontinued)</i> , 2017, 9, 4564-4573.	0.0	2
2905	Multimodal detection of PD-L1: reasonable biomarkers for immune checkpoint inhibitor. <i>American Journal of Cancer Research</i> , 2018, 8, 1689-1696.	1.4	11
2906	Exosomes in cancer therapy: a novel experimental strategy. <i>American Journal of Cancer Research</i> , 2018, 8, 2165-2175.	1.4	22
2907	Compound-therapy based on cancer-immunity cycle: promising prospects for antitumor regimens. <i>American Journal of Cancer Research</i> , 2019, 9, 212-218.	1.4	7
2908	Modeling and Analyzing Stem-Cell Therapy toward Cancer: Evolutionary Game Theory Perspective. <i>Iranian Journal of Public Health</i> , 2020, 49, 145-156.	0.3	0
2909	Ultrathin metal-organic layer-mediated radiotherapy-radiodynamic therapy enhances immunotherapy of metastatic cancers. <i>Matter</i> , 2019, 1, 1331-1353.	5.0	20
2910	IFN γ and TNF α synergistically promote galectin 9 secretion by human osteosarcoma cells MG-63 to prevent T cell killing. <i>International Journal of Clinical and Experimental Pathology</i> , 2020, 13, 2009-2017.	0.5	0
2911	PD-1, TIM-3, and LAG-3 Expression in T Cells in a Patient with Recurrent Ossifying Fibroma: A Case Report. <i>International Journal of Molecular and Cellular Medicine</i> , 2020, 9, 307-312.	1.1	0
2913	Immunotherapy in non-small cell lung cancer: Update and new insights. <i>Journal of Clinical and Translational Research</i> , 2021, 7, 1-21.	0.3	16
2914	Nab-paclitaxel promotes the cancer-immunity cycle as a potential immunomodulator. <i>American Journal of Cancer Research</i> , 2021, 11, 3445-3460.	1.4	2
2915	Nano-engineered immune cells as "guided missiles" for cancer therapy. <i>Journal of Controlled Release</i> , 2022, 341, 60-79.	4.8	15
2916	Tumor-Associated Extracellular Matrix: How to Be a Potential Aide to Anti-tumor Immunotherapy?. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 739161.	1.8	34

#	ARTICLE	IF	CITATIONS
2917	Targeted Mass Spectrometry Enables Multiplexed Quantification of Immunomodulatory Proteins in Clinical Biospecimens. <i>Frontiers in Immunology</i> , 2021, 12, 765898.	2.2	13
2918	5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer. <i>BMC Medicine</i> , 2021, 19, 289.	2.3	48
2919	Pretreatment tumour immune microenvironment predicts clinical response and prognosis of muscle-invasive bladder cancer in the neoadjuvant chemotherapy setting. <i>British Journal of Cancer</i> , 2022, 126, 606-614.	2.9	12
2920	Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 5275-5291.	1.0	5
2921	Response criteria for immunotherapy and the radiologic patterns of immune-related adverse events. <i>European Journal of Radiology</i> , 2022, 146, 110062.	1.2	4
2922	Tailoring Aggregation Extent of Photosensitizers to Boost Phototherapy Potency for Eliciting Systemic Antitumor Immunity. <i>Advanced Materials</i> , 2022, 34, e2106390.	11.1	65
2924	Treatment landscape of triple-negative breast cancer – expanded options, evolving needs. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 91-113.	12.5	414
2925	Rho-Kinase as a Target for Cancer Therapy and Its Immunotherapeutic Potential. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12916.	1.8	28
2926	Photodynamic Therapy-Mediated Immune Responses in Three-Dimensional Tumor Models. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12618.	1.8	13
2927	Comprehensive analysis of PD-L1 in non-small cell lung cancer with emphasis on survival benefit, impact of driver mutation and histological types, and archival tissue. <i>Thoracic Cancer</i> , 2021, , .	0.8	5
2929	PD-L1 blockade exhibits anti-tumor effect on brain metastasis by activating CD8+ T cells in hematogenous metastasis model with lymphocyte infusion. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 335-344.	1.7	0
2930	Increased Risk of Thyroid Dysfunction by PD-1 and CTLA-4 Blockade in Patients Without Thyroid Autoantibodies at Baseline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e1620-e1630.	1.8	15
2931	Antimetastatic defense by CD8+ T cells. <i>Trends in Cancer</i> , 2022, 8, 145-157.	3.8	12
2932	Serpinc1 Acts as a Tumor Suppressor in Hepatocellular Carcinoma Through Inducing Apoptosis and Blocking Macrophage Polarization in an Ubiquitin-Proteasome Manner. <i>Frontiers in Oncology</i> , 2021, 11, 738607.	1.3	6
2933	Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma. <i>Life</i> , 2021, 11, 1318.	1.1	7
2934	Treatment Selection in First-line Metastatic Renal Cell Carcinoma – The Contemporary Treatment Paradigm in the Age of Combination Therapy. <i>JAMA Oncology</i> , 2022, 8, 292.	3.4	35
2935	Emerging biomaterial-based strategies for personalized therapeutic in situ cancer vaccines. <i>Biomaterials</i> , 2022, 280, 121297.	5.7	27
2936	Checkpoint Inhibition in Bladder Cancer: Clinical Expectations, Current Evidence, and Proposal of Future Strategies Based on a Tumor-Specific Immunobiological Approach. <i>Cancers</i> , 2021, 13, 6016.	1.7	19

#	ARTICLE	IF	CITATIONS
2937	Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity. <i>Immunity</i> , 2022, 55, 308-323.e9.	6.6	126
2938	Identification of an Immune-Related Biomarker Model Based on the CircRNA-Associated Regulatory Network for Esophageal Carcinoma. <i>Journal of Oncology</i> , 2021, 2021, 1-13.	0.6	1
2939	Plexin-A4 Mediates Cytotoxic T-cell Trafficking and Exclusion in Cancer. <i>Cancer Immunology Research</i> , 2022, 10, 126-141.	1.6	9
2940	Cancer-Immunity Cycle and Therapeutic Interventions- Opportunities for Including Pet Dogs With Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 773420.	1.3	10
2941	Novel immune targets for the treatment of triple-negative breast cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 815-834.	1.5	11
2942	Nuclear Imaging of Endogenous Markers of Lymphocyte Response. , 2022, , 15-59.		1
2943	Pyroptosis-related gene mediated modification patterns and immune cell infiltration landscapes in cutaneous melanoma to aid immunotherapy. <i>Aging</i> , 2021, 13, 24379-24401.	1.4	12
2944	Pharmacological Activation of cGAS for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 753472.	2.2	13
2945	The Role of Innate Immune Cells in Tumor Invasion and Metastasis. <i>Cancers</i> , 2021, 13, 5885.	1.7	8
2946	Selective IL-1 activity on CD8 ⁺ T cells empowers antitumor immunity and synergizes with neovasculature-targeted TNF for full tumor eradication. , 2021, 9, e003293.		9
2947	Harnessing the combined potential of cancer immunotherapy and nanomedicine: A new paradigm in cancer treatment. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2022, 40, 102492.	1.7	4
2948	Augmentation of anti-tumor function of tumor-infiltrating lymphocytes against triple-negative breast cancer by PD-1 blockade. <i>Cell Biology International</i> , 2021, , .	1.4	2
2949	Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFIREM phase I trial. <i>Lung Cancer</i> , 2022, 166, 255-264.	0.9	13
2950	Emerging role of exosomes as biomarkers in cancer treatment and diagnosis. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103565.	2.0	49
2951	Enhancement of CD8 ⁺ T cell-mediated Tumor Immunotherapy via Magnetic Hyperthermia. <i>ChemMedChem</i> , 2022, 17, .	1.6	9
2952	Immune mechanisms in cancer patients that lead to poor outcomes of SARS-CoV-2 infection. <i>Translational Research</i> , 2022, 241, 83-95.	2.2	12
2953	Going with the Flow: Modeling the Tumor Microenvironment Using Microfluidic Technology. <i>Cancers</i> , 2021, 13, 6052.	1.7	15
2954	Immunotherapy for Melanoma. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 81-111.	0.8	7

#	ARTICLE	IF	CITATIONS
2956	Resistance to Immunotherapy: Mechanisms and Means for Overcoming. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 45-80.	0.8	2
2957	Role of Macrophages in Oxidative Stress Induced Inflammatory Tumor Microenvironment. , 2021, , 1-16.		1
2958	A Darwinian perspective on tumor immune evasion. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188671.	3.3	6
2959	Nevi, dysplastic nevi, and melanoma: Molecular and immune mechanisms involving the progression. <i>Tzu Chi Medical Journal</i> , 2022, 34, 1.	0.4	8
2960	The cGAS/STING Pathway: A Novel Target for Cancer Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 795401.	2.2	37
2961	Combination of CTLA-4 blockade with MUC1 mRNA nanovaccine induces enhanced anti-tumor CTL activity by modulating tumor microenvironment of triple negative breast cancer. <i>Translational Oncology</i> , 2022, 15, 101298.	1.7	7
2962	The CD70-CD27 axis in oncology: the new kids on the block. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 12.	3.5	53
2963	Mechanisms of Antitumor Immunity and Immunosurveillance. <i>Methods in Molecular Biology</i> , 2022, 2435, 1-6.	0.4	1
2964	Immune Landscape and Role of Immunotherapy in Treatment of HPV-Associated Head and Neck Squamous Cell Carcinoma (HNSCC). <i>Current Otorhinolaryngology Reports</i> , 2022, 10, 96-107.	0.2	0
2965	Immunotherapy for prostate cancer: Requirements for a successful regime transfer. <i>Investigative and Clinical Urology</i> , 2022, 63, 3.	1.0	8
2966	Emerging vaccine nanotechnology: From defense against infection to sniping cancer. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 2206-2223.	5.7	52
2967	Re: Cristina Masini, Cinzia Iotti, Ugo De Giorgi, et al. Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2021.09.016 . <i>European Urology</i> , 2022, 81, e96-e96.	0.9	0
2968	Primary Tumor Suppression and Systemic Immune Activation of Macrophages through the Sting Pathway in Metastatic Skin Tumor. <i>Yonsei Medical Journal</i> , 2022, 63, 42.	0.9	7
2969	Basics of immunotherapy for epithelial ovarian cancer. <i>Journal of Gynecology Obstetrics and Human Reproduction</i> , 2022, 51, 102283.	0.6	4
2970	Nanomaterials with changeable physicochemical property for boosting cancer immunotherapy. <i>Journal of Controlled Release</i> , 2022, 342, 210-227.	4.8	16
2971	Polymersomes as a potential platform for cancer immunotherapy. <i>Materials Today Advances</i> , 2022, 13, 100203.	2.5	13
2972	A review on exosome-based cancer therapy. <i>Journal of Cancer Metastasis and Treatment</i> , 0, 2020, .	0.5	8
2973	Current Trends in Anti-Cancer Molecular Targeted Therapies: Renal Complications and Their Histological Features. <i>Journal of Nippon Medical School</i> , 2022, 89, 128-138.	0.3	4

#	ARTICLE	IF	CITATIONS
2974	Perspective on the Immunotherapy of Gastric Cancer. , 2021, , 89-102.		0
2976	Immunotherapy using PD-1/PDL-1 inhibitors in triple-negative breast cancer: a systematic review. <i>Oncology Reviews</i> , 2021, 15, 497.	0.8	8
2977	Prognostic Bone Metastasis-Associated Immune-Related Genes Regulated by Transcription Factors in Mesothelioma. <i>BioMed Research International</i> , 2022, 2022, 1-26.	0.9	1
2978	Microneedle-mediated Intratumoral Delivery of Anti-CTLA-4 Promotes cDC1-dependent Eradication of Oral Squamous Cell Carcinoma with Limited irAEs. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 616-624.	1.9	20
2979	Pro-Resolving Factor Administration Limits Cancer Progression by Enhancing Immune Response Against Cancer Cells. <i>Frontiers in Immunology</i> , 2021, 12, 812171.	2.2	3
2980	Paraneoplastic Autoimmune Neurological Syndromes and the Role of Immune Checkpoint Inhibitors. <i>Neurotherapeutics</i> , 2022, 19, 848-863.	2.1	10
2981	Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1. <i>Oncolmmunology</i> , 2022, 11, 2028960.	2.1	14
2982	Targeting transforming growth factor- β 2 by antisense oligodeoxynucleotide accelerates T cell-mediated tumor rejection in a humanized mouse model of triple-negative breast cancer. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2213-2226.	2.0	5
2983	CD26/DPP4 as a Therapeutic Target in Nonalcoholic Steatohepatitis Associated Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 454.	1.7	9
2984	Immunological Classification of Pancreatic Carcinomas to Identify Immune Index and Provide a Strategy for Patient Stratification. <i>Frontiers in Immunology</i> , 2021, 12, 719105.	2.2	4
2985	Characterization of an Autophagy-Immune Related Genes Score Signature and Prognostic Model and its Correlation with Immune Response for Bladder Cancer. <i>Cancer Management and Research</i> , 2022, Volume 14, 67-88.	0.9	1
2986	NF- κ B-Related Metabolic Gene Signature Predicts the Prognosis and Immunotherapy Response in Gastric Cancer. <i>BioMed Research International</i> , 2022, 2022, 1-30.	0.9	1
2987	Supramolecular cancer photoimmunotherapy based on precise peptide self-assembly design. <i>Chemical Communications</i> , 2022, 58, 2247-2258.	2.2	25
2988	Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. <i>Molecular Cancer</i> , 2022, 21, 28.	7.9	393
2989	Endocrine and Neuroendocrine Tumors Special Issue-Checkpoint Inhibitors for Adrenocortical Carcinoma and Metastatic Pheochromocytoma and Paraganglioma: Do They Work?. <i>Cancers</i> , 2022, 14, 467.	1.7	18
2990	Immune cell-derived small extracellular vesicles in cancer treatment. <i>BMB Reports</i> , 2022, 55, 48-56.	1.1	13
2991	Clinical efficacy of nivolumab is associated with tertiary lymphoid structures in surgically resected primary tumors of recurrent gastric cancer. <i>PLoS ONE</i> , 2022, 17, e0262455.	1.1	12
2992	Lung tumor MHCII immunity depends on in situ antigen presentation by fibroblasts. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	71

#	ARTICLE	IF	CITATIONS
2993	Antigen epitope-TLR7/8a conjugate as self-assembled carrier-free nanovaccine for personalized immunotherapy. <i>Acta Biomaterialia</i> , 2022, 141, 398-407.	4.1	21
2994	Efficacy and predictors of rechallenge with immune checkpoint inhibitors in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2022, 13, 624-630.	0.8	9
2995	Chemotherapy-induced infiltration of neutrophils promotes pancreatic cancer metastasis via Gas6/AXL signalling axis. <i>Gut</i> , 2022, 71, 2284-2299.	6.1	33
2996	Nanomedicine-enabled chemotherapy-based synergetic cancer treatments. <i>Journal of Nanobiotechnology</i> , 2022, 20, 4.	4.2	49
2997	Bioinspired Lipoproteins of Furoxans "Oxaliplatin Remodel Physical Barriers in Tumor to Potentiate T Cell Infiltration. <i>Advanced Materials</i> , 2022, 34, e2110614.	11.1	19
2998	Immunotherapy: A new standard in the treatment of metastatic clear cell renal cell carcinoma. <i>World Journal of Clinical Oncology</i> , 2022, 13, 28-38.	0.9	10
2999	Precision medicine to manage chronic immune-related conditions. , 2022, , 295-318.		1
3000	Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies. , 2022, 10, e003024.		15
3002	Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade. <i>Frontiers in Immunology</i> , 2021, 12, 799455.	2.2	76
3003	Novel Immune-Related Gene-Based Signature Characterizing an Inflamed Microenvironment Predicts Prognosis and Radiotherapy Efficacy in Glioblastoma. <i>Frontiers in Genetics</i> , 2021, 12, 736187.	1.1	3
3004	Emerging strategies for biomaterial-assisted cancer immunotherapy. <i>Korean Journal of Chemical Engineering</i> , 2022, 39, 227-240.	1.2	1
3005	Comprehensive Analysis of Immune Implication and Prognostic Value of IFI44L in Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 798425.	1.3	2
3006	A New Trend in Cancer Treatment: The Combination of Epigenetics and Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, 809761.	2.2	29
3007	Pan-Cancer Analyses Reveal Oncogenic Role and Prognostic Value of F-Box Only Protein 22. <i>Frontiers in Oncology</i> , 2021, 11, 790912.	1.3	4
3008	Future prospects for cancer immunotherapy - Strategies for ineffective cancers. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-3.	1.4	7
3009	Immunotherapy for glioblastoma: the promise of combination strategies. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 35.	3.5	85
3010	OUP accepted manuscript. <i>Oncologist</i> , 2022, , .	1.9	0
3011	Keep a Little Fire Burning "The Delicate Balance of Targeting Sphingosine-1-Phosphate in Cancer Immunity. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1289.	1.8	2

#	ARTICLE	IF	CITATIONS
3012	Revealing Clonal Responses of Tumor-Reactive T-Cells Through T Cell Receptor Repertoire Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 807696.	2.2	13
3013	Role of Macrophages in Oxidative Stress-Induced Inflammatory Tumor Microenvironment. , 2022, , 975-990.		0
3014	Multifunctional Biomimetic Nanovaccines Based on Photothermal and Weakâ€œImmunostimulatory Nanoparticulate Cores for the Immunotherapy of Solid Tumors. <i>Advanced Materials</i> , 2022, 34, e2108012.	11.1	25
3015	Current Advances in Immune Checkpoint Inhibition and Clinical Genomics in Upper Tract Urothelial Carcinoma: State of the Art. <i>Current Oncology</i> , 2022, 29, 687-697.	0.9	9
3016	TNF Familyâ€œBased Signature Predicts Prognosis, Tumor Microenvironment, and Molecular Subtypes in Bladder Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 800967.	1.8	12
3017	Biomarkers in Pulmonary Carcinomas. , 2022, , 99-128.		2
3018	Nanocarriers surface engineered with cell membranes for cancer targeted chemotherapy. <i>Journal of Nanobiotechnology</i> , 2022, 20, 45.	4.2	53
3019	The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1823-1835.	2.0	9
3020	Novel Mouse Models for Cancer Immunology. <i>Annual Review of Cancer Biology</i> , 2022, 6, 269-291.	2.3	9
3021	Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis. <i>Clinical Cancer Research</i> , 2022, 28, 1560-1571.	3.2	33
3022	A 12-chemokine gene signature is associated with the enhanced immunogram scores and is relevant for precision immunotherapy. <i>Medical Oncology</i> , 2022, 39, 43.	1.2	4
3023	Vectorized Treg-depleting $\hat{1}\pm$ CTLA-4 elicits antigen cross-presentation and CD8⁺ T cell immunity to reject â€œcoldâ€™ tumors. , 2022, 10, e003488.		14
3024	PKC agonism restricts innate immune suppression, promotes antigen cross-presentation and synergizes with agonistic CD40 antibody therapy to activate CD8+ T cells in breast cancer. <i>Cancer Letters</i> , 2022, 531, 98-108.	3.2	6
3025	Latest Advances in the Use of Therapeutic Focused Ultrasound in the Treatment of Pancreatic Cancer. <i>Cancers</i> , 2022, 14, 638.	1.7	16
3026	Immunological and Metabolic Alterations in Esophageal Cancer. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2022, 22, 579-589.	0.6	0
3027	Functional nanovesicles displaying anti-PD-L1 antibodies for programmed photoimmunotherapy. <i>Journal of Nanobiotechnology</i> , 2022, 20, 61.	4.2	20
3028	Characterization of Interplay Between Autophagy and Ferroptosis and Their Synergistical Roles on Manipulating Immunological Tumor Microenvironment in Squamous Cell Carcinomas. <i>Frontiers in Immunology</i> , 2021, 12, 739039.	2.2	35
3029	Depiction of Aging-Based Molecular Phenotypes With Diverse Clinical Prognosis and Immunological Features in Gastric Cancer. <i>Frontiers in Medicine</i> , 2021, 8, 792740.	1.2	3

#	ARTICLE	IF	CITATIONS
3030	Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2022, 104, 102352.	3.4	17
3031	Identification of neoantigens for individualized therapeutic cancer vaccines. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 261-282.	21.5	173
3032	Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)., 2022, 10, e004025.		22
3033	Surface glycan targeting for cancer nano-immunotherapy. <i>Journal of Controlled Release</i> , 2022, 342, 321-336.	4.8	10
3034	Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy. <i>Chemical Reviews</i> , 2022, 122, 5977-6039.	23.0	92
3035	Myricetin inhibits interferon- β -induced PD-L1 and IDO1 expression in lung cancer cells. <i>Biochemical Pharmacology</i> , 2022, 197, 114940.	2.0	20
3036	Targeting the NANOG/HDAC1 axis reverses resistance to PD-1 blockade by reinvigorating the antitumor immunity cycle. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	7
3037	Telomerase-based therapies in haematological malignancies. <i>Cell Biochemistry and Function</i> , 2022, 40, 127-140.	1.4	8
3038	PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T cell clonotypes. <i>Cell Reports</i> , 2022, 38, 110331.	2.9	45
3039	Renin-angiotensin-aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2022, 163, 108-118.	1.3	21
3040	Intravenous liposomal vaccine enhances CTL generation, but not until antigen presentation. <i>Journal of Controlled Release</i> , 2022, 343, 1-12.	4.8	11
3041	RNA-seq analysis of peripheral blood dendritic cells matured by dezocine in patients with lung cancer. <i>Molecular Immunology</i> , 2022, 143, 85-93.	1.0	3
3042	Neoantigens and their potential applications in tumor immunotherapy (Review). <i>Oncology Letters</i> , 2022, 23, 88.	0.8	10
3043	Noninvasive Imaging of CD4+ T Cells in Humanized Mice. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 658-666.	1.9	3
3044	Salvage nivolumab and ipilimumab after prior anti-PD-1/ PD-L1 therapy in metastatic renal cell carcinoma: A meta-analysis. <i>Cancer Medicine</i> , 2022, , .	1.3	5
3045	Programme death ligand 1 expressions as a surrogate for determining immunotherapy in cervical carcinoma patients. <i>PLoS ONE</i> , 2022, 17, e0263615.	1.1	11
3046	Knockout of high-mobility group box 1 in B16F10 melanoma cells induced host immunity-mediated suppression of in vivo tumor growth. <i>Medical Oncology</i> , 2022, 39, 58.	1.2	6
3047	The Effect of Hypoxia and Hypoxia-Associated Pathways in the Regulation of Antitumor Response: Friends or Foes?. <i>Frontiers in Immunology</i> , 2022, 13, 828875.	2.2	31

#	ARTICLE	IF	CITATIONS
3048	Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy. <i>Cancer Cell</i> , 2022, 40, 318-334.e9.	7.7	97
3049	Ion Interference Therapy of Tumors Based on Inorganic Nanoparticles. <i>Biosensors</i> , 2022, 12, 100.	2.3	14
3050	Recent Advances of Mesoporous Silica as a Platform for Cancer Immunotherapy. <i>Biosensors</i> , 2022, 12, 109.	2.3	16
3051	Effective Combinations of Immunotherapy and Radiotherapy for Cancer Treatment. <i>Frontiers in Oncology</i> , 2022, 12, 809304.	1.3	23
3052	A DNA-Methylation-Driven Genes Based Prognostic Signature Reveals Immune Microenvironment in Pancreatic Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 803962.	2.2	13
3053	Establishment and External Validation of a Hypoxia-Derived Gene Signature for Robustly Predicting Prognosis and Therapeutic Responses in Glioblastoma Multiforme. <i>BioMed Research International</i> , 2022, 2022, 1-50.	0.9	3
3054	Role of Suprabasin in the Dedifferentiation of Follicular Epithelial Cell-Derived Thyroid Cancer and Identification of Related Immune Markers. <i>Frontiers in Genetics</i> , 2022, 13, 810681.	1.1	3
3055	Senescence and the tumor-immune landscape: Implications for cancer immunotherapy. <i>Seminars in Cancer Biology</i> , 2022, 86, 827-845.	4.3	33
3056	Nanomaterials to improve cancer immunotherapy based on ex vivo engineered T cells and NK cells. <i>Journal of Controlled Release</i> , 2022, 343, 379-391.	4.8	12
3057	Recent advance in nanomaterials for cancer immunotherapy. <i>Chemical Engineering Journal</i> , 2022, 435, 134145.	6.6	16
3058	A Novel TGF- β 2 Risk Score Predicts the Clinical Outcomes and Tumour Microenvironment Phenotypes in Bladder Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 791924.	2.2	24
3059	A Novel Immune Classification for Predicting Immunotherapy Responsiveness in Patients With Adamantinomatous Craniopharyngioma. <i>Frontiers in Neurology</i> , 2021, 12, 704130.	1.1	4
3060	Advanced bioactive nanomaterials for biomedical applications. <i>Exploration</i> , 2021, 1, .	5.4	156
3061	Targeting PI3K/Akt signal transduction for cancer therapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 425.	7.1	302
3062	Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer. <i>Nature Cancer</i> , 2022, 3, 108-121.	5.7	150
3064	The therapeutic potential of immune cell-derived exosomes as an alternative to adoptive cell transfer. <i>BMB Reports</i> , 2021, , .	1.1	2
3066	Immunotherapy in Bladder Cancer: Present and Future. <i>Revista Mexicana De Urologia</i> , 2021, 80, 1-19.	0.0	0
3067	Emerging mechanisms of immunotherapy resistance in sarcomas. <i>Cancer Drug Resistance (Alhambra)</i> , Tj ETQq1 1 0,784314 rgBT /Ov	0.9	0

#	ARTICLE	IF	CITATIONS
3068	Immune checkpoint inhibitor resistance in soft tissue sarcoma. <i>Cancer Drug Resistance (Alhambra)</i> , 2022, 10, 100-109.	0.9	4
3069	Targets in nuclear medicine imaging: Past, present and future. , 2022, , .		0
3070	Counterintuitive production of tumor-suppressive secretomes from Oct4- and c-Myc-overexpressing tumor cells and MSCs. <i>Theranostics</i> , 2022, 12, 3084-3103.	4.6	13
3071	Inorganic nanoparticulate carriers in cancer vaccination. , 2022, , 217-240.		0
3072	Supramolecular biomaterials for enhanced cancer immunotherapy. <i>Journal of Materials Chemistry B</i> , 2022, 10, 7183-7193.	2.9	9
3073	The dawn of precision medicine in diffuse-type gastric cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210830.	1.4	19
3074	Comprehensive Immune Landscape and Molecular Characteristics of Clinical Responses to Chemotherapy, Antiangiogenic Agents and PD-1 Inhibitors in Advanced Nasopharyngeal Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
3075	Cancer mutation profiles predict ICIs efficacy in patients with non-small cell lung cancer. <i>Expert Reviews in Molecular Medicine</i> , 2022, 24, e16.	1.6	1
3076	Effects of Low Dose Splenic Region Irradiation and Low Dose Total Body Irradiation on T Cell Immune Function in Mice. <i>Advances in Clinical Medicine</i> , 2022, 12, 2519-2526.	0.0	0
3077	Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies. , 2022, , 129-148.		0
3078	Multi-Omics Profiling of the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1361, 283-326.	0.8	6
3079	Lipopolyplex-based delivery system for cancer vaccine delivery. , 2022, , 193-216.		1
3080	Noncoding RNAs as novel immunotherapeutic tools against cancer. <i>Advances in Protein Chemistry and Structural Biology</i> , 2022, 129, 135-161.	1.0	3
3081	Establishing a Prognostic Model Based on Ulceration and Immune Related Genes in Melanoma Patients and Identification of EIF3B as a Therapeutic Target. <i>Frontiers in Immunology</i> , 2022, 13, 824946.	2.2	5
3082	Synergistic effect of Abraxane that combines human IL15 fused with an albumin-binding domain on murine models of pancreatic ductal adenocarcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 1955-1968.	1.6	4
3083	Clinicopathological features of PD-L1 protein expression, EBV positivity, and MSI status in patients with advanced gastric and esophagogastric junction adenocarcinoma in Japan. <i>Cancer Biology and Therapy</i> , 2022, 23, 191-200.	1.5	10
3084	Proteasomal Processing Immune Escape Mechanisms in Platinum-Treated Advanced Bladder Cancer. <i>Genes</i> , 2022, 13, 422.	1.0	2
3085	Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice. <i>Neurological Sciences</i> , 2022, 43, 2339-2361.	0.9	16

#	ARTICLE	IF	CITATIONS
3086	Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response. <i>Cell Research</i> , 2022, 32, 530-542.	5.7	54
3087	Targeting the epigenetic processes to enhance antitumor immunity in small cell lung cancer. <i>Seminars in Cancer Biology</i> , 2022, 86, 960-970.	4.3	12
3088	Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes. <i>Nature Communications</i> , 2022, 13, 896.	5.8	46
3089	Evolution of Immunotherapy for Ovarian Cancer from a Bird's-Eye Perspective: A Text-Mining Analysis of Publication Trends and Topics. <i>Frontiers in Oncology</i> , 2022, 12, 795129.	1.3	5
3090	Cancer Vaccine in Cold Tumors: Clinical Landscape, Challenges, and Opportunities. <i>Current Cancer Drug Targets</i> , 2022, 22, 437-453.	0.8	2
3091	Molecular Characteristics, Oncogenic Roles, and Relevant Immune and Pharmacogenomic Features of EVA1B in Colorectal Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 809837.	2.2	10
3092	The New Era of Immunotherapy in Gastric Cancer. <i>Cancers</i> , 2022, 14, 1054.	1.7	68
3093	PD-L1 Expression and Survival Rates Using TPS and CPS for Nivolumab-treated Head-and-Neck Cancer. <i>Anticancer Research</i> , 2022, 42, 1547-1554.	0.5	13
3094	Stromal Characteristics and Impact on New Therapies for Metastatic Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 1238.	1.7	7
3095	Neutrophil-lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 698-706.	0.8	27
3096	Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in <i>KRAS</i> -mutated non-small cell lung cancer with <i>STK11</i> , <i>KEAP1</i> or <i>TP53</i> comutations: subgroup results from the phase III IMpower150 trial. , 2022, 10, e003027.		45
3097	Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis. , 2022, 10, e004036.		24
3098	Current Understanding of Hypoxia in Glioblastoma Multiforme and Its Response to Immunotherapy. <i>Cancers</i> , 2022, 14, 1176.	1.7	28
3099	Identification and Verification of Immune-Related Genes Prognostic Signature Based on ssGSEA for Adrenocortical Carcinoma (ACC). <i>International Journal of General Medicine</i> , 2022, Volume 15, 1471-1483.	0.8	8
3101	System analysis based on the cancer-immunity cycle identifies ZNF207 as a novel immunotherapy target for hepatocellular carcinoma. , 2022, 10, e004414.		10
3102	Establishing Imaging Biomarkers of Host Immune System Efficacy during Glioblastoma Therapy Response: Challenges, Obstacles and Future Perspectives. <i>Metabolites</i> , 2022, 12, 243.	1.3	2
3103	Decoding the influence of the immune system and immunotherapy targets on carcinomas: A hidden prism in oral cancer therapy. <i>Disease-a-Month</i> , 2023, 69, 101353.	0.4	4
3104	Fe(III)-Chelated Polydopamine Nanoparticles for Synergistic Tumor Therapies of Enhanced Photothermal Ablation and Antitumor Immune Activation. <i>ACS Applied Materials & Interfaces</i> , 2022, 14, 15894-15910.	4.0	42

#	ARTICLE	IF	CITATIONS
3105	Reframing How Physical Activity Reduces The Incidence of Clinically-Diagnosed Cancers: Appraising Exercise-Induced Immuno-Modulation As An Integral Mechanism. <i>Frontiers in Oncology</i> , 2022, 12, 788113.	1.3	18
3106	Sex dimorphism in the tumor microenvironment “ From bench to bedside and back. <i>Seminars in Cancer Biology</i> , 2022, 86, 166-179.	4.3	8
3107	Engineered nanomaterials for synergistic photo-immunotherapy. <i>Biomaterials</i> , 2022, 282, 121425.	5.7	57
3108	Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation. <i>Journal of Hematology and Oncology</i> , 2022, 15, 24.	6.9	136
3109	MAOI Antidepressants: Could They Be a Next-Generation ICB Therapy?. <i>Frontiers in Immunology</i> , 2022, 13, 853624.	2.2	4
3110	Pan-cancer analysis revealed the significance of the GTPBP family in cancer. <i>Aging</i> , 2022, 14, 2558-2573.	1.4	2
3111	Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study. <i>British Journal of Dermatology</i> , 2022, 187, 401-410.	1.4	21
3112	An Oxidative Stress-Related Genes Signature for Predicting Survival in Bladder Cancer: Based on TCGA Database and Bioinformatics. <i>International Journal of General Medicine</i> , 2022, Volume 15, 2645-2667.	0.8	9
3113	Strategies for Manipulating T Cells in Cancer Immunotherapy. <i>Biomolecules and Therapeutics</i> , 2022, , .	1.1	0
3114	Roles of the RANKL“RANK Axis in Immunity“Implications for Pathogenesis and Treatment of Bone Metastasis. <i>Frontiers in Immunology</i> , 2022, 13, 824117.	2.2	21
3115	Circadian and Immunity Cycle Talk in Cancer Destination: From Biological Aspects to In Silico Analysis. <i>Cancers</i> , 2022, 14, 1578.	1.7	7
3116	A novel signature based on immune“related gene pairs and clinical features to predict prognosis and treatment effect in “driver gene negative“lung adenocarcinoma. <i>Cancer Medicine</i> , 2022, , .	1.3	4
3117	Expression Profile of Selected Antitumor Immune Response Genes in Pediatric Classic Hodgkin Lymphoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2022, Publish Ahead of Print, .	0.6	0
3118	Glutathione“Depleting Organic Metal Adjuvants for Effective NIR“ Photothermal Immunotherapy. <i>Advanced Materials</i> , 2022, 34, e2201706.	11.1	46
3119	Downregulation of TPX2 impairs the antitumor activity of CD8+ T cells in hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2022, 13, 223.	2.7	11
3120	The interaction of CD4+ helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response. <i>Nature Cancer</i> , 2022, 3, 303-317.	5.7	85
3121	Basic cancer immunology for radiation oncologists. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2022, 66, 508-518.	0.9	2
3122	Immunotherapeutic targeting of activating natural killer cell receptors and their ligands in cancer. <i>Clinical and Experimental Immunology</i> , 2022, 209, 22-32.	1.1	14

#	ARTICLE	IF	CITATIONS
3123	Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 827921.	2.2	43
3124	Immune phenotypic linkage between colorectal cancer and liver metastasis. <i>Cancer Cell</i> , 2022, 40, 424-437.e5.	7.7	129
3126	DNA damage response inhibition-based combination therapies in cancer treatment: Recent advances and future directions. <i>Aging and Cancer</i> , 2022, 3, 44-67.	0.5	2
3127	Targeting Cancer Cell Ferroptosis to Reverse Immune Checkpoint Inhibitor Therapy Resistance. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 818453.	1.8	14
3128	Identification of a Mitochondria-Related Gene Signature to Predict the Prognosis in AML. <i>Frontiers in Oncology</i> , 2022, 12, 823831.	1.3	9
3129	Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses. <i>Immunity</i> , 2022, 55, 512-526.e9.	6.6	118
3130	Revealing the contribution of somatic gene mutations to shaping tumor immune microenvironment. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	6
3131	Advanced Biomaterials for Cell-Specific Modulation and Restore of Cancer Immunotherapy. <i>Advanced Science</i> , 2022, 9, e2200027.	5.6	26
3132	<sc>CD24</sc> is a surrogate for "immune-cold" phenotype in aggressive large B cell lymphoma. <i>Journal of Pathology: Clinical Research</i> , 2022, 8, 340-354.	1.3	9
3133	Comprehensive Analysis of 5-Methylcytosine (m5C) Regulators and the Immune Microenvironment in Pancreatic Adenocarcinoma to Aid Immunotherapy. <i>Frontiers in Oncology</i> , 2022, 12, 851766.	1.3	4
3134	Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 567-591.	1.9	29
3135	Cancer vaccines as promising immuno-therapeutics: platforms and current progress. <i>Journal of Hematology and Oncology</i> , 2022, 15, 28.	6.9	216
3136	Major Vault Protein (MVP) Associated With BRAFV600E Mutation Is an Immune Microenvironment-Related Biomarker Promoting the Progression of Papillary Thyroid Cancer via MAPK/ERK and PI3K/AKT Pathways. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 688370.	1.8	5
3138	Microtube Array Membrane Hollow Fiber Assay (MTAM-HFA) "An Accurate and Rapid Potential Companion Diagnostic and Pharmacological Interrogation Solution for Cancer Immunotherapy (PD-1/PD-L1). <i>Biomolecules</i> , 2022, 12, 480.	1.8	4
3139	Understanding the Complexities and Changes of the Astronaut Microbiome for Successful Long-Duration Space Missions. <i>Life</i> , 2022, 12, 495.	1.1	18
3140	Biomimetic and Materials-Potentiated Cell Engineering for Cancer Immunotherapy. <i>Pharmaceutics</i> , 2022, 14, 734.	2.0	1
3141	Role of the Epigenetic Modifier JMJD6 in Tumor Development and Regulation of Immune Response. <i>Frontiers in Immunology</i> , 2022, 13, 859893.	2.2	9
3142	Efficacy and Safety of Low-Dose Nab-Paclitaxel Plus Tislelizumab in Elderly Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 802467.	1.3	4

#	ARTICLE	IF	CITATIONS
3143	Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers. <i>Cancers</i> , 2022, 14, 1681.	1.7	64
3144	The Treatment Landscape of Advanced Hepatocellular Carcinoma. <i>Current Oncology Reports</i> , 2022, 24, 917-927.	1.8	21
3145	Checkpoint Inhibitors and Induction of Celiac Disease-like Condition. <i>Biomedicines</i> , 2022, 10, 609.	1.4	5
3146	Immunotherapy and Biomarkers in Sarcoma. <i>Current Treatment Options in Oncology</i> , 2022, 23, 415-438.	1.3	12
3147	LRP1B is a Potential Biomarker for Tumor Immunogenicity and Prognosis of HCC Patients Receiving ICI Treatment. <i>Journal of Hepatocellular Carcinoma</i> , 2022, Volume 9, 203-220.	1.8	8
3148	CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 119.	3.5	167
3149	Suppression of the transforming growth factor- β signaling pathway produces a synergistic effect of combination therapy with programmed death receptor 1 blockade and radiofrequency ablation against hepatic carcinoma in mice. <i>Bioengineered</i> , 2022, 13, 9046-9058.	1.4	2
3150	An Update on the Immunotherapy for Oropharyngeal Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 800315.	1.3	2
3151	Novel Immunotherapies for Osteosarcoma. <i>Frontiers in Oncology</i> , 2022, 12, 830546.	1.3	25
3152	Immunotherapy in Gastro-Oesophageal Cancer: Current Practice and the Future of Personalised Therapy. <i>BioDrugs</i> , 2022, 36, 473-485.	2.2	5
3153	Concurrent delivery of immune checkpoint blockade modulates T cell dynamics to enhance neoantigen vaccine-generated antitumor immunity. <i>Nature Cancer</i> , 2022, 3, 437-452.	5.7	19
3154	Role of exosomal non-coding RNAs from tumor cells and tumor-associated macrophages in the tumor microenvironment. <i>Molecular Therapy</i> , 2022, 30, 3133-3154.	3.7	73
3155	The role of endoplasmic reticulum stress in the MHC class I antigen presentation pathway of dendritic cells. <i>Molecular Immunology</i> , 2022, 144, 44-48.	1.0	7
3156	Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 383-400.	1.1	20
3157	A Predictive Biophysical Model of the Combined Action of Radiation Therapy and Immunotherapy of Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 872-884.	0.4	6
3158	CD1B is a Potential Prognostic Biomarker Associated with Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Adenocarcinoma. <i>International Journal of General Medicine</i> , 2022, Volume 15, 3809-3826.	0.8	2
3159	Functionalized chitosan as a promising platform for cancer immunotherapy: A review. <i>Carbohydrate Polymers</i> , 2022, 290, 119452.	5.1	30
3160	All is not lost: learning from 9p21 loss in cancer. <i>Trends in Immunology</i> , 2022, 43, 379-390.	2.9	12

#	ARTICLE	IF	CITATIONS
3161	Epithelialâ€“Mesenchymal Plasticity in Tumor Immune Evasion. <i>Cancer Research</i> , 2022, 82, 2329-2343.	0.4	23
3162	Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2323-2341.	3.3	48
3163	TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy. , 2022, 10, e004711.		69
3164	Multifunctional nanomedicines for synergistic photodynamic immunotherapy based on tumor immune microenvironment. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2022, 173, 103-120.	2.0	1
3165	Concurrent Chemoradiotherapy Increases the Levels of Soluble Immune Checkpoint Proteins in Patients with Locally Advanced Cervical Cancer. <i>Journal of Immunology Research</i> , 2022, 2022, 1-8.	0.9	3
3166	Patient-Derived Tumor Organoids: New Progress and Opportunities to Facilitate Precision Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2022, 12, 872531.	1.3	16
3167	Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers. <i>ESMO Open</i> , 2022, 7, 100419.	2.0	7
3168	Dietary <i>Lactobacillus</i> -Derived Exopolysaccharide Enhances Immune-Checkpoint Blockade Therapy. <i>Cancer Discovery</i> , 2022, 12, 1336-1355.	7.7	56
3169	Typical tumor immune microenvironment status determine prognosis in lung adenocarcinoma. <i>Translational Oncology</i> , 2022, 18, 101367.	1.7	10
3170	Exosomal circGSE1 promotes immune escape of hepatocellular carcinoma by inducing the expansion of regulatory T cells. <i>Cancer Science</i> , 2022, 113, 1968-1983.	1.7	38
3171	Bacteria as Nanoparticle Carriers for Immunotherapy in Oncology. <i>Pharmaceutics</i> , 2022, 14, 784.	2.0	3
3172	First-line chemotherapy plus immune checkpoint inhibitors or bevacizumab in advanced non-squamous non-small-cell lung cancer without <i>EGFR</i> mutations or <i>ALK</i> fusions. <i>Immunotherapy</i> , 2022, 14, 445-457.	1.0	3
3173	The solid tumor microenvironmentâ€”Breaking the barrier for T cells. <i>BioEssays</i> , 2022, 44, e2100285.	1.2	12
3174	Radiotherapy: Brightness and darkness in the era of immunotherapy. <i>Translational Oncology</i> , 2022, 19, 101366.	1.7	17
3175	Dendritic cell-based cancer immunotherapy in the era of immune checkpoint inhibitors: From bench to bedside. <i>Life Sciences</i> , 2022, 297, 120466.	2.0	18
3176	Understanding initiation and progression of hepatocellular carcinoma through single cell sequencing. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188720.	3.3	26
3177	Combined nano cancer immunotherapy based on immune status in a tumor microenvironment. <i>Journal of Controlled Release</i> , 2022, 345, 200-213.	4.8	13
3178	Nanotechnology-based multifunctional vaccines for cancer immunotherapy. <i>Chemical Engineering Journal</i> , 2022, 437, 135505.	6.6	13

#	ARTICLE	IF	CITATIONS
3179	Multimodal predictors for precision immunotherapy. <i>Immuno-Oncology Technology</i> , 2022, 14, 100071.	0.2	4
3180	Old and New Players of Inflammation and Their Relationship With Cancer Development. <i>Frontiers in Oncology</i> , 2021, 11, 722999.	1.3	14
3181	Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy. , 2021, 9, e003439.		10
3182	A Cascade Nanozyme with Amplified Sonodynamic Therapeutic Effects through Comodulation of Hypoxia and Immunosuppression against Cancer. <i>ACS Nano</i> , 2022, 16, 485-501.	7.3	88
3183	A Comprehensive Review of Recent Advancements in Cancer Immunotherapy and Generation of CAR T Cell by CRISPR-Cas9. <i>Processes</i> , 2022, 10, 16.	1.3	13
3184	Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13311.	1.8	54
3185	Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy. <i>Hepatology Research</i> , 2022, 52, 298-307.	1.8	31
3186	Cancer-cell stiffening via cholesterol depletion enhances adoptive T-cell immunotherapy. <i>Nature Biomedical Engineering</i> , 2021, 5, 1411-1425.	11.6	96
3187	Tiltsotolimod: an investigational synthetic toll-like receptor 9 (TLR9) agonist for the treatment of refractory solid tumors and melanoma. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 1-13.	1.9	8
3188	Multifaceted Roles of Chemokines and Chemokine Receptors in Tumor Immunity. <i>Cancers</i> , 2021, 13, 6132.	1.7	29
3189	Identification and validation of xenobiotic metabolism-associated prognostic signature based on five genes to evaluate immune microenvironment in colon cancer. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 2788-2802.	0.6	7
3190	Approaches of the Innate Immune System to Ameliorate Adaptive Immunotherapy for B-Cell Non-Hodgkin Lymphoma in Their Microenvironment. <i>Cancers</i> , 2022, 14, 141.	1.7	8
3191	CTLA4-Mediated Immunosuppression in Glioblastoma is Associated with the Infiltration of Macrophages in the Tumor Microenvironment. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 7315-7329.	1.6	15
3192	Mechanistic diversity in MHC class I antigen recognition. <i>Biochemical Journal</i> , 2021, 478, 4187-4202.	1.7	10
3193	Transcriptome Analysis of Large to Giant Congenital Melanocytic Nevus Reveals Cell Cycle Arrest and Immune Evasion: Identifying Potential Targets for Treatment. <i>Journal of Immunology Research</i> , 2021, 2021, 1-16.	0.9	1
3194	Identification of Hypoxia Signature to Assess the Tumor Immune Microenvironment and Predict Prognosis in Patients with Ovarian Cancer. <i>International Journal of Endocrinology</i> , 2021, 2021, 1-16.	0.6	11
3195	The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 793964.	2.2	13
3196	Targeting Cross-Presentation as a Route to Improve the Efficiency of Peptide-Based Cancer Vaccines. <i>Cancers</i> , 2021, 13, 6189.	1.7	9

#	ARTICLE	IF	CITATIONS
3197	PD-L1 expression and immune cells infiltration in primary tracheobronchial neoplasm. <i>Translational Lung Cancer Research</i> , 2021, 10, 4617-4630.	1.3	2
3198	SEMA6B Overexpression Predicts Poor Prognosis and Correlates With the Tumor Immunosuppressive Microenvironment in Colorectal Cancer. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 687319.	1.6	10
3199	Anti-4-1BB antibody-based combination therapy augments antitumor immunity by enhancing CD11c+CD8+ T cells in renal cell carcinoma. <i>Oncology Letters</i> , 2021, 23, 43.	0.8	2
3200	Pre-Treatment Neutrophil-to-Lymphocyte Ratio (NLR) as a Predictive Marker of Pazopanib Treatment for Soft-Tissue Sarcoma. <i>Cancers</i> , 2021, 13, 6266.	1.7	9
3202	Development of a nonhuman primate challenge model to evaluate CD8 ⁺ T cell responses to an adenovirus-based vaccine expressing SIV proteins upon repeat-dose treatment with checkpoint inhibitors. <i>MAbs</i> , 2022, 14, 1979447.	2.6	1
3203	RNA sequencing of glioblastoma tissue slice cultures reveals the effects of treatment at the transcriptional level. <i>FEBS Open Bio</i> , 2022, 12, 480-493.	1.0	1
3204	Beyond Sequencing: Prioritizing and Delivering Neoantigens for Cancer Vaccines. <i>Methods in Molecular Biology</i> , 2022, 2410, 649-670.	0.4	11
3205	Cellular and Humoral Immune Responses Induced by an HLA Class II-restricted Peptide Cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian Cancer. <i>Journal of Immunotherapy</i> , 2022, 45, 56-66.	1.2	8
3206	Anti-VEGF antibody triggers the effect of anti-PD-L1 antibody in PD-L1 ^{low} and immune desert-like mouse tumors. <i>Oncology Reports</i> , 2021, 47, .	1.2	10
3207	Discovery of Spiro-azaindoline Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1). <i>ACS Medicinal Chemistry Letters</i> , 2022, 13, 84-91.	1.3	17
3208	Immunotherapy in non-small cell lung cancer: rationale, recent advances and future perspectives. <i>Precision Clinical Medicine</i> , 2021, 4, 258-270.	1.3	18
3209	Remodeling Chondroitin-6-Sulfate-Mediated Immune Exclusion Enhances Anti-PD-1 Response in Colorectal Cancer with Microsatellite Stability. <i>Cancer Immunology Research</i> , 2022, 10, 182-199.	1.6	8
3210	FasL ⁺ PD-L2 ⁺ Identifies a Novel Immunosuppressive Neutrophil Population in Human Gastric Cancer That Promotes Disease Progression. <i>Advanced Science</i> , 2022, 9, e2103543.	5.6	11
3211	Adjunctive Probiotic <i>Lactobacillus rhamnosus</i> Probio-M9 Administration Enhances the Effect of Anti-PD-1 Antitumor Therapy via Restoring Antibiotic-Disrupted Gut Microbiota. <i>Frontiers in Immunology</i> , 2021, 12, 772532.	2.2	47
3212	Development of a T-cell activation-related module with predictive value for the prognosis and immune checkpoint blockade therapy response in glioblastoma. <i>PeerJ</i> , 2021, 9, e12547.	0.9	1
3214	ENPEP as a potential predictor of immune checkpoint inhibitor efficacy. <i>Cancer Medicine</i> , 2022, 11, 880-887.	1.3	5
3215	Sustained and Long-Term Release of Doxorubicin from PLGA Nanoparticles for Eliciting Anti-Tumor Immune Responses. <i>Pharmaceutics</i> , 2022, 14, 474.	2.0	15
3216	A 25 Immune-Related Gene Pair Signature Predicts Overall Survival in Cervical Cancer. <i>Cancer Informatics</i> , 2022, 21, 117693512210909.	0.9	1

#	ARTICLE	IF	CITATIONS
3217	Virtual Populations for Quantitative Systems Pharmacology Models. <i>Methods in Molecular Biology</i> , 2022, 2486, 129-179.	0.4	13
3218	Applications of Quantitative System Pharmacology Modeling to Model-Informed Drug Development. <i>Methods in Molecular Biology</i> , 2022, 2486, 71-86.	0.4	0
3219	Conversion therapy with an immune checkpoint inhibitor and an antiangiogenic drug for advanced hepatocellular carcinoma: A review. <i>BioScience Trends</i> , 2022, 16, 130-141.	1.1	14
3220	Tumor Immunogenomic Features Determine Outcomes in Patients with Metastatic Colorectal Cancer Treated with Standard-of-Care Combinations of Bevacizumab and Cetuximab. <i>Clinical Cancer Research</i> , 2022, 28, 1690-1700.	3.2	7
3221	Peptides-Coated Oncolytic Vaccines for Cancer Personalized Medicine. <i>Frontiers in Immunology</i> , 2022, 13, 826164.	2.2	8
3222	Perspectives for Combining Viral Oncolysis With Additional Immunotherapies for the Treatment of Melanoma. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 777775.	1.6	3
3223	A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy. <i>Nature Nanotechnology</i> , 2022, 17, 531-540.	15.6	125
3224	Inhibitors of PD-1 in Non-Small Cell Lung Cancer: A Meta-Analysis of Clinical and Molecular Features. <i>Frontiers in Immunology</i> , 2022, 13, 875093.	2.2	10
3225	A Three-in-One Assembled Nanoparticle Containing Peptide-Radio-Sensitizer Conjugate and TLR7/8 Agonist Can Initiate the Cancer-Immunity Cycle to Trigger Antitumor Immune Response. <i>Small</i> , 2022, 18, e2107001.	5.2	21
3226	Development and Validation of TACE Refractoriness-Related Diagnostic and Prognostic Scores and Characterization of Tumor Microenvironment Infiltration in Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2022, 13, 869993.	2.2	16
3227	Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 4446-4457.	5.7	15
3228	The Role of Type-2 Conventional Dendritic Cells in the Regulation of Tumor Immunity. <i>Cancers</i> , 2022, 14, 1976.	1.7	27
3229	Ultrasound and microbubble-mediated drug delivery and immunotherapy. <i>Journal of Medical Ultrasonics (2001)</i> , 2022, , 1.	0.6	6
3230	Targeting TCTP sensitizes tumor to T cell-mediated therapy by reversing immune-refractory phenotypes. <i>Nature Communications</i> , 2022, 13, 2127.	5.8	7
3231	Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3356-3366.	3.2	13
3232	How Did Conventional Nanoparticle-Mediated Photothermal Therapy Become "Hot" in Combination with Cancer Immunotherapy?. <i>Cancers</i> , 2022, 14, 2044.	1.7	15
3233	Pyroptosis-Related Signature Predicts Prognosis and Immunotherapy Efficacy in Muscle-Invasive Bladder Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 782982.	2.2	19
3234	Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreatic cancer to chemotherapeutics. <i>Oncogene</i> , 2022, 41, 2764-2777.	2.6	26

#	ARTICLE	IF	CITATIONS
3235	A Physiologically Based Pharmacokinetic Framework for Quantifying Antibody Distribution Gradients from Tumors to Tumor-Draining Lymph Nodes. <i>Antibodies</i> , 2022, 11, 28.	1.2	1
3237	Evaluation of Prognostic Factors for Unresectable or Recurrent Gastric Cancer Treated with Nivolumab. <i>Journal of Gastrointestinal Cancer</i> , 2023, 54, 485-491.	0.6	3
3238	Protein Arginine Methylation: An Emerging Modification in Cancer Immunity and Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, 865964.	2.2	9
3239	Vitamin E Enhances Cancer Immunotherapy by Reinvigorating Dendritic Cells via Targeting Checkpoint SHP1. <i>Cancer Discovery</i> , 2022, 12, 1742-1759.	7.7	35
3240	The effect of local non-thermal plasma therapy on the cancer-immunity cycle in a melanoma mouse model. <i>Bioengineering and Translational Medicine</i> , 2022, 7, .	3.9	15
3241	Cytokine Based Immunotherapy for Cancer and Lymphoma: Biology, Challenges and Future Perspectives. <i>Frontiers in Immunology</i> , 2022, 13, 872010.	2.2	23
3242	Engineered cellular immunotherapies in cancer and beyond. <i>Nature Medicine</i> , 2022, 28, 678-689.	15.2	106
3243	Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directions. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 627-641.	1.4	19
3244	Mathematical modeling of radiotherapy and its impact on tumor interactions with the immune system. <i>Neoplasia</i> , 2022, 28, 100796.	2.3	15
3310	Direct and indirect regulation of the tumor immune microenvironment by VEGF. <i>Journal of Leukocyte Biology</i> , 2022, 111, 1269-1286.	1.5	28
3311	Dioscin potentiates the antitumor effect of suicide gene therapy in melanoma by gap junction intercellular communication-mediated antigen cross-presentation. <i>Biomedicine and Pharmacotherapy</i> , 2022, 150, 112973.	2.5	3
3312	PD-L1 siRNA-hyaluronic acid conjugate for dual-targeted cancer immunotherapy. <i>Journal of Controlled Release</i> , 2022, 346, 226-239.	4.8	16
3313	Antigen-derived peptides engage the ER stress sensor IRE1 α to curb dendritic cell cross-presentation. <i>Journal of Cell Biology</i> , 2022, 221, .	2.3	17
3317	Microscale thermophoresis analysis of the molecular interaction between small nuclear ribonucleoprotein polypeptide G and the RING finger domain of RBBP6 towards anti-cancer drug discovery.. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 12775-12785.	0.0	0
3318	Engaging Pattern Recognition Receptors in Solid Tumors to Generate Systemic Antitumor Immunity. <i>Cancer Treatment and Research</i> , 2022, 183, 91-129.	0.2	1
3319	Targeting tumor-associated macrophages for cancer immunotherapy. <i>International Review of Cell and Molecular Biology</i> , 2022, , 61-108.	1.6	13
3320	Diversification of circulating and tumor-infiltrating plasmacytoid DCs towards the P3 (CD80 ⁺ PDL1 ^{hi}) pDC subset negatively correlated with clinical outcomes in melanoma patients. <i>Clinical and Translational Immunology</i> , 2022, 11, e1382.	1.7	6
3322	A Biomathematical Model of Tumor Response to Radioimmunotherapy With α -PDL1 and α -CTLA4. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , 2023, 20, 808-821.	1.9	3

#	ARTICLE	IF	CITATIONS
3323	Current status and advances of immunotherapy in nasopharyngeal carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210962.	1.4	23
3324	Role of immune system in TNBC. , 2022, , 121-148.		8
3325	Immune escape mechanisms and therapeutic approaches in cancer: the cancer-immunity cycle. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210962.	1.4	21
3326	Immunomodulation by Gut Microbiome on Gastrointestinal Cancers: Focusing on Colorectal Cancer. <i>Cancers</i> , 2022, 14, 2140.	1.7	11
3327	CDC25C as a Predictive Biomarker for Immune Checkpoint Inhibitors in Patients With Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 867788.	1.3	3
3328	Immune response induced by hematoporphyrin derivatives mediated photodynamic therapy: Immunogenic cell death and elevated costimulatory molecules. <i>Journal of Innovative Optical Health Sciences</i> , 2022, 15, .	0.5	4
3329	Targeting PARP1 to Enhance Anticancer Checkpoint Immunotherapy Response: Rationale and Clinical Implications. <i>Frontiers in Immunology</i> , 2022, 13, 816642.	2.2	18
3330	A Combined Effect of G-Quadruplex and Neuro-Inducers as an Alternative Approach to Human Glioblastoma Therapy. <i>Frontiers in Oncology</i> , 2022, 12, 880740.	1.3	2
3331	Evidence of Omics, Immune Infiltration, and Pharmacogenomics for BATF in a Pan-Cancer Cohort. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 844721.	1.6	1
3332	Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	9
3333	Recent Reviews on Dendrimers as an Immunotherapy-based Nanosystem for the Effective Treatment of Cancer. <i>Drug Delivery Letters</i> , 2022, 12, 243-257.	0.2	2
3334	Cytokines: Can Cancer Get the Message?. <i>Cancers</i> , 2022, 14, 2178.	1.7	21
3335	Overcoming Chemotherapy Resistance in Germ Cell Tumors. <i>Biomedicines</i> , 2022, 10, 972.	1.4	8
3336	Resistance Mechanisms to Anti-PD Cancer Immunotherapy. <i>Annual Review of Immunology</i> , 2022, 40, 45-74.	9.5	122
3337	Engineering Cancer/Testis Antigens With Reversible S-Cationization to Evaluate Antigen Spreading. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	5
3338	The mutual relationship between the host immune system and radiotherapy: stimulating the action of immune cells by irradiation. <i>International Journal of Clinical Oncology</i> , 2023, 28, 201-208.	1.0	1
3339	Immunotherapy-Based Treatments of Hepatocellular Carcinoma: <i>AJR</i> Expert Panel Narrative Review. <i>American Journal of Roentgenology</i> , 2022, 219, 533-546.	1.0	6
3340	Mimicking tumor microenvironment by 3D bioprinting: 3D cancer modeling. <i>Biofabrication</i> , 2022, 14, 032002.	3.7	26

#	ARTICLE	IF	CITATIONS
3341	GATA3 Predicts the Tumor Microenvironment Phenotypes and Molecular Subtypes for Bladder Carcinoma. <i>Frontiers in Surgery</i> , 2022, 9, .	0.6	3
3342	Framework of Intrinsic Immune Landscape of Dormant Prostate Cancer. <i>Cells</i> , 2022, 11, 1550.	1.8	0
3343	Tumour immunotherapy: lessons from predatorâ€“prey theory. <i>Nature Reviews Immunology</i> , 2022, 22, 765-775.	10.6	41
3344	Targeting tumor extracellular matrix activates the tumor-draining lymph nodes. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2957-2968.	2.0	6
3345	Targeting the tumor biophysical microenvironment to reduce resistance to immunotherapy. <i>Advanced Drug Delivery Reviews</i> , 2022, 186, 114319.	6.6	35
3346	Radionuclide Imaging of Cytotoxic Immune Cell Responses to Anti-Cancer Immunotherapy. <i>Biomedicines</i> , 2022, 10, 1074.	1.4	3
3347	PD-L1 expression in Congolese women with triple negative breast cancer. <i>Journal of Cancer Prevention & Current Research</i> , 2022, 13, 61-63.	0.1	0
3348	Targeting pancreatic cancer immune evasion by inhibiting histone deacetylases. <i>World Journal of Gastroenterology</i> , 2022, 28, 1934-1945.	1.4	7
3349	Vaccine Therapy in Non-Small Cell Lung Cancer. <i>Vaccines</i> , 2022, 10, 740.	2.1	4
3350	Extricating human tumour immune alterations from tissue inflammation. <i>Nature</i> , 2022, 605, 728-735.	13.7	56
3351	Self-assembled nanospheres mediate phototherapy and deliver CpG oligodeoxynucleotides to enhance cancer immunotherapy of breast cancer and melanoma. <i>Nano Today</i> , 2022, 44, 101498.	6.2	17
3352	Local scaffold-assisted delivery of immunotherapeutic agents for improved cancer immunotherapy. <i>Advanced Drug Delivery Reviews</i> , 2022, 185, 114308.	6.6	23
3353	Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: A phase I study. <i>European Journal of Cancer</i> , 2022, 169, 20-31.	1.3	22
3354	Immunogenicity-boosted cancer immunotherapy based on nanoscale metal-organic frameworks. <i>Journal of Controlled Release</i> , 2022, 347, 183-198.	4.8	23
3355	Two distinct receptor-binding domains of human glycyl-tRNA synthetase 1 displayed on extracellular vesicles activate M1 polarization and phagocytic bridging of macrophages to cancer cells. <i>Cancer Letters</i> , 2022, 539, 215698.	3.2	6
3356	Immunity and Autoimmune system-a review. , 0, , 03-07.		0
3357	Prognostic Value of PD-L1 Immunohistochemical Marker in Gastric Carcinoma and Its Correlation with HER2 Status. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 1433-1444.	0.5	3
3358	Atezolizumab plus carboplatin and nabâ€“paclitaxel versus carboplatin and nabâ€“paclitaxel as treatments for Chinese, treatmentâ€“naïve, stage IV, nonâ€“squamous, nonâ€“smallâ€“cell lung cancer patients: A retrospective analysis. <i>Pharmacology Research and Perspectives</i> , 2022, 10, e00941.	1.1	1

#	ARTICLE	IF	CITATIONS
3359	Gene-Immune Therapy of Cancer: Approaches and Problems. Russian Journal of Genetics, 2022, 58, 491-506.	0.2	1
3360	Light-triggered photodynamic nanomedicines for overcoming localized therapeutic efficacy in cancer treatment. Advanced Drug Delivery Reviews, 2022, 186, 114344.	6.6	33
3361	All About (NK Cell-Mediated) Death in Two Acts and an Unexpected Encore: Initiation, Execution and Activation of Adaptive Immunity. Frontiers in Immunology, 2022, 13, .	2.2	23
3362	An optimal portfolio of photothermal combined immunotherapy. Cell Reports Physical Science, 2022, 3, 100898.	2.8	22
3363	Computational Discovery of Cancer Immunotherapy Targets by Intercellular CRISPR Screens. Frontiers in Immunology, 2022, 13, .	2.2	3
3364	Combination of Metal-Phenolic Network-Based Immunoactive Nanoparticles and Bipolar Irreversible Electroporation for Effective Cancer Immunotherapy. Small, 2022, 18, e2200316.	5.2	20
3365	Leveraging STING, Batf3 Dendritic Cells, CXCR3 Ligands, and Other Components Related to Innate Immunity to Induce A "Hot" Tumor Microenvironment That Is Responsive to Immunotherapy. Cancers, 2022, 14, 2458.	1.7	11
3366	Evolution of preclinical characterization and insights into clinical pharmacology of checkpoint inhibitors approved for cancer immunotherapy. Clinical and Translational Science, 2022, 15, 1818-1837.	1.5	4
3367	Cancer Immunoediting in the Era of Immuno-oncology. Clinical Cancer Research, 2022, 28, 3917-3928.	3.2	31
3369	Effect of Atezolizumab plus Bevacizumab in Patients with Hepatocellular Carcinoma Harboring <i>CTNNB1</i> Mutation in Early Clinical Experience. Journal of Cancer, 2022, 13, 2656-2661.	1.2	6
3370	Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non-small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial. Clinical Lung Cancer, 2022, 23, e415-e427.	1.1	7
3371	Harnessing the Immune System with Cancer Vaccines: From Prevention to Therapeutics. Vaccines, 2022, 10, 816.	2.1	7
3372	TGF β 2-Associated Signature Predicts Prognosis and Tumor Microenvironment Infiltration Characterization in Gastric Carcinoma. Frontiers in Genetics, 2022, 13, .	1.1	1
3373	Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies. Frontiers in Oncology, 2022, 12, .	1.3	5
3374	Nanomedicines and nanomaterials for cancer therapy: Progress, challenge and perspectives. Chemical Engineering Journal, 2022, 446, 137147.	6.6	35
3375	Cytokine chemokine network in tumor microenvironment: Impact on CSC properties and therapeutic applications. Cytokine, 2022, 156, 155916.	1.4	9
3376	Red Blood Cells-Based Vaccines for Ameliorating Cancer Chemoimmunotherapy. SSRN Electronic Journal, 0, , .	0.4	0
3377	Clinically approved combination immunotherapy: Current status, limitations, and future perspective. Current Research in Immunology, 2022, 3, 118-127.	1.2	20

#	ARTICLE	IF	CITATIONS
3378	Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 876-887.	5.1	83
3380	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. , 2022, 10, e003956.		16
3381	Turning cold tumors hot: from molecular mechanisms to clinical applications. <i>Trends in Immunology</i> , 2022, 43, 523-545.	2.9	176
3382	The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	94
3383	Clinical Relevance of Estrogen Reactivity in the Breast Cancer Microenvironment. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
3384	Current state and upcoming opportunities for immunoPET biomarkers in lung cancer. <i>Lung Cancer</i> , 2022, 169, 84-93.	0.9	3
3385	Evaluation PD-L1, CD8 and CD20 as early predictor and tracking markers for breast cancer (BC) in Egypt. <i>Heliyon</i> , 2022, 8, e09474.	1.4	1
3386	Towards Immunotherapy-Induced Normalization of the Tumor Microenvironment. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	1.8	7
3387	The Interplay of Four Main Pathways Recomposes Immune Landscape in Primary and Metastatic Gastroenteropancreatic Neuroendocrine Tumors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
3388	Combined analysis of T cell activation and T cell-mediated cytotoxicity by imaging cytometry. <i>Journal of Immunological Methods</i> , 2022, 506, 113290.	0.6	1
3390	The Efficacy of Cancer Immunotherapies Is Compromised by <i>Helicobacter pylori</i> Infection. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	14
3391	Cutaneous Breast Cancer Metastasis Is Effectively Treated With Intralesional Interleukin-2 and Imiquimod: A Case Report and Brief Literature Review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
3393	Bone Microenvironment-Suppressed T Cells Increase Osteoclast Formation and Osteolytic Bone Metastases in Mice. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 1446-1463.	3.1	11
3394	Lymphocytes in tumor-draining lymph nodes co-cultured with autologous tumor cells for adoptive cell therapy. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	7
3395	Comprehensive Analysis of a Cancer-Immunity Cycle-Based Signature for Predicting Prognosis and Immunotherapy Response in Patients With Colorectal Cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
3396	SAR131675, a VEGFR3 Inhibitor, Modulates the Immune Response and Reduces the Growth of Colorectal Cancer Liver Metastasis. <i>Cancers</i> , 2022, 14, 2715.	1.7	3
3397	Immunotherapy discovery on tumor organoid-on-a-chip platforms that recapitulate the tumor microenvironment. <i>Advanced Drug Delivery Reviews</i> , 2022, 187, 114365.	6.6	30
3398	Peptide vaccine-treated, long-term surviving cancer patients harbor self-renewing tumor-specific CD8+ T cells. <i>Nature Communications</i> , 2022, 13, .	5.8	8

#	ARTICLE	IF	CITATIONS
3399	Nanotechnology-Based Diagnostic and Therapeutic Strategies for Neuroblastoma. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	5
3400	Investigation of Tryptic Protein Digestion in Microdroplets and in Bulk Solution. <i>Journal of the American Society for Mass Spectrometry</i> , 2022, 33, 1238-1249.	1.2	14
3401	Targeting protein kinases benefits cancer immunotherapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188738.	3.3	5
3402	Integrative Analysis Identifies a TNF α -Derived Gene Signature for Predicting Prognosis, Tumor Immunity, and Treatment Sensitivity in Gastric Cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
3403	Profiling the Tumor-Infiltrating Lymphocytes in Gastric Cancer Reveals Its Implication in the Prognosis. <i>Genes</i> , 2022, 13, 1017.	1.0	2
3404	Neoadjuvant immunotherapy in gastrointestinal cancers – The new standard of care?. <i>Seminars in Cancer Biology</i> , 2022, 86, 834-850.	4.3	12
3405	Are there differences in the characteristics of patients who respond to gemcitabine plus cisplatin chemotherapy and those who respond to pembrolizumab therapy for metastatic urothelial carcinoma? Multicenter retrospective study. <i>International Journal of Urology</i> , 0, , .	0.5	1
3406	Circadian Rhythm Disruption Increases Tumor Growth Rate and Accumulation of Myeloid-Derived Suppressor Cells. <i>Advanced Biology</i> , 2022, 6, .	1.4	3
3407	KCNN4 is a Potential Biomarker for Predicting Cancer Prognosis and an Essential Molecule that Remodels Various Components in the Tumor Microenvironment: A Pan-Cancer Study. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, .	1.6	7
3408	Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency. <i>Advanced Science</i> , 2022, 9, .	5.6	140
3409	The immune response to major gastrointestinal cancer surgery and potential implications for adjuvant immunotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 175, 103729.	2.0	7
3410	Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment. <i>Advanced Drug Delivery Reviews</i> , 2022, 187, 114357.	6.6	20
3411	Recent advances in hyaluronic acid-based nanomedicines: Preparation and application in cancer therapy. <i>Carbohydrate Polymers</i> , 2022, 292, 119662.	5.1	35
3412	Magnetic hyperthermia induces effective and genuine immunogenic tumor cell death with respect to exogenous heating. <i>Journal of Materials Chemistry B</i> , 2022, 10, 5364-5374.	2.9	16
3413	Emerging insights to lung cancer drug resistance. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 534-40.	0.9	3
3414	Beyond Checkpoint Inhibitors: Enhancing Antitumor Immune Response in Lung Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 673-686.	1.8	3
3415	Update on Treatment of Renal Cell Carcinoma. <i>Journal of the Nihon University Medical Association</i> , 2022, 81, 77-81.	0.0	0
3416	Evaluation of physiological Waldeyer's ring, mediastinal blood pool, thymic, bone marrow, splenic and hepatic activity with 18F-FDG PET/CT: exploration of normal range among pediatric patients. <i>Annals of Nuclear Medicine</i> , 2022, 36, 661-673.	1.2	0

#	ARTICLE	IF	CITATIONS
3417	Selection of RNA-based evaluation methods for tumor microenvironment by comparing with histochemical and flow cytometric analyses in gastric cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
3418	Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. , 2022, 1, .		298
3419	Taming metabolic competition via glycolysis inhibition for safe and potent tumor immunotherapy. <i>Biochemical Pharmacology</i> , 2022, 202, 115153.	2.0	12
3420	Single-Cell Proteomics: The Critical Role of Nanotechnology. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6707.	1.8	9
3421	Tracing New Landscapes in the Arena of Nanoparticle-Based Cancer Immunotherapy. <i>Frontiers in Nanotechnology</i> , 0, 4, .	2.4	3
3422	How to Treat Renal Cell Carcinoma. <i>JACC: CardioOncology</i> , 2022, 4, 271-275.	1.7	3
3423	APOBEC Alteration Contributes to Tumor Growth and Immune Escape in Pan-Cancer. <i>Cancers</i> , 2022, 14, 2827.	1.7	11
3424	PRLHR Immune Genes Associated With Tumor Mutation Burden can be Used as Prognostic Markers in Patients With Gliomas. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
3425	Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer. <i>Molecules</i> , 2022, 27, 3798.	1.7	29
3426	Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio in Hepatocellular Carcinoma Treated with Stereotactic Body Radiotherapy. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2022, 79, 252-259.	0.2	2
3427	Vaccines for immunoprevention of DNA mismatch repair deficient cancers. , 2022, 10, e004416.		21
3428	Recent advances in porous nanomaterials-based drug delivery systems for cancer immunotherapy. <i>Journal of Nanobiotechnology</i> , 2022, 20, .	4.2	19
3429	Impaired Antitumor Immune Response in <i>MYCN</i> -amplified Neuroblastoma Is Associated with Lack of CCL2 Secretion and Poor Dendritic Cell Recruitment. <i>Cancer Research Communications</i> , 2022, 2, 577-589.	0.7	3
3430	Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
3431	Extracellular Vesicle-Based Drug Delivery Systems for Enhanced Antitumor Therapies through Modulating the Cancer Immunity Cycle. <i>Advanced Materials</i> , 2022, 34, .	11.1	43
3432	Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	33
3433	Cancer immunohistogram representing cancer-immunity cycle by immunohistochemistry predicts the efficacy of immune checkpoint inhibitors in urological cancer patients. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
3434	Bifunctional scaffolds for tumor therapy and bone regeneration: Synergistic effect and interplay between therapeutic agents and scaffold materials. <i>Materials Today Bio</i> , 2022, 15, 100318.	2.6	8

#	ARTICLE	IF	CITATIONS
3435	The immune cell atlas of human neuroblastoma. <i>Cell Reports Medicine</i> , 2022, 3, 100657.	3.3	17
3436	Myeloid cell-targeted therapies for solid tumours. <i>Nature Reviews Immunology</i> , 2023, 23, 106-120.	10.6	74
3437	Predictive Biomarkers of Severe Immune-Related Adverse Events With Immune Checkpoint Inhibitors: Prevention, Underlying Causes, Intensity, and Consequences. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	3
3438	Drug Resistance in Colorectal Cancer: From Mechanism to Clinic. <i>Cancers</i> , 2022, 14, 2928.	1.7	34
3439	Automated detection of vascular remodeling in tumor-draining lymph nodes by the deep learning tool <sc>HEV</sc> finder. <i>Journal of Pathology</i> , 0, , .	2.1	1
3440	Systematic co-delivery of dual agonists to enhance cancer immunotherapy. <i>Nano Research</i> , 2022, 15, 8326-8335.	5.8	9
3441	Chemokines and chemokine receptors in colorectal cancer; multifarious roles and clinical impact. <i>Seminars in Cancer Biology</i> , 2022, 86, 436-449.	4.3	16
3442	Plac1 Remodels the Tumor Immune Evasion Microenvironment and Predicts Therapeutic Response in Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
3443	Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances. <i>World Journal of Clinical Oncology</i> , 2022, 13, 448-472.	0.9	6
3444	Anti programmed death-ligand 1 antibody-related cholangitis without bile duct dilation or stenosis. <i>Clinical Journal of Gastroenterology</i> , 0, , .	0.4	1
3445	Lenalidomide bypasses CD28 co-stimulation to reinstate PD-1 immunotherapy by activating Notch signaling. <i>Cell Chemical Biology</i> , 2022, 29, 1260-1272.e8.	2.5	5
3446	Impact of Adding Vascular Endothelial Growth Factor Inhibitor to Immune Checkpoint Inhibitor Therapy. <i>Journal of Thoracic Oncology</i> , 2022, 17, 865-866.	0.5	0
3447	Innovative cancer nanomedicine based on immunology, gene editing, intracellular trafficking control. <i>Journal of Controlled Release</i> , 2022, 348, 357-369.	4.8	3
3448	Glycosylation modification identifies novel molecular phenotypes and prognostic stratifications of glioma. <i>Gene</i> , 2022, 836, 146677.	1.0	0
3451	Integrative pharmacogenomics revealed three subtypes with different immune landscapes and specific therapeutic responses in lung adenocarcinoma. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 3449-3460.	1.9	3
3454	The Predictive Value of Peripheral Immune Cell Counts for the Presence of Brain Metastases in Stage IV Non-Small-Cell Lung Cancer (NSCLC). <i>Avicenna Journal of Medicine</i> , 2022, 12, 067-072.	0.3	2
3455	The Role of Immune Checkpoints in Cancer Progression. , 0, , .		0
3456	ICIs-Related Cardiotoxicity in Different Types of Cancer. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 203.	0.8	11

#	ARTICLE	IF	CITATIONS
3457	ImmunoPET: Antibody-Based PET Imaging in Solid Tumors. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	11
3458	Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
3459	Crosstalk between angiogenesis and immune regulation in the tumor microenvironment. <i>Archives of Pharmacal Research</i> , 2022, 45, 401-416.	2.7	32
3460	The cellular and molecular basis of CD69 function in anti-tumor immunity. <i>International Immunology</i> , 2022, 34, 555-561.	1.8	11
3461	Recent Discoveries on Marine Organism Immunomodulatory Activities. <i>Marine Drugs</i> , 2022, 20, 422.	2.2	14
3462	Emerging insights on immunotherapy in liver cancer. <i>Antioxidants and Redox Signaling</i> , 0, , .	2.5	4
3463	Enhancement of antitumor immune response by radiation therapy combined with dual immune checkpoint inhibitor in a metastatic model of HER2-positive murine tumor. <i>Japanese Journal of Radiology</i> , 2022, 40, 1307-1315.	1.0	1
3464	Single-Cell RNA Sequencing Reveals the Tissue Architecture in Human High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3590-3602.	3.2	57
3465	¹⁸ F FDG PET/CT and Novel Molecular Imaging for Directing Immunotherapy in Cancer. <i>Radiology</i> , 2022, 304, 246-264.	3.6	14
3466	Successful secondary radical operation on unresectable metastatic platinum-sensitive recurrent ovarian cancer by immunotherapy: a case report. <i>Annals of Translational Medicine</i> , 2022, 10, 718-718.	0.7	1
3467	Research progress on immunotherapy in triple-negative breast cancer (Review). <i>International Journal of Oncology</i> , 2022, 61, .	1.4	9
3468	Bioinformatics analysis of SOXF family genes reveals potential regulatory mechanism and diagnostic value in cancers. <i>Annals of Translational Medicine</i> , 2022, 10, 701-701.	0.7	2
3469	Roles of exosomal circRNAs in tumour immunity and cancer progression. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	20
3470	Dendritic cell-mediated cross presentation of tumor-derived peptides is biased against plasma membrane proteins. , 2022, 10, e004159.		5
3471	SFRP4 Is a Potential Biomarker for the Prognosis and Immunotherapy for Gastric Cancer. <i>Journal of Oncology</i> , 2022, 2022, 1-15.	0.6	2
3472	CpG ODN (K3) toll-like receptor 9 agonist induces Th1-type immune response and enhances cytotoxic activity in advanced lung cancer patients: a phase I study. <i>BMC Cancer</i> , 2022, 22, .	1.1	7
3473	Tumor cells dictate anti-tumor immune responses by altering pyruvate utilization and succinate signaling in CD8+ T cells. <i>Cell Metabolism</i> , 2022, 34, 1137-1150.e6.	7.2	78
3474	Innate immunity as a target for novel therapeutics in triple negative breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 781-794.	1.9	2

#	ARTICLE	IF	CITATIONS
3475	Primary and Acquired Resistance against Immune Check Inhibitors in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 3294.	1.7	4
3476	Cancer-targeted photoimmunotherapy induces antitumor immunity and can be augmented by anti-PD-1 therapy for durable anticancer responses in an immunologically active murine tumor model. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 151-168.	2.0	6
3477	Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 855-874.	1.9	2
3478	Age-dependent genomic characteristics and their impact on immunotherapy in lung adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	3
3479	Identification of Endoplasmic Reticulum Stress-Related Subtypes, Infiltration Analysis of Tumor Microenvironment, and Construction of a Prognostic Model in Colorectal Cancer. <i>Cancers</i> , 2022, 14, 3326.	1.7	2
3480	Mechanisms of resistance to immune checkpoint inhibitors. <i>Cancer Science</i> , 2022, 113, 3303-3312.	1.7	12
3481	Cancer vaccines: Building a bridge over troubled waters. <i>Cell</i> , 2022, 185, 2770-2788.	13.5	82
3482	An Integrated Analysis of Prognostic Signature and Immune Microenvironment in Tongue Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
3483	Cross-Talk of Multiple Types of RNA Modification Regulators Uncovers the Tumor Microenvironment and Immune Infiltrates in Soft Tissue Sarcoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	15
3484	Comprehensive Analysis of Immune-Related Metabolic Genes in Lung Adenocarcinoma. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	1
3485	Design, synthesis, and structure-activity relationships of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as inhibitors of the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) immune checkpoint pathway. <i>Medicinal Chemistry Research</i> , 0, , .	1.1	0
3486	Complement activation in cancer: Effects on tumor-associated myeloid cells and immunosuppression. <i>Seminars in Immunology</i> , 2022, 60, 101642.	2.7	9
3487	Tumor-derived exosomes in the cancer immune microenvironment and cancer immunotherapy. <i>Cancer Letters</i> , 2022, 548, 215823.	3.2	21
3488	Immune response to primary glioblastoma. <i>Pediatrician (St Petersburg)</i> , 2022, 13, 49-60.	0.1	2
3489	Improved anti-solid tumor response by humanized anti-podoplanin chimeric antigen receptor transduced human cytotoxic T cells in an animal model. <i>Genes To Cells</i> , 2022, 27, 549-558.	0.5	12
3490	The role of imaging in targeted delivery of nanomedicine for cancer therapy. <i>Advanced Drug Delivery Reviews</i> , 2022, 189, 114447.	6.6	24
3491	TransCon IL-2 \hat{I}^2/\hat{I}^3 : a novel long-acting prodrug with sustained release of an IL-2R \hat{I}^2/\hat{I}^3 -selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer. , 2022, 10, e004991.		15
3492	CD47/SIRP \hat{I}^{\pm} axis: bridging innate and adaptive immunity. , 2022, 10, e004589.		25

#	ARTICLE	IF	CITATIONS
3493	DeCAF: a novel method to identify cell-type specific regulatory variants and their role in cancer risk. <i>Genome Biology</i> , 2022, 23, .	3.8	1
3494	Natural killer cell awakening: unleash cancer-immunity cycle against glioblastoma. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	15
3495	A Novel Therapeutic Tumor Vaccine Targeting MUC1 in Combination with PD-L1 Elicits Specific Anti-Tumor Immunity in Mice. <i>Vaccines</i> , 2022, 10, 1092.	2.1	3
3496	Validation of the Optimum Timing of Assessment of Tumor Infiltrating Lymphocytes During Preoperative Chemotherapy for Breast Cancer. <i>Cancer Diagnosis & Prognosis</i> , 2022, 2, 443-451.	0.3	0
3497	An Immune-Related Gene Signature Can Predict Clinical Outcomes and Immunotherapeutic Response in Oral Squamous Cell Carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	5
3498	The Role of Immunotherapy in the Management of Soft Tissue Sarcomas: Current Landscape and Future Outlook. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 834-844.	2.3	11
3499	Development and Validation of a 6-Gene Hypoxia-Related Prognostic Signature For Cholangiocarcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
3500	Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	58
3501	Extrahepatic targeting of lipid nanoparticles in vivo with intracellular targeting for future nanomedicines. <i>Advanced Drug Delivery Reviews</i> , 2022, 188, 114417.	6.6	42
3502	CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	48
3503	Mesoporous Silica Materials as an Emerging Tool for Cancer Immunotherapy. <i>Advanced Science</i> , 2022, 9, .	5.6	18
3504	Metabolic signatures associated with oncolytic myxoma viral infections. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
3505	Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	13
3506	Potential association factors for developing effective peptide-based cancer vaccines. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
3507	Simulations of tumor growth and response to immunotherapy by coupling a spatial agent-based model with a whole-patient quantitative systems pharmacology model. <i>PLoS Computational Biology</i> , 2022, 18, e1010254.	1.5	17
3508	Psychological Impact of COVID-19 on Oncology Patients: Perceptions of Oncology Health Care Providers. <i>Western Journal of Nursing Research</i> , 2023, 45, 152-160.	0.6	0
3509	Targeting the antigen processing and presentation pathway to overcome resistance to immune checkpoint therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
3510	Distinct Predictive Immunogenomic Profiles of Response to Immune Checkpoint Inhibitors and IL2: A Real-world Evidence Study of Patients with Advanced Renal Cancer. <i>Cancer Research Communications</i> , 2022, 2, 894-903.	0.7	0

#	ARTICLE	IF	CITATIONS
3511	Targeting PD-1/PD-L1 axis as new horizon for ovarian cancer therapy. <i>Life Sciences</i> , 2022, 306, 120827.	2.0	11
3512	Resident Immune Cells of the Liver in the Tumor Microenvironment. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	10
3513	Emerging advances in nanomedicine for breast cancer immunotherapy: opportunities and challenges. <i>Immunotherapy</i> , 2022, 14, 957-983.	1.0	3
3514	Discovery and Characterization of a Novel Aryl Hydrocarbon Receptor Inhibitor, IK-175, and Its Inhibitory Activity on Tumor Immune Suppression. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1261-1272.	1.9	7
3515	Neuropilin (NRPs) Related Pathological Conditions and Their Modulators. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8402.	1.8	7
3516	PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine. <i>Nature Immunology</i> , 2022, 23, 1183-1192.	7.0	36
3517	Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 1167-1179.	5.1	79
3518	Molecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP. <i>Targeted Oncology</i> , 2022, 17, 407-431.	1.7	8
3519	Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic viruses. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	8
3520	Differential Expression and Prognostic Correlation of Immune Related Factors Between Right and Left Side Colorectal Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
3521	Immunotherapy: Reshape the Tumor Immune Microenvironment. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	77
3522	Immunotherapy landscape analyses of necroptosis characteristics for breast cancer patients. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	9
3523	Histone Deacetylase Inhibitors Restore Cancer Cell Sensitivity towards T Lymphocytes Mediated Cytotoxicity in Pancreatic Cancer. <i>Cancers</i> , 2022, 14, 3709.	1.7	3
3524	Radiotherapy combined with immunotherapy: the dawn of cancer treatment. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	142
3525	Bojungikki-Tang Enhances the Effect of PD-1 Blockade in a Syngeneic Murine Model of Lung Carcinoma. <i>Processes</i> , 2022, 10, 1683.	1.3	0
3526	Identification of ferroptosis-related signature with potential implications in prognosis and immunotherapy of renal cell carcinoma. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2022, 27, 946-960.	2.2	2
3527	Identification of immune-related and autophagy-related genes for the prediction of survival in bladder cancer. <i>BMC Genomic Data</i> , 2022, 23, .	0.7	2
3528	Oncogene or tumor suppressor gene: An integrated pan-cancer analysis of NBPF1. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	1

#	ARTICLE	IF	CITATIONS
3529	Aging-based molecular classification and score system in ccRCC uncovers distinct prognosis, tumor immunogenicity, and treatment sensitivity. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
3531	NAPSB as a predictive marker for prognosis and therapy associated with an immuno-hot tumor microenvironment in hepatocellular carcinoma. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	3
3532	Poly lactic-co-glycolic acid-based nanoparticles as delivery systems for enhanced cancer immunotherapy. <i>Frontiers in Chemistry</i> , 0, 10, .	1.8	8
3533	The potential of gas plasma technology for targeting breast cancer. <i>Clinical and Translational Medicine</i> , 2022, 12, .	1.7	9
3534	Pericyte mediates the infiltration, migration, and polarization of macrophages by CD163/MCAM axis in glioblastoma. <i>IScience</i> , 2022, , 104918.	1.9	1
3535	Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer. <i>Nature Medicine</i> , 2022, 28, 1646-1655.	15.2	42
3536	Nano-Chemotherapy synergize with immune checkpoint inhibitor- A better option?. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
3537	Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights. <i>Acta Pharmacologica Sinica</i> , 2023, 44, 288-307.	2.8	14
3538	Emerging Immune-Monitoring System for Immune Checkpoint Inhibitors. <i>Life</i> , 2022, 12, 1229.	1.1	4
3539	Application of lipid-based nanoparticles in cancer immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
3540	Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
3541	Adverse Renal Effects of Anticancer Immunotherapy: A Review. <i>Cancers</i> , 2022, 14, 4086.	1.7	3
3542	EMT-Related Gene Signature Predicts the Prognosis in Uveal Melanoma Patients. <i>Journal of Oncology</i> , 2022, 2022, 1-19.	0.6	5
3543	Immune Checkpoint Inhibitors for Vaccine Improvements: Current Status and New Approaches. <i>Pharmaceutics</i> , 2022, 14, 1721.	2.0	10
3545	Phase 1b clinical trial of pucotenlimab (HX008), a novel anti-PD-1 monoclonal antibody, combined with gemcitabine and cisplatin in the first-line treatment of metastatic triple-negative breast cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
3546	Hyperprogressive disease in patients suffering from solid malignancies treated by immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
3547	The time window for the reversal of depigmentation from aggravation to recovery in a non-small-cell lung cancer patient with pre-existing vitiligo using anti-programmed cell death-1 therapy: A case report. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
3548	Research advances in nanomedicine applied to the systemic treatment of colorectal cancer. <i>International Journal of Cancer</i> , 2023, 152, 807-821.	2.3	5

#	ARTICLE	IF	CITATIONS
3549	Neuromuscular junction dysfunctions due to immune checkpoint inhibitors therapy: An analysis of FAERS data in the past 15 years. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
3551	De-risking clinical trial failure through mechanistic simulation. <i>Immunotherapy Advances</i> , 2022, 2, .	1.2	2
3552	CKD-516 potentiates the anti-cancer activity of docetaxel against epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer. <i>Toxicological Research</i> , 2023, 39, 61-69.	1.1	1
3553	The Landscape of Early Growth Response Family Members 1-4 in Hepatocellular Carcinoma: Their Biological Roles and Diagnostic Utility. <i>Disease Markers</i> , 2022, 2022, 1-8.	0.6	1
3554	Iron-based nanoscale coordination polymers synergistically induce immunogenic ferroptosis by blocking dihydrofolate reductase for cancer immunotherapy. <i>Biomaterials</i> , 2022, 288, 121724.	5.7	21
3555	CD8 T cell function and cross-reactivity explored by stepwise increased peptide-HLA versus TCR affinity. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
3556	Dendritic Cell-Based Vaccines Against Cancer: Challenges, Advances and Future Opportunities. <i>Immunological Investigations</i> , 2022, 51, 2133-2158.	1.0	20
3557	Triple negative breast cancer: Pitfalls and progress. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	110
3558	Tislelizumab in combination with gemcitabine plus cisplatin chemotherapy as first-line adjuvant treatment for locally advanced or metastatic bladder cancer: a retrospective study. <i>BMC Urology</i> , 2022, 22, .	0.6	6
3559	Machine learning algorithm-generated and multi-center validated melanoma prognostic signature with inspiration for treatment management. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 599-615.	2.0	4
3560	Bioinformatic analysis of RNA-seq data from TCGA database reveals prognostic significance of immune-related genes in colon cancer. <i>Medicine (United States)</i> , 2022, 101, e29962.	0.4	0
3561	STUB1 is an intracellular checkpoint for interferon gamma sensing. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
3562	Ablation of NLRP3 inflammasome rewires MDSC function and promotes tumor regression. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
3563	Temporally restricted activation of IFN γ signaling underlies response to immune checkpoint therapy in mice. <i>Nature Communications</i> , 2022, 13, .	5.8	12
3564	Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
3566	Cuproptosis-related gene index: A predictor for pancreatic cancer prognosis, immunotherapy efficacy, and chemosensitivity. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	24
3567	Glycan targeting nanoparticle for photodynamic immunotherapy of melanoma. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 1903-1918.	5.7	7
3568	A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100388.	0.6	4

#	ARTICLE	IF	CITATIONS
3569	Nanocarrier Co-formulation for Delivery of a TLR7 Agonist plus an Immunogenic Cell Death Stimulus Triggers Effective Pancreatic Cancer Chemo-immunotherapy. <i>ACS Nano</i> , 2022, 16, 13168-13182.	7.3	20
3570	A novel signature to predict thyroid cancer prognosis and immune landscape using immune-related LncRNA pairs. <i>BMC Medical Genomics</i> , 2022, 15, .	0.7	1
3571	Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2022, 21, 420-429.	0.6	9
3572	Construction and experimental verification of user-friendly molecular subtypes mediated by immune-associated genes in hepatocellular carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
3573	Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
3574	Characterization of anti-CD79b/CD3 bispecific antibody, a potential therapy for B cell malignancies. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 493-507.	2.0	4
3575	Comprehensive analyses unveil novel genomic and immunological characteristics of micropapillary pattern in lung adenocarcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
3576	m6A-Related lncRNA Signature Is Involved in Immunosuppression and Predicts the Patient Prognosis of the Age-Associated Ovarian Cancer. <i>Journal of Immunology Research</i> , 2022, 2022, 1-16.	0.9	3
3577	Robust pyroptosis risk score guides the treatment options and predicts the prognosis of bladder carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
3578	Prognostic alternative splicing events related splicing factors define the tumor microenvironment and pharmacogenomic landscape in lung adenocarcinoma. <i>Aging</i> , 2022, 14, 6689-6715.	1.4	2
3579	Soluble Immune Checkpoint Protein CD27 Is a Novel Prognostic Biomarker of Hepatocellular Carcinoma Development in Hepatitis C Virus-“Sustained Virological Response Patients. <i>American Journal of Pathology</i> , 2022, 192, 1379-1396.	1.9	4
3580	Indocyanine green conjugated phototheranostic nanoparticle for photodiagnosis and photodynamic therapy. <i>Photodiagnosis and Photodynamic Therapy</i> , 2022, 39, 103041.	1.3	4
3581	Annexin A5 as a targeting agent for cancer treatment. <i>Cancer Letters</i> , 2022, 547, 215857.	3.2	11
3582	Anti-tumor effect of aquaporin 3 monoclonal antibody on syngeneic mouse tumor model. <i>Translational Oncology</i> , 2022, 24, 101498.	1.7	2
3583	Intratumoral xenogeneic tissue-specific cell immunotherapy inhibits tumor growth by increasing antitumor immunity in murine triple negative breast and pancreatic tumor models. <i>Cancer Letters</i> , 2022, 545, 115478.	3.2	8
3584	Icaritin and intratumoral injection of CpG treatment synergistically promote T cell infiltration and antitumor immune response in mice. <i>International Immunopharmacology</i> , 2022, 111, 109093.	1.7	6
3585	The trilogy of P21 activated kinase, autophagy and immune evasion in pancreatic ductal adenocarcinoma. <i>Cancer Letters</i> , 2022, 548, 215868.	3.2	9
3586	Personalized Targeted Therapeutic Strategies against Oral Squamous Cell Carcinoma. An Evidence-Based Review of Literature. <i>International Journal of Nanomedicine</i> , 0, Volume 17, 4293-4306.	3.3	10

#	ARTICLE	IF	CITATIONS
3587	Identification of Prognostic Signature of Necroptosis-Related lncRNAs and Molecular Subtypes in Glioma. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-21.	0.7	1
3588	Landscape of prognosis and immunotherapy responsiveness under tumor glycosylation-related lncRNA patterns in breast cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
3589	Reprogramming dysfunctional dendritic cells by a versatile metabolism nano-intervenor for enhancing cancer combinatorial immunotherapy. <i>Nano Today</i> , 2022, 46, 101618.	6.2	5
3590	Concordance of PD-L1 expression in triple-negative breast cancers in Chinese patients: A retrospective and pathologist-based study. <i>Pathology Research and Practice</i> , 2022, 238, 154137.	1.0	1
3591	Hot and cold tumor: Recent developments and perspectives on oral cancer. <i>Oral Oncology</i> , 2022, 134, 106114.	0.8	1
3592	Combination of apatinib with apo-IDO1 inhibitor for the treatment of colorectal cancer. <i>International Immunopharmacology</i> , 2022, 112, 109233.	1.7	2
3593	Diagnostic Applications of Nuclear Medicine: Gastric Cancers. , 2022, , 1-18.		0
3594	Mechanisms of Action of Radiotherapy and Immunotherapy in Lung Cancer: Implications for Clinical Practice. <i>Medical Radiology</i> , 2022, , .	0.0	1
3595	Engineering neoantigen vaccines to improve cancer personalized immunotherapy. <i>International Journal of Biological Sciences</i> , 2022, 18, 5607-5623.	2.6	15
3596	Diagnostic Applications of Nuclear Medicine: Gastric Cancers. , 2022, , 829-846.		0
3597	Machine learning-based identification of tumor-infiltrating immune cell-associated lncRNAs for improving outcomes and immunotherapy responses in patients with low-grade glioma. <i>Theranostics</i> , 2022, 12, 5931-5948.	4.6	57
3598	Identification of circadian clock genes as regulators of immune infiltration in Hepatocellular Carcinoma. <i>Journal of Cancer</i> , 2022, 13, 3199-3208.	1.2	4
3599	Dynamic alteration and prognostic significance of tumor-associated CD68 ⁺ and CD68 ⁺ PD-L1 ⁺ macrophages in muscle-invasive bladder cancer treated with neoadjuvant chemotherapy. <i>Cancer Medicine</i> , 0, , .	1.3	1
3600	Structural Basis of a Novel Agonistic Anti-OX40 Antibody. <i>Biomolecules</i> , 2022, 12, 1209.	1.8	2
3601	Alum-anchored intratumoral retention improves the tolerability and antitumor efficacy of type I interferon therapies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	15
3602	Identification and validation of roles of lysyl oxidases in the predictions of prognosis, chemotherapy and immunotherapy in glioma. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
3603	Discovery and characterization of tumor antigens in hepatocellular carcinoma for mRNA vaccine development. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 4047-4061.	1.2	2
3604	Gemcitabine combined with apatinib and toripalimab in recurrent or metastatic nasopharyngeal carcinoma. <i>Med</i> , 2022, 3, 664-681.e6.	2.2	5

#	ARTICLE	IF	CITATIONS
3605	Lipid Nanoparticles for mRNA Delivery to Enhance Cancer Immunotherapy. <i>Molecules</i> , 2022, 27, 5607.	1.7	12
3606	Cancer Metabolism and Ischemia-Reperfusion Injury: Two Sides of the Same Coin. <i>Journal of Clinical Medicine</i> , 2022, 11, 5096.	1.0	3
3607	Impact of Lymph Node Dissection on Programmed Death 1/ Programmed Death Ligand 1 Inhibitor Therapy in Postoperative Recurrence of Non-small cell Lung Cancer. <i>Japanese Journal of Lung Cancer</i> , 2022, 62, 304-310.	0.0	0
3608	A robust CD8+ T cell-related classifier for predicting the prognosis and efficacy of immunotherapy in stage III lung adenocarcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
3609	The Prognostic Role of Cuproptosis in Head and Neck Squamous Cell Carcinoma Patients: A Comprehensive Analysis. <i>Disease Markers</i> , 2022, 2022, 1-32.	0.6	3
3610	Tumorous expression of NAC1 restrains antitumor immunity through the LDHA-mediated immune evasion. , 2022, 10, e004856.		8
3611	VG161 activates systemic antitumor immunity in pancreatic cancer models as a novel oncolytic herpesvirus expressing multiple immunomodulatory transgenes. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	6
3612	Can EGFR be a therapeutic target in breast cancer?. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188789.	3.3	14
3613	Harnessing Self-Cyclic Cascade System for Reactive Oxygen Species-Boosted Photothermal Immunotherapy. <i>Chemistry of Materials</i> , 2022, 34, 8219-8229.	3.2	2
3614	Incorporating Immunotherapy in the Management of Gastric Cancer: Molecular and Clinical Implications. <i>Cancers</i> , 2022, 14, 4378.	1.7	3
3615	Tumor accomplice: T cell exhaustion induced by chronic inflammation. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
3616	Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	35
3617	Boosting the Immune Response—Combining Local and Immune Therapy for Prostate Cancer Treatment. <i>Cells</i> , 2022, 11, 2793.	1.8	3
3618	Machine learning-based tumor-infiltrating immune cell-associated lncRNAs for predicting prognosis and immunotherapy response in patients with glioblastoma. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	45
3620	Novel macrophage-related gene prognostic index for glioblastoma associated with M2 macrophages and T cell dysfunction. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
3621	GSTA4 Governs Melanoma Immune Resistance and Metastasis. <i>Molecular Cancer Research</i> , 2023, 21, 76-85.	1.5	0
3622	Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
3623	Immunogenic cell death related risk model to delineate ferroptosis pathway and predict immunotherapy response of patients with GBM. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4

#	ARTICLE	IF	CITATIONS
3624	Prognosis-related genes participate in immunotherapy of renal clear cell carcinoma possibly by targeting dendritic cells. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	4
3625	Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2022, 17, 1335-1354.	0.5	40
3626	Clinical predictive value of naïve and memory T cells in advanced NSCLC. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
3627	Artificial Intelligence Meets Whole Slide Images: Deep Learning Model Shapes an Immune-Hot Tumor and Guides Precision Therapy in Bladder Cancer. <i>Journal of Oncology</i> , 2022, 2022, 1-27.	0.6	4
3628	The hypoxia-related signature predicts prognosis, pyroptosis and drug sensitivity of osteosarcoma. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	3
3629	Gamma radiation in association with moderate training reduce the effects of asthma in mice. <i>Brazilian Journal of Radiation Sciences</i> , 2022, 10, .	0.0	0
3630	Plasmacytoid Dendritic Cells as a Novel Cell-Based Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11397.	1.8	10
3631	Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC). , 2022, 10, e005413.		6
3632	Nucleic acid-triggered tumoral immunity propagates pH-selective therapeutic antibodies through tumor-driven epitope spreading. <i>Cancer Science</i> , 2023, 114, 321-338.	1.7	2
3633	Effects of tumor-infiltrating CD8+ T cells, PD1/PD-L1 axis, and expression patterns of HLA class I on the prognosis of patients with malignant pleural mesothelioma who underwent extra-pleural pneumonectomy. <i>Cancer Immunology, Immunotherapy</i> , 0, , .	2.0	2
3634	Novel cellular therapies for hepatobiliary malignancies. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2022, , .	0.6	1
3635	Comprehensive analysis of LAMC1 expression and prognostic value in kidney renal papillary cell carcinoma and clear cell carcinoma. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	5
3636	Combination immunotherapy for pancreatic cancer: challenges and future considerations. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 1173-1186.	1.3	4
3637	Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
3638	Intratumoral delivery of TransCon, TLR7/8 Agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine induction. <i>Cancer Cell International</i> , 2022, 22, .	1.8	9
3639	METTL16 predicts a favorable outcome and primes antitumor immunity in pancreatic ductal adenocarcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	6
3640	Engaging innate immunity for targeting the epidermal growth factor receptor: Therapeutic options leveraging innate immunity versus adaptive immunity versus inhibition of signaling. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
3641	Elicitation of stem-like CD8 ⁺ T cell responses via lymph node-targeted chemoimmunotherapy evokes systemic tumor control. , 2022, 10, e005079.		2

#	ARTICLE	IF	CITATIONS
3642	Therapeutic strategies for gastric cancer targeting immune cells: Future directions. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	12
3643	Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade. <i>Nature Cancer</i> , 2022, 3, 1123-1136.	5.7	71
3644	Multi-functional extracellular vesicles: Potentials in cancer immunotherapy. <i>Cancer Letters</i> , 2022, 551, 215934.	3.2	2
3645	An EMT-based risk score thoroughly predicts the clinical prognosis, tumor immune microenvironment and molecular subtypes of bladder cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
3646	Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury. <i>Nature Reviews Nephrology</i> , 2022, 18, 794-805.	4.1	20
3647	Nanoformulation improves antitumor efficacy of MAOI immune checkpoint blockade therapy without causing aggression-related side effects. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
3648	Cord Blood-Derived Natural Killer Cell Exploitation in Immunotherapy Protocols: More Than a Promise?. <i>Cancers</i> , 2022, 14, 4439.	1.7	6
3649	Role of 5-methylcytosine in determining the prognosis, tumor microenvironment, and applicability of precision medicine in patients with hepatocellular carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
3650	IL-10 in cancer: an essential thermostatic regulator between homeostatic immunity and inflammation – a comprehensive review. <i>Future Oncology</i> , 2022, 18, 3349-3365.	1.1	9
3651	Anti-cancer activity of human gastrointestinal bacteria. , 2022, 39, .		2
3652	The new progress in cancer immunotherapy. <i>Clinical and Experimental Medicine</i> , 2023, 23, 553-567.	1.9	6
3653	Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 4616.	1.7	18
3654	A Bioinformatic Approach to Enhance Undergraduate Student Understanding of the Cancer-Immunity Cycle. <i>Journal of Cancer Education</i> , 0, , .	0.6	0
3655	PLXDC1 Can Be a Biomarker for Poor Prognosis and Immune Evasion in Gastric Cancer. <i>Journal of Inflammation Research</i> , 0, Volume 15, 5439-5455.	1.6	1
3656	Intratumoral administration of CD1c (BDCA-1) and CD141 (BDCA-3) myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial. , 2022, 10, e005141.		11
3657	CDCA3 Predicts Poor Prognosis and Affects CD8+ T Cell Infiltration in Renal Cell Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-12.	0.6	2
3659	Oncolytic Adenoviruses: The Cold War against Cancer Finally Turns Hot. <i>Cancers</i> , 2022, 14, 4701.	1.7	12
3660	Mechanism of action of DSP-7888 (adegramotide/nelatimotide) Emulsion, a peptide-based therapeutic cancer vaccine with the potential to turn up the heat on non-immunoreactive tumors. <i>Clinical and Translational Oncology</i> , 0, , .	1.2	3

#	ARTICLE	IF	CITATIONS
3661	Cuproptosis-related modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of kidney renal clear cell carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	19
3662	A novel T-cell proliferation-associated regulator signature pre-operatively predicted the prognostic of bladder cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
3663	Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer. <i>Thoracic Cancer</i> , 2022, 13, 3152-3161.	0.8	11
3664	Galectin-3 as a biomarker in breast neoplasms: Mechanisms and applications in patient care. <i>Journal of Leukocyte Biology</i> , 0, , .	1.5	2
3665	Manganese Coordination Micelles That Activate Stimulator of Interferon Genes and Capture In Situ Tumor Antigens for Cancer Metalloimmunotherapy. <i>ACS Nano</i> , 2022, 16, 16909-16923.	7.3	37
3666	Nanocarriers for cancer nano-immunotherapy. <i>Drug Delivery and Translational Research</i> , 2023, 13, 1936-1954.	3.0	17
3667	Cisplatin-induced HSF1-HSP90 axis enhances the expression of functional PD-L1 in oral squamous cell carcinoma. <i>Cancer Medicine</i> , 2023, 12, 4605-4615.	1.3	12
3668	Identification and validation of a hypoxia-immune signature for overall survival prediction in lung adenocarcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
3669	Molecular dynamics identifies semi-rigid domains in the PD-1 checkpoint receptor bound to its natural ligand PD-L1. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	2
3670	Association between the efficacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: a retrospective study. <i>BMC Cancer</i> , 2022, 22, .	1.1	3
3672	Natural killer cell-related prognosis signature characterizes immune landscape and predicts prognosis of HNSCC. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	62
3673	Immunotherapy improves disease prognosis by affecting the tumor microenvironment: A bibliometric study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
3674	DKK1 Promotes Tumor Immune Evasion and Impedes Anti-PD-1 Treatment by Inducing Immunosuppressive Macrophages in Gastric Cancer. <i>Cancer Immunology Research</i> , 2022, 10, 1506-1524.	1.6	21
3675	A minimally designed PD-L1-targeted nanocomposite for positive feedback-based multimodal cancer therapy. <i>Materials Today</i> , 2022, 60, 52-68.	8.3	9
3676	Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1788-1797.	1.9	0
3677	Role of AI and digital pathology for colorectal immuno-oncology. <i>British Journal of Cancer</i> , 2023, 128, 3-11.	2.9	7
3678	Advantage of extracellular vesicles in hindering the CD47 signal for cancer immunotherapy. <i>Journal of Controlled Release</i> , 2022, 351, 727-738.	4.8	4
3679	The development of small-molecule inhibitors targeting HPK1. <i>European Journal of Medicinal Chemistry</i> , 2022, 244, 114819.	2.6	12

#	ARTICLE	IF	CITATIONS
3680	Upregulated YTHDF1 associates with tumor immune microenvironment in head and neck squamous cell carcinomas. <i>Translational Cancer Research</i> , 2022, 11, 3986-3999.	0.4	2
3681	Plasmacytoid Dendritic Cells and Cancer. , 2022, , 133-145.		0
3682	A Retrospective Cohort Study of Multiple Immune-Related Adverse Events and Clinical Outcomes Among Patients With Cancer Receiving Immune Checkpoint Inhibitors. <i>Cancer Control</i> , 2022, 29, 107327482211305.	0.7	4
3683	Exosomal Communication Between the Tumor Microenvironment and Innate Immunity and Its Therapeutic Application. <i>Immune Network</i> , 2022, 22, .	1.6	7
3684	Platelet-derived TLT-1 promotes tumor progression by suppressing CD8+ T cells. <i>Journal of Experimental Medicine</i> , 2023, 220, .	4.2	14
3685	From Cold to Hot: Changing Perceptions and Future Opportunities for Quantitative Systems Pharmacology Modeling in Cancer Immunotherapy. <i>Clinical Pharmacology and Therapeutics</i> , 2023, 113, 963-972.	2.3	6
3686	A Bioinformatics-Based Analysis of an Anoikis-Related Gene Signature Predicts the Prognosis of Patients with Low-Grade Gliomas. <i>Brain Sciences</i> , 2022, 12, 1349.	1.1	32
3687	Current status of immunotherapy for non-small cell lung cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	11
3688	Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade-Resistant Advanced NSCLC. <i>JTO Clinical and Research Reports</i> , 2023, 4, 100423.	0.6	1
3689	Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
3691	TGF- β -dependent lymphoid tissue residency of stem-like T cells limits response to tumor vaccine. <i>Nature Communications</i> , 2022, 13, .	5.8	9
3692	Diet Influences Immunotherapy Outcomes in Cancer Patients: A Literature Review. <i>Nutrition and Cancer</i> , 2023, 75, 415-429.	0.9	1
3694	Combination of oral STING agonist MSA-2 and anti-TGF- β /PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	52
3695	Immune Checkpoint Inhibitors and RAS-ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma. <i>Biomolecules</i> , 2022, 12, 1562.	1.8	5
3696	Immune checkpoint inhibitors in cervical cancer: Current status and research progress. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
3697	Patient-Specific Mathematical Model of the Clear Cell Renal Cell Carcinoma Microenvironment. <i>Journal of Personalized Medicine</i> , 2022, 12, 1681.	1.1	3
3698	PD-1/PD-L1 inhibitors for advanced or metastatic cervical cancer: From bench to bed. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
3699	Radiomics to evaluate interlesion heterogeneity and to predict lesion response and patient outcomes using a validated signature of CD8 cells in advanced melanoma patients treated with anti-PD1 immunotherapy. , 2022, 10, e004867.		11

#	ARTICLE	IF	CITATIONS
3700	Nanomaterials-Boosted Tumor Immunotherapy Through Natural Killer Cells. <i>Advanced NanoBiomed Research</i> , 2022, 2, .	1.7	4
3701	Red blood cell-based vaccines for ameliorating cancer chemoimmunotherapy. <i>Acta Biomaterialia</i> , 2022, 154, 401-411.	4.1	3
3702	Multiplexed In Situ Spatial Protein Profiling in the Pursuit of Precision Immuno-Oncology for Patients with Breast Cancer. <i>Cancers</i> , 2022, 14, 4885.	1.7	5
3703	NSAIDs affect dendritic cell cytokine production. <i>PLoS ONE</i> , 2022, 17, e0275906.	1.1	0
3704	GNAI2 Is a Risk Factor for Gastric Cancer: Study of Tumor Microenvironment (TME) and Establishment of Immune Risk Score (IRS). <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-35.	1.9	5
3705	Phase I/II study of nedaplatin and nab-paclitaxel for patients with previously untreated advanced squamous cell lung cancer: Kanto Respiratory Disease Study Group (KRSG) 1302. <i>International Journal of Clinical Oncology</i> , 0, , .	1.0	0
3706	First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors. , 2022, 10, e004235.		20
3707	Metabolic guidance and stress in tumors modulate antigen-presenting cells. <i>Oncogenesis</i> , 2022, 11, .	2.1	3
3708	Current Status of Immune Checkpoint Inhibitors. <i>Nihon Kikan Shokudoka Gakkai Kaiho</i> , 2022, 73, 303-307.	0.0	0
3709	Effects of Low-dose Splenic Irradiation on T lymphocyte Immune Function. <i>Health Physics</i> , 2022, 123, 486-491.	0.3	0
3710	Phosphorous Dendron Micelles as a Nanomedicine Platform for Cooperative Tumor Chemoimmunotherapy via Synergistic Modulation of Immune Cells. <i>Advanced Materials</i> , 2023, 35, .	11.1	22
3711	Nanohydroxyapatite Stimulates PD-L1 Expression to Boost Melanoma Combination Immunotherapy. <i>ACS Nano</i> , 2022, 16, 18921-18935.	7.3	3
3712	Enhancing the Efficiency of Mild-Temperature Photothermal Therapy for Cancer Assisting with Various Strategies. <i>Pharmaceutics</i> , 2022, 14, 2279.	2.0	16
3713	A Comprehensive Analysis of KRT19 Combined with Immune Infiltration to Predict Breast Cancer Prognosis. <i>Genes</i> , 2022, 13, 1838.	1.0	2
3714	Antitumor Immunotherapy of Sialic Acid and/or GM1 Modified Coenzyme Q10 Submicron Emulsion. <i>AAPS PharmSciTech</i> , 2022, 23, .	1.5	0
3715	IL2RA is a prognostic indicator and correlated with immune characteristics of pancreatic ductal adenocarcinoma. <i>Medicine (United States)</i> , 2022, 101, e30966.	0.4	3
3716	Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
3717	Emerging target discovery and drug repurposing opportunities in chordoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3

#	ARTICLE	IF	CITATIONS
3718	The Cancer Epitope Database and Analysis Resource (CEDAR). <i>Nucleic Acids Research</i> , 2023, 51, D845-D852.	6.5	13
3719	Single-Cell Analysis Reveals a CD4+ T-cell Cluster That Correlates with PD-1 Blockade Efficacy. <i>Cancer Research</i> , 2022, 82, 4641-4653.	0.4	13
3722	Rational design of a Nivolumab-based ANTI-PD-1 single chain variable fragment that blocks the interaction between PD-1 expressed on T-CELLS and PD-L1 ON CHO cells. <i>Protein Expression and Purification</i> , 2023, 202, 106196.	0.6	2
3723	Integrated tumor genomic and immune microenvironment analysis identifies predictive biomarkers associated with the efficacy of neoadjuvant therapy for triple-negative breast cancer. <i>Cancer Medicine</i> , 2023, 12, 5846-5858.	1.3	4
3724	Aggregation-Induced Emission Photosensitizer-Loaded Nano-Superartificial Dendritic Cells with Directly Presenting Tumor Antigens and Reversed Immunosuppression for Photodynamically Boosted Immunotherapy. <i>Advanced Materials</i> , 2023, 35, .	11.1	16
3725	The role of bacteria and its derived biomaterials in cancer radiotherapy. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 4149-4171.	5.7	7
3726	Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability. <i>Cancers</i> , 2022, 14, 4974.	1.7	15
3727	Advances in immunotherapy for glioblastoma multiforme. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	24
3728	Migratory Engineering of T Cells for Cancer Therapy. <i>Vaccines</i> , 2022, 10, 1845.	2.1	8
3730	Chemopreventive and anti-tumor potential of vitamin E in preclinical breast cancer studies: A systematic review. <i>Clinical Nutrition ESPEN</i> , 2023, 53, 60-73.	0.5	5
3731	The benefits of propofol on cancer treatment: Decipher its modulation code to immunocytes. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
3732	Improvement of TNBC immune checkpoint blockade with a microwave-controlled ozone release nanosystem. <i>Journal of Controlled Release</i> , 2022, 351, 954-969.	4.8	3
3733	Modern Biomedical Applications of Magnetic Nanoparticles. <i>Springer Briefs in Molecular Science</i> , 2023, , 25-91.	0.1	1
3734	Understanding the Immunoenvironment of Primary Liver Cancer: A Histopathology Perspective. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 1149-1169.	1.8	3
3735	Combination immunotherapy strategies for triple-negative breast cancer: current progress and barriers within the pharmacological landscape. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 1399-1413.	1.3	3
3736	Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer. <i>Medicina (Lithuania)</i> , 2022, 58, 1572.	0.8	5
3737	Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagers. <i>Trends in Immunology</i> , 2022, 43, 932-946.	2.9	22
3738	Excessive HSP70/TLR2 activation leads to remodeling of the tumor immune microenvironment to resist chemotherapy sensitivity of mFOLFOX in colorectal cancer. <i>Clinical Immunology</i> , 2022, 245, 109157.	1.4	4

#	ARTICLE	IF	CITATIONS
3739	Targeting STING for cancer immunotherapy: From mechanisms to translation. <i>International Immunopharmacology</i> , 2022, 113, 109304.	1.7	11
3740	Combination therapy with nivolumab (anti-PD-1 monoclonal antibody): A new era in tumor immunotherapy. <i>International Immunopharmacology</i> , 2022, 113, 109365.	1.7	6
3741	Unlocking the Potential of Immuno-Oncology in Advanced Cutaneous Squamous Cell Carcinoma: Role of Checkpoint Blockade. <i>EMJ Dermatology</i> , 0, , 2-10.	0.0	0
3742	Unlocking the Potential of Immuno-Oncology in Advanced Cutaneous Squamous Cell Carcinoma: Role of Checkpoint Blockade. <i>EMJ Dermatology</i> , 0, , 2-10.	0.0	0
3743	T-Cell Based Therapies: Clinical Applications and Challenges. , 2022, , 1-13.		0
3744	Harnessing the Tumor Microenvironment for Cancer Immunotherapy. , 2022, , 1-25.		1
3745	Identification of Immune-Related Subtypes and Construction of a Novel Prognostic Model for Bladder Urothelial Cancer. <i>Biomolecules</i> , 2022, 12, 1670.	1.8	6
3746	Integration of local and systemic immunity in ovarian cancer: Implications for immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
3747	Systematic assessment and optimizing algorithm of tumor mutational burden calculation and their implications in clinical decision-making. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
3748	Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
3749	Significance of the Lung Immune Prognostic Index for Assessment of the Reliability of the Clinical Treatment Outcome for Advanced Non-Small-Cell Lung Cancer in Patients with COVID-19 Infection. <i>Journal of Clinical Medicine</i> , 2022, 11, 6695.	1.0	1
3750	T cellâ€inflamed gene expression profile is associated with favorable diseaseâ€specific survival in nonâ€hypermuted microsatelliteâ€stable colorectal cancer patients. <i>Cancer Medicine</i> , 2023, 12, 6583-6593.	1.3	4
3751	Integration of cancer stemness and neoantigen load to predict responsiveness to anti-PD1/PDL1 therapy. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	0
3752	Low expression of INMT is associated with poor prognosis but favorable immunotherapy response in lung adenocarcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
3753	Oxidative Phosphorylation-Related Signature Participates in Cancer Development, and PTPRG Overexpression Suppresses the Cancer Progression in Clear Cell Renal Cell Carcinoma. <i>Journal of Immunology Research</i> , 2022, 2022, 1-18.	0.9	1
3754	Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13696.	1.8	0
3756	Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
3757	The effects of dendritic cell-based vaccines in the tumor microenvironment: Impact on myeloid-derived suppressor cells. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10

#	ARTICLE	IF	CITATIONS
3758	Once upon a prime: DCs shape cancer immunity. <i>Trends in Cancer</i> , 2023, 9, 172-184.	3.8	6
3760	USP7 Inhibitors in Cancer Immunotherapy: Current Status and Perspective. <i>Cancers</i> , 2022, 14, 5539.	1.7	8
3761	ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer. <i>Future Oncology</i> , 2022, 18, 3563-3572.	1.1	6
3762	cGAS-STING Pathway as the Target of Immunotherapy for Lung Cancer. <i>Current Cancer Drug Targets</i> , 2023, 23, 354-362.	0.8	2
3763	Nanoparticles for Chemoimmunotherapy Against Triple-Negative Breast Cancer. <i>International Journal of Nanomedicine</i> , 0, Volume 17, 5209-5227.	3.3	5
3764	Sorafenib inhibits doxorubicin-induced PD-L1 upregulation to improve immunosuppressive microenvironment in Osteosarcoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 5127-5138.	1.2	3
3765	Integrative prognostic analysis of tumor-infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2023, 197, 287-297.	1.1	4
3766	Current nonclinical approaches for immune assessments of immuno-oncology biotherapeutics. <i>Drug Discovery Today</i> , 2022, , 103440.	3.2	1
3767	Triple Combination of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in BRAFV600 Melanoma: Current Status and Future Perspectives. <i>Cancers</i> , 2022, 14, 5489.	1.7	4
3768	Long-term (>5-year) survivors among unresectable or metastatic cancer patients treated with zoledronate-activated killer cells: Seven case reports. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, .	0.2	0
3769	Efficacy and Safety of Immune Checkpoint Inhibitors in Triple-negative Breast Cancer: A Study Based on 41 Cohorts Incorporating 6558 Participants. <i>Journal of Immunotherapy</i> , 0, Publish Ahead of Print, .	1.2	0
3771	CNS and CNS diseases in relation to their immune system. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
3772	What's next for cancer vaccines. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	8
3773	Adenovirus-Inspired Virus-like-Particles Displaying Melanoma Tumor Antigen Specifically Target Human DC Subsets and Trigger Antigen-Specific Immune Responses. <i>Biomedicines</i> , 2022, 10, 2881.	1.4	0
3774	Two-Stage SN38 Release from a Core-Shell Nanoparticle Enhances Tumor Deposition and Antitumor Efficacy for Synergistic Combination with Immune Checkpoint Blockade. <i>ACS Nano</i> , 2022, 16, 21417-21430.	7.3	22
3775	The effect of neoadjuvant chemotherapy on the tumor immune microenvironment in gastrointestinal tumors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
3776	Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy. <i>World Journal of Gastroenterology</i> , 0, 28, 6034-6044.	1.4	6
3777	Nanovaccines in cancer immunotherapy: Focusing on dendritic cell targeting. <i>International Immunopharmacology</i> , 2022, 113, 109434.	1.7	10

#	ARTICLE	IF	CITATIONS
3778	Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers. <i>Advances in Clinical Chemistry</i> , 2022, , .	1.8	0
3779	Characterization of the impact of immune checkpoint inhibitors on platelet activation and aggregation. <i>Immunobiology</i> , 2023, 228, 152311.	0.8	2
3780	Intra-Tumor Cell Heterogeneity: Different Immune Responses for Different Cells. , 2022, , 1-26.		0
3781	The Immune System in Liver Cancer: From Beginning to Progression. , 2022, , 85-105.		0
3782	Covalently triggered self-assembly of peptide-based nanodrugs for cancer theranostics. <i>IScience</i> , 2023, 26, 105789.	1.9	6
3783	Nanomedicines in cancer immunotherapy: challenges and opportunities. , 2023, , 231-246.		0
3784	The Tumor Microenvironment in Hepatocellular Carcinoma. , 2022, , 107-137.		0
3785	Multiomic analysis for optimization of combined focal and immunotherapy protocols in murine pancreatic cancer. <i>Theranostics</i> , 2022, 12, 7884-7902.	4.6	3
3786	The landscape of TIGIT target and clinical application in diseases. , 2022, 1, .		0
3787	Atypical responses to neoadjuvant chemotherapy combined with accelerated partial breast tumor-directed radiotherapy: two cases and considerations for future clinical trials. <i>Reports of Practical Oncology and Radiotherapy</i> , 2022, 27, 1114-1118.	0.3	1
3788	Neo-peripheral adaptive immune score predicts neoadjuvant chemotherapy for locally advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 0, , .	1.1	0
3789	Dying of Stress: Chemotherapy, Radiotherapy, and Small-Molecule Inhibitors in Immunogenic Cell Death and Immunogenic Modulation. <i>Cells</i> , 2022, 11, 3826.	1.8	8
3790	Cell-Based Drug Delivery Systems Participate in the Cancer Immunity Cycle for Improved Cancer Immunotherapy. <i>Small</i> , 2023, 19, .	5.2	10
3791	High-content CRISPR screening in tumor immunology. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
3792	Advances in the Lung Cancer Immunotherapy Approaches. <i>Vaccines</i> , 2022, 10, 1963.	2.1	6
3793	Targeting PIM Kinases to Improve the Efficacy of Immunotherapy. <i>Cells</i> , 2022, 11, 3700.	1.8	4
3794	New Challenges Facing Systemic Therapies of Advanced HCC in the Era of Different First-Line Immunotherapy-Based Combinations. <i>Cancers</i> , 2022, 14, 5868.	1.7	5
3795	Glomerular diseases after immune checkpoint inhibitors use: What do We know so far?. <i>Renal Failure</i> , 2022, 44, 2058-2067.	0.8	1

#	ARTICLE	IF	CITATIONS
3796	PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
3798	Advances in Organoid Culture Research. <i>Global Medical Genetics</i> , 2022, 09, 268-276.	0.4	0
3799	Hydrogel-guided strategies to stimulate an effective immune response for vaccine-based cancer immunotherapy. <i>Science Advances</i> , 2022, 8, .	4.7	25
3800	Comprehensive analysis of cuproptosis-related genes in prognosis, tumor microenvironment infiltration, and immunotherapy response in gastric cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	3
3801	Reinventing the human tuberculosis (TB) granuloma: Learning from the cancer field. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
3802	Comprehensive analysis of the expression, prognostic significance, and regulation pathway of G2E3 in breast cancer. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	1
3803	Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer. <i>Breast Cancer: Targets and Therapy</i> , 0, Volume 14, 417-432.	1.0	1
3804	Pro- and Anti-Tumoral Factors Involved in Total Body Irradiation and Interleukin-2 Conditioning in Adoptive T Cell Therapy of Melanoma-Bearing Rag1 Knock-Out Mice. <i>Cells</i> , 2022, 11, 3894.	1.8	0
3805	Prognostic value of TMEM59L and its genomic and immunological characteristics in cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
3806	The Lymphatic Endothelium in the Context of Radioimmuno-Oncology. <i>Cancers</i> , 2023, 15, 21.	1.7	0
3807	Development of Monoclonal Antibodies Targeting Canine PD-L1 and PD-1 and Their Clinical Relevance in Canine Apocrine Gland Anal Sac Adenocarcinoma. <i>Cancers</i> , 2022, 14, 6188.	1.7	4
3808	MeVa2.1.dOVA and MeVa2.2.dOVA: two novel BRAFV600E-driven mouse melanoma cell lines to study tumor immune resistance. <i>Melanoma Research</i> , 2023, 33, 12-26.	0.6	3
3809	Germline genetic variation and predicting immune checkpoint inhibitor induced toxicity. <i>Npj Genomic Medicine</i> , 2022, 7, .	1.7	8
3810	Peptide self-assembled nanomedicine induces antitumor immunity by blocking the PD-1/PD-L1 axis. <i>Frontiers in Materials</i> , 0, 9, .	1.2	0
3811	Nivolumab-induced capillary leak syndrome associated with chylothorax in a melanoma patient: A case report and review of the literature. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
3812	Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy. <i>Angiogenesis</i> , 2023, 26, 279-293.	3.7	12
3813	Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells. <i>Nature Biomedical Engineering</i> , 0, , .	11.6	20
3814	Potent and Selective Biaryl Amide Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1). <i>ACS Medicinal Chemistry Letters</i> , 2023, 14, 116-122.	1.3	1

#	ARTICLE	IF	CITATIONS
3815	A first-in-human phase 1 study of cavrotolimod, a TLR9 agonist spherical nucleic acid, in healthy participants: Evidence of immune activation. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
3816	TGF- β 2: A novel predictor and target for anti-PD-1/PD-L1 therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	22
3817	Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response Rates. <i>International Journal of Molecular Sciences</i> , 2023, 24, 41.	1.8	6
3818	Interaction between glycolysis–cholesterol synthesis axis and tumor microenvironment reveal that gamma-glutamyl hydrolase suppresses glycolysis in colon cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
3819	Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy. <i>Cancer Cell International</i> , 2022, 22, .	1.8	3
3821	Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
3822	Characterization of <sc>CPH</sc>:<sc>SA</sc> microparticle–based delivery of interleukin–1 alpha for cancer immunotherapy. <i>Bioengineering and Translational Medicine</i> , 2023, 8, .	3.9	0
3823	Identification and validation of RNA methylation-related alternative splicing gene signature for low-grade glioma to predict survival and immune landscapes. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	0
3824	Expression and Clinical Significance of Various Checkpoint Molecules in Advanced Osteosarcoma: Possibilities for Novel Immunotherapy. <i>Orthopaedic Surgery</i> , 0, , .	0.7	3
3826	Biomaterials for enhanced immunotherapy. <i>APL Bioengineering</i> , 2022, 6, .	3.3	7
3827	<sc>Layer–by–layer</sc> interleukin–12 nanoparticles drive a safe and effective response in ovarian tumors. <i>Bioengineering and Translational Medicine</i> , 2023, 8, .	3.9	7
3828	Nanomedicine–boosting icaritin-based immunotherapy of advanced hepatocellular carcinoma. <i>Military Medical Research</i> , 2022, 9, .	1.9	7
3829	Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
3830	Resistance to immune checkpoint inhibitors and the tumor microenvironment. <i>Experimental Dermatology</i> , 2023, 32, 240-249.	1.4	5
3831	Chasing Uterine Cancer with NK Cell-Based Immunotherapies. <i>Future Pharmacology</i> , 2022, 2, 642-659.	0.6	3
3832	Discovery of Pyrazolopyridine Derivatives as HPK1 Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2023, 14, 5-10.	1.3	0
3833	Anlotinib reduces the suppressive capacity of monocytic myeloid-derived suppressor cells and potentiates the immune microenvironment normalization window in a mouse lung cancer model. <i>Anti-Cancer Drugs</i> , 2023, 34, 1018-1024.	0.7	1
3835	Recent advances in the liposomal nanovesicles based immunotherapy in the treatment of cancer: A review. <i>Saudi Pharmaceutical Journal</i> , 2023, 31, 279-294.	1.2	3

#	ARTICLE	IF	CITATIONS
3836	Guidelines for DC preparation and flow cytometry analysis of mouse nonlymphoid tissues. <i>European Journal of Immunology</i> , 2023, 53, .	1.6	5
3837	Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistance. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
3838	Impact of the Human Cell Atlas on medicine. <i>Nature Medicine</i> , 2022, 28, 2486-2496.	15.2	59
3839	Immunotherapies targeting neoantigens are effective in <sc>PD</sc> blockade-resistant tumors. <i>International Journal of Cancer</i> , 2023, 152, 1463-1475.	2.3	2
3840	A hypoxia risk score for prognosis prediction and tumor microenvironment in adrenocortical carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
3841	CAF-immune cell crosstalk and its impact in immunotherapy. <i>Seminars in Immunopathology</i> , 2023, 45, 203-214.	2.8	10
3843	PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	36
3844	ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma. <i>BMC Pulmonary Medicine</i> , 2022, 22, .	0.8	0
3846	Severe neuromuscular immune-related adverse events of immune checkpoint inhibitors at national cancer center in Korea. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 5583-5589.	1.2	6
3847	Bispecific Aptamer-Based Recognition-then-Conjugation Strategy for PD1/PDL1 Axis Blockade and Enhanced Immunotherapy. <i>ACS Nano</i> , 2022, 16, 21129-21138.	7.3	19
3848	Cellular senescence enhances adaptive anticancer immunosurveillance. <i>Oncolmmunology</i> , 2023, 12, .	2.1	4
3849	Construction of a machine learning-based artificial neural network for discriminating PANoptosis related subgroups to predict prognosis in low-grade gliomas. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
3850	Combining local regional therapy and systemic therapy: Expected changes in the treatment landscape of recurrent hepatocellular carcinoma. <i>World Journal of Gastrointestinal Oncology</i> , 0, 15, 1-18.	0.8	0
3851	Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF- κ B Activation in T Cells and Suppressing Antitumor Immunity. <i>Cancer Research</i> , 2023, 83, 906-921.	0.4	13
3852	Tertiary lymphoid structures are critical for cancer prognosis and therapeutic response. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
3853	Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592211383.	1.4	3
3854	Separate and combined effects of advanced age and obesity on mammary adipose inflammation, immunosuppression and tumor progression in mouse models of triple negative breast cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
3855	DNA Nanomaterials-Based Platforms for Cancer Immunotherapy. <i>Small Methods</i> , 2023, 7, .	4.6	11

#	ARTICLE	IF	CITATIONS
3856	Strategies for Heating Up Cold Tumors to Boost Immunotherapies. <i>Annual Review of Cancer Biology</i> , 2023, 7, 149-170.	2.3	10
3857	BCAT2 Shapes a Noninflamed Tumor Microenvironment and Induces Resistance to Anti-PD1/PD-L1 Immunotherapy by Negatively Regulating Proinflammatory Chemokines and Anticancer Immunity. <i>Advanced Science</i> , 2023, 10, .	5.6	23
3858	Intratumoral STING activation causes durable immunogenic tumor eradication in the KP soft tissue sarcoma model. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
3859	Natural biomolecules and derivatives as anticancer immunomodulatory agents. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
3860	High-Dose Ascorbate in Combination with Anti-PD1 Checkpoint Inhibition as Treatment Option for Malignant Melanoma. <i>Cells</i> , 2023, 12, 254.	1.8	1
3861	Mathematical and Numerical Modelling of Interference of Immune Cells in the Tumour Environment. <i>Discrete Dynamics in Nature and Society</i> , 2023, 2023, 1-18.	0.5	0
3862	The frequency of differentiated CD3+CD27-CD28- T cells predicts response to CART cell therapy in diffuse large B-cell lymphoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
3863	Partners in crime: The feedback loop between metabolic reprogramming and immune checkpoints in the tumor microenvironment. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
3864	Efficient Delivery of GSDMD mRNA by Engineered Extracellular Vesicles Induces Pyroptosis for Enhanced Immunotherapy. <i>Small</i> , 2023, 19, .	5.2	11
3865	Configuring Therapeutic Aspects of Immune Checkpoints in Lung Cancer. <i>Cancers</i> , 2023, 15, 543.	1.7	8
3866	CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor. <i>Immunity</i> , 2023, 56, 107-124.e5.	6.6	75
3867	Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma. <i>Cancers</i> , 2023, 15, 348.	1.7	3
3868	Challenges and exploration for immunotherapies targeting cold colorectal cancer. <i>World Journal of Gastrointestinal Oncology</i> , 0, 15, 55-68.	0.8	3
3869	Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome. <i>Cancers</i> , 2023, 15, 321.	1.7	21
3870	Positron emission tomography molecular imaging to monitor anti-tumor systemic response for immune checkpoint inhibitor therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 1671-1688.	3.3	2
3871	Canine melanoma: A review of diagnostics and comparative mechanisms of disease and immunotolerance in the era of the immunotherapies. <i>Frontiers in Veterinary Science</i> , 0, 9, .	0.9	4
3872	Prognostic role of the innate immune signature CD163 and α -signal calreticulin in clear cell renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 0, , .	2.0	0
3873	In vivo induction of activin A-producing alveolar macrophages supports the progression of lung cell carcinoma. <i>Nature Communications</i> , 2023, 14, .	5.8	6

#	ARTICLE	IF	CITATIONS
3874	Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages. <i>Cancer Cell International</i> , 2023, 23, .	1.8	5
3875	Identification of a tissue resident memory CD8 T cell-related risk score signature for colorectal cancer, the association with TME landscapes and therapeutic responses. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
3876	Time to Sleep: Immunologic Niche Switches Tumor Dormancy at Metastatic Sites. , 2023, , 1-27.		0
3877	Immunosuppressive functions of melanoma cell-derived exosomes in plasma of melanoma patients. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	2
3878	Pan-cancer analysis identifies proteasome 26S subunit, ATPase (PSMC) family genes, and related signatures associated with prognosis, immune profile, and therapeutic response in lung adenocarcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
3879	Radiological response criteria in non-small cell lung cancer treated with immunotherapy: RECIST1.1 vs. iRECIST. <i>Journal of Radiological Review</i> , 2023, 9, .	0.1	0
3880	Radiation-Induced Immunoediting of Cancer. , 2023, , 1-20.		0
3881	Neoadjuvant checkpoint blockade in combination with Chemotherapy in patients with tripe-negative breast cancer: exploratory analysis of real-world, multicenter data. <i>BMC Cancer</i> , 2023, 23, .	1.1	7
3882	Cancer Immunotherapy Elicited by Immunogenic Cell Death Based on Smart Nanomaterials. <i>Small Methods</i> , 2023, 7, .	4.6	8
3883	In situ Vaccination Followed by Intramuscular poly-ICLC Injections for the Treatment of Hepatocellular Carcinoma in Mouse Models. <i>Pharmacological Research</i> , 2023, , 106646.	3.1	0
3884	Neoantigens: promising targets for cancer therapy. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	112
3885	<i>CAV1</i> Impacts the Tumor Immune Microenvironment and Has Potential Value of Predicting Response to Immunotherapy in Esophageal Cancer. <i>DNA and Cell Biology</i> , 2023, 42, 27-42.	0.9	1
3886	Acidâ€ionizable Iron Nanoadjuvant Augments STING Activation for Personalized Vaccination Immunotherapy of Cancer. <i>Advanced Materials</i> , 2023, 35, .	11.1	23
3887	Interstitial pneumonitis associated with combined regimen of immunotherapy and conventional therapiesâ€pharmacovigilance database analysis with real-world data validation. <i>BMC Medicine</i> , 2023, 21, .	2.3	2
3888	Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	0
3889	Multiparameter single-cell proteomic technologies give new insights into the biology of ovarian tumors. <i>Seminars in Immunopathology</i> , 0, , .	2.8	2
3890	Rationales for Combining Therapies to Treat Cancer: Independent Action, Response Correlation, and Collateral Sensitivity Versus Synergy. <i>Annual Review of Cancer Biology</i> , 2023, 7, 247-263.	2.3	4
3891	Absolute lymphocyte count changes during neoadjuvant chemotherapy are associated with prognosis of human epidermal growth factor receptor 2-positive breast cancer patients. <i>Clinical Breast Cancer</i> , 2023, , .	1.1	0

#	ARTICLE	IF	CITATIONS
3892	Wnt/ β -Catenin Signaling and Resistance to Immune Checkpoint Inhibitors: From Non-Small-Cell Lung Cancer to Other Cancers. <i>Biomedicines</i> , 2023, 11, 190.	1.4	9
3893	Purinergic signaling: Diverse effects and therapeutic potential in cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	7
3894	Spatial genomics reveals a high number and specific location of B cells in the pancreatic ductal adenocarcinoma microenvironment of long-term survivors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
3895	The crosstalk between the gut microbiota and tumor immunity: Implications for cancer progression and treatment outcomes. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
3896	MHC-dressing on dendritic cells: Boosting anti-tumor immunity via unconventional tumor antigen presentation. <i>Seminars in Immunology</i> , 2023, 66, 101710.	2.7	5
3897	Anti-tumor immunity enhancement by photodynamic therapy with talaporfin sodium and anti-programmed death 1 antibody. <i>Molecular Therapy - Oncolytics</i> , 2023, 28, 118-131.	2.0	8
3898	Tislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma. <i>Medicine (United States)</i> , 2022, 101, e32459.	0.4	1
3899	Implementation of microsatellite instability testing for the assessment of solid tumors in clinical practice. <i>Cancer Medicine</i> , 2023, 12, 7932-7940.	1.3	2
3900	Long Non-Coding RNAs as Epigenetic Regulators of Immune Checkpoints in Cancer Immunity. <i>Cancers</i> , 2023, 15, 184.	1.7	3
3901	The Cancer-Associated Fibroblasts-Related Gene COMP Is a Novel Predictor for Prognosis and Immunotherapy Efficacy and Is Correlated with M2 Macrophage Infiltration in Colon Cancer. <i>Biomolecules</i> , 2023, 13, 62.	1.8	5
3902	The Performance of UMAP plus Linkage Compared with Daura-Clustering of Molecular Dynamics of the PD-1 Checkpoint Receptor. , 2022, , .		1
3903	Improved cancer immunotherapy strategies by nanomedicine. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2023, 15, .	3.3	7
3904	Combination of Expanded Allogeneic NK Cells and T Cell-Based Immunotherapy Exert Enhanced Antitumor Effects. <i>Cancers</i> , 2023, 15, 251.	1.7	3
3905	Dermatologic autoimmunity associated with immune checkpoint inhibitors. , 2023, , 311-327.		0
3906	Multifunctional Nano- α Biomaterials for Cancer Therapy via Inducing Enhanced Immunogenic Cell Death. <i>Small Methods</i> , 2023, 7, .	4.6	12
3907	PD-L1 and PD-L2 expression in colorectal cancer. <i>Indian Journal of Pathology and Microbiology</i> , 2023, 66, 31.	0.1	4
3908	Nur77 Serves as a Potential Prognostic Biomarker That Correlates with Immune Infiltration and May Act as a Good Target for Prostate adenocarcinoma. <i>Molecules</i> , 2023, 28, 1238.	1.7	0
3909	By integrating single-cell RNA-seq and bulk RNA-seq in sphingolipid metabolism, CACYBP was identified as a potential therapeutic target in lung adenocarcinoma. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	25

#	ARTICLE	IF	CITATIONS
3910	Melanoma molecular subtyping and scoring model construction based on ligand-receptor pairs. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	0
3911	CAR T-cell behavior and function revealed by real-time imaging. <i>Seminars in Immunopathology</i> , 2023, 45, 229-239.	2.8	6
3912	The Immune Landscape and Therapy of Upper Tract Urothelial Carcinoma. , 2023, , .		0
3913	[18F]FDG PET/CT Imaging in Cancer Treatment with Checkpoint Inhibitors. , 2023, , 1-40.		0
3914	Targeting Driver Oncogenes and Other Public Neoantigens Using T Cell Receptorâ€“Based Cellular Therapy. <i>Annual Review of Cancer Biology</i> , 2023, 7, .	2.3	1
3915	Real-world Efficacy and Safety of Atezolizumab Plus Bevacizumab, Paclitaxel and Carboplatin for First-line Treatment of Japanese Patients With Metastatic Non-squamous Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2023, 43, 713-724.	0.5	4
3916	The Role of Hypoxia in Brain Tumor Immune Responses. <i>Brain Tumor Research and Treatment</i> , 2023, 11, 39.	0.4	1
3917	Current â€œstate of the artâ€“ on dendritic cell-based cancer vaccines in melanoma. <i>Current Opinion in Oncology</i> , 0, Publish Ahead of Print, .	1.1	2
3918	Yin and yang roles of B lymphocytes in solid tumors: Balance between antitumor immunity and immune tolerance/immunosuppression in tumor-draining lymph nodes. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
3919	Current State of Cold Atmospheric Plasma and Cancerâ€™Immunity Cycle: Therapeutic Relevance and Overcoming Clinical Limitations Using Hydrogels. <i>Advanced Science</i> , 2023, 10, .	5.6	12
3921	Biomaterials tools to modulate the tumour microenvironment in immunotherapy. , 2023, 1, 125-138.		34
3922	RUNX1/CD44 axis regulates the proliferation, migration, and immunotherapy of gliomas: A single-cell sequencing analysis. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
3923	Rapid disease progression on immune checkpoint inhibitors in young patients with stage IV melanoma. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	2
3924	Interferon-Î³ secreted by recruited Th1 cells in peritoneal cavity inhibits the formation of malignant ascites. <i>Cell Death Discovery</i> , 2023, 9, .	2.0	2
3925	TYRO3 blockade enhances anti-PD-1 therapy response by modulating expression of CCN1 in tumor microenvironment. , 2023, 11, e006084.		2
3926	Conversion surgery for advanced hepatocellular carcinoma after combination treatment of lenvatinib and camrelizumab: a case report. <i>World Journal of Surgical Oncology</i> , 2023, 21, .	0.8	0
3928	Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy. <i>BMC Cancer</i> , 2023, 23, .	1.1	6
3930	Role of FABP5 in T Cell Lipid Metabolism and Function in the Tumor Microenvironment. <i>Cancers</i> , 2023, 15, 657.	1.7	2

#	ARTICLE	IF	CITATIONS
3931	BASP1 is a prognostic biomarker associated with immunotherapeutic response in head and neck squamous cell carcinoma. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
3932	Integrated analysis of tertiary lymphoid structures in relation to tumor-infiltrating lymphocytes and patient survival in pancreatic ductal adenocarcinoma. <i>Journal of Gastroenterology</i> , 2023, 58, 277-291.	2.3	6
3933	Spatiotemporal local and abscopal cell death and immune responses to histotripsy focused ultrasound tumor ablation. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	9
3934	Bioactive Peptide Nanodrugs Based on Supramolecular Assembly for Boosting Immunogenic Cell Death-induced Cancer Immunotherapy. <i>Small Methods</i> , 2023, 7, .	4.6	14
3935	Nanotheranostics: The Afterglow for Cancer Immunotherapy. , 2023, , 1-43.		0
3936	Chemotherapy to potentiate the radiation-induced immune response. <i>International Review of Cell and Molecular Biology</i> , 2023, , 143-173.	1.6	1
3937	Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy. <i>Cancers</i> , 2023, 15, 703.	1.7	11
3938	Biological effects of prostaglandin E2-EP4 antagonist (AAT-008) in murine colon cancer in vivo: enhancement of immune response to radiotherapy and potential as a radiosensitizer. <i>Translational Cancer Research</i> , 2023, .	0.4	0
3939	Nanovaccine Based on a Biepitope Antigen to Potentiate the Immunogenicity of a Neoantigen. <i>ACS Macro Letters</i> , 2023, 12, 281-287.	2.3	4
3940	Immune Checkpoint Inhibition and Radiotherapy in Head and Neck Squamous Cell Carcinoma: Synergisms and Resistance Mechanisms. , 2023, , 11-21.		0
3941	Prognostic value of tumor-infiltrating T-lymphocytes density in the therapeutic response to initial platinum-based chemotherapy in patients with non-small cell lung cancer. <i>Vojnosanitetski Pregled</i> , 2023, , 19-19.	0.1	0
3942	Impact of autoantibodies on the proliferation of lymphocytes in the rat thyroid cells. <i>AIP Conference Proceedings</i> , 2023, , .	0.3	0
3943	Role of Immune Cells in the Tumor Microenvironment. , 2023, , .		0
3944	Role of nanotechnology in cancer therapies: recent advances, current issues, and approaches. , 2023, , 73-95.		0
3945	Alarmin IL-33 orchestrates antitumoral T cell responses to enhance sensitivity to 5-fluorouracil in colorectal cancer. <i>Theranostics</i> , 2023, 13, 1649-1668.	4.6	2
3946	Clinical Applications of Novel Delivery Routes of Immunotherapy Drugs and Vaccines. , 2023, , 1-25.		0
3947	Gastrointestinal perforation associated with novel antineoplastic agents: A real-world study based on the FDA Adverse Event Reporting System. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 0, 26, .	0.9	1
3948	Risk factors indicating immune-related adverse events with combination chemotherapy with immune checkpoint inhibitors and platinum agents in patients with non-small cell lung cancer: a multicenter retrospective study. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 2169-2178.	2.0	1

#	ARTICLE	IF	CITATIONS
3949	Establishment and external verification of an oxidative stress-related gene signature to predict clinical outcomes and therapeutic responses of colorectal cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	5
3950	Integrated analysis of the relation to tumor immune microenvironment and predicted value of Stonin1 gene for immune checkpoint blockage and targeted treatment in kidney renal clear cell carcinoma. <i>BMC Cancer</i> , 2023, 23, .	1.1	0
3951	Discordance of PD-L1 expression in primary and metastatic ovarian high-grade serous carcinoma and its correlation with CD8 tumor-infiltrating lymphocytes and patient prognosis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2023, 482, 755-766.	1.4	3
3952	Research into the characteristic molecules significantly affecting liver cancer immunotherapy. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
3953	Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment. , 2023, 11, e005509.		7
3954	TKIs in combination with immunotherapy for hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2023, 23, 279-291.	1.1	29
3955	Tumor-associated macrophages employ immunoeediting mechanisms in colorectal tumor progression: Current research in Macrophage repolarization immunotherapy. <i>International Immunopharmacology</i> , 2023, 116, 109569.	1.7	12
3956	3D cancer models: One step closer to in vitro human studies. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	6
3957	Digital Spatial Profiling Links Beta-2-microglobulin Expression with Immune Checkpoint Blockade Outcomes in Head and Neck Squamous Cell Carcinoma. <i>Cancer Research Communications</i> , 2023, 3, 558-563.	0.7	6
3958	Metformin-containing hydrogel scaffold to augment CAR-T therapy against post-surgical solid tumors. <i>Biomaterials</i> , 2023, 295, 122052.	5.7	8
3959	Biomaterial-based platforms for modulating immune components against cancer and cancer stem cells. <i>Acta Biomaterialia</i> , 2023, 161, 1-36.	4.1	5
3960	Current Landscape of Immunotherapy for Advanced Sarcoma. <i>Cancers</i> , 2023, 15, 2287.	1.7	3
3961	NLRC5-CIITA Fusion Protein as an Effective Inducer of MHC-I Expression and Antitumor Immunity. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7206.	1.8	2
3962	Cancer Resistance to Immunotherapy: Comprehensive Insights with Future Perspectives. <i>Pharmaceutics</i> , 2023, 15, 1143.	2.0	13
3963	Multi-Institutional Study of Pathologist Reading of the Programmed Cell Death Ligand-1 Combined Positive Score Immunohistochemistry Assay for Gastric or Gastroesophageal Junction Cancer. <i>Modern Pathology</i> , 2023, 36, 100128.	2.9	7
3964	Deciphering the immune heterogeneity dominated by natural killer cells with prognostic and therapeutic implications in hepatocellular carcinoma. <i>Computers in Biology and Medicine</i> , 2023, 158, 106872.	3.9	2
3965	Research progress on PD-1 and PD-L1 inhibitors in the treatment of metastatic urothelial carcinoma. <i>International Immunopharmacology</i> , 2023, 119, 110158.	1.7	2
3966	Dendritic cell-derived exosomes: A new horizon in personalized cancer immunotherapy?. <i>Cancer Letters</i> , 2023, 562, 216168.	3.2	7

#	ARTICLE	IF	CITATIONS
3967	Ionizable polymeric nanocarriers for the codelivery of bi-adjuvant and neoantigens in combination tumor immunotherapy. <i>Bioactive Materials</i> , 2023, 26, 169-180.	8.6	3
3968	Elaborating on anti CTLA-4 mechanisms of action using an agent-based modeling approach. <i>Frontiers in Applied Mathematics and Statistics</i> , 0, 8, .	0.7	1
3969	Cuproptosis and its application in different cancers: an overview. <i>Molecular and Cellular Biochemistry</i> , 2023, 478, 2683-2693.	1.4	2
3970	Exhausted T cells hijacking the cancer-immunity cycle: Assets and liabilities. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
3971	Integrating immunopeptidome analysis for the design and development of cancer vaccines. <i>Seminars in Immunology</i> , 2023, 67, 101750.	2.7	3
3972	Targeting ZDHHC9 potentiates anti-programmed death-ligand 1 immunotherapy of pancreatic cancer by modifying the tumor microenvironment. <i>Biomedicine and Pharmacotherapy</i> , 2023, 161, 114567.	2.5	5
3973	<i>Lactiseibacillus rhamnosus</i> Probio-M9 enhanced the antitumor response to anti-PD-1 therapy by modulating intestinal metabolites. <i>EBioMedicine</i> , 2023, 91, 104533.	2.7	11
3978	Derivation of Macroscopic Equations from Homogeneous Thermostatted Kinetic Equations in the Cancer-Immune System Competition. , 2022, , 225-236.		0
3981	Firefly luciferase-based chronological measurement of effector CD8 ⁺ T-cell activity using a multi-chamber luminometer. <i>Bioanalysis</i> , 2022, 14, 1413-1421.	0.6	0
3982	Bibliometric analysis of single-cell sequencing researches on immune cells and their application of DNA damage repair in cancer immunotherapy. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
3983	PD-1 blockade augments CD8 ⁺ T cell dependent antitumor immunity triggered by Ad-SGE-REIC in Egfr-mutant lung cancer. <i>Lung Cancer</i> , 2023, 178, 1-10.	0.9	0
3984	Tissue-specific abundance of interferon-gamma drives regulatory T cells to restrain DC1-mediated priming of cytotoxic T cells against lung cancer. <i>Immunity</i> , 2023, 56, 386-405.e10.	6.6	22
3985	Cavrotolimod, a Nanoparticle Toll-like Receptor 9 Agonist, Inhibits Tumor Growth and Alters Immune Cell Composition in Mouse Models of Skin Cancer. <i>ACS Applied Nano Materials</i> , 2023, 6, 2682-2696.	2.4	1
3986	Radiotherapy/Chemotherapy-Immunotherapy for Cancer Management: From Mechanisms to Clinical Implications. <i>Oxidative Medicine and Cellular Longevity</i> , 2023, 2023, 1-9.	1.9	5
3987	Molecular characteristics, oncogenic roles, and relevant immune and pharmacogenomic features of NEK2 in gastric cancer. <i>International Immunopharmacology</i> , 2023, 116, 109737.	1.7	2
3988	Identification and validation of a novel survival prediction model based on the T-cell phenotype in the tumor immune microenvironment and peripheral blood for gastric cancer prognosis. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	2
3989	Recent Advances in Cancer Immunotherapy Delivery Modalities. <i>Pharmaceutics</i> , 2023, 15, 504.	2.0	5
3990	Role of Neoadjuvant Immune Checkpoint Inhibitors in Resectable Non-Small Cell Lung Cancer. <i>Pharmaceutics</i> , 2023, 16, 233.	1.7	1

#	ARTICLE	IF	CITATIONS
3991	Tantalum-Zirconium Co-Doped Metal-Organic Frameworks Sequentially Sensitize Radio-Radiodynamic Immunotherapy for Metastatic Osteosarcoma. <i>Advanced Science</i> , 2023, 10, .	5.6	12
3992	Boosting Checkpoint Immunotherapy with Biomaterials. <i>ACS Nano</i> , 2023, 17, 3225-3258.	7.3	20
3993	The Combination of Immune Checkpoint Blockade with Tumor Vessel Normalization as a Promising Therapeutic Strategy for Breast Cancer: An Overview of Preclinical and Clinical Studies. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3226.	1.8	3
3994	Safety and tolerability of stereotactic radiotherapy combined with durvalumab with or without tremelimumab in advanced non-small cell lung cancer, the phase I SICI trial. <i>Lung Cancer</i> , 2023, 178, 96-102.	0.9	1
3995	Prognostic relevance of tumor-resident memory T cells in metastatic lymph nodes of esophageal squamous cell carcinoma. <i>Cancer Science</i> , 2023, 114, 1846-1858.	1.7	3
3996	Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract Carcinoma. <i>Cancers</i> , 2023, 15, 1066.	1.7	4
3997	Radiotherapy, PARP Inhibition, and Immune-Checkpoint Blockade: A Triad to Overcome the Double-Edged Effects of Each Single Player. <i>Cancers</i> , 2023, 15, 1093.	1.7	4
3998	Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	19
3999	Cold atmospheric plasma: Novel opportunities for tumor microenvironment targeting. <i>Cancer Medicine</i> , 2023, 12, 7189-7206.	1.3	6
4000	Head and neck cancer patient-derived tumouroid cultures: opportunities and challenges. <i>British Journal of Cancer</i> , 0, , .	2.9	2
4001	Integration of single sample and population analysis for understanding immune evasion mechanisms of lung cancer. <i>Npj Systems Biology and Applications</i> , 2023, 9, .	1.4	0
4002	Silver nanoparticles induce a non-immunogenic tumor cell death. <i>Journal of Immunotoxicology</i> , 2023, 20, .	0.9	3
4003	The emerging landscape of neo/adjuvant immunotherapy in renal cell carcinoma. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	4
4004	Review of biomarkers for response to immunotherapy in HNSCC microenvironment. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
4005	Knowledge mapping of image-guided tumor ablation and immunity: A bibliometric analysis. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
4006	Prevalent Pseudoprogression and Pseudoresidue in Patients With Rectal Cancer Treated With Neoadjuvant Immune Checkpoint Inhibitors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2023, 21, 133-142.e3.	2.3	5
4007	Are charged particles a good match for combination with immunotherapy? Current knowledge and perspectives. <i>International Review of Cell and Molecular Biology</i> , 2023, , 1-36.	1.6	4
4008	Optimising Cancer Immunotherapy: Challenges and Opportunities. <i>European Medical Journal (Chelmsford, England)</i> , 0, , 26-43.	3.0	0

#	ARTICLE	IF	CITATIONS
4009	TRIM21 inhibits irradiation-induced mitochondrial DNA release and impairs antitumour immunity in nasopharyngeal carcinoma tumour models. <i>Nature Communications</i> , 2023, 14, .	5.8	11
4010	Hydrogel systems for targeted cancer therapy. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 11, .	2.0	10
4011	Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Nonâ€“Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2023, 9, 527.	3.4	37
4012	PTPN18 Serves as a Potential Oncogene for Glioblastoma by Enhancing Immune Suppression. <i>Oxidative Medicine and Cellular Longevity</i> , 2023, 2023, 1-21.	1.9	0
4013	The advent of immune stimulating CAFs in cancer. <i>Nature Reviews Cancer</i> , 2023, 23, 258-269.	12.8	22
4014	Checkpoint TIPE2 Limits the Helper Functions of NK Cells in Supporting Antitumor CD8⁺ T Cells. <i>Advanced Science</i> , 2023, 10, .	5.6	6
4015	A nitric-oxide driven chemotactic nanomotor for enhanced immunotherapy of glioblastoma. <i>Nature Communications</i> , 2023, 14, .	5.8	27
4016	Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia. <i>BMC Cancer</i> , 2023, 23, .	1.1	1
4017	Angiogenic inhibitor preâ€“administration improves the therapeutic effects of immunotherapy. <i>Cancer Medicine</i> , 2023, 12, 9760-9773.	1.3	3
4018	New Biomarkers Based on Dendritic Cells for Breast Cancer Treatment and Prognosis Diagnosis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4058.	1.8	0
4020	Advanced Biomaterials with Intrinsic Immunomodulation Effects for Cancer Immunotherapy. <i>Small Methods</i> , 2023, 7, .	4.6	3
4021	Prognostic Significance of Iron Metabolism Related Genes in Human Lung Adenocarcinoma. <i>Cancer Management and Research</i> , 0, Volume 15, 203-216.	0.9	1
4022	Developing an m5C regulatorâ€“mediated RNA methylation modification signature to predict prognosis and immunotherapy efficacy in rectal cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
4023	Construction of a TTN Mutation-Based Prognostic Model for Evaluating Immune Microenvironment, Cancer Stemness, and Outcomes of Colorectal Cancer Patients. <i>Stem Cells International</i> , 2023, 2023, 1-21.	1.2	2
4024	Strategies for Treatment of Thyroid Cancer. <i>Current Drug Targets</i> , 2023, 24, 406-415.	1.0	1
4025	Cell death, therapeutics, and the immune response in cancer. <i>Trends in Cancer</i> , 2023, 9, 381-396.	3.8	29
4026	An artificial intelligence networkâ€“guided signature for predicting outcome and immunotherapy response in lung adenocarcinoma patients based on 26 machine learning algorithms. <i>Cell Proliferation</i> , 2023, 56, .	2.4	10
4027	Diagnostic Predictors of Immunotherapy Response in Head and Neck Squamous Cell Carcinoma. <i>Diagnostics</i> , 2023, 13, 862.	1.3	4

#	ARTICLE	IF	CITATIONS
4028	⁺ sinus macrophages in regional lymph nodes do not predict mismatch repair status of patients with colorectal cancer. <i>Cancer Medicine</i> , 2023, 12, 10199-10211.	1.3	5
4029	Pathologic Complete Response after Chemotherapy with Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma with Tumor Thrombus in the Main Portal Trunk. <i>Digestive Surgery</i> , 2023, 40, 84-89.	0.6	2
4030	Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment. <i>Bone Research</i> , 2023, 11, .	5.4	38
4031	Inhibitors targeting epigenetic modifications in cancer. , 2023, , 287-324.		0
4033	Dual-Responsive Core Shell Tecto Dendrimers Enable Efficient Gene Editing of Cancer Cells to Boost Immune Checkpoint Blockade Therapy. <i>ACS Applied Materials & Interfaces</i> , 2023, 15, 12809-12821.	4.0	7
4034	Identification of anoikis-related molecular patterns to define tumor microenvironment and predict immunotherapy response and prognosis in soft-tissue sarcoma. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	4
4035	ACER2 forms a cold tumor microenvironment and predicts the molecular subtype in bladder cancer: Results from real-world cohorts. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	2
4036	Immunotherapies: How Do They Work?. <i>Praxis</i> , 2023, 112, 131-134.	0.2	1
4037	Construction of Osteosarcoma Diagnosis Model by Random Forest and Artificial Neural Network. <i>Journal of Personalized Medicine</i> , 2023, 13, 447.	1.1	2
4038	Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions. <i>Cell Communication and Signaling</i> , 2023, 21, .	2.7	5
4039	Cancer Initiation and Inflammation. , 2023, , 1-15.		0
4040	Crosstalk between Mesenchymal Stem Cells and Cancer Stem Cells Reveals a Novel Stemness-Related Signature to Predict Prognosis and Immunotherapy Responses for Bladder Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4760.	1.8	6
4041	Dancing with the Surgeon: Neoadjuvant and Adjuvant Immunotherapies from the Medical Oncologist's Perspective. <i>Journal of Chest Surgery</i> , 2023, 56, 67-74.	0.2	2
4042	CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy. <i>Nature Communications</i> , 2023, 14, .	5.8	14
4043	Raddeanin A Enhances Mitochondrial DNA-GAS/STING Axis-Mediated Antitumor Immunity by Targeting Transactive Responsive DNA-Binding Protein 43. <i>Advanced Science</i> , 2023, 10, .	5.6	8
4044	Immunotherapy in Gastrointestinal Cancer Focusing on CAR-T Cell Therapy. , 2023, , 251-268.		0
4045	Interleukin-37 promotes DMBA/TPA skin cancer through SIGIRR-mediated inhibition of glycolysis in CD103 DC cells. <i>MedComm</i> , 2023, 4, .	3.1	0
4046	Immune Compartments and Extracellular Matrix Crosstalk Involved in Tumor Dissemination. , 2023, , 1-22.		0

#	ARTICLE	IF	CITATIONS
4047	Harnessing Nanomaterials for Cancer Sonodynamic Immunotherapy. <i>Advanced Materials</i> , 2023, 35, .	11.1	33
4048	Evaluation of tumor antigen-specific antibody responses in patients with metastatic triple negative breast cancer treated with cyclophosphamide and pembrolizumab. , 2023, 11, e005848.		1
4049	Delivering mRNA to a human NK cell line, NK-92 cells, by lipid nanoparticles. <i>International Journal of Pharmaceutics</i> , 2023, 636, 122810.	2.6	2
4050	Recent Emerging Immunological Treatments for Primary Brain Tumors: Focus on Chemokine-Targeting Immunotherapies. <i>Cells</i> , 2023, 12, 841.	1.8	3
4051	The Role of PRMT5 in Immuno-Oncology. <i>Genes</i> , 2023, 14, 678.	1.0	1
4052	Anti-tumor efficacy of a bevacizumab preconditioning followed by etoposide and cisplatin regimen in human epidermal growth factor receptor-2-positive breast cancer brain metastasis refractory to whole brain radiotherapy. <i>Journal of Cancer Research and Practice</i> , 2023, 10, 11.	0.2	0
4053	Remodeling Tumor Immunogenicity with Dual-Activatable Binary CRISPR Nanomedicine for Cancer Immunotherapy. <i>ACS Nano</i> , 2023, 17, 5713-5726.	7.3	5
4054	Multi-omics studies in interpreting the evolving standard model for immune functions. <i>Briefings in Functional Genomics</i> , 2024, 23, 75-81.	1.3	0
4055	Tumor microenvironment mimicking 3D models unveil the multifaceted effects of SMAC mimetics. <i>IScience</i> , 2023, 26, 106381.	1.9	0
4056	B cells in the tumor microenvironment: Multi-faceted organizers, regulators, and effectors of anti-tumor immunity. <i>Cancer Cell</i> , 2023, 41, 466-489.	7.7	16
4057	Sonodynamic-immunomodulatory nanostimulators activate pyroptosis and remodel tumor microenvironment for enhanced tumor immunotherapy. <i>Theranostics</i> , 2023, 13, 1571-1583.	4.6	14
4058	Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy. , 2023, 11, e005920.		5
4059	Analysis of the Clinicopathological Characteristics, Prognosis, and Lymphocyte Infiltration of Esophageal Neuroendocrine Neoplasms: A Surgery-Based Cohort and Propensity-Score Matching Study. <i>Cancers</i> , 2023, 15, 1732.	1.7	0
4060	A novel immune-related model to predict prognosis and responsiveness to checkpoint and angiogenesis blockade therapy in advanced renal cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
4061	Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors. , 2023, 11, e005921.		6
4062	Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies. , 2023, 11, e005923.		4
4064	IFN- γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma. <i>Journal of Experimental Medicine</i> , 2023, 220, .	4.2	19
4065	Neurological adverse events of immune checkpoint inhibitors: An update of clinical presentations, diagnosis, and management. <i>Revue Neurologique</i> , 2023, 179, 506-515.	0.6	5

#	ARTICLE	IF	CITATIONS
4066	Imaging Features of Immunotherapy. IDKD Springer Series, 2023, , 169-176.	0.8	0
4067	Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironment. Nature Cancer, 2023, 4, 516-534.	5.7	9
4068	Three distinct mechanisms underlying human $\gamma\delta$ T cell-mediated cytotoxicity against malignant pleural mesothelioma. Frontiers in Immunology, 0, 14, .	2.2	1
4070	A prospective study on the role of immunotherapy in metastatic cancer patients at Combined Military Hospital Dhaka. International Journal of Research in Medical Sciences, 2023, 11, 1056-1059.	0.0	0
4071	Neuroimmune Mechanisms of Cerebellar Ataxias. , 2023, , 631-639.		0
4072	Current literature review on the tumor immune micro-environment, its heterogeneity and future perspectives in treatment of advanced non-small cell lung cancer. Translational Lung Cancer Research, 2023, .	1.3	1
4073	Immunotherapies for advanced hepatocellular carcinoma. Frontiers in Pharmacology, 0, 14, .	1.6	4
4074	Neoadjuvant chemotherapy enhances anti-tumor immune response of tumor microenvironment in human esophageal squamous cell carcinoma. IScience, 2023, 26, 106480.	1.9	2
4075	Identification of a centrosome-related prognostic signature for breast cancer. Frontiers in Oncology, 0, 13, .	1.3	3
4076	Targeting CD70 in combination with chemotherapy to enhance the anti-tumor immune effects in non-small cell lung cancer. OncoImmunology, 2023, 12, .	2.1	3
4077	Predicting outcome in dogs with diffuse large B-cell lymphoma with a novel immune landscape signature. Veterinary Pathology, 2023, 60, 308-315.	0.8	2
4078	Extracellular vesicles as novel drug delivery systems to target cancer and other diseases: Recent advancements and future perspectives. F1000Research, 0, 12, 329.	0.8	2
4080	Add fuel to the fire: Inflammation and immune response in lung cancer combined with COVID-19. Frontiers in Immunology, 0, 14, .	2.2	1
4081	Progress in the Study of Hepatocellular Carcinoma Microenvironment and Its Clinical Significance. Advances in Clinical Medicine, 2023, 13, 4415-4420.	0.0	0
4082	Risk stratification based on DNA damage-repair-related signature reflects the microenvironmental feature, metabolic status and therapeutic response of breast cancer. Frontiers in Immunology, 0, 14, .	2.2	2
4084	Cancer Treatment and Immunomodulation by Nonthermal Plasma Technology. Topics in Applied Physics, 2023, , 35-59.	0.4	0
4085	Immune Checkpoint Blockade Response Biomarkers. , 2023, , 1-34.		0
4086	Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment. Molecular Cancer, 2023, 22, .	7.9	18

#	ARTICLE	IF	CITATIONS
4087	Multiparameter prediction model of immune checkpoint inhibitors combined with chemotherapy for non-small cell lung cancer based on support vector machine learning. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
4088	A machine learning model to predict efficacy of neoadjuvant therapy in breast cancer based on dynamic changes in systemic immunity. <i>Cancer Biology and Medicine</i> , 2023, 20, 218-228.	1.4	2
4090	Immunotherapy in Gastrointestinal Malignancies. , 2023, , 1-23.		0
4091	Molecular imaging for cancer immunotherapy. , 2023, 1, 3-17.		4
4092	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Strategies and Biomarkers Predicting Response and/or Resistance. <i>Biomedicines</i> , 2023, 11, 1020.	1.4	6
4093	Novel Immunotherapeutic Approaches to Treating HPV-Related Head and Neck Cancer. <i>Cancers</i> , 2023, 15, 1959.	1.7	3
4094	The advancement of metaloadjuvant for cancer immunotherapy. <i>Science Bulletin</i> , 2023, 68, 756-758.	4.3	2
4095	Oncogenic epidermal growth factor receptor signal-induced histone deacetylation suppresses chemokine gene expression in human lung adenocarcinoma. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
4096	Clonal Spreading of Tumor-Infiltrating T Cells Underlies the Robust Antitumor Immune Responses. <i>Cancer Immunology Research</i> , 2023, 11, 847-862.	1.6	1
4097	Pathologic Response to Neoadjuvant Sequential Chemoradiation Therapy in Locally Advanced Breast Cancer: Preliminary, Translational Results from the French Neo-APBI-01 Trial. <i>Cancers</i> , 2023, 15, 2030.	1.7	0
4098	Advances in research of biological functions of Isthmin-1. <i>Journal of Cell Communication and Signaling</i> , 2023, 17, 507-521.	1.8	2
4099	The Role of the Gut Microbiome in Cancer Immunotherapy: Current Knowledge and Future Directions. <i>Cancers</i> , 2023, 15, 2101.	1.7	3
4100	Ovarian clear cell carcinoma with or without endometriosis origin in a single institution cohort. <i>Discover Oncology</i> , 2023, 14, .	0.8	0
4102	Increasing Systemic Immune-inflammation Index During Treatment in Patients With Advanced Pancreatic Cancer is Associated With Poor Survival. <i>Annals of Surgery</i> , 2023, 278, 1018-1023.	2.1	6
4103	STING Protein-Based In Situ Vaccine Synergizes CD4 ⁺ T, CD8 ⁺ T, and NK Cells for Tumor Eradication. <i>Advanced Healthcare Materials</i> , 2023, 12, .	3.9	2
4104	Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study. <i>EclinicalMedicine</i> , 2023, 58, 101917.	3.2	12
4106	Engineering a HER2-CAR-NK Cell Secreting Soluble Programmed Cell Death Protein with Superior Antitumor Efficacy. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6843.	1.8	6
4107	Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	8

#	ARTICLE	IF	CITATIONS
4108	Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma. , 2023, 11, e004150.		4
4109	Comprehensive characterization of endoplasmic reticulum stress in bladder cancer revealing the association with tumor immune microenvironment and prognosis. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	0
4111	Mechanism of inert inflammation in an immune checkpoint blockade-resistant tumor subtype bearing transcription elongation defects. <i>Cell Reports</i> , 2023, 42, 112364.	2.9	0
4112	Palmitoyl transferases act as novel drug targets for pancreatic cancer. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	5
4113	Role of Surgical Pathologist for the Detection of Immuno-oncologic Predictive Factors in Non-small Cell Lung Cancers. <i>Advances in Anatomic Pathology</i> , 2023, 30, 174-194.	2.4	0
4114	Cancer and Immunology â€œ The Homeostasis Dance. , 2023, , 1-38.		0
4115	Regulative Roles of Metabolic Plasticity Caused by Mitochondrial Oxidative Phosphorylation and Glycolysis on the Initiation and Progression of Tumorigenesis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7076.	1.8	3
4116	Flexible Monitoring, Diagnosis, and Therapy by Microneedles with Versatile Materials and Devices toward Multifunction Scope. <i>Research</i> , 2023, 6, .	2.8	6
4117	Immune checkpoint therapyâ€™current perspectives and future directions. <i>Cell</i> , 2023, 186, 1652-1669.	13.5	114
4118	An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma. <i>Cancer Cell</i> , 2023, 41, 919-932.e5.	7.7	6
4119	Neoadjuvant immune checkpoint blockade triggers persistent and systemic T _{reg} activation which blunts therapeutic efficacy against metastatic spread of breast tumors. <i>Oncolimmunology</i> , 2023, 12, .	2.1	5
4120	Identification and validation of a novel CD8+ T cell-associated prognostic model based on ferroptosis in acute myeloid leukemia. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
4121	Cancer Surveillance. , 2023, , 271-341.		0
4122	Neutrophil membrane-derived nanoparticle loading TLR7 agonists augments radiotherapy efficacy and boosts abscopal effect via regulating tumor microenvironment. <i>Cancer Nanotechnology</i> , 2023, 14, .	1.9	1
4123	Comprehensive Analysis of NABP2 as a Prognostic Biomarker and Its Correlation with Immune Infiltration in Hepatocellular Carcinoma. <i>Journal of Inflammation Research</i> , 0, Volume 16, 1783-1804.	1.6	0
4124	Can Patients with HER2-Low Breast Cancer Benefit from Anti-HER2 Therapies? A Review. <i>Breast Cancer: Targets and Therapy</i> , 0, Volume 15, 281-294.	1.0	1
4137	Stimuli-Responsive Polymeric Nanovaccines Toward Next-Generation Immunotherapy. <i>ACS Nano</i> , 2023, 17, 9826-9849.	7.3	9
4142	Transforming Growth Factor- β 1 in Cancer Immunology: Opportunities for Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 309-328.	0.8	5

#	ARTICLE	IF	CITATIONS
4156	Exosomes and circular RNAs: promising partners in hepatocellular carcinoma from bench to bedside. <i>Discover Oncology</i> , 2023, 14, .	0.8	1
4159	Cancer immunotherapy. , 2023, , 681-741.		0
4162	Beyond starving cancer: anti-angiogenic therapy. <i>Journal of Medical Ultrasonics</i> (2001), 0, , .	0.6	1
4168	New genetic and epigenetic insights into the chemokine system: the latest discoveries aiding progression toward precision medicine. , 2023, 20, 739-776.		5
4175	Therapeutic Strategies in Immune-Mediated Cerebellar Ataxias. <i>Contemporary Clinical Neuroscience</i> , 2023, , 665-678.	0.3	0
4178	Novel Immunotherapeutic Approaches for the Treatment of Glioblastoma. <i>BioDrugs</i> , 2023, 37, 489-503.	2.2	1
4186	Editorial: The regulatory immune system as a target to improve adjuvants and novel vaccines. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 13, .	1.8	0
4196	The endocannabinoid system in the immunobiology of dendritic cells. , 2023, , 429-436.		0
4274	Harnessing 3D in vitro systems to model immune responses to solid tumours: a step towards improving and creating personalized immunotherapies. <i>Nature Reviews Immunology</i> , 2024, 24, 18-32.	10.6	2
4290	New insights into T-cell exhaustion in liver cancer: from mechanism to therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 12543-12560.	1.2	1
4308	Akkermansia muciniphila: a potential booster to improve the effectiveness of cancer immunotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 13477-13494.	1.2	2
4310	Immune modulation during anti-cancer radio(immuno)therapy. <i>International Review of Cell and Molecular Biology</i> , 2023, , .	1.6	0
4311	Supramolecular Immunotherapy on Diversiform Immune Cells. <i>Journal of Materials Chemistry B</i> , 0, , .	2.9	0
4317	Principles of Clinical Oncology and Systemic Treatments. , 2023, , 225-246.		0
4321	How pH deregulation favors the hallmarks of cancer. , 2023, , 101-121.		0
4346	Roles of RIPK1 as a stress sentinel coordinating cell survival and immunogenic cell death. <i>Nature Reviews Molecular Cell Biology</i> , 2023, 24, 835-852.	16.1	3
4351	Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	5
4352	Phytochemical-Based Nanomedicine for Targeting Tumor Microenvironment and Inhibiting Cancer Chemoresistance: Recent Advances and Pharmacological Insights. <i>Molecular Pharmaceutics</i> , 2023, 20, 5254-5277.	2.3	2

#	ARTICLE	IF	CITATIONS
4390	Heterogeneity of the tumor immune microenvironment and clinical interventions. <i>Frontiers of Medicine</i> , 2023, 17, 617-648.	1.5	0
4392	The role of TXNIP in cancer: a fine balance between redox, metabolic, and immunological tumor control. <i>British Journal of Cancer</i> , 2023, 129, 1877-1892.	2.9	1
4404	Case report: Remarkable response to sintilimab, lenvatinib, and nab-paclitaxel in postoperative metastatic chemotherapy-resistant combined hepatocellular-cholangiocarcinoma. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
4405	Emerging Vaccine for the Treatment of Cancer via Nanotechnology. , 2023, , 227-244.		0
4413	Molecular testing in colorectal cancer. , 2024, , 339-358.		0
4420	IONPs-Based Treatment Methods. <i>Nanomedicine and Nanotoxicology</i> , 2023, , 129-240.	0.1	0
4437	Immune checkpoints targeting dendritic cells for antibody-based modulation in cancer. <i>International Review of Cell and Molecular Biology</i> , 2024, , 145-179.	1.6	0
4439	Nanomedicine – Immune System Interactions: Limitations and Opportunities for the Treatment of Cancer. <i>Handbook of Experimental Pharmacology</i> , 2023, , .	0.9	0
4446	Diversities of Various Nanomaterials-Based Vaccines for Healthcare Applications. , 2023, , 1-21.		0
4448	Cancer Immunotherapy. , 2023, , 121-154.		0
4486	Locally advanced non-small cell lung cancer. , 2024, , 155-174.		0
4491	Immunotherapies landscape and associated inhibitors for the treatment of cervical cancer. , 2023, 40, .		0
4500	Improvement of the effectiveness of sonodynamic therapy: by optimizing components and combination with other treatments. <i>Biomaterials Science</i> , 2023, 11, 7489-7511.	2.6	0
4515	CXCL9, CXCL10, CXCL11/CXCR3 Axis and Immune Activation. , 2023, , 271-289.		0
4527	Application of exosomes as nanocarriers in cancer therapy. <i>Journal of Materials Chemistry B</i> , 0, , .	2.9	1
4528	Natural cationic polymer-derived injectable hydrogels for targeted chemotherapy. <i>Materials Advances</i> , 2023, 4, 6064-6091.	2.6	1
4531	Cancer stem cells, signalling pathways and chemopreventive effects of phytochemicals in androgen-regulated cancers. , 2024, , 409-437.		0
4537	EMT-induced immune evasion: connecting the dots from mechanisms to therapy. <i>Clinical and Experimental Medicine</i> , 2023, 23, 4265-4287.	1.9	2

#	ARTICLE	IF	CITATIONS
4539	Leveraging mesoporous silica nanomaterial for optimal immunotherapeutics against cancer. <i>In Vitro Models</i> , 2023, 2, 153-169.	1.0	0
4541	Development of nano-immunotherapy for cancer treatment: achievements and scopes. <i>Journal of Pharmaceutical Investigation</i> , 2023, 53, 827-844.	2.7	0
4562	Dissecting the tumor microenvironment in response to immune checkpoint inhibitors via single-cell and spatial transcriptomics. <i>Clinical and Experimental Metastasis</i> , 0, , .	1.7	1
4598	Hydrogel-mediated tumor T cell infiltration and immune evasion to reinforce cancer immunotherapy. <i>Nanoscale Horizons</i> , 0, , .	4.1	0
4600	Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. <i>Nature Reviews Immunology</i> , 0, , .	10.6	2
4607	In Vitro Evaluation of Cancer Cell Immunogenicity and Antigen-Specific T-Cell Cytotoxicity by Flow Cytometry. <i>Methods in Molecular Biology</i> , 2024, , 13-28.	0.4	0
4619	Microphysiological systems for solid tumor immunotherapy: opportunities and challenges. <i>Microsystems and Nanoengineering</i> , 2023, 9, .	3.4	1
4620	Same yet different “ how lymph node heterogeneity affects immune responses. <i>Nature Reviews Immunology</i> , 0, , .	10.6	1
4670	Tumor-derived extracellular vesicles: how they mediate glioma immunosuppression. <i>Molecular Biology Reports</i> , 2024, 51, .	1.0	0
4699	Multifunctional nanocarrier-mediated delivery for targeting and treating skin cancer. , 2024, , 113-138.		1
4705	Antigen presenting cells in cancer immunity and mediation of immune checkpoint blockade. <i>Clinical and Experimental Metastasis</i> , 0, , .	1.7	0
4710	Insulin resistance, hyperinsulinemia, and cancer: pathogenic considerations and therapeutic opportunities. , 2023, , 285-314.		0
4721	Intratumoral Injection of Large Surface Area Microparticle Taxanes in Carcinomas Increases Immune Effector Cell Concentrations, Checkpoint Expression, and Synergy with Checkpoint Inhibitors: A Review of Preclinical and Clinical Studies. <i>Oncology and Therapy</i> , 2024, 12, 31-55.	1.0	0
4722	Recent advances in light-triggered cancer immunotherapy. <i>Journal of Materials Chemistry B</i> , 2024, 12, 2650-2669.	2.9	0
4733	Current status, challenges, and future perspective of nanomedicine-based cancer immunotherapy. , 2024, , 495-516.		0
4735	Nanotechnology as an emerging option in cancer immunotherapy. , 2024, , 37-70.		0
4778	Immunomodulation and Cancer. , 2023, , 17-25.		0
4796	Current and Future Perspectives of Combining Chemotherapy and Stereotactic Body Radiation Therapy with Immunotherapy in the Treatment of Lung Cancer. , 2024, , 265-295.		0

#	ARTICLE	IF	CITATIONS
4808	Introduction to Lung Cancer. , 2024, , 1-9.		0
4809	CTLA-4 Inhibitors for the Treatment of Lung Cancer. , 2024, , 87-99.		0